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Summary 
 
An interruption of the blood supply to the brain, as occurs during ischemic stroke, 
results in a rapid decline of ATP levels and a subsequent loss of neuronal function 
and viability. Under physiological conditions the brain reuses ATP degradation 
metabolites, such as hypoxanthine, via the purine salvage pathway, to restore its 
ATP pool. However, the massive degradation of ATP during ischemia results in the 
accumulation and loss of diffusible purine metabolites and thereby leads to a 
reduction in the post-ischemic ATP pool size, leaving the brain more vulnerable to 
secondary ischemic insults (recurrent strokes) and less able to deploy reparative 
mechanisms. The aim of this study was to improve the recovery of post-ischemic 
ATP levels by enhancing the purine salvage pathway, with substances that are 
already known to be tolerated in humans. 
 
Using acute hippocampal rat brain slices, I found that 1 mM Ribose (Rib) and 50 μM 
Adenine (Ade), two main metabolites of the purine salvage pathway, significantly 
increased the tissue ATP levels under basal conditions. Rib/Ade pre-treatment results 
in accelerated decline of synaptic transmission after onset of oxygen/glucose 
deprivation (OGD), due to increased adenosine release. However, this intervention 
does not delay the onset of anoxic depolarisation, or improve the recovery of 
synaptic transmission after prolonged ischemic periods. Pre-treatment of brain slices 
with 1 mM creatine, which increases phosphocreatine levels and thereby buffers the 
rapid decline of ATP levels upon energy shortage, significantly delays the onset of 
AD and helps to improve the recovery of synaptic transmission. By using cultured 
cerebellar granule cells, for more protracted studies on cell viability after OGD, I 
show that addition of Rib/Ade after ischemia helps to improves cell viability.  
 
Therefore my results suggest that both, delaying the decline of ATP upon onset of 
OGD (pre-treatment with creatine), or enhancing the post-ischemic recovery of ATP 
(post-treatment with Rib/Ade) are useful strategies to improve cell survival and 
function after in vitro ischemia. 
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1.1 Cerebral ischemia 
 
1.1.1 Ischemic stroke 
 
Cerebral stroke is the consequence of a cerebrovascular accident that is caused by a 
rupture of a blood vessel in the brain (haemorrhagic stroke) or by an interruption of 
the blood supply to the brain (ischemic stroke). Haemorrhagic stroke accounts for 
about 15 - 20 % of all strokes and occurs when a weakened blood vessel ruptures due 
to aneurysms or arteriovenous malformations. Ischemic stroke, which will be the 
main focus of this thesis,  is the more common type and accounts for about 80 - 85 % 
of all strokes (Feigin et al., 2003). The central event in ischemic stroke is the 
interruption of the blood flow to the brain due to local thrombosis or embolic 
particles. Globally stroke is the second leading cause of death and the most common 
cause of long term disabilities (Feigin et al., 2003; Flynn et al., 2008).  About 8 - 12 
% of ischemic strokes and ~ 38 % of haemorraghic strokes result in death within 30 
days (Writing Group et al., 2010). Furthermore in patients suffering a first stroke 
there is an increased risk of recurrent strokes within 5 years (Flynn et al., 2008; 
Writing Group et al., 2010).  
 
Since the brain relies on a constant blood supply to match its high energy demand, 
even brief periods of cerebral ischemia result in immediate neurological 
dysfunctions. If the blood flow to the affected area is restored spontaneously and 
neurological symptoms recover completely this event is termed transient ischemic 
attack (TIA). TIAs often precede a full ischemic stroke, which occurs when the 
blood supply is interrupted for prolonged periods and the brain tissue suffers 
irreversible damage resulting in persistent neurological dysfunction (Flynn et al., 
2008).  
 
Depending on the area affected by stroke, stroke survivors may suffer from paralysis, 
sensory impairments including pain, aphasia, cognitive impairments, seizures and 
epilepsy or emotional disturbances (Kelly-Hayes et al., 1998). Furthermore stroke 
patients have an increased risk of depression (Kelly-Hayes et al., 1998; Pascoe et al., 
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2011) and dementia (Desmond et al., 2002) following the months after stroke. 
Fifteen to thirty percent of all stroke patients remain disabled and about 20 % require 
institutional care within 3 months (Writing Group et al., 2010). Furthermore, 
including the cost related to increasing awareness, treatment of stroke, rehabilitation 
as well as loss of work – 21 billion € were spent in EU healthcare systems on stroke 
in the year of 2003 (Flynn et al., 2008). These facts reflect the major beneficial 
impact new stroke therapies would have for the life quality of individual patients and 
relatives as well as for financial expenditures of health care systems.  
 
1.1.1.1   Current treatments for ischemic stroke patients 
 
After committal of a stroke patient to the hospital it is critical to determine which 
type of stroke the patient had suffered (e.g.  by computed axial tomography) in order 
to provide the appropriate treatment. So far FDA (Food and Drug Administration) 
approved therapeutic agents for ischemic stroke patients are limited, and only target 
the restoration of the blood supply to the brain. This should be done as quickly as 
possible since “time is brain” and the typical stroke patient loses 1.9 million 
neurons/min stroke is untreated (Saver, 2006).  
 
The blood supply can be restored upon mechanically removing the blood clot (Smith 
et al., 2008), or upon administration of the thrombolytic agent recombinant tissue 
plasminogen activator (rtPA). However, rtPA must be given within ~ 3 h after stroke 
and is associated with an increased risk of intracerebral haemorrhage and other 
potential complications (Adams et al., 2003; Adams et al., 2007).  Therefore only a 
small percentage of acute ischemic stroke patients (~ 8%) qualify for rtPA treatment, 
due to the delay in  assessment of patients and the stringent selection criteria for rtPA 
treatment (Kleindorfer et al., 2004). The antiplatelet agent aspirin is frequently 
administered after thrombolytic therapy (within 24 – 48 h) in an effort to reduce the 
event of recurrent strokes (Adams et al., 2003).   
 
However, all these treatments aim to restore vascular function and exert their 
protective effect via hemodynamic mechanisms. Because of this reason research 
focuses on the development of neuroprotective drug therapies, which target the 
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actual brain tissue and aim to prevent the sequence of damaging events which would 
otherwise result in irreversible ischemic injury. These strategies could be used as 
prophylactic treatment for patients with a known risk of ischemic stroke, or as 
treatment for actue ischemic stroke patients to prevent the continuous loss of brain 
cells during ischemia as well as reperfusion (restoration of the blood supply).  
 
1.1.2 Ischemic core and penumbra  
 
The massive reduction of blood flow in the central area of ischemia (cerebral blood 
flow is < 10 ml/g/min) results in necrotic cell death and irreversible damage within 
minutes. Tissue in this area is termed the ischemic core and is beyond therapeutic 
rescue (Moustafa and Baron, 2008). Within the surrounding penumbra, where 
collaterals provide residual circulation, tissue is affected by ischemia, but still viable 
and can be potentially rescued. However, the extent of salvageable tissue decreases 
over time and penumbral tissue can be recruited to the ischemic core even during 
reperfusion so that  the final degree of the ischemic infarct can enlarge over a period 
of hours to days (Dirnagl et al., 1999). Increased survival of penumbral tissue is 
associated with improved neurological recovery, and is therefore a key target for 
neuroprotective interventions (Mergenthaler et al., 2004; Moustafa and Baron, 
2008).  
 
The main aim of this work was to help the post-ischemic brain to restore the balance 
of its energy metabolism, which might be protective in the penumbra, where cells are 
energetically challenged by ischemia. As mentioned above the brain has a very high 
energy demand and exclusively depends on a constant oxygen and nutrient supply 
from the blood. Therefore the next sections will give a background on the brains 
energy metabolism as well as the damaging events during ischemia and reperfusion 
that contribute to the continuous loss of brain cells. 
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1.2 Cerebral energy metabolism 
 
1.2.1 Cellular respiration 
 
Mitochondrial respiration and the associated synthesis of the energy carrier 
adenosine triphosphate (ATP) are the two pathways forming the core of cellular 
metabolism. During respiration the reducing agents NADH (nicotineamide adenine 
dinucleotide) and FADH2 (flavin adenine dinucleotide) are oxidised by molecular 
oxygen, through a chain of electron transfer complexes which generate a proton 
motive force across the inner mitochondrial membrane. The transport of protons 
down their gradient through ATP synthase is then coupled to the transfer of 
orthophosphate (Pi) to ADP (adenosine diphosphate) thereby generating ATP. This 
process is termed oxidative phosphorylation, and the generated ATP is exported to 
the cytosol in exchange for ADP. NADH and FADH2 are mainly provided by the 
degradation of glucose
1
 via glycolysis in the cytosol and the tricarboxylic acid 
(TCA) cycle in the mitochondria. During glycolysis glucose is degraded to 2 
molecules of pyruvate, thereby yielding 2 molecules of ATP and NADH. Pyruvate 
can be converted to lactate by lactate dehydrogenase, with the reaction products 
lactate and NAD
+
, the latter being used to drive anaerobic glycolysis. Alternatively, 
pyruvate can be decarboxylated to acetyl-coenzyme-A (acetyl-CoA), by the pyruvate 
dehydrogenase complex in the mitochondira, releasing NADH and CO2. Acetyl-CoA 
subsequently enters the TCA cycle, where it is degraded to CO2 and H2O in a series 
of steps yielding a further 3 molecules of NADH and one molecule of FADH2 per 
acetyl-Co-A used. Glycolysis, the TCA cycle and oxidative phosphorylation produce 
30 molecules of ATP per molecule of glucose (as opposed to 2 molecules of ATP/ 
molecule of glucose via glycolysis alone) (Stryer et al., 1995). 
 
 
 
 
                                                 
1
 Alternatively NADH can be generated by degradation of other fuels such as fatty acids or amino 
acids. However glucose is the main substrate for brain tissue. 
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1.2.2 Cerebral energy consumption and stores 
 
Although the human brain represents only 2% of the total body weight, it receives 
about 15% of the cardiac output and consumes 20% of total body oxygen and 
glucose consumption (Schurr and Rigor, 1989; Shulman et al., 2004). These values 
reflect the high metabolic rate and energy demand of the brain under basal 
conditions. As seen in Figure 1.1 ~ 80% of the brains’ energy in form of ATP is used 
for events associated with neuronal firing (mainly ion homeostasis by Na
+
/K
+
 
ATPase) and supporting processes (Erecinska and Silver, 1994; Ames, 2000). 
 
Although glucose is the main energy source for the brain and the majority of the 
glucose consumed is converted to H2O and CO2 during glycolysis and the TCA 
cycle, lactate can maintain the function of hippocampal brain slices even in the 
absence of glucose (Schurr et al., 1988).  The astrocyte-neuron lactate shuttle 
hypothesis states that astrocytes play the primary role in glycolysis and release 
lactate during periods of high energy demand which is taken up by neurons, 
converted to pyruvate and subsequently used in the TCA cycle to support their 
energetic demand (Pellerin and Magistretti, 1994).  
 
 
 
Figure 1.1: Energy consuming processes in the brain together with their relative 
estimates on ATP consumption.The highest amount of energy is spent on ion 
homeostasis and supporting processes for neurotransmission. Values are taken from 
(Erecinska and Silver, 1994; Ames, 2000; Attwell and Laughlin, 2001). 
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Unlike other tissues with a high energy demand, such as muscles, the brain has very 
little energy stores in the form of glycogen.  Cerebral glycogen is mostly stored in 
astrocytes, and made available for neurons in the form of released lactate (Brown 
and Ransom, 2007). However, cerebral glycogen stores only account for ~ 0.1 % of 
the total brain weight (Brown, 2004), and can therefore not satisfy the brain’s energy 
demand during periods of ischemia. It has been calculated that if the brain would 
continue at its normal metabolic rate, it would be completely depleted of all energy
2
 
within 80 seconds following cardiac arrest (Ames, 2000). It is therefore not 
surprising that the brain is highly vulnerable to disturbances of its nutrient and 
oxygen supply, as occurs during stroke.  
 
1.3 Ischemia and Reperfusion – factors contributing to    
loss of cells 
 
The decline of ATP during ischemia, due to the lack of oxygen and glucose, leads to 
multiple cascades of damaging cellular events that result in a loss of cells during 
ischemia as well as reperfusion. The main contributors to cell death are the toxic 
release of excitatory neurotransmitters (excitoxicity), imbalances in ion homeostasis, 
periinfarct depolarisations (PIDs), oxidative and nitrative stress, inflammation and 
apoptosis. All these processes occur on different time scales (see Figure 1.2) and 
contribute to the loss of neurons, glial cells as well as vascular cells over the course 
of minutes to days (Dirnagl et al., 1999; Heiss et al., 1999).  
 
                                                 
2
 In form of the high energy phosphate bond ~P from ATP and phosphocreatine 
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Figure 1.2: Pathophysiological processes during ischemia and reperfusion that 
contribute to irreversible damage of brain tissue. Adapted from (Dirnagl et al., 
1999; Heiss et al., 1999).  
 
1.3.1 Excitotoxicity 
 
Due to the lack of ATP, membrane ion-transport systems, which use up to 60 % of 
the cellular ATP store (see Figure 1.1), fail and neurons become depolarized. The 
resulting influx of calcium leads to release of a number of neurotransmitters, 
including large quantities of the excitatory neurotransmitter glutamate. Glutamate in 
turn activates NMDA and AMPA receptors on postsynaptic cells, resulting in entry 
of calcium and sodium as well as efflux of potassium. Accordingly postsynaptic 
neurons become depolarized, causing further calcium influx, further glutamate 
release, and local amplification of the initial ischemic insult.  These series of events 
are termed excitotoxicity, since it is caused by the toxic release of excitatory 
neurotransmitters (Lipton, 1999; White et al., 2000). Additionally acidosis due to 
anaerobic metabolism results in activation of acid sensing ion channels, which lead 
to a further increase of intracellular calcium levels (acidotoxicity) (Ginsberg, 2008). 
 
High intracellular calcium levels are responsible for activation of a series of 
destructive enzymes such as proteases, lipases, and endonucleases, resulting in the 
loss of cellular integrity and necrotic cell death in the ischemic core (Siesjo, 1981; 
Lipton, 1999).  
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There are numerous studies on the neuroprotective effect of calcium antagonists or 
NMDA or AMPA receptor blockers. Despite these agents being beneficial in in vivo 
animal models of stroke, there was no beneficial effect in clinical trials. Indeed 
NMDA receptor antagonists had severe side effects (e.g.  hallucinations) and were 
sometimes associated with increased mortatlity (Ginsberg, 2008). However, as will 
be discussed in Chapter 9, the negative outcomes of neuroprotective strategies in 
human stroke patients were potentially due to poor translation of preclinical studies 
into clinical trials (Ginsberg, 2008). 
 
1.3.2 Peri-infarct depolarisations 
 
Due to the loss of ion homeostasis neurons in the centre of the ischemic core 
undergo an event termed anoxic depolarisation and they never repolarise. Periinfarct 
depolarisations (PIDs, also called spreading depression-like depolarisations) are 
triggered by elevated extracellular potassium and glutamate levels and propagate 
from the ischemic core through the penumbra (Somjen, 2002). These waves of 
depolarisation, which  also occur in human stroke patients (Dohmen et al., 2008),  
are associated with increased energy demand of already challenged neurons as well 
as increases in intracellular Ca
2+
 levels and therefore lead to further ischemic injury 
and recruitment of penumbral tissue to the ischemic core (Doyle et al., 2008).  
 
1.3.3 Oxidative and nitrative stress 
 
Oxygen radicals (such as superoxide anion, hydrogen peroxide and hydroxyl radical) 
are generated via the mitochondrial electron transfer chain and by various cytosolic 
enzymes (e.g. xanthine oxidase or NADH oxidase). Under physiological conditions 
cellular antioxidant enzymes (e.g. superoxide dismutase, glutathione peroxidase and 
catalase) and molecular antioxidants (e.g. glutathione, ascorbic acid and alpha-
tocopherol) detoxify radicals. However, during ischemia-reperfusion radical 
generation is enhanced and cannot be matched by endogenous radical scavengers 
(Yoshida et al., 1982).  
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Reactive oxygen radicals directly damage lipids, proteins and nucleic acids whilst 
the opening of the mitochondrial transition pore (MTP) is facilitated by radical 
production (Chan, 2001). This in turn results in the loss of the proton gradient across 
the inner mitochondrial membrane and initiates a cascade of events leading to 
apoptosis. Upon reperfusion and re-oxygenation the loss of mitochondrial function 
further contributes to the generation of radical oxygen species.  Additionally the 
generation of nitrative radicals, such as NO via activation of nitric oxide synthase 
contributes to a further loss of cellular integrity. NO production is linked to over 
activation of poly(ADP-ribose)polymerase-1 (PARP-1), a DNA repair enzyme. 
PARP-1 catalyzes the transformation of NAD
+
 into nicotinamide and poly(ADP-
ribose) and upon over-activation results in depletion of the cellular NAD
+
 pool, as 
well as DNA damage (Ying, 2008). Oxidative tissue damage can also lead to 
microvascular injury and dysfunction of the blood-brain barrier and thereby 
contribute to the infiltration of inflammatory mediators from the blood (Lakhan et 
al., 2009). 
 
Accordingly therapeutic strategies with antioxidant molecules were extensively 
studied in various animal models of cerebral ischemia. Several molecules with 
antioxidant properties, such as resveratrol  had encouraging neuroprotective effects 
in in vivo animal studies (Li et al., 2010). However, the first clinical trials did not 
show a beneficial effect potentially due to the low blood brain permeability of the 
molecule (NXY-059 a radical spin trap agent) (Ginsberg, 2008). Other radical 
scavenging molecules such as edaravone (oxygen radical scavenger) proved more 
beneficial and might deserve further clinical trials (Ginsberg, 2008). 
 
1.3.4 Ischemia/reperfusion injury – inflammation, radical generation, 
apoptosis 
 
Although the restoration of the blood supply to hypoperfused brain tissue is critical 
after ischemia it can paradoxically result in further tissue damage, termed 
ischemia/reperfusion injury. Increased levels of oxygen radicals can trigger the 
release of pro-inflammatory mediators such as cytokines, which results in expression 
of adhesion molecules on endothelial cells and promote the infiltration of 
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neutrophiles into the peripheral areas of the infarct. Additionally, activated 
microglial cells, which are the mediators of the immune system in the brain, can 
release pro-inflammatory cytokines resulting in further tissue damage (Lakhan et al., 
2009). The post-ischemic inflammation response leads to a further deterioration of 
the blood brain barrier, brain oedema formation and initiation of apoptosis (Lakhan 
et al., 2009). Apoptosis is an energy-dependent and controlled form of cell death that 
can be triggered via intrinsic or extrinsic mechanisms. The intrinsic pathway is 
activated by the opening of the mitochondrial transition pore, release of cytochrome 
c, activation of caspases and initiation of pro-apoptotic genes. Alternatively 
extracellular ligands can activate caspases via death receptor signalling. Triggers of 
apoptosis include protease activation via increased cellular Ca
2+
 levels, reactive 
oxygen and nitrogen species, death receptor ligation, DNA damage and 
inflammation and affects neuronal, glia and endothelial cells (Broughton et al., 
2009).  
 
Both apoptosis and inflammation contribute to brain tissue damage over the course 
of hours to days (see Figure 1.2) and are therefore extensively studied targets for 
neuroprotective interventions. 
 
1.3.5 Recovery of cerebral energy metabolism after ischemia 
 
In addition to the damaging events described above, the restoration of ATP is 
delayed during reperfusion. In in vivo models of stroke ATP levels are at best 
incompletely restored during reperfusion (Kleihues et al., 1974; Onodera et al., 1986; 
Hermann et al., 2001) and often undergo a secondary deterioration (Hata et al., 
2000b; Lust et al., 2002). The extent of ATP recovery during early reperfusion 
depends on the duration of the ischemic period (Ljunggren et al., 1974; Yatsu et al., 
1975; Sims and Zaidan, 1995; Lust et al., 2002) and full recovery of ATP levels may 
take up to 24 h (Kleihues et al., 1975; Levy and Duffy, 1977; Lipton, 1999; Hermann 
et al., 2001). This itself prolongs the period of energy depletion and may further 
contribute to a loss of challenged neurons during reperfusion (Hashimoto et al., 
1992). Furthermore these compromised ATP levels leave the tissue more vulnerable 
to secondary ischemic insults that often occur after stroke (Phillips, 2008). 
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Therefore, the factors limiting ATP recovery are potentially subjects for new 
neuroprotective strategies.  
 
The main aim of this thesis was to improve the recovery of ATP levels in in vitro 
models of cerebral ischemia and to evaluate the effect on synaptic transmission and 
viability. Therefore the following section will focus on ATP degradation and 
restoration and the potential basis for the reduced ATP levels after cerebral ischemia. 
 
1.4 Purine metabolism 
 
1.4.1 ATP as cellular energy currency 
 
ATP was first discovered by the German biochemist Karl Lohman in 1929 
(Lohmann, 1929) and in the same year independently by a group in Harvard (Fiske 
and Subbarow, 1929). Its chemical structure has been correctly proposed in 1935 
(Makino, 1935) and established in 1945 (Lythgoe and Todd, 1945; Maruyama, 
1991). ATP consists of the purine base adenine, the pentose sugar ribose and three 
phosphoanhydride bonds (see Figure 1.3) and usually exists in a complex with  
Mg
2+
. The concept of the high energy phosphate bond (~P) was first described in 
1941 by Lipmann (Lipmann, 2006) and it is now well known that the hydrolysis of 
the γ-phosphoanhydride bond releases free energy (~∆Gº’ = -50kJ/mol) which can be 
used to drive thermodynamically unfavourable reactions (Stryer et al., 1995), such as 
ion transport against the electrochemical gradient (N
+
/K
+
 ATPase).  
 
Figure 1.3: Structure of adenosine triphosphate (ATP).  
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Under physiological conditions ATP is the main nucleotide in the total adenine 
nucleotide pool (TAN), which is composed of ATP, ADP and adenosine 
monophosphate (AMP).  Accordingly, the rate of ATP consuming and ATP 
generating processes is balanced, in order to maintain the ATP/ADP ratio (≥ 10) and 
the ATP/AMP ratio (≥ 100) many orders of magnitudes away from equilibrium 
(Hardie and Hawley, 2001). The capacity of ATP to drive energy requiring processes 
lies in this displacement from equilibrium (Nicholls and Ferguson, 1992). This is 
analogous to the chemicals in a fully charged battery. Hence, the cellular energy 
charge (EC) has been proposed as being an indicator of the metabolic available 
energy (in terms of phospho-anhydride bonds) in the TAN pool: 
[(ATP+0.5xADP)/(ATP+ADP+AMP)] (Atkinson, 1968).  
 
Although ATP synthesis is in close proximity to the site of consumption (e.g. 
ATPases), and there is a close relationship between cerebral activity and the rate of 
oxidative phosphorylation (Du et al., 2008), simple diffusion of ATP from the side 
of generation (mitochondria, glycolysis) to the site of consumption would require a 
significant concentration gradient and would result in build up of ADP and 
subsequent inhibition of ATPases by ADP, Pi and H
+ 
(Dzeja and Terzic, 2003). 
Therefore it is not surprising that in addition to mitochondrial ATP synthases and 
glycolytic ATP production there are two more enzymes involved in maintaining high 
cytosolic ATP levels: adenylate kinase and creatine kinase.  
 
Both these enzymes ensure a quick transport of ~P from the site of production to the 
site of consumption and they help to prevent marked changes in adenylate levels 
(Ames, 2000; Dzeja and Terzic, 2003) (see Figure 1.4). The functioning of this 
phosphoryl-transfer network requires both enzymes to be present at the site of ATP 
production as well as the site of ATP consumption. 
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1.4.1.1 Adenylate kinase 
 
The different isoforms of adenylate kinase (1-6) are expressed in a tissue- and cell 
type-specific manner and in different cellular compartments. Adenylate kinase 1 and 
5 are cytosolic, adenylate kinase 2, 3 and 4 are mitochondrial and adenylate kinase 6 
is located in the nucleus (Noma, 2005). Adenylate kinases catalyse the reversible 
transfer of the γ-phosphate group from ATP (Adenylate kinases 1, 2, 5 and 6) or 
guanosine triphosphate (GTP, adenylate kinase 3) to AMP, yielding 2 ADP or ADP 
+ GDP (2 ADP ↔ ATP + AMP; AMP + GTP ↔ GDP + ADP). The brain expresses 
adenylate kinase 1, 3, 4, and 5 (Inouye et al., 1999; Van Rompay et al., 1999; 
Miyoshi et al., 2009). Mitochondrial adenylate kinase 3 salvages accumulated AMP 
by using GTP as a phosphate donor and provides ADP for ATP synthases and GDP 
as a cofactor for the TCA cycle. Cytosolic adenylate kinases 1 and 5 are mainly 
regulated by the availability of the substrates AMP and ADP. Therefore these 
enzymes maintain an appropriate ATP/ADP ratio as soon as ADP levels decrease at 
the site of ATP generation (glycolysis) or increase at the site of consumption (e.g. 
ATPases, see Figure 1.4) (Noma, 2005). 
 
1.4.1.2 Creatine kinase 
 
Creatine kinase also exists in a mitochondrial (uMT-CK for brain tissue) and a 
cytosolic isoform (BB-CK for brain tissue (Andres et al., 2008)). Both isoformes 
contribute to the build up of a large cytosolic phosphocreatine pool (~ double the 
amount of ATP) by transferring the γ-phosphate group from ATP to creatine in a 
reversible reaction (creatine + ATP ↔ phosphocreatine + ADP) (Andres et al., 
2008). Mitochondrial creatine kinases and creatine kinases in close proximity to 
glycolysis, provide ADP and help build up a high phosphocreatine pool. Since 
phosphocreatine has a higher phosphoryl-group transfer potential than ATP, 
cytosolic creatine kinase can buffer the decline of ATP in the proximity of ATP-
using enzymes, thereby maintaining an appropriate ATP/ADP ratio  (see Figure 1.4) 
(Dzeja and Terzic, 2003).  
 
Chapter 1 
15 
 
 
Figure 1.4: Phospho-transfer reactions catalysed by adenylate kinase (AK) and 
creatine kinase (CK). I ATP is produced by mitochondrial ATP synthase. 
Mitochondrial AK salvages accumulated AMP by transfering the γ-phosphate group 
from GTP yielding ADP + GDP. Mitochondrial CK uses the accumulated ATP to 
generate phosphocreatine (PCr) which is transported to the cytoplasm via 
mitochondrial creatine transporters. II ATP produced by glycolysis is converted to 
ADP by AK and CK, the latter reaction contributing to a high intracellular PCr 
pool. AK and CK thereby help to ensure a continuous presence of ADP for 
glycolysis. III On the side of ATP consumption AK helps to maintain a high 
ATP/ADP ratio by converting ADP to ATP+AMP. Likewise CK transfers the 
phosphate group from PCr to ADP.  IV The same reactions occur at membrane-
bound ATPases. These phospho-transfer reactions facilitate the transport of ~P 
across the cell and help to maintain an appropriate ATP/ADP ratio at the site of 
production and consumption of ATP. Circles refer to ATP producing reactions (e.g. I 
ATP synthase in the mitochondria, or II phosphoglycerate kinase and pyruvate 
kinase during glycolysis) as well as ATP consuming reactions (e.g. III and IV 
ATPases). Graph was adapted from (Ames, 2000; Dzeja and Terzic, 2003; Andres et 
al., 2008).  
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1.4.2 Intracellular degradation of ATP during metabolic stress 
 
Despite these enzymatic systems of adenylate kinase and creatine kinase, the lack of 
oxygen and glucose during metabolic stress results in a rapid degradation of ATP, 
preceded by a fall in phosphocreatine levels with a resulting increase in ADP levels 
(Whittingham et al., 1984a). The accumulated ADP is converted to AMP and ATP 
by adenylate kinase, resulting in an increase of AMP (Figure 1.5). AMP can be 
deaminated to inosine monophosphate (IMP) by AMP deaminase or 
dephosphorylated to the purine nucleoside adenosine by 5'-nucleotidase. There are 3 
cytosolic 5'nucleotidases (e-Ns, c-N-I and c-N-II) as well as an ecto-5'-nucleotidase 
(e-N).  e-Ns and c-N-I have a preference for AMP and c-N-II has been shown to 
hydrolyse GMP and IMP, resulting in guanosine and inosine formation (Marques et 
al., 1998; Sala-Newby et al., 2000).  Adenosine can also be re-phosphorylated to 
AMP by adenosine kinase, but it has been shown that this enzyme is downregulated 
during oxygen-glucose deprivation in vitro (Lynch et al., 1998), since adenosine 
kinase requires ATP as phosphate donor and is inhibited by high intracellular 
adenosine concentrations (Yamada et al., 1980). Therefore during metabolic stress, 
adenosine is either released to the extracellular space or irreversibly deaminated to 
inosine by adenosine deaminase. Unlike adenosine, inosine cannot be 
rephosphorylated to IMP, due to the lack of a specific kinase (Mascia et al., 2000). 
Hence inosine is either released or further degraded to the purine base hypoxanthine 
and the sugar moiety Ribose-1-phosphate by purine nucleoside phosphorylase, 
whilst hypoxanthine can be reconverted to the purine nucleotide IMP and 
subsequently to AMP via the purine salvage pathway, which will be discussed in the 
next section. Alternatively, hypoxanthine is released or converted to xanthine and 
subsequently uric acid and hydrogen peroxide in two reactions catalysed by xanthine 
oxidase. Unlike hypoxanthine, xanthine and uric acid cannot be recoverted to purine 
nucleotides and are therefore lost from the purine nucleotide pool. As will be 
discussed later, the release of upstream metabolites of hypoxanthine as well as its 
further degradation to xanthine contribute to the reduction of the post-ischemic TAN 
and ATP pool, since the brain mainly relies on the purine salvage pathway to 
maintain its purine nucleotide levels (Gerlach et al., 1971; Allsop and Watts, 1980). 
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From Figure 1.5 it is obvious that AMP degradation to inosine can follow two 
distinct routes (via IMP or via adenosine). AMP deaminase (AMP → IMP) and 
cytosolic c-N-II (IMP → inosine) are stimulated by ATP, and c-N-II is inhibited by 
Pi (Chapman and Atkinson, 1973; Van den Berghe et al., 1992; Ipata et al., 2011).  
Accodingly it has been shown that the AMP → IMP → inosine pathway is favoured 
in rat brain extracts upon physiological ATP concentrations (5mM) (Barsotti and 
Ipata, 2004).  Cytosolic 5'nucleotidase c-N-I , which favours AMP as substrate, is 
stimulated by ADP not ATP (Itoh et al., 1986). In rat brain extracts at low ischemic 
ATP concentrations (< 2 mM ATP) ATP is mainly degraded via the adenosine 
pathway with only a little IMP formation (Barsotti and Ipata, 2004; Ipata et al., 
2011). In primary neuronal cell cultures it has been shown that under physiological 
condition the flux through both pathways is equal, whereas upon inhibition of 
mitochondrial respiration adenosine production is dominant (Brosh et al., 1996). 
Likewise the activity of myocardial cytosolic 5’nucleotidase activity is increased by 
decreasing the cellular energy charge (Itoh et al., 1986), further showing that upon 
metabolic stress ATP degradation is shifted towards adenosine formation. Though 
the release of adenosine means a loss of this metabolite from the cellular nucleotide 
pool, it is important and protective during ischemia. 
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Figure 1.5: Degradation of ATP: ATP is generated by mitochondrial ATP synthases 
and used by cytosolic enzymes, such as ATPases, or DNA ligases. Adenylate kinase 
interconverts adenine nucleotides. AMP is degraded to adenosine by 1 
5’nucelotidase. Adenosine can be rephosphorylated by 2 adenosine kinase or 
deaminated to inosine by 3 adenosine deaminase. Inosine is degraded to the purine 
base hypoxanthine by 4 purine nucleoside phosphorylase and hypoxanthine can be 
either degraded to xanthine and uric acid by 5 xanthine oxidase or converted to IMP 
via the purine salvage pathway by 6 hypoxanthine guanine 
phosphoribosyltransferase. Inosine can also be derived from IMP via 
dephosphorylation by 7 5’nucleotides (c-N-II). Likewise AMP can be converted to 
IMP by 8 AMP deaminase and IMP can be reconverted to AMP via the intermediate 
adenylosuccinate catalysed by 9 adenylosuccinate synthetase and 10 
adenylosuccinate lyase. All the substances indicated with an arrowhead can be 
released from the cell and washed out to the peripheral circulation.These substances 
are therefore lost from the cellular adenine nucleotide pool. 
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1.4.3 Neuroprotective role of adenosine during ischemia 
 
1.4.3.1 Purinergic signaling 
 
Although ATP and its degradation metabolite adenosine have been traditionally 
viewed as having only intracellular roles, mainly as cellular energy source, 
precursors of RNA and DNA as well as the second messenger cAMP, about 80 years 
ago Drury and Szent-Gyorgyi discovered that exogenous adenosine and ATP have 
potent actions on the heart (Drury and Szent-Gyorgyi, 1929). About 40 years later it 
was proposed that ATP or a related nucleotide is a transmitter released by nerves in 
the gut (Burnstock et al., 1970) and the term purinergic signalling was first proposed 
in 1971 (Burnstock, 1971). It is now well known that both ATP and adenosine 
participate in a wide range of physiological responses in the central, peripheral and 
enteric nervous system (Burnstock, 1993; Fredholm et al., 1994; Zimmermann, 
1994) and several receptors for ATP (P2 receptors) and adenosine (P1 receptors) 
have been identified, cloned and characterised.  
 
1.4.3.2 Adenosine receptor subtypes 
 
Four G protein-coupled adenosine receptors have been cloned and characterized: A1, 
A2A, A2B and A3. These receptors differ by their affinity for adenosine, their 
pharmacological specificity as well as by their distribution and abundance 
throughout the brain. The main intracellular signaling pathways involve the 
formation of cAMP by adenylate cyclase, with A1 and A3 receptors causing 
inhibition of adenylate cylcase via inhibitory G proteins Gi/o, and A2A and A2B 
receptors causing its activation via a stimulatory G protein Gs (Fredholm et al., 
2001). A1 receptors inhibit neurotransmission, by activation of K
+
 channels and 
inhibition of Ca
2+
 channels, whereas A2A and A2B receptors are generally considered 
to have excitatory effects on neurotransmission (Dunwiddie and Masino, 2001). A3 
receptors are poorly characterized, but have been shown to desensitize A1 receptors 
in the hippocampus (Dunwiddie et al., 1997).  However, this is controversial (Lopes 
et al., 2003), and A3 receptor activation has been shown to both, inhibit synaptic 
transmission (Piccinin et al., 2010) as well as facilitate long term potentiation (LTP) 
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(Costenla et al., 2001). All adenosine receptors are expressed in the brain with A1 
being most abundant (Dunwiddie and Masino, 2001). 
 
Adenosine is thought to be a neuromodulator in the brain since it is not stored and 
released in synaptic vesicles, but is rather formed from extracellular degradation of 
ATP or intracellular production and subsequent release. Adenosine is involved in 
both normal and pathophysiological processes, such as regulation of sleep and 
arousal or neuroprotection (de Mendonca et al., 2000; Dunwiddie and Masino, 
2001). Many different stimuli can induce adenosine release, such as increased 
extracellular K
+
, electrical stimulation, seizure activity, and most dramatically 
hypoxia or ischemia (Dunwiddie and Masino, 2001; Frenguelli et al., 2007; Dale and 
Frenguelli, 2009).  
 
1.4.3.3 Role of nucleoside transporters in adenosine release 
 
There are two types of nucleoside transporters in the brain: equilibrative nucleoside 
tranporters (ENT 1 - 4), which mediate transport in both directions and Na
+
-
dependent concentrative nucleoside transporters (CNT 1 - 3) (Podgorska et al., 
2005). The involvement of adenosine tranporters in adenosine release has been 
studied by using nitrobenzylthioinosine (NBTI), which inhibits NBTI-sensitive 
ENTs (es) and dipyridamole (DIPY), which equally affects es and NBTI-insensitive 
ENTs (is) in rat tissue (Latini and Pedata, 2001). Due to the lack of inhibitors the 
role of CNT in adenosine tranport is less clear  (Latini and Pedata, 2001). 
 
Inhibition of ENTs with NBTI/DIPY under physiological conditions results in a slow 
build up of extracellular adenosine, suggesting that these transporters are mainly 
involved in the uptake of extracellular adenosine (Frenguelli et al., 2007). 
Intracellular adenosine is rapidly converted to AMP by cytosolic adenosine kinase, 
thereby maintaining the inward concentration gradient (Boison, 2006). During 
ischemia, when intracellular adenosine levels increase (Latini et al., 1996), the 
concentration gradient is outwardly directed. However, the exact mechanism of 
adenosine release during ischemia/hypoxia is uncertain since administration of 
NBTI/DIPY has been shown to enhance adenosine release (Frenguelli et al., 2007), 
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suggesting that ENTs may limit its extracellular accumulation. The reversal of the 
Na
+
 gradient during ischemia could power adenosine efflux via CNT (Gray et al., 
2004). However adenosine levels increase immediately following ischemia, in 
advance of the loss of ion gradients (Frenguelli et al., 2007). Therefore some yet 
undefined mechanism, such as exocytosis or retrograde signalling may be 
responsible for the rapid adenosine outflow during ischemia (Dale and Frenguelli, 
2009).  
 
1.4.3.4 Neuroprotective actions of adenosine during ischemia 
 
Extracellular adenosine concentrations of in vivo brain are in the nanomolar range 
(90 - 120 nM), sufficiently high enough to activate A1 and A2A receptors (Dunwiddie 
and Masino, 2001; Latini and Pedata, 2001). Release of ATP from glial cells and 
subsequent degradation to adenosine by ecto-nucleotidases is believed to be 
responsible for this adenosine tone in the CNS (Pascual et al., 2005; Wall and Dale, 
2008). Adenosine may also arise from release and degradation of cAMP, by ecto-
phosphodiesterase and 5’-nucleotidase, and this route may avcount for slow changes 
of extracellular adenosine levels (Figure 1.6) (Brundege et al., 1997; Latini and 
Pedata, 2001). 
 
However, during ischemia or hypoxia adenosine levels increase rapidly in in vitro 
and in vivo brain, reaching levels of up to 20 -30 µM  (Fredholm et al., 1984; 
Kobayashi et al., 1998; Dale et al., 2000; de Mendonca et al., 2000; Parkinson et al., 
2002; Frenguelli et al., 2003; Frenguelli et al., 2007).  
 
During ischemic/hypoxic conditions adenosine is mainly produced from intracellular 
sources, rather than extracellular degradation of ATP (Lloyd et al., 1993; Frenguelli 
et al., 2007). As explained above, the main pathway for intracellular adenosine 
formation involves AMP degradation via c-N-I, hence adenosine production is 
enhanced when the energy demand is greater than energy production, resulting in an 
increase of AMP levels and subsequent dephosphorylation (Dunwiddie and Masino, 
2001). Intracellular adenosine can also be derived from S-adenosylhomocysteine in a 
reversible reaction catalysed by S-adenosylhomocysteine hydrolase (Figure 1.6). 
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This pathway is not involved in energy metabolism, but in transmethylation 
reactions and does not play a major role for adenosine release during ischemia 
(Latini et al., 1996). 
 
Subsequent release of adenosine and activation of A1 receptors prevents glutatmate 
release via combined presynaptic inhibition of Ca
2+
 channels, direct interference 
with the vesicle release machinery and postsynaptic activation of K
+ 
channels 
coupled with hyperpolarisation (see Figure 1.6) (Rudolphi et al., 1992; de Mendonca 
et al., 2000; Cunha, 2001; Ribeiro et al., 2002, 2003). All these actions reduce 
excitotoxic damage by reducing Ca
2+ 
entry and the energy demand of cells, thereby 
helping to preserve ATP levels (Dunwiddie and Masino, 2001).  
 
Accordingly, strategies that increase adenosine levels, such as inhibition of 
adenosine uptake (Dux et al., 1990; Gidday et al., 1995), inhibition of adenosine 
metabolising enzymes (Phillis and O'Regan, 1989) or administration of A1 receptor 
agonists (de Mendonca et al., 2000; Ribeiro et al., 2003), have been shown to exert a 
neuroprotective effect during ischemia. Furthermore, adenosine released from the 
brain can, via activation of arterial A2A receptors, vasodilate cerebral blood vessels, 
and therefore contribute to neuroprotection by enhancing cerebral blood flow 
(Phillis, 1989), whereas activation of cerebral A2A receptor in the adult brain 
exaggerates neuronal damage, as seen in attenuated ischemic brain injury in A2A 
knockout animals (Chen et al., 1999).  
 
Interestingly the ischemic damage induced by global ischemia in A1 receptor knock 
out mice is not different to wild type animals, allthough pre-administration of the A1 
receptor antagonist 8-CPT (8-cyclopentyltheophylline) exacerbated the neuronal 
damage following ischemia in wild type animals, suggesting that some effects of the 
A1 receptor are compensated for in knockout animals (Olsson et al., 2004). 
Additionally in immature brain inhibition of A1 receptors attenuates 
hypoxic/ischemic damage, by reducing white matter loss (Turner et al., 2003), 
whereas the hypoxic/ischemic damage is exabberated in immature A2A receptor 
knockout mice (Aden et al., 2003). This suggests that, in contrast to adult brain, A2A 
receptors are neuroprotective in neonates (Fredholm et al., 2005).  
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Like adenosine, inosine levels increase dramatically during ischemia  (Dux et al., 
1990; Phillis et al., 1996; Kobayashi et al., 1998; Weigand et al., 1999). On that note 
it is worth mentioning that exogenous inosine can preserve neuronal and glial cell 
viability during oxygen/glucose deprivation  (Rudolphi et al., 1992; Jurkowitz et al., 
1998; Litsky et al., 1999; Rathbone et al., 1999) and improve behavioural outcome 
after middle cerebral artery occlusion in rats (Chen et al., 2002; Shen et al., 2005). 
The effects of inosine are mediated by its conversion to hypoxanthine and 
subsequently ATP (Litsky et al., 1999; Giannecchini et al., 2005), however, inosine 
can also promote axonal regrowth (Chen et al., 2002; Benowitz and Carmichael, 
2010) and the protective effect of inosine pre-administration during in vivo ischemia 
may also involve suppression of glutamate responses and A3 receptor activation 
(Shen et al., 2005).  
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Figure 1.6: Intra and extracullar pathways for the formation of adenosine and the 
role of A1 receptors in neuroprotection: AMP, derived from ATP via adenylate 
kinase or cAMP via phosphodiesterase (PDE) is degraded to adenosine by 
5’nucleotidase (5’N). Adenosine can be rephosphorylated to AMP by adenosine 
kinase (AdK) or deaminated to inosine by adenosine deaminase (AD). Adenosine can 
also be derived from S-adenosylhomocysteine (SAH) in a reversible rection 
catalysed by SAH hydrolase (SAHH). Adenosine is transported to the extracellular 
space where it inhibits synaptic transmission via combined activation of pre- and 
postsynaptic A1 receptors. Direct release of ATP and subsequent degradation to 
adenosine also contributes to increased extracellular adenosine levels. Likewise 
cAMP can be transported to the extracellular space and subsequently degraded to 
adenosine. NMDAR NMDA receptor. Adapted from (de Mendonca et al., 2000; 
Pearson et al., 2003). 
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These facts show that simply inhibiting ATP degradation during ischemia would not 
be a promising strategy to improve post-ischemic ATP levels, since that would also 
interfere with the neuroprotective release of purine nucleosides. Therefore, a more 
promising approach would be to enhance the re-synthesis of ATP rather than 
interfere with its degradation.  
 
1.4.4 Restoration of ATP 
 
The two main pathways for restoring and maintaining a constant TAN pool are the 
purine de novo synthesis and the purine salvage pathways. The sugar precursor to 
ATP is derived from the pentose phosphate pathway and is used in both pathways. 
Whereas the purine de novo synthesis is an energy-dependent process where the 
purine base is built from low molecular weight precursors, the purine salvage 
pathway re-uses preformed purine bases to restore purine nucleotides.  
 
1.4.4.1 The synthesis of the sugar precursor 
 
The activated sugar donor for the synthesis of purine nucleotides, 5-phosphoribosyl-
1-pyrophosphate (PRPP) is derived from Ribose-5-phosphate, an intermediate of the 
pentose phosphate pathway (PPP, also called phosphogluconate pathway or hexose 
monophospahte shunt). Alternatively Ribose-1-phosphate, derived from purine 
nucleoside phosphorylase (see Figure 1.5, enzyme 4) can be isomerised to Ribose-5-
phosphate by phosphopentomutase (Tozzi et al., 2006).  
 
The PPP interlinks glucose, fatty acid and purine/pyrimidine metabolism and can be 
separated into an oxidative branch and a nonoxidative branch (Figure 1.7). In the 
oxidative branch glucose-6-phosphate, derived from glycolysis or glycogenolysis is 
converted to ribulose-5-phosphate in 3 reactions, thereby producing 2 molecules of 
NADPH. NADPH is used for the synthesis of free fatty acids as well as for the 
conversion of oxidised to reduced glutathione, a radical scavenger. In the non-
oxidative branch ribulose-5-phosphate is converted to ribose-5-phosphate (by 
ribulose-5-phosphate isomerase) and xylulose-5-phosphate (by ribulose-5-phosphate 
epimerase). Both these sugars are subsequently converted to the glycolytic 
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intermediates fructose-6-phosphate and glycerinaldehyde-3-phosphate. Ribose-5-
phosphate is however, also the substrate for PRPP synthetase, which uses ATP and 
transfers its pyrophosphate group to ribose-5-phosphate, yielding PRPP and AMP 
(Figure 1.7) (Stryer et al., 1995). 
 
PRPP is used as a phosphoribosyl group donor in purine and pyrimidine nucleotide 
as well as NAD
+
 synthesis (Stryer et al., 1995). Specific Phosphoribosyltransferases 
(PRTases) catalyse the transfer of ribose-5-phosphate from PRPP to a nitrogen-
containing nucleophile (purine or pyrimidine base for salvage pathways, glutamine 
for purine de novo synthesis and quinolate for NAD
+
 synthesis) producing a β-
substituted ribose-5-phosphate and PPi (Sinha and Smith, 2001).  
 
The PRPP pool is strongly regulated and maintained in the low micromolar range to 
avoid excessive purine and pyrimidine synthesis. PRPP synthetase is inhibited by 
high ATP concentrations as well as PRPP and it is strongly activated by Pi (Murray, 
1971). Excessive purine synthesis, caused by abnormally high activity of PRPP 
synthetase or defects in purine metabolism can lead to uric acid overproduction and 
crystallisation and subsequently gout (Cameron et al., 1993).  
 
In the brain only 1 - 3 % of the consumed glucose is metabolised via the PPP 
(Gaitonde and Evans, 1982; Gaitonde et al., 1983) and the rate limiting step in this 
pathway is the first reaction of the oxidative branch, catalysed by glucose-6-
phosphate dehydrogenase, which converts glucose-6-phosphate to 6-
phosphogluconate (Kauffman et al., 1969). In heart tissue the activity of  glucose-6-
phosphate dehydrogenase has been shown to be rate limiting for purine de novo 
synthesis as well as purine salvage (Zimmer, 1998). 
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Figure 1.7: The pentose phosphate pathway: Glucose-6-phosphate, derived from 
glycolysis or glycogenolysis is converted to ribulose-5-phosphate by glucose-6-
phosphate dehydrogenase, gluconolactonase and 6-phosphogluconate 
dehydrogenase in the oxidative branch. The 2 dehydrogenases provide the reducing 
agent NADPH. In the non-oxidative branch ribulose-5-phosphate is converted to 
ribose-5-phosphate and xylulose-5-phosphate by ribulose-5-phosphate isomerase 
and ribulose-5-phosphate epimerase, respectively. These two pentose sugars are 
reconverted to the glycolytic intermediates fructose-6-phosphate and 
glycerinaldehyde-3-phosphate via 2 reactions catalysed by transketolase and 1 
reaction catalysed by transaldolase. Ribose-5-phosphate is also the substrate for 
PRPP synthesases, which transfers the terminal PPi group from ATP to the C1 
position of Ribose-5-phosphate, yielding AMP and 5-phosphoribosyl-1-
pyrophosphate. PRPP is then subsequently used for purine salvage and de novo 
synthesis as an activated sugar donor. 
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1.4.5 Purine de novo synthesis 
 
Purine nucleotide de novo synthesis is an energy-dependent process, which results in 
formation of inosine monophosphate (IMP) from simple precursors upon 
expenditure of 6 molecules of ATP. This process involves 10 steps and 6 enzymes 
(three monofunctional, two bifunctional and one trifunctional enzyme) all of which 
are located in the cytosol and can form clusters in response to increased purine de 
novo synthesis (purinosome) (An et al., 2008). The purine ring is formed by amino 
acids, CO2 and derivates of tetrahydrofolate,  whilst the ribose phosphate moiety is 
derived from PRPP (Stryer et al., 1995). The origin of the various carbon and 
nitrogen atoms in the purine ring is shown in Figure 1.8.   
 
 
Figure 1.8: Origin of atoms in the purine ring: adapted from (Stryer et al., 1995) 
 
The rate limiting step is the first reaction catalysed by glutamine phosphoribosyl 
amidotransferase, which converts glutamine and PRPP to 5-phosphoribosylamine 
(see Figure 1.9). The availability of PRPP, various feedback inhibitions of purine de 
novo synthesis intermediates as well as purine nucleotides are the main regulators of 
purine de novo synthesis (Watts, 1983).  
 
The endproduct IMP acts as a common intermediate for the interconversion of 
adenine and guanine nucleotides. The first step of the conversion of IMP to GMP is 
catalysed by IMP dehydrogenase in an NAD
+
-dependent reaction with ATP as 
energy donor. The intermediate xanthosine monophosphate (XMP) is then converted 
Chapter 1 
29 
 
to GMP by GMP synthase (Tozzi et al., 2006). Guanine nucleotides are involved in 
protein synthesis, cell signalling and GTP can serve as an energy donor in specific 
metabolic reactions. 
 
The conversion of IMP to AMP is catalysed by adenylosuccinate synthetase (AS) 
and adenylosuccinate lyase (AL). AS is the rate limiting enzyme, which catalyses the 
condensation of IMP and aspartate into adenylosuccinate, using GTP as energy 
donor. The activity of AS is mainly regulated by the intracellular IMP concentration, 
and the reaction products adenylosuccinate and GDP, as well as GMP, ADP and 
AMP are inhibitors of the enzyme (Van den Berghe et al., 1992). AL converts 
adenylosuccinate to AMP and fumarate, and is also the 8
th
 enzyme of the purine de 
novo synthesis, cleaving SAICAR (phosphoribosyl aminoimidazole 
succinocarboxamide) into AICAR (aminoimidazole carboxamide ribonucleotide) 
and fumarate.  AMP, AICAR and fumarate exert a feedback inhibition on AL (Van 
den Berghe et al., 1992).  
 
Purine de novo synthesis is dominant in the liver, which is responsible for the 
majority of circulating purine nucleosides and bases (Ipata et al., 2011), whereas it 
has been shown to be slow and weak in the brain (Gerlach et al., 1971; Allsop and 
Watts, 1980).  
 
1.4.6 Purine salvage pathway 
 
In contrast to the energy dependent-reactions of purine de novo synthesis, preformed 
purine bases can be returned to the nucleotide pool by an energy saving pathway 
referred to as the purine salvage pathway. This is the predominant route for the brain 
(Gerlach et al., 1971; Allsop and Watts, 1980; Mascia et al., 2000; Barsotti and Ipata, 
2002) as well as the heart (Zimmer, 1998; Pauly et al., 2003) to restore and maintain 
their adenine nucleotides.  
 
Hypoxanthine-guanosine-phosphoribosyltranserfase (HGPRT) and adenine 
phosphoribosyl-transferase (APRT) are the central enzymes of this pathway. HGPRT 
catalyzes the transfer of ribose-5-phosphate from PRPP to guanine or hypoxanthine 
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yielding PPi,  GMP or IMP respectively (Murray, 1971). Hypoxanthine and guanine 
are derived from purine nucleoside phosphorylase (see Figure 1.5) and the affinity of 
HGPRT for both is approximately equal (Manfredi and Holmes, 1985). The reaction 
products IMP, GMP and PPi are inhibitors of the enzyme. However the inhibitory 
constants are high suggesting that under physiological conditions none of the 
products would be a physiological effector (Manfredi and Holmes, 1985). HGPRT is 
expressed in all tissues, and is very abundant in the brain, a further proof for the 
importance of the salvage pathway in this organ (Murray, 1966, 1971; Adams and 
Harkness, 1976; Allsop and Watts, 1980). Purification of HGPRT from rat brain 
showed that most of the enzyme is present in the cytosol, although a small but 
significant fraction was found in synaptosomes (Gutensohn, 1973). It is worth noting 
that an X-linked neurological disorder, Lesch-Nyhan syndrome, which is associated 
with an almost complete lack of HGPRT activity, results in mental retardation, 
chorea and compulsive/aggressive self injury (Nyhan, 2005).  
 
APRT catalyses the PRPP-dependent phosphoribosylation of adenine to AMP and 
PPi. Like HGPRT, APRT is expressed in the brain, although its activity is lower 
compared to HGPRT (Allsop and Watts, 1980). The purine base adenine is derived 
from methylthioadenosine phosphorylase, which catalyses the cleavage of 
methylthioadenosine, a byproduct of polyamine synthesis, to adenine and 
methylthioribose-1-phosphate (Della Ragione et al., 1986; Ipata et al., 2011).  
Furthermore it has been shown that adenine can be derived from adenosine in 
primary rat neuronal cultures (Brosh et al., 1996), although it has been previously 
suggested that purine nucleoside phosphorylase does not react with adenosine 
(Murray, 1971). 
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Figure 1.9: Phosphoribosyltransferases catalyse the reactions of the purine 
salvage pathway as well as the first step of the purine de novo synthesis. PRPP (5-
phosphoribosyl-1-pyrophosphate) is used as an activated sugar donor, to salvage 
accumulated purine bases to the respective nucleotides (Adenine and hypoxanthine/ 
guanine phosphoribosyltransferases). PRPP is also used as a sugar donor in purine 
de novo synthesis. 
 
In addition to intracellular purine base levels, circulating purine nucleosides and 
bases can be taken up from the blood, via specific nucleobase and nucleoside 
transporters (Cornford and Oldendorf, 1975; Pardridge and Oldendorf, 1977). CNT2 
mediates the Na
+
-dependent uptake of adenosine, inosine, guanosine and uridine 
across the blood brain barrier. ENTs mediate the bidirectional transport of 
nucleosides and are regulated by the concentration gradient (Ipata et al., 2011). 
Additionally nucleobase transporters, of which there are Na
+
-dependent and 
independent types (Isakovic et al., 2008) mediate the uptake and efflux of 
hypoxanthine and adenine. The equilibrative nucleobase transporters are located in 
the blood brain barrier and are not powerful enough to mediate significant purine 
base uptake (Spector, 1987). The concentrative nucleobase transporters in the 
choroid plexus, however, have been shown to be involved in uptake of salvageable 
purine bases from the blood (Washington and Giacomini, 1995). 
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1.4.7 Basis for the reduced post-ischemic adenine nucleotide pool 
 
Since ATP degradation during ischemia results in the accumulation and release of 
large quantities of adenosine, inosine and hypoxanthine these substances can be 
washed out of the brain to the systemic circulation via the activity of equilibrative 
nucleoside and nucleobase transporters (Isakovic et al., 2008; Ipata et al., 2011). 
 
The release of purine metabolites during ischemia/hypoxia has not only been 
observed in in vitro (Fredholm et al., 1984; Kobayashi et al., 1998; Dale et al., 2000; 
de Mendonca et al., 2000; Parkinson et al., 2002; Frenguelli et al., 2003; Frenguelli 
et al., 2007) and in vivo animal models (Hillered et al., 1989; Dux et al., 1990; Phillis 
et al., 1991; Phillis et al., 1996; Kobayashi et al., 1998; Valtysson et al., 1998) but 
also in humans. Adenosine, hypoxanthine, xanthine and uric acid were detected in 
blood and cerebrospinal fluid of stroke patients (Stover et al., 1997; Laghi Pasini et 
al., 2000). Adenosine was also detected in human plasma during moderate hypoxia 
(Saito et al., 1999), in jugular venous blood of humans undergoing carotid 
endarterectomy with insufficient collateral blood supply of the brain (Weigand et al., 
1999) and in transient ischemic attack as well as stroke patients (Laghi Pasini et al., 
2000). These observations show that large quantities of purine metabolites are 
washed out from the brain and subsequently lost from the adenine nucleotide pool.  
 
Additionally it has been shown that repeated episodes of hypoxia and ischemia result 
in a reduced release of adenosine in vitro (Pearson et al., 2001; Pearson et al., 2003) 
and in vivo (Dux et al., 1990; DiGeronimo et al., 1998; Valtysson et al., 1998), 
suggesting that the brain cannot replenish the released adenosine at a sufficiently fast 
rate to support non-depleting adenosine release. Since adenosine is neuroprotective 
during ischemia (see above) any reduction in adenosine release leaves the brain more 
susceptible to excitotoxic damage during secondary strokes. 
 
Furhtermore considering the brain’s reliance on the purine salvage pathway, any loss 
of salvageable ATP degradation metabolites to the systemic circulation, as well as 
production of unsalvageable xanthine and uric acid by xanthine oxidase, might limit 
the potential recovery of post-ischemic TAN and ATP levels (Pearson et al., 2003). 
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Since the purine de novo synthesis in the brain is not up-regulated after ischemia 
(Gerlach et al., 1971) a complete restoration of normal nucleotide levels may be 
achieved by de novo synthesis at a slow rate, which may last several hours or days 
(Gerlach et al., 1971; Kleihues et al., 1974; Ljunggren et al., 1974). This could 
explain the slow and incomplete recovery of ATP during short reperfusion periods, 
and – considering intracellular ATP as a primary source of adenosine - the reduced 
adenosine release, after subsequent ischemic/hypoxic periods.  
 
Balancing these two competing consequences of ATP degradation – the beneficial 
release of neuroprotective modulators and the concomitant depletion of the TAN 
pool respectively – can therefore only be achieved by enhancing the restoration of 
ATP in the post-ischemic brain, hence the purine salvage pathway.  
 
1.5 Manipulations of purine salvage pathway 
 
The main aim of this study was to improve post-ischemic ATP recovery by (i) 
increasing the availability of PRPP and/or by (ii) increasing the availability of the 
free purine bases hypoxanthine and adenine. This was achieved with simple 
manipulations, which are known to be tolerated in humans. Therefore, results of this 
study may provide important information for development of new treatments for 
stroke patients.  
 
1.5.1 D-Ribose to increase the available PRPP pool 
 
As in brain, brief periods of ischemia produces a rapid depletion in myocardial ATP 
levels (Zimmer, 1992). Likewise, the restoration of post-ischemic ATP levels is 
slow, due to the heart’s dependence on the purine salvage pathway and the loss of 
salvageable purine metabolites to the systemic circulation (Zimmer, 1992, 1998; 
Pauly et al., 2003). It has been shown that due to the weak capacity of the oxidative 
PPP, the available pool of PRPP is small and limits post-ischemic cardiac adenine 
nucleotide synthesis via de novo and salvage pathways (Zimmer, 1998). Therefore, 
elevating the PRPP pool by bypassing the rate limiting step of the oxidative PPP is a 
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possibility to enhance adenine nucleotide synthesis. This can be achieved by 
administration of D-ribose, a simple pentose sugar, which is directly phosphorylated 
to ribose-5-phosphate by ribokinase (Park et al., 2007), and subsequently 
phosphoribosylated to PRPP by PRPP synthetase. 
 
In fact, addition of D-ribose increases myocardial PRPP levels and efficiently 
improves postischemic recovery of the myocardial ATP in rat hearts by enhanced 
purine salvage as well as de novo synthesis (Zimmer and Gerlach, 1978; Zimmer, 
1992, 1996, 1998).  Accordingly this metabolic approach has been utilized in 
different experimental in vivo models: for example during myocardial infarction in 
rats (Zimmer, 1982; Zimmer et al., 1989) or after global myocardial ischemia in dogs 
(St Cyr et al., 1989), where it has been shown to enhance the functional recovery of 
the heart. 
 
Ribose is known to be tolerated in humans (Gross and Zollner, 1991; Pauly et al., 
2003) and administration of 10 mmol/kg per day has has no adverse effects in 
humans (Salerno et al., 1999). In patients with coronary artery disease D-Ribose 
improved cardiac function, exercise tolerance and general quality of life (Pliml et al., 
1992). Ribose has also been given to a patient with fibromyalgia, a disease which is 
correlated with reduced ATP levels in muscles, where it decreased certain symptoms 
such as muscle pain, weakness or sleeping disturbances (Gebhart and Jorgenson, 
2004).  
 
In rat brain extracts ribose is phosphorylated to ribose-5-phosphate and subsequently 
PRPP, thereby implying the presence of ribokinase (Mascia et al., 2000; Barsotti and 
Ipata, 2002). Therefore – similar to the heart - increasing the available PRPP pool for 
APRT and HGPRT might help brain cells to recover their ATP pools faster after 
periods of ischemia and may improve functional recovery as well as cell viability. 
Therefore the D-Ribose administration will be tested as a potential neuroprotective 
intervention for the post-ischemic in vitro brain tissue. 
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1.5.2 Xanthine oxidase inhibition to increase available hypoxanthine levels 
 
As explained above, the conversion of hypoxanthine to xanthine and uric acid, 
catalysed by xanthine oxidase, also contributes to a reduction of the TAN pool, since 
neither of these metabolites can be used in the purine salvage pathway. In rat 
forebrain following focal cerebral ischemia (Kanemitsu et al., 1988), as well as in 
cerebrospinal fluids of human stroke patients (Stover et al., 1997) xanthine and uric 
acid levels are increased, suggesting a role of xanthine oxidase in the degradation of 
hypoxanthine. Therefore, another possibility to enhance the purine salvage pathway 
could be to inhibit xanthine oxidase, and thereby increase the available hypoxanthine 
pool for HGPRT. The xanthine oxidase inhibitor allopurinol is known to be well 
tolerated in humans, since it is a commonly used drug to treat gout (Pacher et al., 
2006). 
 
This approach of inhibiting xanthine oxidase has already been studied in in vivo 
models of cerebral ischemia and pre-treatment of rodents with oxypurinol, the active 
inhibitor, has been shown to enhance the postischemic recovery of adenine 
nucleotide levels in the brain (Phillis et al., 1995). In other experiments pretreatment 
with allopurinol increased adenosine and inosine levels in cerebral cortex of 
newborn piglets, which was believed to be responsible for the protective effects of 
allopurinol during ischemia (Marro et al., 2006). Therefore, allopurinol will be used 
for comparative studies to D-ribose and its effect on postischemic recovery of 
cellular ATP levels and synaptic transmission will be studied. 
 
1.5.3 Administration of the purine base adenine to enhance APRT activity 
 
I further tested whether addition of the free purine base adenine can help to improve 
post-ischemic ATP recovery by enhancing the activity of APRT. In rat heart it has 
been shown that adenine is effectively converted to ATP and can further enhance the 
D-ribose mediated purine salvage (Brown et al., 1985; Zimmer, 1996; Kalsi et al., 
1998). Likewise high concentrations of adenine can improve the post-ischemic 
recovery of ATP levels in brain slices (Newman et al., 1998).  
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Adenine has been given to humans suffering from Lesh-Nyhan syndrome (Schulman 
et al., 1971). However, adenine has to be administered in combination with 
allopurinol, to avoid its degradation by xanthine oxidase to an insoluble metabolite, 
2,8-dihydroxy-adenine,  that can cause the formation of kidney stones (Greenwood 
et al., 1982). Therefore it will be tested, whether adenine and adenine/allopurinol 
administration is an effective strategy to improve post-ischemic recovery of ATP and 
synaptic transmission, as well as cell viability. 
 
Other work in this field attempted to maintain nucleotide levels by pre-incubation 
with creatine, to increase phospho-creatine levels, and thereby delay the degradation 
of ATP during ischemia (Balestrino et al., 1999; Balestrino et al., 2002). Therefore, 
experiments with creatine will be used for comparative purposes, but the main focus 
of this study will be on D-Ribose, allopurinol and adenine supplementation.  
 
 
1.6 In vitro models for cerebral ischemia 
 
As in vitro models of cerebral ischemia, I used hippocampal brain slices and 
cerebellar granule cells. In vitro models serve as a good cost-effective screening 
system for neuroprotective interventions. Furthermore the extracellular environment 
can be completely controlled, bypassing the blood brain barrier, and brain slices and 
cell cultures can be used for combined, functional, metabolic, morphological and cell 
viability analysis. However, the major limitations of in vitro models are the lack of 
inputs and outputs from the brain, the lack of blood-borne components (e.g. 
inflammatory mediators) as well as behavioural output. Nevertheless, cell cultures 
and brain slices show similar changes in response to the lack of oxygen and glucose 
with respect to biochemical and physiological properties of brain tissue, and are 
therefore widely used for electrophysiological, metabolic and cell viability studies 
into neuroprotection (Schurr and Rigor, 1989; Woodruff et al., 2011).  
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1.6.1 Hippocampal brain slices 
 
The hippocampus is a bilateral structure embedded in the medial temporal lobe. The 
hippocampus is composed of two regions, the dentate gyrus (DG) and the cornu 
ammonis (CA), both of which are structured into layers (strata). The main cell types 
are granule cells in the DG and pyramidal cells in the CA regions. The DG has a 
stratum moleculare, a stratum granulosum with the cell bodies of granule cells, and a 
polymorphic layer. The CA regions can be separated into stratum moleculare (apical 
dendrites), stratum lacunosum, stratum radiatum, stratum lucidum, stratum 
pyramidale (cell body layer), stratum oriens (basal dendrites) and the alveus. The 
polymorphic layer and stratum radiatum and oriens contain various interneurons, 
basket cells, bipolar cells and mossy cells.  
 
The CA region can be separated into 3
3
 various subfields (CA1 - 3) with distinct 
connectivity, electrophysiological properties and vulnerability to insults. The 
hippocampus receives its afferents from various neighbouring brain regions, with the 
entorhinal cortex being the most important. The entorhinal cortex projects onto 
granule cells of the DG in the perforant path. DG granule cells send axons onto CA3 
pyramidal cells in the mossy fibre pathway, and CA3 pyramidal cells send the so 
called Schaffer collateral-commisural fibres through the stratum radiatum to the CA1 
pyramidal cells thereby forming the third pathway in the tri-synaptic circuit (see 
Figure 1.10) as well as to the contralateral hippocampus (Andersen et al., 2006).  
 
 
                                                 
3
 Sometimes the polymorphic layer of the DG is referred to as CA4, since the densely packed 
pyramidal cell layer begins to spread out into a more polymorphic layer. 
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Figure 1.10: Sagittal hippocampal brain slice: The entorhinal cortex (EC) projects 
to granule cells in the dentate gyrus (DG) in the perforant path (PP). Granule cells 
send axons to pyramidal cells in Cornu Ammonis 3 (CA3) in the mossy fiber pathway 
(MF). CA3 neurons project to CA1 pyramidal neurons in the Schaffer collateral 
pathway (SC), completing the trisynaptic circuit.The grey areas are the cell body 
layers of the DG (stratum granulosum) and CA subregions (stratum pyramidale). 
The position of the stimulating (Stim.) and recording (Rec.) electrodes (El.), as well 
as the null and Adenosine (Ado) biosensors (Sens.) during experiments are shown in 
blue.  
 
Hippocampal brain slices were introduced in the early 1950s (McIlwain, 1951) and 
have since been a widely used in vitro model system of CNS function. The 
hippocampus is best known for its role in learning and memory and hence 
hippocampal brain slices are frequently used in studies of synaptic transmission and 
plasticity.  
 
Additionally, hippocampal neurons in the area CA1 are amongst the most vulnerable 
neurons to cerebral ischemia, and are therefore frequently as in vitro model for 
cerebral ischemia and neuroprotective interventions (Schurr and Rigor, 1989; 
Nitatori et al., 1995). 
 
However, since their introduction it was heavily debated how similar the energetic 
state of the tissue is to the in vivo brain, since their preparation involves an ischemic 
period caused by cervical dislocation and decapitation. Accordingly many different 
Chapter 1 
39 
 
preparation and maintenance procedures have been suggested to make the “best 
brain slices” (Aitken et al., 1995; Lipton et al., 1995). Therefore a great part of the 
thesis will deal with the energetic state of the slices and the appropriate incubation 
conditions to achieve a metabolic state which is as close to the in vivo brain as 
possible as a prelude to investigating the influence of purine salvage manipulations. I 
further tested the consequences of improved energetic recovery on synaptic 
transmission and plasticity. After having established the optimal incubation 
conditions hippocampal brain slices were used for metabolic and combined 
adenosine release and electrophysiological studies, to investigate the effect of D-
ribose, allopurinol and/or adenine as well as creatine on the recovery of postischemic 
ATP levels and synaptic transmission. 
 
1.6.2 Cerebellar granule cells 
             
To establish the effect of the various interventions of the purine salvage pathway on 
post-ischemic cell viability after prolonged reperfusion periods, I used cerebellar 
granule cells (CGC), a primary neuronal cell culture. CGCs were introduced about 
30 years ago (Gallo et al., 1982) and are today a widely used primary neuronal cell 
culture for studies into developmental, functional, and pathological aspects of 
neurobiology. Unlike other cell cultures, such as hippocampal neurons, they 
represent a relatively pure (~ 90 %) neuronal culture. Accordingly CGC are 
frequently used for studies into neuronal cell death and neuroprotection 
(Contestabile, 2002).  
 
Therefore, the combined use of these two in vitro models allowed me to establish the 
effect of enhanced purine salvage activity before or after OGD on the energetic state 
of the tissue (intracellular adenine nucleotide levels), adenosine release (adenosine 
biosensors) and the decline and recovery of synaptic transmission during brief 
ischemic (minutes) and reperfusion periods (hours) in hippocampal brain slices as 
well as on cell viability after longer ischemic (hours) and reperfusion periods 
(overnight) in CGC.  
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2 Material and 
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
41 
 
2.1 Preparation and maintenance of Cerebellar granule 
cell cultures 
 
Cerebellar granule cells (CGCs) were prepared from P 6 – 8 Sprague Dawley rats, as 
described previously (Tomaselli et al., 2008; Wall et al., 2010). For each preparation 
one or two pups were killed by cervical dislocation in accordance with Schedule 1 of 
the UK Government Animals (Scientific Procedures) Act 1986 and with local 
Ethical Review procedures. After decapitation the skin was removed, the skull was 
opened and the cerebellum was carefully isolated with tweezers and placed into a 
petri dish containing Krebs solution (NaCl 124 mM; KCl 5.4 mM; NaH2PO4H2O 1 
mM; Glucose 14.4 mM; Phenolred 28 μM; HEPES 20 mM; MgSO4 150 μM; BSA 
0.3 g; pH 7.4; 37°C) with 0.01 % Penicillin/Streptomycin (Pen/Strep). Meninges and 
blood vessels were removed and cerebella were triturated in 10 ml Krebs solution. 
After centrifugation (1500 rpm, 3 min), the tissue was resuspended in fresh Krebs 
solution containing 0.025 % trypsin and incubated for 15 min at 37°C in the water 
bath. Thereafter the trypsin containing cell suspension was diluted with 3.6 ml 
solution 3 (Krebs solution containing 0.52 mg/ml Trypsin inhibitor and 0.1 mg/ml 
DNAse) and 6.4 ml Krebs solution. After centrifugation (1500 rpm, 3 min), cells 
were thoroughly dissociated with a glass pasteur pipette (with a flamed opening, to 
reduce cell damage and improve dissociation of cells) in one volume solution 3 and 
two volumes solution 5, and passed through a 40 μm cell strainer (BD biosciences) 
to remove remaining cell clumps. The suspension was spun at 1900 rpm for 5 min 
and cerebellar granule neurons were purified from glial cells by a pre-plating step (1 
h, 37°C) in 3 ml Neurobasal medium (supplemented with 2 % B27, 1.5 mM 
glutamine and 0.01 % Pen/Strep). During this incubation step glial cells will attach 
to the uncoated surface of the petri dish, whereas neurons will remain in suspension. 
The petri dish was washed with Neurobasal medium and the cells were spun at 1900 
rpm for 5 min. The cell pellet was resuspended in 3 ml Neurobasal medium and cells 
were counted using a haemocytometer. CGCs were plated at a density of 1.3 x 10
5
 
on poly-l-ornithine coated borosilicate glass coverslips (placed in 12 well plates), at 
a density of 6 x 10
6 
- 1 x 10
7 
in 60 mm dishes, and at a density of 1 x 10
5
/well
 
in 96 
well plates. Neurons were cultured for 7 - 8 days in Neurobasal medium, containing 
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KCl 25 mM, B27 2 %, glutamine 1.5 mM, and Pen/Strep 0.01% in a humidified 
atmosphere with 5 % CO2, before being used for experiments. For coating of 
dishes/coverslips Poly-L-ornithine was added for 2 – 3 h, thereafter 
wells/coverslips/dishes were washed twice with sterile water and allowed to dry 
before being used. For compositions of the different solutions refer to Appendix 1, 
section 10.1. 
CGC have to be maintained in high K
+
 (Gallo et al., 1987), to depolarise the neurons, 
and promote a survival-supporting effect via Ca
2+
 influx and Ca
2+
/calmodulin-
dependent protein kinase (Hack et al., 1993). If maintained under these conditions 
CGCs form a neuronal network after 6 – 7 days in vitro, as seen by the neuronal 
marker MAP-2 (Microtubulus-associated protein 2) and the synaptic marker 
synapsin I (Figure 2.1). 
 
 
 
 
 
 
Figure 2.1: Staining of cerebellar granule cells after 7 days in vitro for MAP-2 
(green stain) and synapsin I (red stain). Cells were prepared from P 6 – 8 Sprague 
Dawley rats and maintained in a humidified atmosphere with 5 % CO2 at 37°C in 
supplemented Neurobasal medium with 25 mM KCl. Cells were fixed  in 4 % PFA 
for 15 min, washed twice with PBS and permeabilised with 0.3 % Triton X-100 in 
PBS for 15 min. After washing in PBS cells were blocked with 1 % BSA in PBS for 
20 min, washed again and the primary antibodies were added in PBS containing 0.1 
% BSA and Triton X-100 overnight at 4°C (1:500 dilution). On the next day cells 
were washed with PBS and the secondary Alexa labelled antibody was added in PBS 
containing 0.1 % BSA and Triton X-100, protected from light for 1 h at room 
temperature (1:1000 dilution). Coverslipes were washed and mounted onto 
microscopic slides in Vectashield, sealed with nail vanish and stored at 4°C, 
protected from light until being imaged (within 3 weeks). 
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2.2 Preparation and maintenance of hippocampal brain 
slices 
 
Male Sprague-Dawley rats (P 17 - 28) were killed by cervical dislocation in 
accordance with Schedule 1 of the UK Government Animals (Scientific Procedures) 
Act 1986 and with local Ethical Review procedures. To keep experiments consistent 
most animals were P 20 – P 25 and only occasionally younger/older animals had to 
be used. The animal was decapitated, the skull was opened, meninges were removed 
and the brain was quickly placed into ice cold 11 mM Mg
2+
- containing artificial 
cerebrospinal fluid (aCSF). The temporal parts of the brain were trimmed, the 
hemispheres were separated along the midline and mounted onto a metal block using 
cyanoacrylate (RS components). Sagittal brain slices (400 μm), composed of 
hippocampus and overlying neocortex, were then prepared in ice-cold, 11 mM Mg
2+
-
containing aCSF using a Microm HM 650 V microtome. If not otherwise stated 
slices were transferred to a chamber (50 - 100 ml) (Edwards et al., 1989) and 
submerged in continuously circulating, oxygenated standard aCSF kept at 34°C. The 
composition of the standard aCSF solution was: NaCl 124 mM; KCl 3 mM; CaCl2 2 
mM; NaHCO3 26 mM; NaH2PO4 1.25 mM; D-glucose 10 mM; MgCl2 1 mM; pH 
7.4 with 95 % O2/5 % CO2 (Appendix 1, section 10.2).   
In chapter 4 the preparation and maintenance of brain slices differed from the 
standard procedure described above, therefore the exact incubation conditions will 
be described individually for this chapter. 
 
2.3 In vitro ischemia models 
 
Oxygen/glucose deprivation (OGD) is a widely used model for in vitro ischemia in 
slices and cell cultures. It is comparable to transient global ischemia and reperfusion 
is easily achieved by exchanging the oxygen/glucose deprived medium/aCSF for 
standard medium/aCSF. 
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2.3.1 Induction of OGD in cerebellar granule cells 
 
In cerebellar granule cells OGD was induced by replacing the Neurobasal medium 
with PBS or glucose free Neurobasal medium (supplemented with 0.01 % Pen/Strep, 
1.5 mM Glutamine, 25 mM KCl and 2 % B27 supplement), which has been 
equilibrated with 95 % N2/5 % CO2 for 3 hrs in a sealed tupperware chamber. Cells 
were transferred into a tupperware chamber, which was then equilibrated with 95 % 
N2/5 % CO2 for another 30 min. Thereafter the chamber was thoroughly sealed with 
parafilm and tape and placed back into the incubator for 6 h, if not otherwise stated. 
After this ischemic insult cells were fixed immediately for Hoechst/Propidium iodide 
staining or the OGD medium was replaced with the previous culture medium for a 
12 – 14 h reperfusion period.  
 
2.3.2 Induction of OGD in brain slices 
 
In hippocampal brain slice experiments OGD was induced by replacing glucose in 
the aCSF with 10 mM sucrose and bubbling the solution with 95 % N2/5 % CO2 for 
at least 1 h before slices were transferred (for HPLC analysis) or the perfusion 
system was switched (for electrophysiological recordings and sensor measurements). 
Slices were exposed to OGD for various time points and reperfusion was achieved 
by transferring the slices or switching the perfusion system back to standard aCSF 
for various time points. 
 
2.4 Protein extraction 
 
For each time point 2 - 3 brain slices were placed in ice cold aCSF to stop enzymatic 
activities. Slices were homogenised in 100 µl protein lysis buffer with a Kontes® 
pellet pestle motor (Sigma-Aldrich, UK). The suspension was centrifuged (30 min, 
4°C, 16060 g) and the supernatant was stored at -80°C for kinase assays and western 
blot analysis. The composition of the protein lysis buffer was: Tris-HCl, pH 7.5 50 
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mM; EGTA 0.1 mM; EDTA 1 mM; Triton X-100 1%; sodium orthovanadate 1 mM; 
sodium fluoride 50 mM; sodium pyrophosphate 5mM; sucrose 270 mM; β-
mercaptoethanol 0.1%; sodium azide 0.02%; 1 protease inhibitor tablet for 16.6 ml 
lysis buffer. 
 
2.5 Nucleotide extraction 
 
2.5.1 Nucleotide extraction of brain slices  
 
Two brain slices were placed in ice cold standard aCSF to stop enzymatic 
degradation. Slices were transferred into 1 ml ice cold 5 % perchloric acid (PCA) 
with a small spatula, to minimise fluid transfer, and immediately homogenized with 
a Kontes® pellet pestle motor. After centrifugation (2 min, 4°C, 13000 rpm) the 
PCA was precipitated with 1 ml of tri-n-octylamine in 1,1,2-trichlorotrifluoroethane 
(1:1; v/v) (Khym, 1975). The suspension was vortexed for 20 s and kept on ice for 
10 minutes. After centrifugation (2 min, 12100 g), the organic extraction was 
repeated twice with the upper aqueous phase. Thereafter the aqueous phase had a pH 
of 6 and contained water-soluble cell components, such as purine 
nucleotides/nucleosides and bases. HPLC analysis of extracts was performed on the 
same day (Zur Nedden et al., 2009). The protein pellet was resuspended in 1 ml 0.5 
M NaOH, and protein concentration was determined by Bradford assay, with BSA as 
standard.  
In chapter 4 the nucleotide extraction of brain slices differed from the standard 
procedure described above, therefore the exact extraction conditions will be 
described individually for this chapter. 
 
2.5.2 Nucleotide extraction of cerebellar granule cells 
 
The Neurobasal medium was removed and cells were washed with PBS twice before 
500 μl ice cold 5 % PCA were added into the dish. Cells were kept on ice and 
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detached from the dish using a cell scraper. The cell suspension was transferred into 
a 1.5 ml eppendorf tube and cells were homogenised with a pellet pestle motor. After 
centrifugation (2 min, 4°C, 13000 rpm) the PCA extract was neutralized as described 
above. If not otherwise stated the extract was kept at - 20°C over night and analysed 
with HPLC on the next day. 
 
2.6 Etheno-derivatisation 
 
250 μl of the standard or sample mixture were incubated with 5 % chloroacetaldhyde 
at 80°C in a heating block for indicated time points. After addition of 
chloroacetaldehyde the pH of the solution was 3 - 5, as measured with a pH paper.  
 
2.7 Bradford assay 
 
BSA standards were prepared from 0.5 – 10 mg BSA/ml 1 M NaOH. 20 µl of 
standards and of sample extracts were diluted in 480 µl destilled water and 10 µl of 
these suspensions were added to 200 µl Bradford reagent in 96 well plates. Care was 
taken that all samples were well mixed at all times. The absorbance was read at a 
wavelength of 620 nm with a spectrophotometer, and the amount of protein in 
samples was calculated on the calibration curve of standard BSA. 
 
2.8 High performance liquid chromatography 
 
2.8.1 HPLC apparatus 
 
The HPLC system (Thermo Scientific) consisted of a vacuum degasser (SCM 1000), 
Spectra System binary gradient pumps (P2000), an injector with a 20 µl injection 
valve and a Spectra System photodiode array UV detector (UV 6000), equipped with 
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a 10 µl flow cell. Unless otherwise stated a Supelcosil LC-18-T reverse phase 
column (150 mm x 4.6 mm i.d., 3µm) protected with a HPLC Security Guard 
Cartridge (C8, 4 x 3.0 mm, Phenomenex) was used for the UV detection of purine 
and pyrimidine metabolites. For fluorescence detection of etheno-metabolites a Luna 
C8 (2) (150 mm x 4.5 mm i.d., 5 µm) and a FL 3000 fluorescence detector (Spectra 
system) was used. Peak analysis and quantification was performed with the 
Chromquest 4.2.34 software. For UV detection HPLC chromatograms were obtained 
at a wavelength of 254 nm. However, the UV spectrum from 220-360 nm was 
scanned for all runs and used for spectral and purity analysis of sample and standard 
peaks. For fluorescence detection of etheno-adenine derivatives the FL 3000 detector 
was set to an excitation wavelength of 230 nm and an emission wavelength of 420 
nm (Zur Nedden et al., 2009). 
 
2.8.2 HPLC method for UV detection of purine and pyrimidine metabolites 
 
If not otherwise stated the mobile phase consisted of buffer A (65 mM potassium 
phosphate buffer, composed of 39 mM dipotassium hydrogen phosphate and 26 mM 
potassium dihydrogen phosphate, adjusted to pH 6 with orthophosphoric acid, 4 mM 
TBAHS) and buffer B (65 mM potassium phosphate buffer composed of 39 mM 
dipotassium hydrogen phosphate and 26 mM potassium dihydrogen phosphate, 
adjusted to pH 6 with orthophosphoric acid and 25% methanol). The methanol in 
Buffer B was added after the pH of the solution was adjusted, and after addition of 
methanol the solution was mixed for 10 – 15 min. Both buffers were prepared in 
deionised water, and filtered through a 0.4 µm filter before use. For each day of 
analysis the Supelcosil LC-18-T column was equilibrated with 10 - 20 column 
volumes of buffer B, and 30 – 50 column volumes of buffer A (flow rate 1 ml/min). 
The retention times of standard compounds stabilised after two blank injections 
(gradient profile described below) and analytical separation could then be performed. 
The flow rate was 1 ml/min and the gradient profile used was: 1 min 100 % buffer A, 
3 min to 30 % buffer B, 7.5 min to 80 % buffer B and 10 min to 100 % buffer B. The 
run was kept at 100 % buffer B for 3 more minutes before it was completed and the 
gradient was returned to 100 % buffer A. Run time for the elution of relevant 
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compounds was 13 min. A 10 minute re-equilibration between runs was sufficient to 
restore initial conditions. Concentrations were calculated by comparing the peak area 
of sample peaks with calibration curves for peak areas of each standard compound. 
All concentrations are expressed as nmol/mg protein (Zur Nedden et al., 2009). 
Standard solutions were prepared in deionised water/or 0.1 M NaOH as stock 
solutions at 1, 10 or 100 mM (if NaOH had to be used) concentration, and stored at -
20°C. For preparation of HPLC buffers please refer to Appendix 1, section 10.3.  
 
2.8.3 HPLC method for fluorescence detection of etheno-adenine-metabolites 
 
 
For detection of etheno (ε)-metabolites a Luna C8 (2) column (Phenomenex) and a 
Luna C8 (2) guard column (Phenomenex) was used. Buffer A was composed of 20 
mM potassium phosphate buffer, pH 6 and buffer B consisted of 20 mM phosphate 
buffer, pH 6 and 25 % methanol (see Appendix 1, section 10.3). For elution of ε -
ATP, ε - ADP, ε - AMP and ε -adenosine a 10 min linear gradient from 100 % buffer 
A to 100 % buffer B at a flow rate of 1 ml/min was used. For preparation of reverse 
phase HPLC buffers please refer to Appendix 1, section 10.3. 
 
2.8.4 Column protection 
 
 
To keep the column performance optimal, special care was taken in column 
protection. The column (Supelcosil) was washed after each day with 25 column 
volumes of 25 % methanol in order to remove any residual phosphate buffer. The 
guard cartridge was changed after 200-300 injections. When the peak shapes started 
to show broadening and the backpressure increased (250 - 350 injections), the 
column was regenerated by flushing it with 30 column volumes of water (40-60°C), 
100 % methanol, 100 % acetonitrile, 20 column volumes of 100 % tetrahydrofuran 
and 100 % methanol in reverse flow direction, at a flow rate of 0.4 ml/min, as per 
manufacturer's instructions (Zur Nedden et al., 2009).  
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For Luna C8 (2) column a 95 % organic modifier/ 5 % water mixture was used, as 
per manufacturer’s instructions. The flow rate, the order of organic modifiers and the 
volumes was the same as described above.  
 
2.9 Electrophysiology 
 
For electrophysiological recordings slices were transferred to a submerged type 
recording chamber, with a fluid volume of 2 - 3 ml kept at 33.5 ± 0.5°C and a flow 
rate of 6 - 8 ml/min.  A small harp was placed onto the slice to prevent it from 
moving. A twisted bipolar teflon coated tungsten wire was placed to stimulate the 
Schaffer collateral/commissural pathway every 15 s and field excitatory postsynaptic 
potentials (fEPSPs) were recorded from stratum radiatum in area CA1 of the 
hippocampus with a glass microelectrode filled with aCSF (1 MΩ) as described 
previously (Frenguelli et al., 2007; Zur Nedden et al., 2011). The stimulus intensity 
was adjusted to 50 – 60 % of that required to evoke a population spike. Stimulus 
parameters and acquisition and analysis of fEPSPs were under the control of LTP 
software.  
 
2.10  Adenosine biosensor measurements 
 
Adenosine and null microelectrode biosensors (50 μm diameter /500 μm length) 
were purchased from Sarissa Biomedical Ltd (Coventry, UK). The adenosine sensor 
relies upon an enzyme cascade immobilized within a matrix on the surface of a Pt/Ir 
electrode to metabolize adenosine thereby liberating H2O2, which is oxidized on the 
Pt/Ir electrode. This gives rise to an oxidation current proportional to the 
concentration of adenosine. The null sensor lacks enzymes and is used to establish 
the presence of any electroactive interferents. Both sensors were inserted in the 
stratum radiatum of the CA1 region of hippocampal slices in between recording and 
stimulating electrodes, or with the stimulating electrode placed between both sensors 
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at an equal distance. Recording of fEPSP was started 30 – 45 min after insertion of 
sensors. fEPSPs, adenosine and null sensor traces were recorded simultaneously. 
After each experiment sensors were taken out of the tissue and calibrated with 10 
μM adenosine in the recording chamber. To monitor the unspecific response to 
electroactive substances, 10 μM serotonin was applied and if the response was 
smaller than 50 pA, the adenosine signal during the experiment was assumed to be 
specific. Since no non-specific electroactive release could be detected on the null 
sensor, adenosine release was calculated without subtraction of the null trace and the 
values are given as µM´ to reflect that the adenosine sensor measures adenosine and 
its metabolites (Frenguelli et al., 2007). In order to integrate the area under the curve 
of adenosine sensor traces, the baseline had to be set to 0, which was achieved by 
subtracting from the sensor trace a linear regression based on 5 minutes of baseline 
(Zur Nedden et al., 2009). 
 
2.11  Cell death staining with Hoechst and propidium 
iodide  
 
Cells were incubated in the dark at 37°C for 10 minutes with Hoechst (cell 
permeable blue stain; 8 µM), followed by a further 5 minutes with propidium iodide 
(cell impermeable red stain; 5 μg/ml, see Appendix 1, section 10.4 for preparation). 
During this incubation all cells will be stained with Hoechst, and cells with broken 
membranes (dead cells) will be stained with propidium iodide (see Figure 2.2). Cells 
were washed twice with PBS and fixed with 4 % paraformaldehyde (PFA) for 15 
min.  After washing cells thoroughly with PBS, coverslips were mounted onto 
microscope slides using Vectashield (Vector Laboratories), sealed with nail vanish 
and stored at 4°C, protected from light until being imaged (within 3 weeks). 
Imaging was conducted with a 20 x objective on an epifluoerescent microscope 
using the appropriate filter for Hoechst (UV) and propidium iodide (510 nm).  Four 
to five images were captured of each coverslip, at distributed locations that were 
representative of the cells present.  
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Hoechst and propidium iodide pictures were merged in Photoshop (Adobe) and cells 
were assessed as being either viable (blue; Hoechst staining alone), or inviable (pink; 
co-merged Hoechst and propidium iodide staining).  Only cells greater than 3 µm in 
diameter were included in the analysis.  The percentage of cell death was calculated 
for each image (% cell death = dead cells x 100/total cell number), and the five 
values for each condition averaged to give total percentage of cell death per 
condition. 
 
Figure 2.2: Cell death can be assessed with Hoechst (blue stain, all cells) and 
propidium iodide (red stain, dead cells): Cerebellar granule cells were treated with 
5 µM rotenone for 5 h to induce cell death. Cells were stained immediately with 10 
µM Hoechst for 15 min and 2 µM propidium iodide for 5 min. Hoechst and 
propidium iodide images were merged and all pink cells were considered as being 
dead. 
 
2.12  XTT cell viability assay 
 
In the XTT assay cell viability is assessed by measuring the activity of mitochondrial 
succinate dehydrogenases, which convert the yellow tetrazolium salt XTT  (2,3-
bis[2-methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium-5-carboxyanilide) to orange 
formazan when incubated with the electron coupling agent phenazine methosulphate 
(PMS). The resulting colour change can then be quantified using a 
spectrophotometer.   
20 μm
5 μM Rotenone
Control
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For this assay cells were grown in 96 well plates. Cells were washed thoroughly with 
PBS and incubated for 4 hours at 37C with 100 µl XTT solution in PBS per well 
(1mg/ml XTT; 25 µM PMS).  Wells containing XTT solution in the absence of cells 
were used as blanks.  The preparation of the XTT solution is described in Appendix 
1, section 10.4. The intensity of the colour change was detected using a 
spectrophotometer (Labsystems; Multiscan Ascent).  Plates were shaken to ensure 
even solutions and the absorbance at 450 nm was recorded, with a reference 
wavelength at 690 nm.  After subtraction of the blank values average absorbance 
values (from 4 – 5 wells) for each condition were determined. 
 
2.13  Chemicals and stocksolutions 
 
All chemicals and stock solutions are summarised in Appendix 1, section 10.5. 
 
2.14  Statistical analysis 
 
All values are expressed as mean ± S.E.M. For the electrophysiological and 
adenosine sensor measurements N values refer to the number of slices per 
experimental condition, which for most cases is also equal to the number of animals 
used. Slices were used in duplicate for nucleotide extraction and in triplicate for 
protein extraction. In these cases N values represent the number of animals used. In 
experiments with CGC N values refer to the average of 5 images per coverslip per 
animal used. For statistical analysis of more than two groups one way ANOVA with 
Bonferroni’s multiple comparison test was applied, whereas for comparisons 
between two independent groups unpaired t-tests were used. For comparison of 
adenosine release before and after application of different drugs a paired t-test was 
applied. Calculations were carried out with Prism 4; p-values < 0.05 were considered 
as statistically significant.  
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3.1 Introduction 
 
An important part of this project was the assessment of adenine nucleotide levels in 
hippocampal brain slices, before, during and after ischemic insults, under control 
conditions and after various interventions of the purine salvage pathway. In addition 
to absolute adenine nucleotide values, equations that describe the relation of the 
individual nucleotides in the total adenine nucleotide pool ([TAN] = Σ ([ATP] + 
[ADP] + [AMP]), such as the adenylate energy charge (EC = ([ATP] + 
0.5[ADP]/[TAN])) (Atkinson, 1968), are frequently used to assess the energetic state 
of tissues or cells, since it reflects the energy supply (ATP) to demand (ADP, AMP) 
relationship better than the absolute adenine nucleotide values (Kammermeier, 
1993). The EC describes the relative proportion of charged adenine nucleotides (in 
terms of their phospho-anhydride bonds) in the TAN pool, and has a maximum value 
of 1, when all the adenine nucleotides are in the form of ATP. As such, accurate 
determinations of in situ adenine nucleotide concentrations are required for many 
investigations into the energetic state of tissue.  
 
There are several possible ways of measuring tissue adenylate levels, with 
bioluminescence assays and high performance chromatography methods (HPLC) 
most frequently used (Manfredi et al., 2002). HPLC has the advantage of high 
sensitivity and it allows the separation and quantification of a wide range of purine 
and pyrimidine nucleotides/nucleosides and free bases in one run. Therefore the 
main aim of this chapter was to develop a HPLC method for the simultaneous and 
accurate detection of tissue adenylate levels and most metabolites involved in the 
purine salvage pathway. For measurement of purine nucleotides, nucleosides and 
bases, ion-pair reversed-phase HPLC is commonly used (Stocchi et al., 1987; 
Kochanowski et al., 2006), since the separation of purine nucleotides is difficult with 
reverse phase columns and purine nucleosides are only poorly retained in anion 
exchange HPLC (Zakaria and Brown, 1981). 
 
In reverse phase HPLC the stationary phase is packed into a column and consists of 
spherical silica particles (usually 3 – 5 μm in diameter) masked with alkyl chains 
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(such as C4, C8 or C18), and therefore provides a nonpolar, hydrophobic environment. 
The mobile phase is polar and consists of an aqueous solution, buffered to a certain 
pH. After injection of the sample or standard mixture, separation is achieved because 
individual sample/standard compounds (analytes) will interact with the mobile and 
stationary phase to different extents, based on their hydrophobic characteristics (or 
their relative polarity)
4
. Elution of analytes from the column is generally achieved by 
gradually reducing the polarity of the mobile phase by increasing the percentage of 
an organic modifier (such as methanol or acetonitrile).  
 
Purine nucleosides or bases, which are uncharged and relatively nonpolar, can be 
easily separated with this type of HPLC. However, in order to achieve a separation 
of charged molecules (such as nucleotides), which will not sufficiently interact with 
the stationary phase, an ion pairing agent can be added to the mobile phase. The 
most commonly used ion pairing agents for negatively charged analytes are 
quaternary amines such as tetrabutylammonium hydrogen sulphate (TBAHS).  
TBAHS consists of 4 alkyl chains, which interact with the stationary phase, and a 
positively charged ammonium head group, which will form ion pairs with the 
negatively charged compounds in the sample mixture and thereby prolong their 
retention time. The addition of TBAHS to the mobile phase still allows 
uncharged/non polar compounds to interact with the stationary phase.  
 
In this section I will describe the disadvantages of fluorescence-based detection of 
adenine nucleotides for the accurate detection of the in situ energetic state and the 
development of a fast, sensitive, ion-pair reversed-phase UV-based HPLC method, 
which allows the analysis of at least 11 purine metabolites, including adenine 
nucleotides and their most important degradation metabolites. This method is 
suitable for low analyte concentrations and its rapidity (13 min runtime) means that 
many fresh samples can be run in one day avoiding degradation of adenine 
nucleotides in frozen tissue or upon thawing (Cappeln et al., 1999). Furthermore, 
keeping the separation runtime short also helps to save the cost of each analysis, 
                                                 
4
 The actual nature of the interaction of analytes with the stationary/mobile phases is debated in the 
literature: Vailaya A., Horváth C. (1998) Retention in reversed-phase chromatography: partition or 
adsorption? J. Chrom. A 829:1-27. 
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since ion-pairing agents are expensive.  
 
I will describe how the analytical separation is obtained using a 3-µm Supelcosil LC-
18-T column, with a gradient elution at room temperature. I have used this method to 
determine the energetic state of hippocampal brain slices and furthermore to evaluate 
changes in adenine nucleotide levels caused by snap-freezing in liquid nitrogen.  
 
 
3.2 Results 
 
3.2.1 Reversed phase HPLC 
 
3.2.1.1  Fluorescence-based detection of adenine nucleotides and adenosine 
 
There are two possible ways to detect adenine nucleotides/nucleosides in biological 
samples: with UV detectors at a wavelength of 240 - 270 nm, or with fluorescence 
detection of etheno-adenine (ε-adenine) metabolites. The latter method is achieved 
by derivatising adenine metabolites in samples with chloroacetaldhyde (ClCH2CHO) 
to fluorescent 1,N
6
-ε-adenine derivatives. During this process (at an ideal pH of 3 – 
5) a new imidazol ring structure is formed by an “ethylene bridge” that links the 
nitrogen (N-1) of the ring structure with the aminogroup at the C-6 atom (Kost and 
Ivanov, 1980) as shown in Figure 3.1. The presence of an aminogroup (-NH2) is 
necessary and therefore this process is limited to adenine and cytosine metabolites, 
and to a lesser extent (at a pH of 6.5) to guanosine metabolites. In order to achieve 
an efficient derivatisation samples/standards have to be incubated with 
chloroacetaldehyde at 60°C - 100°C (Sonoki et al., 1989; Howard et al., 1998), with 
increasing incubation times at lower temperatures, such as 24 hrs at 37°C (Ramos-
Salazar and Baines, 1985). A commonly-used temperature for the derivatisation of 
adenine metabolites is 80°C (Fenton and Dobson, 1992).  
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Figure 3.1: Principle of etheno-derivatisation adapted from (Lin et al., 2004): 1,N
6
-
ε-adenosine is formed when adenosine is incubated with chloroacetaldehyde 
(ClCH2CHO) at high temperatures. 
 
The advantage of using 1,N
6
-ε-derivates and fluorescence detection is the very low 
detection limit (picomolar to femtomolar range) (Katayama et al., 2001). 
Furthermore, the problem of co-eluting purine/pyrimidine metabolites can be 
disregarded since, as mentioned above, only adenine and cytosine metabolites will 
be effectively derivatised and detected.  
 
In a first set of experiments I determined the derivatisation efficiency of 100 μM 
standard ATP upon incubation with 5 % chloroacetaldehyde in aqueous solution (pH 
3 - 4) at 80°C. The integrated peak areas obtained from derivatised ε-ATP after 
various incubation time points (10 min – 2 h) were compared to the peak area 
obtained from 100 μM standard ε-ATP (indicated by the black dotted line in Figure 
3.2 A). As seen in Figure 3.2 A, a complete derivatisation of 100 μM ATP to 100 
μM ε-ATP was never reached and, although the derivatisation efficiency improved 
with increasing incubation duration (to a maximum of 60 % after 40 min incubation), 
a simultaneous degradation of ATP could be observed, as seen in the increase of ε-
ADP, ε-AMP and ε-Adenosine peak areas (Figure 3.2 AB). Due to degradation of 
ATP during this process this precludes an accurate determination of the energetic 
state, and thereby underestimates key parameters such as the energy charge (Figure 
3.2 C). The derivatisation efficiency could not be improved by incubating standard 
ATP at lower temperatures (37°C - 4°C) or with higher chloroacetaldehyde 
concentrations (10 %; data not shown).  
 
6 
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             adenosine                                       1,N6-ε-adenosine 
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Figure 3.2: Etheno-derivatisation results in degradation of adenine nucleotides. A 
100 μM ATP was incubated with 5 % chloroacetaldehyde for various time points at 
80°C and analysed by fluorescence-based HPLC. The peak area of standard 100 μM 
1,N
6
-etheno-ATP is indicated by the horizontal black dotted line. Longer incubation 
periods resulted in better derivatisation efficiency, peaking after 40 minutes. 
However, due to degradation of ATP, peak areas of ADP, AMP and adenosine 
progressively increased with longer incubation time points; All values are presented 
as mean ± S.E.M.; N = 3 - 8. B Representative HPLC traces of 100 μM ATP after 
10, 40 or 60 min incubation with 5 % chloroacetaldehyde at 80°C. Arrowheads refer 
to ε-ATP (red), ε-ADP (green), ε-AMP (blue) or ε-adenosine (orange). Scalebar 
indicates 10 V. C Calculation of the energy charge (EC = [ATP]+0.5[ADP])/[TAN] 
of derivatised 100 μM ATP from (A) after various incubation time points at 80°C. An 
energy charge value of 1 (all ATP) was never reached, indicating that an accurate 
determination of the energy charge is not possible due to degradation of ATP. All 
values are presented as mean ± S.E.M.; N = 3 - 8.  
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For the derivatisation of tissue samples, brain slice extracts were incubated with 5 % 
chloroacetaldehyde at 80°C for 20 min, to avoid major degradation of ATP seen 
after 40 min incubation (Figure 3.2 AB). As seen in Figure 3.3 not only was the yield 
of ε-derivatised adenine metabolites very variable (Figure 3.3 B) but also the relative 
increases in adenosine levels (Figure 3.3 C). These observations most likely reflect 
differences in the derivatisation efficiency and degradation of ATP, rather then 
differences of in situ adenine nucleotide levels in brain slices. Furthermore the 
retention times of sample peaks were not stable: peaks showed tailing, and 
sometimes closely co-eluted (Figure 3.3 D), suggesting that the HPLC method 
lacked sufficient reproducibility.  
 
Despite the inaccurate detection of in situ tissue adenylate levels, another 
disadvantage of this detection method was the fact that other purine salvage 
metabolites such as hypoxanthine or IMP could not be detected. Therefore the 
system had to be optimised for UV-based detection.  
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Figure 3.3: Etheno-derivatisation of brain slice extracts results in variable 
derivatisation efficiency and degradation of ATP. A Separation of standard ε-
adenine metabolites. B-C Brain slices were incubated in standard aCSF at room 
temperature for indicated time points, snap frozen in liquid nitrogen and stored at -
80°C for < 1 month. After extraction and neutralisation, brain slice extracts were 
etheno-derivatised by incubating extracts with 5 % chloroacetaldehyde for 20 min at 
80°C (pH 4 – 5). 20 min incubation was chosen in order to avoid massive 
degradation of ATP, which was observed after 40 min (Figure 3.2 AB). HPLC 
analysis was performed on the day of etheno-derivatisation. Note the very unstable 
retention times of ε-metabolites and the unreliable derivatisation efficiency. 
Arrowheads refer to ε-ATP (red), ε-ADP (green), ε-AMP (blue) or ε-adenosine 
(orange). Scalebar indicates 2 V. 
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3.2.1.2 UV-based detection of purine and pyrimidine metabolites 
 
All pyrimidine- and purine-based metabolites absorb at UV ranges around 240 - 270 
nm, due to the ring structures of their bases. Therefore, by using a UV detector, a 
very good separation method is necessary in order to obtain pure peaks, which are 
not contaminated by other co-eluting compounds. By applying the same HPLC 
method as used for fluorescence-based detection (see Chapter 2, section 2.8.3), 
purine/pyrimidine metabolites could not be sufficiently separated in a standard 
mixture (Figure 3.4 A) or brain slice extracts (Figure 3.4 B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Sufficient separation of purine/pyrimidine metabolites is not possible 
with the HPLC method used for detection of 1,N
6ε-adenine metabolites: 
Standard/sample compounds were separated on a Luna-C8(2) column using a 10 
min linear gradient from 20 mM phosphate buffer, pH 6 to 20 mM phosphate buffer 
with 25% methanol. A Separation of standard metabolites and B Separation of 
nucleotide extracts from a brain slice; 1 GTP, 2 GMP, 3 IMP, 4 ATP, 5 ADP, 6 
hypoxanthine, 7 xanthine, 8 AMP, 9 inosine, 10 guanosine, 11 adenosine. Note the 
co-elution of GTP, GMP, IMP and ATP.  Arrowheads indicate milli absorbance 
units (mAU) 
 
 
There are numerous parameters that influence the separation of sample compounds 
in reverse phase HPLC, some of which are shown in Appendix 2, Table 11.1. In 
general, changes to the mobile phase will affect its elutive capacity whereas changes 
to the stationary phase will affect its retentive capacity.  
 
Chapter 3 
62 
 
Before adding an ion pairing agent, which permanently changes a reverse phase 
HPLC column, I tried to change several parameters of the mobile phase and the 
stationary phase as summarised in Appendix 2, Table 11.2. However, none of these 
parameters resulted in a sufficient resolution of ATP/GMP and/or IMP as well as 
AMP/hypoxanthine/xanthine. This is due to the fact that the primary phosphate 
group of nucleotides is a strong acid (pKA < 2) (Jordan, 1952). Therefore, in order to 
suppress phosphate ionisation the pH would have to be adjusted to < 1, which cannot 
be done with silica based columns, since they have a pH operating range of 2 - 8 
(with decreases in column efficiency upon long exposure to low (<3) or high (>7) 
pH).  
 
3.2.2 Ion pairing reversed phase HPLC 
 
The addition of an ion pairing agent to the HPLC buffers (Tetrabutylammonium 
hydrogen sulphate, TBAHS see Figure 3.5) greatly improved separation. TBAHS 
consists of an alkyl chain, which allows it to interact with the stationary phase, and a 
positively charged ammonium group, which forms ion pairs with negatively charged 
analytes, such as ATP. Upon addition of TBAHS the retention times of nucleotides 
will be greater compared to nucleosides, therefore the elution of compounds is 
reversed compared to conventional reverse phase HPLC methods, and the retention 
time will increase with increasing number of phosphate groups. 
 
 
 
 
 
 
 
Figure 3.5: Tetrabutylammonium hydrogen sulphate (TBAHS). 
 
I tried to avoid using high TBAHS (8 mM) and buffer concentrations (100 mM) 
(Stocchi et al., 1987) because of salt precipitations in the HPLC system. A good and 
reproducible separation of standard compounds was achieved by using a Luna-C8 (2) 
column, 50 mM potassium phosphate buffer (pH 6), 15 min linear gradient to 25% 
N+ S O 
OH 
O 
O- 
Interacts with negatively charged analytes 
Interacts with the stationary phase 
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methanol and 4 mM TBAHS in both buffers. With this method most compounds 
(apart from GMP/IMP) could be well separated in standard mixtures (Figure 3.6). 
However, further peaks appeared at the end of the run (Figure 3.6 peaks 11 and 13), 
which were classified as ghost peaks (Williams, 2004), since they were not caused 
by any of the standard compounds injected.  
 
 
 
 
 
 
 
 
 
Figure 3.6: Separation of a standard mixture of purine and pyrimidine metabolites 
on Luna C8 (2) column with 4 mM TBAHS: 1 hypoxanthine, 2 xanthine, 3 inosine, 
4 IMP/GMP, 5 guanosine, , 7 adenosine, 8 AMP, 9 ADP, 10 GTP, 11 ghost peak, 12 
ATP, 13 ghost peak. mAU milliabsorbance units 
 
The same method was used to analyse brain slice extracts obtained from brain slices, 
which had been incubated in standard aCSF at room temperature for various 
timepoints (0.5 – 6 h), snap frozen in liquid nitrogen and kept at -80°C for 3 - 5 
weeks. However, after HPLC analysis (Figure 3.7 A) and calculation of the energy 
charge of these brain slice extracts (Figure 3.7 B) two things became obvious: Firstly 
the separation of un-retained material and hypoxanthine/xanthine as well as IMP and 
GMP was very poor and/or not possible, and secondly the energy charge obtained for 
brain slices from 1 to 6 h incubation was very low (0.6 – 0.78), potentially reflecting 
partial adenine nucleotide degradation in the samples and/or compromised energetic 
state of the tissue. I therefore tried to improve the qualitiy of the separation by using 
a column with longer alkyl chains (C18) and a smaller silica particle size (3 μm), a 
higher buffer concentration and by adjusting the gradient profile of the run to 
achieve optimal separation of these compounds.  Furthermore, I aimed to improve 
the extraction of brain slices to ensure an accurate detection of in situ adenine 
nucleotide levels and energetic parameters. 
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Figure 3.7: Separation of brain slice extracts on a Luna C8 (2) column with 4 mM 
TBAHS: Brain slices were snap frozen in liquid nitrogen at various timepoints after 
cutting and incubation in aCSF at room temperature. Slices were stored at -80°C for 
3 - 5 weeks before being used for perchloric acid extraction and HPLC analysis. A 
Representative HPLC traces of brain slices at time of cutting and after 30 or 60 min 
incubation in aCSF at RT. Numbers on traces refer to the following compounds: ● 
unretained material, 1 hypoxanthine, 2 xanthine, 3 inosine, 4 IMP/GMP, 5 
Guanosine, 6 NAD, 7 Adenosine, 8 AMP, 9 ADP, 10 GTP, 11 ghost peak, 12 ATP – 
note the poor separation of HX/X and IMP/GMP. B Calculation of the Energy 
charge (EC = ATP + 0.5 x ADP / (ATP + ADP + AMP)) of brain slices after various 
incubation times in aCSF at RT. Values are presented as mean ± S.E.M, N = 3 - 6, 
mAU milliabsorbance units. 
 
 
The best separation of all purine metabolites (including IMP/GMP) was achieved by 
using 65 mM potassium phosphate buffer and 4 mM TBAHS, pH 6 for buffer A and 
65 mM potassium phosphate buffer, pH 6 with 25 % methanol for buffer B (Figure 
3.8). The gradient profile used was 1 min 100% buffer A, 3 min at up to 30% buffer 
B, 7.5 min at up to 80% buffer B and 10 min at up to 100% buffer B. The run was 
kept at 100% buffer B for 3 more minutes before it was completed and the gradient 
was returned to 100% buffer A.  
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Figure 3.8: HPLC chromatograms of purine standards. A 100 μM standard 
mixture of 12 compounds. B 500 nM mixture of CTP, GTP, ADP and ATP injected 
after 5 minutes re-equilibration time. Numbers on traces refer to the following 
compounds: 1 hypoxanthine, 2 xanthine, 3 GMP, 4 IMP, 5 inosine, 6 adenosine, 7 
AMP, 8 GDP, 9 CTP, 10 GTP, 11 ADP, 12 ATP. ● ghost peaks; mAU milli 
absorbance units. 
 
 
3.2.2.1 Method validation 
 
3.2.2.1.1 Chromatographic separation 
 
Using the chromatographic procedure, described above, at least 12 different purine 
metabolite standards could be separated within 13 minutes, as shown in Figure 3.8 A 
(100 μM standard mixture; 2000 pmol).  
 
To keep the relative standard deviation of the retention times for each compound 
(Table 3.1) below ± 2.5 %, the re-equilibration time after each run was kept at 10 
minutes. Shorter re-equilibration times (~ 5 min) led to unstable retention times of 
hypoxanthine and xanthine, whereas longer re-equilibration times (~ 15 min) 
resulted in co-elution of GMP and IMP at 5.5 minutes (Figure 3.9). Although the 
retention times of CTP, GTP, ADP and ATP were very stable, even after a 5 minutes 
re-equilibration time (Figure 3.8 B, 500 nM, 10 pmol), I chose to adopt a constant re-
equilibration time of 10 minutes as this allowed optimal and consistent separation of 
all compounds of interest. Furthermore, the retention times of all standard 
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compounds did not change when the flow direction of the column was reversed, 
which allowed me to use the column for longer. 
 
At high gain, the baseline showed several small peaks, eluting after 10 minutes and a 
larger ghost peak eluting after ATP (black dots in Figure 3.8 B) whose size 
increased, and whose retention time decreased with the column life time. The nature 
of these peaks could not be clearly determined. They were not due to an impurity in 
any of the buffer components, to contamination of the injection valve, to the re-
equilibration time, or to the fact that the ion-pairing agent was only used in buffer A. 
A possible reason could be a precipitation of TBAHS during the gradient elution, 
which can occur when using potassium phosphate buffers. However, since the ghost 
peak could be clearly distinguished from the ATP peak, even at low concentrations 
of ATP, and in order to keep the runtime to a reasonable length, neither the gradient 
profile nor buffer composition were changed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Re-equilibration time influences the retention times of early eluting 
compounds: After 5 min equilibration the retention times of hypoxanthine (1) and 
xanthine (2) were variable. After 10 min re-equilibration time the retention times 
stabilised. However, after 15 min re-equilibration times GMP (3) and IMP (4) co-
eluted around 5.5 min. Therefore a 10 min re-equilibration time was chosen between 
all runs; Numbers on traces refer to following compounds: 1 hypoxanthine, 2 
xanthine, 3 GMP, 4 IMP, 5 inosine. 
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3.2.2.1.2 UV absorbance spectra 
 
The UV absorbance spectra (220-360 nm) for all standard and sample compounds 
were measured for all runs. Figure 3.10 A shows a contour graph and Figure 3.10 B 
shows the respective three dimensional graphs of all standard compounds (100 μM, 
2000 pmol). The two dimensional UV absorbance spectrum for trinucleotides, 
nucleosides and free purine bases are shown in Figure 3.10 C and D and the 
respective UV absorbance maxima are summarised in Table 3.1. Hypoxanthine, 
inosine and IMP had the lowest UV absorbance maximum (247 nm), whereas 
xanthine (267 nm) and CTP (270 nm) had the highest absorbance maxima. The 
quantitative analysis was performed at a wavelength of 254 nm (black line in Figure 
3.10 A). This was chosen to encompass the absorbance spectra of all separated 
compounds. 
 
 
Figure 3.10: Spectral view of HPLC chromatograms obtained from a 100 μM 
standard mixture. A contour graph, B three dimensional graph of all separated 
standard compounds; Y axis indicates the wavelength (220-360 nm); X axis shows 
the retention time, Z axis shows the absorbance intensity in milli absorbance units 
(mAU). The black dotted line in A indicates 254 nm, the wavelength that was used 
for quantitative analysis of standard and sample compounds. Compounds are 
numbered as in Figure 1. C, D UV absorbance spectra (220-360 nm) for C purine 
nucleotides and D purine nucleosides and free bases; UV absorbance maxima are 
summarised in Table 3.1. 
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3.2.2.1.3 Limit of detection/quantification 
 
The limits of detection (LOD, evaluated with a signal to noise ratio > 3) and 
quantification (LOQ, evaluated with a signal to noise ratio > 10) are summarised in 
Table 3.1 and shown for AMP in Figure 3.11. The LOD for standard compounds 
dissolved in deionised water ranged between 0.1-10 pmol, whereas the LOQ ranged 
between 0.5-10 pmol at 254 nm. The higher LOD and LOQ for GTP, ADP and ATP 
were due to the baseline peaks shown in Figure 3.8 B, which merged with the 
standard peaks at concentrations below 500 nM (10 pmol) and thereby made an 
accurate determination of the analyte peaks unreliable. 
 
The LOQ estimated for sample peaks was between 1 pmol (hypoxanthine, xanthine, 
IMP, GMP, inosine), 2 pmol (adenosine, AMP, GDP) and 10 pmol (CTP, GTP, 
ADP, ATP). The smallest amount of standards added to samples, which could be 
reliably detected by an increase in peak height ranged between 1 – 2 pmol for 
hypoxanthine, xanthine, IMP, GMP, inosine, adenosine, AMP and GDP. Due to the 
baseline peaks eluting after 10 minutes (see Figure 3.8 B) and due to the larger size 
of GTP and ATP peaks in samples (see Figure 3.12), the smallest amount of reliably 
detectable standards, determined by an increase in the peak area, for CTP, GTP, 
ADP and ATP was 10 pmol.  
 
3.2.2.1.4 Linearity 
 
A linear response, as indicated by correlation coefficients (R
2
) in excess of 0.99, was 
observed for each compound ranging from the LOQ for standard compounds in 
water to at least 2000 pmol (100 µM). The calibration curves for ATP, ADP, and 
AMP are shown in Figure 3.11 B and the respective R
2
 values for all resolvable 
standard metabolites are summarised in Table 3.1.  
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Figure 3.11: Calibration curves for adenine nucleotides. A limit of detection (LOD; 
signal to noise ratio > 3) and quantification (LOQ; signal to noise ratio > 10) for 
AMP B calibration curves for ATP, ADP and AMP (LOQ-2000 pmol). 
 
3.2.2.1.5 Recovery of standard compounds after perchloric acid extraction 
 
Perchloric acid (PCA) is commonly used to precipitate proteins of tissue samples 
and thereby to extract acid-soluble cell compounds, such as nucleotides, for 
subsequent analysis. However during the neutralisation process of PCA extracts, 
ATP can be adsorbed to the perchlorate precipitate (Wiener et al., 1974; Williams 
and Forrester, 1976). To evaluate to what extent PCA extraction influenced the yield 
of nucleotides and metabolites, standard compounds were added to half of a brain 
slice sample, whilst the other half had an equivalent volume of distilled water added. 
Both samples were subjected to PCA extraction and subsequently neutralised to pH 
6 by a threefold organic extraction with tri-n-octylamine/trichlorotrifluoroethane.  
 
Since this protocol required the injection of two aliquots from the same brain sample 
(spiked and unspiked), I needed first to determine the intra-sample variability of 
these two injections. For two unspiked aliquots of the same brain samples, as treated 
above, the difference between the two peak areas, expressed as a percentage of the 
mean peak area, was between 2.1 ± 0.9 % (ATP), 6.8 ± 1.6 (ADP) and 14.4 ± 8.2 
(AMP) (N = 4). These values likely overestimate any variability as the percentages 
do not take into account the size of the peak areas. Thus for smaller peaks (eg AMP), 
subtle differences between aliquots would have a proportionately larger effect. This 
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may also explain the reduction in apparent variability as the peaks become larger 
from ADP to ATP.  
 
Nonetheless, to test whether these values reflected variability in the detection 
system, I injected sequential aliquots from solutions of standard compounds. This 
yielded much lower variability: the difference of the peak areas of subsequent 
injections of 20 μM (400 pmol) ATP, ADP and AMP standards from the mean peak 
area was 1.3 ± 0.5 %, 1.1 ± 0.4 % and 0.2 ± 0.1 %, respectively (N = 7). Hence, the 
variability between the peak areas of two aliquots from the same brain slices is not 
due to poor precision of the system, but more likely reflects subtle differences 
between the initial aliquots, which involved separating the homogenised tissue in 
two, a possible source of intra-sample variability. This was only performed during 
these spiked sample experiments.  
 
I observed that the recovery of all standard compounds in spiked brain samples was 
between 90 and 109 % of the standard when dissolved in water (Table 3.1). Given 
the intra-sample variability described above, we assumed a 100 % recovery for all 
standard metabolites. 
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Table 3.1: HPLC Method validation: Limit of detection (LOD) of standard 
compounds dissolved in deionised water was classified as the concentration of the 
analyte 3 times the noise level, limit of quantification (LOQ) was classified as the 
analyte concentration 10 times the noise level. At 10 min re-equilibration between 
runs the retention times (RT) varied by ≤ ± 2.5%. The correlation coefficient values 
(R
2
) for each calibration curve (LOQ-2000 pmol), measured at 254 nm are also 
indicated. Furthermore the UV absorption maximum (λmax) is given for every 
compound. Recovery of standard compounds after perchloric acid (PCA) extraction 
was determined by spiking sample homogenates with various concentrations of 
standard compounds; all values are presented as means from 3 – 9 determinations.  
 
Compound LOD LOQ 
TR 
[min] 
λmax 
[nm] 
 (R
2
) 
% Recovery 
after PCA 
extraction 
ATP 500 nM 
(10 pmol) 
500 nM 
(10 pmol) 
11.99 258 0.996 102.8 ± 4.0 
ADP 500 nM  
(10 pmol) 
500 nM 
(10 pmol) 
10.6 259 0.996 109.3 ± 7.4 
GTP 500 nM 
(10 pmol) 
500 nM  
(10 pmol) 
10.47 252 0.999 95.3 ± 5.7 
CTP 100 nM 
(2 pmol) 
500 nM  
(10 pmol) 
9.68 270 0.999 90.9 ± 4.9 
GDP 50 nM 
(1 pmol) 
100 nM  
 (2 pmol) 
8.65 252 0.998 100.5 ± 2.4 
AMP 50 nM 
(1 pmol) 
100 nM 
(2 pmol) 
8.3 259 0.997 99.4 ± 2.5 
Adenosine 5 nM 
(0.1 pmol) 
25 nM 
(0.5 pmol) 
7.76 259 0.999 103.8 ± 2.5 
Inosine 5 nM 
(0.1 pmol) 
25 nM 
(0.5 pmol) 
6.32 247 0.991 95.8 ± 2.6 
IMP 10 nM 
(0.2 pmol) 
100 nM 
(2 pmol) 
5.47 247 0.999 98.1 ± 2.3 
GMP 10 nM 
(0.2 pmol) 
50 nM 
(1 pmol) 
5.35 252 0.999 99.4 ± 1.7 
Xanthine 10 nM 
(0.2 pmol) 
50 nM 
(1 pmol) 
4.48 267 0.994 103.7 ± 10.1 
Hypoxanthine 10 nM 
(0.2 pmol) 
50 nM 
(1 pmol) 
3.9 250 0.999 102.2 ± 5.5 
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3.2.2.1.6 Analysis of brain slice extracts  
 
To evaluate whether this HPLC method is suitable for studying the adenine 
nucleotide levels of biological tissue, I applied it to neutralised PCA extracts of 
hippocampal brain slices. A representative HPLC chromatogram is shown in Figure 
3.12 A, and the contour and three dimensional graphs of the absorbance spectra are 
shown in Figure 3.12 B and C. The identity of each sample peak was determined by 
comparison of the retention times with the respective standard compound, by spiking 
samples with standards, by comparison of the UV spectra with the particular 
standard compound, and by peak purity analysis, as shown for ATP in Figure 3.12 
D. Peak purity analysis showed that sample adenine nucleotides were as pure as 
standard adenine nucleotides. However, the GTP peak was contaminated due to co-
elution with UTP. It is possible that these compounds could be individually resolved 
by appropriate changes to the buffer gradient profile, but since all adenine 
nucleotides were clearly separated, this was not pursued. 
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Figure 3.12: Representative HPLC chromatogram from neutralised hippocampal 
brain slice extracts. Brain slices were incubated for 3 hours in aCSF at 34°C and 
nucleotide extraction was performed on fresh tissue without prior freezing in liquid 
nitrogen. A representative HPLC chromatogram obtained from brain slice extracts 
at 254 nm. B Respective contour and C three dimensional graph for separated 
compounds. Numbers on traces refer to the following compounds: 8 GDP 9 CTP 10 
GTP/UTP ● ghost peak; mAU milli absorbance units; D Sample ATP peak 
verification by a peak purity analysis, Sim. Index similarity index = 0.99 b spectral 
library search; sample ATP UV absorbance spectrum was 100% similar to standard 
ATP absorbance spectrum. 
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3.2.2.1.7 Effect of liquid nitrogen freezing on tissue adenylate levels 
 
It is often convenient to snap-freeze tissue after the experiment for analysis at a later 
date. This may be the case when the analysis procedure or HPLC runtime is lengthy, 
thereby obviating the possibility of running several fresh samples on the day of the 
experiment. Given the known labile nature of adenine nucleotides and the low 
energy charge values observed for snap-frozen brain slices after various incubation 
time points (see Figure 3.7 B), I sought to determine whether snap freezing in liquid 
nitrogen and/or subsequent extraction results in a change of adenine nucleotide 
levels. For this purpose brain slices were transferred into ice-cold aCSF. One set of 
slices was immediately homogenised in PCA, and another set of slices was frozen in 
liquid nitrogen for 30 - 60 minutes. Frozen slices were powdered under liquid 
nitrogen and subsequently homogenised in PCA. All neutralised extracts were 
analysed on the same day of slice preparation.  
 
Representative HPLC chromatograms, adenine nucleotide and EC levels of fresh and 
liquid nitrogen frozen brain slices are shown in Figure 3.13. EC values from fresh 
tissue slices, are very high (0.95 ± 0.003; N = 4), indicating that the slices are in 
good metabolic condition. In contrast, snap-freezing in liquid nitrogen led to 
significantly higher ADP (1.1 ± 0.2 nmol/mg protein for fresh slices and 2.5 ± 0.3 
nmol/mg protein for snap-frozen slices; N = 4; p < 0.01; unpaired t-test) and AMP 
levels (0.2 ± 0.02 nmol/mg protein for fresh slices and 0.5 ± 0.04 nmol/mg protein 
for snap-frozen slices; N = 4; p < 0.001; unpaired t-test), indicating degradation of 
ATP during the freezing/extraction process. This results in significantly lower EC 
values (0.95 ± 0.003 for fresh slices and 0.88 ± 0.009 for snap-frozen slices, N = 4; p 
< 0.001, unpaired t-test). However, there was no further degradation of adenine 
nucleotides in snap frozen slices, since the TAN pool was not significantly different 
between both groups (15.9 ± 1.4 nmol/mg protein for fresh slices; 14.2 ± 1.4 
nmol/mg protein for snap frozen slices, N = 4, p > 0.05, unpaired t-test). This 
degradation of ATP is dependent on the presence of tissue since freezing of standard 
ATP in liquid nitrogen did not lead to ATP breakdown (data not shown).  
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Figure 3.13: Effect of liquid nitrogen freezing on adenine nucleotide levels. HPLC 
chromatograms from A unfrozen brain slices, B frozen slices. Numbers on traces 
refer to the following compounds: 8 GDP 9 CTP 10 GTP/UTP ● ghost peak. The 
rising baseline in Figure 5B is due to a short re-equilibration time between runs. C 
ATP and TAN levels, D ADP, AMP and EC values of fresh and liquid nitrogen 
frozen slices. Values are expressed as mean ± S.E.M., N = 4, (**) p < 0.01, (***) p 
< 0.001 for AMP and EC, unpaired t-test. 
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3.3 Discussion 
 
Since the accurate determination of adenine nucleotides is most significant in the 
study of energy metabolism, I aimed to develop a fast, high-resolution ion-pair 
reversed-phase HPLC method that allows the analysis of multiple fresh samples in 
one day, thereby avoiding freeze-thaw degradation of nucleotides. Reverse phase 
HPLC methods without ion pairing agents or ion-exchange methods, usually take 
long runtimes in order to achieve sufficient separation of analytes (Zakaria and 
Brown, 1981). With the method described here at least 11 different purine 
compounds can be separated within 13 minutes, with a subsequent 10 minutes re-
equilibration time. This method is particularly useful for studying changes in the 
adenine nucleotide levels associated with experimental manipulations, extraction 
efficiency or tissue storage. The short time of analysis and the accurate evaluation of 
the compounds, make this method useful for routine and relatively high throughput 
use.  
 
The sensitivity, as determined by the LOQ, lies in the range of previously published 
UV-based HPLC methods (Tomiya et al., 2001; Kochanowski et al., 2006), and 
calibration curves for standard compounds showed that they were linear over a wide 
concentration range (LOQ-2000 pmol). Since the signal of each standard compound 
increases linearly with increasing injection volume (Kochanowski et al., 2006), 
injecting more than 20 μl on the column may result in even lower LOD and LOQ. 
Nonetheless, the absolute sensitivity is still lower than fluorescence-based HPLC 
analysis of adenine nucleotides (Katayama et al., 2001). However, for this method 
purine compounds of sample extracts have to be etheno-derivatised with 
chloroacetaldehyde, a process that requires incubation at high temperatures (most 
commonly 80°C), and limits the analysis to compounds containing an amino group 
in the purine or pyrimidine ring (such as adenine and cytosine). Furthermore, the 
derivatisation efficiency of standard ATP is variable and never reached 100 % 
(Figure 3.2 A). This precludes an accurate determination of the energetic state, due 
to degradation of ATP during this process and thereby underestimates key 
parameters such as the energy charge (Figure 3.2 C). Therefore, UV-based HPLC 
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analysis of adenine nucleotides, although less sensitive, results in a more reliable 
detection of the in situ energetic state.   
 
This method is also suitable for analysis of hippocampal brain slices, which are the 
main in vitro stroke model for this thesis. Tissue nucleotides were extracted with 
PCA and for neutralisation a threefold organic extraction with tri-n-
octylamine/trichlorotrifluoroethane was used. It is known that acid extraction and 
subsequent neutralization can lead to adsorption of ATP to the acid-salt precipitate 
(Wiener et al., 1974; Williams and Forrester, 1976) and the recovery of ATP has 
been reported to be between 45 - 96 % (Levitt et al., 1984; Shryock et al., 1986; Au 
et al., 1989; Kochanowski et al., 2006), depending on the type of extraction and 
neutralization. In this study there was a complete recovery of standard compounds 
added to sample extracts. This may be due to the use of tri-n-
octylamine/trichlorotrifluoroethane since it has been reported that the neutralisation 
of PCA with tri-n-octylamine/trichlorotrifluoroethane can result in a better recovery 
of nucleotides than, for example, precipitation as KClO4 (Brown et al., 1982). The 
additional advantages of using tri-n-octylamine/trichlorotrifluoroethane for 
neutralisation of acid extracts have been pointed out previously (Pogolotti and Santi, 
1982). Most importantly this method does not introduce additional salts into the 
extracts, which could interfere with HPLC separations. Furthermore, there is no 
possibility of making the solution too alkaline. In fact the threefold organic 
extraction used in this study always resulted in a pH of 6, which allowed the best 
separation of all sample/standard compounds in the method described here, since the 
buffers used had the same pH. 
 
HPLC chromatograms obtained from hippocampal brain slice extracts showed that 
all purine nucleotide compounds were clearly separated. Peak purity analysis and 
UV absorbance spectra comparisons further established the nature of the specific 
sample compounds. Including the time for slice preparation (30 minutes), slice 
incubation (3 hours), extraction for tissue nucleotides (30 minutes) and washing of 
the column after use (50 minutes), at least 10 sample extracts could be analysed in 
one day. 
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An interesting observation of this study is that freezing the brain tissue in liquid 
nitrogen and/or subsequent extraction can result in a significant change of adenine 
nucleotide levels. This has implications for the storage of tissue, especially if it is to 
be used for metabolic studies and might explain the low EC values of brain slices 
obtained after 3 - 4 weeks storage at -80°C (Figure 3.7).  
 
Due to the high activities of ATPases in fresh samples, changes in the adenine 
nucleotide levels take place very quickly when ATPase enzymes are not inactivated 
immediately. Snap-freezing of tissues in liquid nitrogen is a simple and widely used 
way to instantly stop any enzymatic activities and to store the sample for subsequent 
extraction. However the maintenance of freezing conditions during the nucleotide 
extraction procedure is critical, since thawing of the tissue will result in a recovery of 
enzymatic activities and potential degradation of ATP. Although samples in this 
report were kept and powdered in liquid nitrogen, there was a significant change in 
adenine nucleotide levels. This resulted in significantly lower EC values compared to 
fresh sample extracts (Figure 3.13), and is potentially responsible for the even lower 
observed EC values after longer storage conditions (Figure 3.7 B). Freezing of 
standard ATP in liquid nitrogen did not lead to a degradation of ATP. Furthermore it 
is unlikely that snap freezing is not quick enough to stop enzymatic degradation of 
ATP or that enzymatic activities recover at such low temperatures. Since brain slices 
were powdered under liquid nitrogen the degradation of ATP most likely occurs 
during the homogenisation procedure. The tissue powder might thaw and therefore 
ATPase activities might recover before proteins are effectively precipitated with 
PCA.  
 
Since tissue is frequently frozen in liquid nitrogen and stored at -80 to -20°C for 
subsequent extraction and HPLC analysis, assumptions about the EC have to be 
made very carefully, as they might not reflect the in situ values. Hence, transferring 
tissue slices into ice-cold aCSF and performing the PCA extraction immediately 
leads to a more reliable evaluation of adenine nucleotide levels. 
 
In summary I report a method which is suitable for the detailed analysis of tissue 
adenine nucleotide levels and, due to its rapidity, allows within-day sample analysis. 
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This helps to bypass the problem of freeze/thaw degradation of adenine nucleotides, 
and results in an accurate determination of the tissue energy charge.   
 
The development of this method (Zur Nedden et al., 2009) further allowed me to 
study the basal energetic state of brain slices under control conditions in Chapter 4 
and the effects of various interventions of the purine salvage pathway before during 
and after OGD in subsequent chapters.  
 80 
 
4 Metabolic 
recovery of 
hippocampal brain 
slices after 
preparation 
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4.1 Introduction 
 
The use of brain slices has revolutionised the study of the mammalian central 
nervous system and has now become a standard preparation in many laboratories and 
in many areas of neuroscience. Their versatility lends them to many types of 
investigation into the genomic, proteomic, molecular and cellular properties of the 
brain. A major advantage of brain slices is that they can be used for combined 
functional, metabolic, morphological and pharmacological experiments with 
maximal control over the extracellular environment and greater experimental access. 
Hippocampal brain slices are particularly widely used for studies into the 
fundamental properties of synaptic transmission and plasticity. Furthermore, given 
the vulnerability of the mammalian hippocampus to a wide variety of insults, 
including stroke, they are a common in vitro model system for the study of cerebral 
ischemia (Whittingham et al., 1984a; Schurr et al., 1989; Schurr et al., 1999; 
Kreisman et al., 2000) and for the assessment and screening of the efficacy of 
putative neuroprotectants (Galeffi et al., 2000).  
 
Notwithstanding the value of brain slices it is an unavoidable fact that the 
preparation of brain slices is associated with ischemia (decapitation) and tissue 
trauma (dissection/slice cutting) and thereby results in a substantially compromised 
energetic state of the tissue at time of cutting (Fredholm et al., 1984; Whittingham et 
al., 1984b). However, as described as far back as the 1950s (McIlwain et al., 1951; 
McIlwain, 1952), brain slices show remarkable metabolic recovery after preparation 
and it is now common practise to allow a period of incubation (usually 1 hour) 
before they can be used for experiments. Although every in vitro model system is a 
naturally simplified representation of the in vivo situation, it should strive to 
approach the in vivo condition as closely as possible, in particular with respect to the 
specific problem of interest. For “in vitro ischemia” studies the energetic state of the 
tissue is of special importance. The fact that control conditions in hippocampal slices 
might represent a post-ischemic recovery state (Hossmann, 2008), and the fact that 
high energy phosphate levels (ATP, phosphocreatine) of brain slices have 
traditionally been registered as lower than their in situ values (Thomas, 1957; 
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Whittingham et al., 1984a; Schurr and Rigor, 1989), are strong arguments against 
their usefulness as in vitro models for ischemia studies. However, as brain slice 
preparations have an irreplaceable role for the investigation and separation of the 
many variables that interact in the in vivo situation a balance has to be struck that at 
least includes some key parameters approaching the in vivo condition.  
 
Since hippocampal brain slices will be the main in vitro model for ischemia studies 
in this thesis the aims of this chapter were to study the metabolic recovery after slice 
preparation and to determine the best incubation conditions in order to approach the 
in vivo situation as closely as possible. This was achieved by (1) establishing the 
influence of the incubation temperature on the recovery of adenine nucleotides and 
energetic parameters, including the activity of AMP activated protein kinase 
(AMPK), an enzyme exquisitely sensitive to the cellular ATP/AMP ratio; and (2) 
separating and investigating the potential causes for the reduced ATP content of 
brain slices compared to the values reported in vivo. Through this we have added 
more information to existing work in this field about the recovery and stability of 
adenine nucleotides after slice cutting (Zur Nedden et al., 2011).  
 
 
4.2 Materials and methods 
 
4.2.1 Preparation of brain slices 
 
Rat brain slices were prepared as described in the Methods section (Chapter 2, 
Section 2.2) and were either analysed immediately upon cutting for their purine 
nucleotide content or transferred to an incubation chamber with continuously 
circulating, oxygenated standard aCSF, at room temperature (RT; 22 ± 0.5°C) or 34 
± 1°C. 
 
In a separate set of experiments nucleotide concentrations of 1) the intact 
hippocampus and cortex, and 2) slices of varying thickness were analysed. For this 
purpose one hemisphere was used to dissect and separate hippocampus and cortex, 
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and the other hemisphere was used to cut slices of varying thickness (200 μm – 3600 
μm). Since with the microtome used no slices over 1500 μm could be cut 
automatically, 3600 μm had to be measured with a guide. For these experiments all 
nucleotide extractions of were performed immediately after preparation.  
 
4.1.1 Nucleotide extraction 
 
Nucleotide extraction was performed as described in Chapter 2, section 2.5.1. For 
analysis of the TAN content of whole hippocampus and neocortex, and 1200, 1500 
and 3600 μm slices, the tissue was first homogenized in 500 μl 5% PCA. The 
amount of this suspension containing 20 mg wet weight (equivalent to four 200 μm, 
two 400 μm, or one 800 μm slice) of the tissue was mixed with 5 % PCA to a final 
volume of 1 ml and neutralized as described above. 
 
4.2.2 Kinase assays 
 
Kinase assays of brain slice protein extracts were performed by Simon Hawley and 
Grahame Hardie at the University of Dundee. AMPK from extracts was 
immunoprecipitated with a mixture of α1 and α2 antibodies and AMPK activity in 
the immunoprecipitates was determined using the AMARA peptide assay as 
described in (Hardie et al., 2000; Gadalla et al., 2004). The enzyme activity is 
expressed as units (U)/ mg protein. 1 U is the amount of enzyme that catalyses the 
conversion of 1 µmol substrate/min. 
 
4.2.3 Western blot analysis 
 
Western blot analysis of brain slice protein extracts was performed by Simon 
Hawley and Grahame Hardie at the University of Dundee. The detection of dual-
labelled western blots by infrared imaging was carried out as previously described 
(Hawley et al., 2003), except that in the present study the phosphorylation state of 
the native full length protein was determined. 
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4.3 Results 
 
4.3.1 Metabolic recovery of hippocampal brain slices after preparation 
 
4.3.1.1 Recovery of adenine nucleotides  
 
To study the recovery of adenine nucleotides after slice preparation, HPLC analysis 
of slice extracts was performed on fresh slices immediately after cutting and after 
various incubation time points in aCSF (10 min - 5 h) at room temperature (22°C) 
and 34°C (Figure 4.1 A).  
 
Immediately after cutting ATP, ADP and AMP were present in nearly equal amounts 
(6.0 ± 0.3, 4.0 ± 0.4 and 5.2 ± 0.8 nmol/mg protein, respectively; N = 7; Figure 4.1 
B-D). ATP levels significantly increased after only 10 min incubation (10.7 ± 1.0 
and 11.0 ± 0.9 nmol/mg protein at 22°C and 34°C, respectively; N = 7; p < 0.001, 
one way ANOVA) with a concomitant decrease of ADP (1.9 ± 0.3 and 1.5 ± 0.1 
nmol/mg protein at 22°C and 34ºC, respectively; N = 7; p < 0.001, one way 
ANOVA) and AMP levels (1.1 ± 0.3 and 0.5 ± 0.1 nmol/mg protein at 22°C and 
34ºC respectively; N = 7; p < 0.001, one way ANOVA).  
 
After the initial recovery, ATP, ADP and AMP levels did not significantly change 
during the incubation time points tested (up to 5 h incubation) and there were no 
significant differences between adenine nucleotides of slices kept at 22°C and 34°C 
(Figure 4.1 B-D). As a consequence of these complementary changes in individual 
nucleotides, the total adenine nucleotide pool (TAN = [ATP] + [ADP] + [AMP]; 
Figure 4.1 E) did not significantly change when slices were transferred from the ice-
cold cutting solution (15.2 ± 1.1 nmol/mg protein; N = 7) into aCSF at 22°C (13.7 ± 
1.4 nmol/mg protein; N = 7) or 34°C (13.0 ± 1.1 nmol/mg protein; N = 7), 
suggesting that most of the accumulated AMP is rephosphorylated to ATP rather 
then dephosphorylated to adenosine (via cytosolic 5’-nucleotidase) or deaminated to 
IMP (via AMP deaminase). 
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The TAN pool remained stable over an incubation period of 5 h. Average TAN 
concentrations from all time points tested (10 min – 5 h) were 14.1 ± 0.3 nmol/mg 
protein in slices at 22°C and 15.4 ± 0.9 in slices at 34°C, with ATP accounting for 
about 85 % and 89 %, respectively.  
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Figure 4.1: Rapid recovery of adenine nucleotides after slice preparation. A 
Representative HPLC traces obtained from brain slices after slice cutting (black 
trace) and various incubation times in aCSF at room temperature (22ºC, blue 
traces) and 34ºC (red traces). Note the consistently higher AMP levels in slices 
incubated at 22ºC. Numbers on traces refer to the following compounds: 1 
adenosine 2 GDP 3 GTP/UTP; arrowheads indicate, from left to right, AMP, ADP 
and ATP; mAU milli absorbance units. B-E Recovery of B ATP, C ADP, D, AMP 
and E total adenine nucleotides (TAN = [ATP]+[ADP]+[AMP]) from time of 
cutting (black circles, time zero) and various incubation times (0.1 – 5 h) in aCSF at 
22ºC (blue circles) or 34ºC (red circles). Values are expressed as mean ± S.E.M, N 
= 5 – 7; (###) p < 0.001 for slices at 22°C and 34°C compared to time of cutting, 
one way ANOVA with Bonferroni’s multiple comparison test. Where no error bars 
can be seen they are smaller than the symbol. 
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4.3.1.2 Recovery of energetic parameters  
 
The energetic state of a tissue is commonly reported as the ratio of adenine 
nucleotides, since this reflects the energy supply (ATP) to demand (ADP, AMP) 
relationship better than their individual concentrations. Additionally to the EC, 
another sensitive parameter of the energetic state is the ATP/AMP ratio. This ratio is 
predominantly controlled by adenylate kinase (see Chapter 1, section 1.4.1.1), which 
catalyses the reversible reaction 2ADP ↔ ATP + AMP. As it works at equilibrium it 
is mainly regulated by the availability of ADP and AMP, thereby generating ATP 
and AMP, as soon as ADP levels rise via increased metabolic activity or inadequate 
energy supply (Hardie and Hawley, 2001).  
 
Due to the nearly equal amounts of ATP, ADP and AMP at the time of cutting, the 
EC was very low (0.54 ± 0.03; N = 7; Figure 4.2 A), but it recovered significantly 
after only 10 min incubation at 22°C (0.86 ± 0.019, N = 7, p < 0.001, one way 
ANOVA) and 34°C (0.90 ± 0.007, N = 7; p < 0.001, one way ANOVA). After 3 h 
the EC stabilized at 0.93 ± 0.003 for slices kept at 22°C and at 0.95 ± 0.002 for slices 
kept at 34°C and, as for adenine nucleotides, there were no significant differences 
between slices incubated at 22°C and 34°C.   
 
The ATP/AMP ratio significantly recovered from time of cutting (1.4 ± 0.4; N = 7; 
Figure 4.2 B) after only 10 min in slices at 34°C (22.9 ± 2.7; N = 7; p < 0.001; one 
way ANOVA) whereas it took approximately 30 min to recover in slices incubated 
at 22°C (20.1 ± 1.8; N = 6; p < 0.001; one way ANOVA). Similar to the EC, the 
ATP/AMP ratio stabilized after 3 h, but with considerable differences between slices 
incubated at 22°C and at 34°C. At 22°C the ATP/AMP ratio ranged between 35.2 - 
38.0, whilst at 34°C the ATP/AMP ratio was much higher at between 63.5 - 64.2. 
The differences in the ATP/AMP ratio values between the two incubation 
temperatures became statistically significant after 30 min (N = 6 - 8; p < 0.01; one 
way ANOVA) and remained statistically significant for the rest of the incubation 
period (N = 5 - 8; p < 0.001; one way ANOVA).  
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Figure 4.2: Differential influence of temperature on the recovery of energetic 
parameters after slice cutting. A Recovery of the tissue energy charge ((ATP + 
0.5ADP)/TAN) is not influenced by temperature, whereas B the ATP/AMP ratio is 
significantly higher at elevated temperature (N = 5 – 7). All values are expressed as 
mean ± S.E.M. (###) p < 0.001 for slices at 22°C and 34°C compared to time of 
cutting; (**) p < 0.01, (***) p < 0.001 compared between slices at 22°C and 34°C, 
one way ANOVA with Bonferroni’s multiple comparison test. Where no error bars 
can be seen they are smaller than the symbol. 
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4.3.1.3 Recovery of AMPK activity 
 
Since the cellular ATP/AMP ratio is monitored by AMP-activated protein kinase 
(AMPK), a main sensor and regulator of cellular energy metabolism (Hardie and 
Hawley, 2001; Hardie, 2007) I further investigated whether the lower ATP/AMP 
ratio in slices at 22°C is reflected by a higher AMPK activity.  
 
Kinase assays and western blot analysis of AMPK activity and phosphorylation 
status supported this assumption. The AMPK activity (Figure 4.3 A) decreased from 
0.066 ± 0.003 U/mg protein at time of cutting to 0.04 ± 0.001 U/mg protein after 30 
min at 22°C (1.6 fold decrease; N = 3; p < 0.001, one way ANOVA), by which time 
at 34°C AMPK activity had fallen 3.4-fold (N = 2). After 3 h AMPK was 3 times 
more active in slices at 22°C (0.03 ± 0.003 U/mg protein, N = 3) than in slices at 
34°C (0.01 ± 0.001 U/mg protein; N = 3; p < 0.001, one way ANOVA).   
 
Western blot analysis of the phosphorylation status of AMPK and one of its 
downstream targets, acetyl-CoA carboxylase (ACC), was performed to further 
support these findings and to evaluate whether a higher AMPK activity is reflected 
in a higher phosphorylation of its substrates (Figure 4.3 BC). ACC-1 catalyses the 
first step of fatty acid synthesis, whereas ACC-2 inhibits fatty acid oxidation. Both 
isoforms are phosphorylated, and thereby inactivated by AMPK, resulting in 
inhibition of fatty acid synthesis and activation of fatty acid oxidation, respectively 
(Hardie and Pan, 2002). The phospho-AMPK/total-AMPK ratio decreased from 2.8 
at time of cutting to 1.9 in slices at 22°C and to 1.1 in slices at 34°C after 3 h 
incubation (N = 2, Figure 4.3 C). Likewise the phospho-ACC/total-ACC ratio 
decreased from 1.6 at time of cutting to 1.0 in slices at 22°C and to 0.5 in slices at 
34°C after 3 h incubation.  
 
These observations suggest that despite similarities between TAN pools and EC 
values between slices incubated at room temperature and more physiological 
temperatures, the ATP/AMP ratio can influence the activity of key intracellular 
enzymes with potentially important consequences for neuronal and glial properties. 
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Figure 4.3: Differential influence of temperature on the recovery of AMPK 
activity after slice cutting. A AMPK activity in brain slices, as measured by pseudo-
substrate phosphorylation, is lower at higher incubation temperature reflecting the 
higher ATP/AMP ratio (N = 3 except for 0.5 hr, 34°C, N = 2). Black circles: slices 
at time of cutting (time zero); blue circles: slices incubated in aCSF at room 
temperature (22°C); red circles: slices incubated in aCSF at 34°C; All values are 
expressed as mean ± S.E.M. (###) p < 0.001 for slices at 22°C and 34°C compared 
to time of cutting; (**) p < 0.01, (***) p < 0.001 compared between slices at 22°C 
and 34°C, one way ANOVA with Bonferroni’s multiple comparison test. Where no 
error bars can be seen they are smaller than the symbol. B Confirmation of 
increased AMPK activity through western blot analysis of increased phosphorylation 
of AMPK (p-AMPK) and a downstream target, Acetyl CoA carboxylase (p-ACC) in 
two separate sets of slices. Also shown is total AMPK and ACC at different durations 
and temperature of incubation. C Mean ratio of phospho-AMPK/ACC to total 
AMPK/ACC signal of two separate sets of slices.  
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4.3.2 Basis of reduced TAN concentration in slices 
 
Although EC values of brain slices reported here (Figure 4.2 A) show that slices are 
in a very good metabolic condition, and comparable to those reported in vivo (see 
Appendix 3, Table 12.1), absolute TAN levels (Figure 4.1 E) are about 60 - 40 % 
lower than published in vivo values, which are typically around 33.6 ± 4.7 nmol/mg 
protein (arithmetic mean ± SD of all published data in Appendix 3 Table 12.1). 
However, there is considerable variability in published TAN levels for the rat brain 
in vivo ranging from 27 – 44.5 nmol/mg protein with most values below the 
arithmetic mean (Figure 4.4). This variability most likely reflects different extraction 
and/or detection methods rather than differences in the in situ TAN levels.  
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Figure 4.4: Scatter plot for reported TAN values from Appendix 3 Table 12.1. Data 
is presented as individual values (red circles) and in black the mean ± SD for either 
all values (all data), values reported for cortex, hippocampus or the whole brain. 
 
 
Despite this, published ATP and TAN values for rat brain in vitro (Appendix 3 Table 
12.2), including my own results, clearly show that brain slices have lower ATP and 
TAN levels. This raises questions as to the basis of this discrepancy and the nature of 
the adenine nucleotide loss in brain slices.  
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In this study the loss of adenine nucleotides occurred either before or during slice 
preparation, since TAN levels were already ~ 55 % (~ 18.4 nmol/mg protein) lower 
at the time of cutting than published in vivo studies. There are several possible 
explanations underlying this observation. (1) The ischemic period leads to 
accumulation and subsequent loss of diffusible ATP degradation products, thereby 
resulting in a reduced TAN pool. (2) The tissue might suffer from physical damage, 
during decapitation, dissection and slicing, thereby resulting in further metabolic 
stress. (3) The slicing procedure leaves a layer of damaged and dead tissue on each 
side of the slice (35 - 50 µm) (Feig and Lipton, 1990; Siklos et al., 1997; Frenguelli 
et al., 2003), which might not contain adenine nucleotides, but which will contribute 
to the protein content of the tissue. Therefore, by relating the observed nucleotide 
levels to the total protein content of the tissue one would underestimate the amount 
of cellular nucleotides in the viable core of the slice. I investigated each of these 
parameters in turn. 
 
4.3.2.1 The ischemic period leads to loss of diffusible ATP degradation products 
 
As regards the loss of diffusible ATP metabolites, the sum of ATP degradation 
metabolites (adenosine, inosine, hypoxanthine, xanthine, IMP) at time of cutting is 
approximately ~ 5 nmol/mg protein (Table 4.1). Like ADP and AMP levels, these 
metabolites declined during the first 10 - 30 min of incubation, but since no similar 
rise in the TAN pool was observed, they are likely to be mostly lost from the tissue, 
rather than being incorporated into the adenine nucleotide pool, and thereby 
contribute to the reduced adenine nucleotide content of brain slices. 
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Table 4.1: Recovery of purine nucleosides, bases and inosine monophosphate 
(IMP) after slice cutting in slices incubated at 22°C or 34°C. All values are 
presented as mean ± S.E.M.; N = 4 - 7; (
###
) p < 0.001; (
##
) p < 0.01; (
#
) p < 0.05 
compared to slices after cutting; (***) p < 0.001 between slices at different 
temperatures, one way ANOVA with Bonferroni’s multiple comparisons test. 
 
 
4.3.2.2 The tissue suffers from physical damage causing additional loss of 
adenine nucleotides 
 
To establish if the additional dissection of tissue associated with slicing caused 
further loss of adenine nucleotides, I determined the TAN content immediately after 
decapitation/dissection in entire hippocampus and cortex (since slices in this study 
were composed of hippocampus and overlaying neocortex). The TAN content of 
intact hippocampal and cortical tissue was higher than that in combined 
hippocampal/neocortical slices at 23.0 ± 2.1 and 28.9 ± 2.9 nmol/mg protein, 
respectively (Figure 4.5 A, N = 5; p > 0.05 between hippocampal and cortical tissue, 
 
time 
[min] 
Adenosine 
[nmol/mg protein] 
Inosine 
[nmol/mg protein] 
Hypoxanthine 
[nmol/mg protein] 
22°C 34°C 22°C 34°C 22°C 34°C 
 
cutting 
 
0.6±0.2 
 
0.7±0.4 
 
0.63±0.17 
10 0.28±0.15 0.17±0.08 0.32±0.1 0.05±0.01 0.34±0.19 0.16±0.08
##
 
30 0.21±0.18 0.16±0.12 0.19±0.02 0.09±0.04 0.12±0.02
###
 0.05±0.01 
60 0.13±0.09
#
 0.05±0.01
#
 0.08±0.02
#
 0.04±0.02
#
 0.07±0.02 0.05±0.01 
180 0.04±0.01 0.05±0.01 0.08±0.02 0.10±0.01 0.09±0.01 0.14±0.09 
300 0.10±0.06 0.10±0.05 0.04±0.03 0.20±0.09 0.04±0.01 0.07±0.02 
time  
[min] 
IMP 
[nmol/mg protein] 
Xanthine 
[nmol/mg protein] 
22°C 34°C 22°C 34°C 
 
cutting 
 
                        2.5±0.3 
 
                    0.7±0.2 
10 2.13±0.43 0.74±0.17
###,***
 0.14±0.05
##
 0.14±0.01
##
 
30 0.89±0.08
###
 0.40±0.06 0.12±0.02 0.09±0.04 
60 0.55±0.09 0.23±0.01 0.07±0.02 0.06±0.03 
180 0.30±0.04 0.16±0.03 0.15±0.05 0.11±0.03 
300 0.28±0.03 0.33±0.07 0.09±0.03 0.23±0.11 
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unpaired t-test). The value for cortex is close to that reported in vivo (33.6 ± 4.7 
nmol/mg protein; Figure 4.5 A), but TAN levels in the hippocampus are somewhat 
lower than those reported in vivo. This suggests that the ischemic period during 
decapitation results in a loss of adenine nucleotides, especially in hippocampal tissue 
(~ 10 nmol/mg protein, ~ 29 %), which additionally requires more physical and 
potentially traumatic dissection for removal. The differences between TAN levels in 
hippocampal and cortical tissue may also be due to the fact that the cortex undergoes 
more rapid cooling when the whole brain is dropped into ice cold aCSF.  
 
To analyse whether the difference in TAN levels between cortex and hippocampus 
can also be seen in slices, I separated neocortical/hippocampal slices after cutting 
into hippocampus and cortex and analysed them immediately for their TAN content 
(Figure 4.5 A). I observed the same pattern as for the whole tissue: the TAN levels of 
hippocampal slices were significantly lower than the TAN levels of cortical slices 
(16.4 ± 1.1 nmol/mg protein and 20.7 ± 0.7 nmol/mg protein, respectively, N = 3, p 
< 0.05, unpaired t-test). However, these values were about 28 % lower than the 
respective whole tissue values reported above (~ 8.2 nmol/mg protein for cortical 
tissue and ~ 6.6 nmol/mg protein for hippocampal tissue), and about 38 (cortex, ~ 
12.9 nmol/mg protein) – 50 % (hippocampus, ~ 17.5 nmol/mg protein) lower than 
reported in vivo values (33.6 ± 4.7 nmol/mg protein as shown by the grey area for the 
mean ± SD in Figure 4.5 A). This additional difference might be either caused by 
ongoing ischemia and/or physical damage during slice preparation, or by the protein 
content of dead slice edges, which might distort the calculation of metabolite levels 
in the viable core of the tissue.  
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Figure 4.5: Tissue thickness and handling influences calculation of adenine 
nucleotide content of brain tissue. A Total adenine nucleotide (TAN) content of 
whole hippocampus (N = 5) and cortex (N = 5), immediately after dissection, and 
hippocampal (N = 3) and neocortical slices (N = 3) immediately after cutting. Note 
that whole tissue TAN levels of hippocampus are lower than reported in vivo values 
(grey area represents the arithmetic mean ± SD for all reported values from 
Appendix 3 Table 12.1), possibly reflecting increased handling/trauma, with only 
whole cortex approaching in vivo values. Slices of these regions show the same 
pattern, but have substantially lower TAN levels than the in vivo brain. B TAN levels 
of neocortical/hippocampal slices of varying thickness (200, 400, 800, 1200, 1500, 
3600 μm) immediately after cutting. All values are presented as mean ± S.E.M.; N = 
3 – 8. (*) p < 0.05, unpaired t-test. 
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4.3.2.3 The dead layer on slice surfaces distorts adenine nucleotide 
measurements  
 
To test the latter hypothesis, I prepared neocortical/hippocampal slices of different 
thickness, thereby changing the ratio of dead to viable tissue. As there were no 
significant changes in the TAN levels between slice cutting and 5 h incubation 
(Figure 4.1 E) and in order to bypass the problem of a possible emerging ischemic 
core in very thick slices, the analysis was performed immediately after cutting.  
 
Interestingly, the TAN content of slices, relative to the amount of protein, increased 
approximately 26 % with increasing thickness from 15.2 ± 1.7 nmol/mg protein in a 
200 µm slice to 20.6 ± 1.0 nmol/mg protein in a 1200 µm slice (Figure 4.5 B, N = 5 - 
8, p < 0.05, unpaired t-test). There was no further increase in the TAN levels in 1500 
µm slices (20.3 ± 2.3 nmol/mg protein, N = 4) and I obtained a value of 21.1 ± 2.6 
nmol/mg protein (N = 3) for 3600 μm slices.  
 
To better understand the dependence of TAN content on slice thickness, Professor 
Nicholas Dale assisted in the formulation of a mathematical model for the relation 
between slice thickness and TAN levels. In this method the assumption is made that 
the TAN is proportional to the volume of the tissue (l
3
) as defined by a unit of length 
l (Figure 4.6). If in a slice there is a layer of dead tissue devoid of adenine 
nucleotides at either face of the slice of thickness d then the volume of tissue 
contributing to the TAN is l
2
(l-d). I further assumed that d is constant and does not 
depend on slice thickness and expressed d as a proportion of l (d = αl). The volume 
of tissue contributing to the TAN is thus l
3
(1 - α). If a unit of volume is considered 
(i.e. l=1), then a plot of 1-α against the normalized TAN for different slice 
thicknesses, assuming constant d, should fit the observed data and provide a 
theoretical estimate of the dead layer of tissue at either face of the slice. 
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Figure 4.6: Illustration of the development of mathematical model describing the 
volume of the tissue contributing to the TAN levels: l length; l
3
 total volume of the 
tissue, d thickness of the dead tissue layer, l
2
(l-d) volume of the tissue contributing to 
the TAN level; α constant describing the thickness of d as a proportion of l.  
 
 
In Figure 4.7 AB I have plotted theoretical curves for the relative contribution of a 
dead tissue layer (d) of 20 µm (40 µm in total), 35 µm (70 µm in total) and 50 µm 
(100 µm in total) on both slice edges to the total tissue thickness (l, from 100 to 3600 
μm slices in 20 μm steps). By normalizing the measured TAN values in Figure 4.5 B 
to the TAN value obtained for 3600 µm slices (21.1 nmol/mg protein) and plotting it 
on the same graph, I observed a very good fit of these measured values to the 
theoretical curve obtained for an estimated total dead cut edge layers of 70 µm, or 35 
µm for each edge (Figure 4.7, black dotted line). Based on histological assessment of 
400 µm slices an estimate of 35 µm of the dead slice layer has been reported 
previously (Frenguelli et al., 2003), revealing a remarkable degree of consistency 
between this experimental observation and the theoretical model, described here.  
 
0.5d l
 
l
2
(l-d) 
l
3 
0.5d = αl 
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Figure 4.7: Theoretical curves (Y = 1-α; α = d/l; dotted lines) to estimate the 
relative contribution of dead cut edges (d) to the total tissue thickness of slices (l, 
ranging from 100 μm to 3600 μm  in 20 μm  steps in A and to 2000 μm in B), 
assuming a total thickness for the two dead cut edges of 40 μm (green dotted line, 20 
μm on each side of the slice), 70 μm (black dotted line, 35 μm on each side of the 
slice) or 100 μm (red dotted line, 50 μm on each side of the slice). By normalising 
the TAN levels obtained from slices at different thicknesses from Figure 4.5 B to the 
TAN values obtained for 3600 μm slices (plotted as black dots), I found that these 
normalized values fit the curve for a total dead cut edge layer of 70 μm (black dotted 
line), which is in agreement with histological estimates obtained previously for dead 
slice edges in 400 µm hippocampal slices (Frenguelli et al., 2003).  
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With this curve (for a total dead tissue layer of 70 µm) an asymptotic value is 
approached at a tissue thickness of 3600 µm (1-α = 0.980), suggesting that the dead 
cut edges account for only 2 % of the whole tissue thickness. Therefore, assuming a 
maximal TAN value of 21.1 nmol/mg protein (3600 µm slices) in slices, the TAN 
content of the viable core tissue in a 400 μm slice (17.1 ± 1.5 nmol/mg protein) is 
underestimated by ~ 4 nmol/mg protein, approximately 19 %. 
 
Nonetheless, when corrected for this amount, slice TAN levels in 400 μm 
neocortical/hippocampal slices remain ~ 37 % (~ 12.5 nmol/mg protein) lower than 
reported in vivo values (33.6 ± 4.7 nmol/mg protein). Hence, this difference is likely 
due to the loss of adenine nucleotides and precursors during the physical trauma and 
ischemia during slice preparation. 
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4.4 Discussion 
 
Although brain slice preparations have become widely used in vitro model systems 
for studying the central nervous system, the extent to which they accurately reflect 
the energetic status of the in vivo brain has been a subject of debate since their 
introduction. Many investigations have been carried out to study and/or improve the 
metabolic integrity of brain slices (Thomas, 1957; Orrego and Lipmann, 1967; 
Fredholm et al., 1984; Whittingham et al., 1984b; Hesse and Shashoua, 1990).  The 
aim of this chapter was to re-address this issue and to study (i) the energetic recovery 
of brain slices and (ii) the reasons for reduced levels of ATP.  
 
4.4.1 Metabolic recovery after slice preparation 
 
My results show that adenine nucleotide levels in brain slices recover quickly and 
remain stable for at least 5 h, independently of the incubation temperature. This is 
supported by earlier findings, which reported that slice ATP levels recover during 
the first hour of incubation, and remain stable and/or improve over a period of 8 h 
(Fredholm et al., 1984; Whittingham et al., 1984b; Whittingham et al., 1984a).  
 
Likewise the EC and ATP/AMP ratio show a very rapid recovery after slice 
preparation, but it takes 3 h until they approach a steady state. EC values presented 
here for slices at 34°C (0.95 ± 0.002), are higher than values reported by others in 
vitro (EC = 0.73-0.9) (Kass and Lipton, 1982; Fredholm et al., 1984; Whittingham et 
al., 1989; Paschen and Djuricic, 1995; Milusheva et al., 1996; Galeffi et al., 2000). 
However, in this study the nucleotide extraction was performed on fresh tissue, since 
snap freezing in liquid nitrogen and subsequent extraction can lead to changes of in 
situ adenine nucleotide levels (see Chapter 3 Figure 3.13) (Zur Nedden et al., 2009). 
This makes a comparison with data in the literature somewhat difficult, since it 
cannot be said whether the higher EC is due to a better metabolic integrity of slices 
or to different extraction procedures. Likewise published EC values from in vivo 
brain vary between 0.80-0.97 (Appendix 3 Table 12.1), which might also be due to 
different extraction methods rather than differences in the energetic state of the 
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tissue. Therefore, the only conclusion that can be drawn is that the EC of 
hippocampal brain slices recovers to an asymptotic value after 3 h, which is similar 
to those reported at the higher end of the in vivo range and values predicted to reflect 
metabolic integrity. 
 
It is worth noting that not only adenine nucleotide levels, but also other metabolites, 
such as the second messengers cGMP and cAMP, lactate or phospho-creatine require 
1 - 3 h to achieve a steady state (Whittingham et al., 1984b). Similarly the 
phosphorylation state of proteins involved in synaptic plasticity, such as GluA1, 
ERK2 and MEK1/2, undergoes changes especially during the first 3 h of incubation 
(Ho et al., 2004). A recovery period of 4 h has also been suggested on the basis of 
achieving stable and reliable long term recordings for synaptic plasticity studies in 
brain slices (Sajikumar and Frey, 2004; Sajikumar et al., 2005; Redondo et al., 
2010). Therefore the recovery period of slices after cutting is critical and should be 
carefully selected for the specific purpose for which the brain slices are to be used.  
 
Hence, slices for future studies were allowed to rest for 3 h, to avoid running the risk 
of exposing pre-stressed slices to experimental manipulations.  
 
4.4.2 Higher AMPK activity at lower temperatures 
 
My results further showed that slices at 34°C have a significantly higher ATP/AMP 
ratio compared to slices at room temperature. The potential basis for this might lie in 
the activity of adenylate kinase (2 ADP ↔ ATP + AMP). In a computational model 
of this enzyme, it has been predicted that the rate of conformational switching, which 
is the rate limiting step of the catalysis (Sheng et al., 1999), is faster at temperatures 
beyond 32°C (Lu and Wang, 2008). According to this, adenylate kinase would work 
more efficiently at 34°C, resulting in a better turnover of AMP and ATP to ADP.  
 
Since AMPK is exquisitely sensitive to the cellular ATP/AMP ratio, this translated 
into slices incubated at 22°C showing a 3 fold higher activity of AMPK than slices at 
34°C. AMPK is activated upon phosphorylation by upstream kinases, and binding of 
AMP inhibits its dephosphorylation and causes allosteric activation of the enzyme, 
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whereas both effects are antagonized by high intracelluar ATP levels (Hardie et al., 
2006; Sanders et al., 2007). Downstream targets of AMPK are involved in 
metabolism of lipids, carbohydrates, proteins as well as cell signalling (Hardie, 
2007). Furthermore it has been shown that the function of GABAB receptors, which 
participate in the suppression of neuronal excitation, is increased by phosphorylation 
through AMPK (Hardie and Frenguelli, 2007; Kuramoto et al., 2007) and it was 
reported that AMPK activation inhibits calcium-activated potassium channels (αβ-
BKCa) by direct phosphorylation (Wyatt et al., 2007).  
 
A proteomic in vitro screen for identification of new brain specific substrates 
revealed 12 further potential downstream targets (Tuerk et al., 2007). The authors 
proposed that AMPK might have a general role in shutting down neuronal excitation 
during energy shortage by phosphorylation of synapsin I, thereby affecting synaptic 
vesicle transport and release of neurotransmitters, and by phosphorylation of 
PACSIN1 (protein kinase C and casein kinase substrate in neurons 1), thereby 
causing endocytosis of NMDA receptors. Therefore, AMPK activity should be 
preferentially low in brain slices in order to better mimic the state of energy 
metabolism of normal in vivo tissue, with respect to the activity of metabolic 
enzymes and synaptic transmission. Since ACC, one of the downstream targets of 
AMPK, shows a higher phosphorylation in slices incubated at room temperature than 
at 34°C (Figure 4.3 BC), other downstream targets are likely to show the same 
pattern. Hence, incubating slices at elevated temperatures will help to approach the 
state of energy metabolism of the in vivo situation more closely.  
 
4.4.3 Reduced ATP and TAN concentrations of brain slices 
 
As seen in this and many other reports (Appendix 3, Table 12.2), brain slices have 
lower ATP and TAN concentrations compared to the respective values of in vivo 
brain (~ 40 - 50 %).  
 
The ischemic period during slice preparation is inevitable, and, as seen in the 
accumulation of ATP degradation metabolites in the tissue at time of cutting (Table 
4.1), clearly contributes to a reduction in the TAN pool.  
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The extent to which the dead slice edges affect the calculation of slice metabolites 
has been raised previously (Fredholm et al., 1984; Whittingham et al., 1984a). My 
data shows that decreasing the ratio of dead tissue to viable tissue by increasing the 
slice thickness results in an increase of TAN levels, suggesting that the protein 
content of the dead slice edges contributes to an underestimation of the TAN levels 
in the viable core tissue by ~ 4 nmol/mg protein (~ 20 %).  
  
However, given that the brain tissue remains more or less inactive, as soon as it is 
placed into ice cold aCSF and unable to further metabolise ATP, the EC values 
obtained from slices immediately after cutting (0.54 ± 0.03) would reflect the 
severity of the ischemic insult, caused by decapitation and removal of the brain. 
Similar EC values were observed within 3 min of decapitation-induced ischemia 
(Whittingham et al., 1984a).  
 
There are many reports showing that cerebral TAN/ATP levels after brief periods of 
ischemia (1 - 5 min) recover close to preischemic control values, upon short 
reperfusion time points (60 - 90 min) (Ljunggren et al., 1974; Kobayashi et al., 1977; 
Nowak et al., 1985). However, there was no significant increase in TAN levels in 
slices over a 5 h incubation period (Figure 4.1 E). This might be due to a lack of 
purine precursor metabolites in the aCSF which could be used to restore tissue ATP 
levels via purine salvage or de novo synthesis. In fact it has been shown that addition 
of adenine or adenosine to the aCSF can increase the adenine nucleotide content of 
cortical slices from 0.85 ± 0.03 μmol/g wet weight to 1.01 ± 0.02 μmol/g wet weight 
(0.85 mM adenine) (Thomas, 1957). In aCSF supplemented with 1 mM adenosine, 
tissue TAN levels in 400 μm hippocampal slices can be increased up to 26.54 ± 1.33 
nmol/mg protein within 2 h, and are maintained even if adenosine is removed from 
the incubation medium (Whittingham et al., 1989), showing that brain slices have the 
capacity to improve the recovery of ATP levels in the viable core tissue. However, 
the use of adenosine should be carefully considered since it has strong receptor based 
actions (see Chapter 1, section 1.4.3.4) (Cunha, 2001; Dunwiddie and Masino, 2001; 
Fredholm et al., 2001).  
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In conclusion I report that the full recovery of energetic parameters (EC, ATP/AMP 
ratio) in neocortical/hippocampal brain slices is reached 3 h after slice preparation. 
The incubation of slices closer to physiological temperatures helps to approach the 
energy state of the in vivo situation more closely and reduce the activation of AMPK, 
which is known to influence ion channel and GABAB receptor function. I further 
showed that the ischemic period during slice preparation results in a substantial loss 
of adenine nucleotides, but that the protein content of the dead slice edges likewise 
distorts the calculation of TAN levels. Although the TAN levels in slices are clearly 
not identical to the in vivo situation, the metabolic integrity (EC, ATP/AMP ratio) of 
brain slices is robust.  
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5 Effect of purine 
salvage metabolites 
on the post-
ischemic recovery 
of ATP levels in 
brain slices after 
preparation 
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5.1 Introduction 
 
As seen in the previous Chapter hippocampal brain slices have lower ATP levels  
compared to the in vivo brain. This is due to i) the ischemic period during slice 
preparation leading to an accumulation and loss of ATP degradation/precursor 
metabolites, and ii) the protein content of the dead slice edges resulting in an 
underestimation of the ATP content of the viable core tissue. However, as shown in 
the literature hippocampal brain slices have the capacity to increase basal ATP levels 
if incubated with ATP precursor/degradation metabolites, such as adenosine or 
adenine (Thomas, 1957; Whittingham et al., 1989). Thus, brain slices are a good 
model system to screen the efficiency of purine salvage pathway metabolites on 
improving the recovery of basal ATP levels after slice preparation.   
 
In the purine salvage pathway (see Figure 5.1) the ATP degradation metabolite 
hypoxanthine (HX) or adenine
5
 (Ade) are combined with the activated sugar donor 
PRPP (5-phospho-ribosyl-1-pyrophosphate) in order to form the respective purine 
nucleotides inosine monophosphate (IMP, derived from hypoxanthine) or AMP 
(derived from adenine). The enzymes catalyzing these reactions are hypoxanthine 
guanine phosphoribosyltransferase (HGPRT) and adenine phosphoribosyltransferase, 
respectively (APRT, see Figure 5.1). IMP can then be reconverted to AMP, via the 
intermediate adenylosuccinate, a process which involves the two enzymes 
adenylosuccinate synthetase and adenylosuccinate lyase.  
 
The purine salvage pathway is a quick and energy efficient way of maintaining 
adenine nucleotide levels. In a slower and energy dependent process ATP can be 
generated from low molecular weight precursors in the purine de novo synthesis. As 
for the purine salvage pathway the sugar donor is PRPP and the end product is IMP, 
but its synthesis is not dependent on pre-existing purine metabolites. It has been 
shown that in heart tissue the availability of PRPP is a limiting factor for both the 
purine salvage pathway and the purine de novo synthesis (Zimmer, 1983). The basis 
for the low PRPP pool lies in the weak capacity of the pentose phosphate pathway to 
                                                 
5
 Adenine derives from polyamine synthesis, see introduction 1.4.6 
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synthesise ribose-5-phosphate and subsequently PRPP (Zimmer, 1992, 1996). Since 
the brain, like the heart, mainly relies on the purine salvage pathway to maintain 
constant ATP levels (Gerlach et al., 1971; Mascia et al., 2000), the availability of 
PRPP and/or the free purine bases Ade or HX might be a limiting factor for the 
complete recovery of ATP levels in brain slices after slice preparation.  
 
 
 
Figure 5.1: Degradation/restoration of ATP levels pathway for adenine and D-
ribose utilization: Adenine nucleotides (ATP, ADP and AMP) are degraded to 
adenine nucleosides (adenosine and inosine), purine bases (hypoxanthine and 
xanthine) and uric acid. Substances indicated with an arrowhead can be released 
from the cell and lost to the systemic circulation. In the purine salvage pathways 
(shown in blue) the free purine bases hypoxanthine or adenine are combined with 
the activated sugar donor 5-phosphoribosyl-1-pyrophosphate (PRPP) to build up the 
respective purine nucleotide IMP via hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) or AMP via adenine phosphoribosyl transferase (APRT). Solid 
lines indicate direct routes, dashed lines indicate indirect routes.  
 
 
Therefore, the main aim of this chapter was to test the hypothesis that tissue adenine 
nucleotide levels of hippocampal brain slices can be increased upon incubation with 
the pentose D-Ribose (Rib) and/or the free purine bases Ade and HX (see Figure 5.1 
and Chapter 1, section 1.5). Rib bypasses the rate limiting step of the pentose 
phosphate pathway as it can be directly phosphorylated to ribose-5-phosphate by 
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ribokinase  and subsequently to PRPP by and PRPP synthetase (Zimmer, 1996). The 
beneficial effects of Rib on postischemic myocardial ATP recovery and function 
have been demonstrated in many in vitro (Smolenski et al., 1998; Wallen et al., 
2003) and in vivo animal models (Zimmer and Gerlach, 1978; Zimmer, 1982; St Cyr 
et al., 1989; Zimmer et al., 1989; Zimmer, 1992). However, the effect of Rib or 
combined Rib/Ade, Rib/HX application on adenine nucleotide levels and their 
functional consequences in in vitro or in vivo brain tissue has not been studied yet.  
 
I will show that Rib/Ade are used by brain slices to produce ATP, and that slice 
TAN levels, when corrected for the influence of the dead cut edges values (~ 4 
nmol/mg protein), closely approach reported in vivo values. Furthermore I tested the 
effect of acute Rib/Ade application on basal electrophysiological properties as well 
as the recovery of synaptic transmission after slice preparation.  
 
 
5.2 Results 
 
5.2.1 Screening of the effects of purine salvage metabolites on basal ATP levels 
 
To screen the effect of purine salvage metabolites on basal ATP levels, brain slices 
were incubated with Rib alone or in combination with Ade or HX for 3 h at 34°C 
immediately after slice preparation, and nucleotide extraction was performed 
thereafter. The incubation time was chosen on the basis of previous results, which 
showed that the full recovery of energetic parameters after slice preparation takes 3 h 
(see Chapter 4, Figure 4.2).  
 
The values for adenine nucleotides as well as IMP (since this is the end product of 
Rib/HX) are shown in Table 5.1. The concentrations of Rib and/or Ade/HX are 
based on previous studies in heart tissue (Brown et al., 1985; Smolenski et al., 1998; 
Zimmer, 1998). Rib on its own was not effective at increasing ATP or TAN levels, 
even at high concentrations (10 mM). In contrast, the combination of Rib and Ade 
significantly increased slice ATP and TAN levels, whereas Rib/HX (N = 2) was less 
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effective. However, basal IMP levels in slices treated with 10 mM Rib were 
significantly higher compared to control slices, suggesting that Rib might stimulate 
purine slavage and/or de novo synthesis. Likewise, the combination of Rib/HX 
resulted in elevated IMP levels, likely due to enhanced salvage of intracellular HX.  
 
Since Rib/Ade treatment was more effective at increasing TAN levels than Rib/HX, 
I focused on Rib/Ade supplementation.  
 
Substrate ATP 
[nmol/mg 
protein] 
ADP 
[nmol/mg 
protein] 
AMP 
[nmol/mg 
protein] 
TAN 
[nmol/mg 
protein] 
IMP 
[nmol/mg 
protein] 
Control 
( N = 4) 
 
16.21 ± 1.10 1.33 ± 0.20 0.25 ± 0.06 17.8 ± 1.1 0.14 ± 0.01 
2.5 mM Rib 
(N = 3) 
 
15.47 ± 2.41 1.42 ± 0.07 0.23 ± 0.03 17.1 ± 2.5  0.15 ± 0.03 
10 mM Rib 
(N = 5) 
 
16.55 ± 1.18 1.1 ± 0.12 0.29 ± 0.04 17.9 ± 1.2 0.25 ± 0.03* 
2.5 mM Rib/ 
50 uM Ade 
(N = 3) 
 
22.89 ± 1.01* 1.64 ± 0.23 0.21 ± 0.01 24.7  ± 0.8* 0.21 ± 0.02 
2.5 mM Rib/ 
50 uM HX 
(N = 2) 
18.77 1.56 0.225 20.6 0.31 
 
Table 5.1: Effect of various purine salvage metabolites on basal ATP levels. Brain 
slices were incubated with D-Ribose (Rib), adenine (Ade) or hypoxanthine (HX) 
immediately after slice preparation for 3 h at 34°C. Control slices were incubated 
with 2.5 mM Sucrose. Supplementation of aCSF with 2.5 mM Rib and 50 µM Ade 
resulted in significant elevation of basal ATP and TAN levels. (*) p < 0.05 compared 
to Control slices, one way ANOVA, Bonferroni’s  multiple comparison test.  
 
 
5.2.2 Effect of Ribose and adenine on basal ATP levels 
 
Since 2.5 mM Rib/50 µM Ade treatment resulted in significant elevation of basal 
ATP/TAN levels (Table 5.1), I further aimed to study the effect of various Ade (50 
or 100 µM) and Rib(0.5 – 10 mM) concentrations on basal adenine nucleotide and 
adenine levels after a 3 h treatment period at 34 °C.  
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I observed a significant elevation of ATP and TAN levels after 3 h incubation in 1 
mM Rib/50 µM Ade (Figure 5.2, 25.8 ± 0.7 nmol/mg protein compared to 19.1 ± 1.2 
nmol/mg protein, N = 3 - 5; p < 0.01 one way ANOVA). The tissue Ade content 
reached a maximum after 1 h incubation with no further increase after 3 h ((Figure 
5.2 B, p < 0.001 compared to control slices, one way ANOVA). In order to establish 
whether these elevated levels of TAN and ATP persisted when Rib/Ade was 
removed, I incubated slices in standard aCSF for 2 h after 3 hrs in Rib/Ade (slice age 
was 5 h). During this time tissue adenine content decreased back to baseline (Figure 
5.2 B). However, the higher TAN levels were maintained even when Rib and Ade 
were washed out of the slices (Figure 5.2 A 24.8 ± 0.4 nmol/mg protein, N = 3; p < 
0.01 compared to standard slices, one way ANOVA).  
 
When corrected for the influence of the protein content of the dead slice edges (~ 4 
nmol/mg protein; Figure 4.4), these values (~ 30 nmol/mg protein, light green bar in 
Figure 5.2 A) are close to the values reported for in vivo tissue (33.6 ± 4.7 nmol/mg 
protein as shown by the grey area for the mean ± SD in Figure 5.2 A). The elevated 
TAN and ATP levels in Rib/Ade treated slices did not significantly impact on the 
EC, which stabilised at 0.96 ± 0.001, and the ATP/AMP ratio (141.7 ± 17.5 in 
Rib/Ade treated slices, compared to 94.9 ± 23.5 for slices incubated in standard 
aCSF; Figure 5.2 C, N = 3 to 5, p > 0.05, one way ANOVA).  
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Figure 5.2: A TAN (left y axis) and ATP (right y axis) levels in slices after 3 h 
incubation in standard aCSF (-, black bars) or aCSF supplemented with 1 mM D-
Ribose (Rib)/50 μM Adenine (Ade) (+, green bars). Under these conditions, and with 
the correction for dead tissue on the edge of slices (~ 4 nmol/mg protein), slice TAN 
levels (+*, light green bar) are close to those reported in vivo (grey area represents 
the arithmetic mean ± SD for all reported values from Figure 4.4). Elevated TAN 
levels are maintained when Rib/Ade are washed out (w) of the tissue (dashed green 
bars) by transferring the slices to standard aCSF for 2 h. B  Tissue Adenine levels 
are significantly elevated after 1 h incubation in Rib/Ade (green bar), but decline 
back to baseline within 1 h washout (dashed green bars). C Energy charge (left y 
axis) and ATP/AMP levels (right y axis) are not significantly different in slices after 
3 h incubation in standard aCSF (-, black bars), in aCSF supplemented with Rib/Ade 
(+, green bars) or after washout (w) of Rib/Ade (dashed green bars) by transferring 
the slices to standard aCSF for 2 h. All values are expressed as mean ± S.E.M, N = 3 
– 5; (**) p < 0.01, (***) p < 0.001 compared to slices incubated in standard aCSF, 
one way ANOVA with Bonferroni’s multiple comparison test. Where no error bars 
can be seen they are smaller than the symbol. 
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The full time course of recovery of adenine nucleotide levels, EC and ATP/AMP 
ratio in 1 mM Rib/50 µM Ade supplemented aCSF slices from 0.5 - 5 h is shown in 
Figure 5.3. From these data it became clear that the maximal TAN levels were 
reached after a 2 h incubation (25.4 ± 2.3 nmol/mg protein) with no further increase 
after 3 h (25.8 ± 0.7 nmol/mg protein) or 5 h (25.4 ± 0.91 nmol/mg protein, Figure 
5.3 AB). Likewise the Energy charge (EC) stabilised after 1 - 2 h incubation (0.96 ± 
0.004, Figure 5.3 C). However, the ATP/AMP ratio showed a significant recovery 
after 2 h (127 ± 1.3, p < 0.01 compared to 30 min at 67 ± 7.6, one way ANOVA), 
stabilising after a 3 h incubation period (141.7 ± 17.5, p < 0.001 compared to 30 min, 
one way ANOVA).  
 
Higher Rib or Ade concentrations did not result in a further increase of ATP or TAN 
levels (Table 5.2). In contrast, tissue Ade levels were significantly elevated by 
increasing the Ade concentration from 50 μM to 100 μM (Table 5.2). However, there 
was no significant increase in the adenine nucleotide content, suggesting that the 
accumulated Ade was not salvaged to produce more ATP. Interestingely, the tissue 
Ade content was higher if slices were incubated with 1mM Rib/50 μM Ade than with 
50 μM Ade on its own, suggesting that Rib facilitated Ade uptake.  
 
These data suggest that the full recovery of slice ATP levels is limited by the lack of 
ATP precursors in the aCSF, and that incubation in Rib/Ade-supplemented aCSF for 
a recovery period of 2 - 3 h helps the viable core of brain slices to restore ATP levels 
close to reported in vivo values.  
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Figure 5.3: Full time-course of recovery of adenine nucleotide levels and energetic 
parameters from 30 min to 5 h incubation in aCSF supplemented with 1 mM 
Ribose and 50 μM adenine. Maximum TAN levels were reached after 2 h (25.4 ± 2.3 
nmol/mg protein) and did not further increase after 3 h incubation (25.8 ± 0.6 
nmol/mg protein). The ATP/AMP ratio significantly recovered after 2 h and 
stabilised after 3 h at 141.7 ± 17.5. Values are expressed as mean ± S.E.M, N = 3 – 
5.Where no error bars can be seen they are smaller than the symbol. 
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Substrate ATP 
[nmol/mg 
protein] 
ADP  
[nmol/mg 
protein] 
AMP 
[nmol/mg 
protein] 
TAN 
[nmol/mg 
protein] 
Adenine 
[nmol/mg 
protein] 
50 uM Ade 
(N = 3) 
20.7 ± 0.3 1.00 ± 0.14 0.15 ± 0.02 21.8 ± 0.4 0.55 ± 0.09 
      
1 mM Rib/ 
50 uM Ade
#
 
(N = 5) 
 
23.7 ± 0.5 1.93 ± 0.25 0.18 ± 0.03 25.8 ± 0.7*  0.95 ± 0.03* 
5 mM Rib/ 
50 uM Ade 
(N = 5) 
 
22.5 ± 0.2 1.70 ± 0.20 0.16 ± 0.02 23.1 ±1.1 0.8 ± 0.06 
10 mM Rib/ 
50 uM Ade 
(N = 5) 
 
21.7 ± 1.4 1.79 ± 0.32 0.19 ± 0.02 24.4 ± 1.3 0.82 ± 0.06 
100 uM Ade 
(N = 3) 
 
20.9 ± 1.7 2.11 ± 0.42 0.25 ± 0.06 23.3 ± 1.3 1.55 ± 0.18*** 
10 mM Rib/ 
100 uM Ade 
(N = 3) 
22.8 ± 1.0 1.84 ± 0.39 0.12 ± 0.02 25.9 ± 0.7 1.36 ± 0.14** 
 
Table 5.2: Effect of various D-Ribose (Rib) and/or adenine (Ade) concentrations 
on basal adenine nucleotide and adenine levels: Slices were incubated with Rib 
and/or Ade immediately after cutting for 3 h at 34°C. (*) p < 0.05, (**) p < 0.01, 
(***) p<0.001 compared to 50 µM Ade, one way ANOVA with Bonferri’s multiple 
comparison test.(
#
) data taken from Figure 5.2 A. 
 
 
5.2.3 Effect of Ribose and adenine on synaptic transmission 
 
To my knowledge no other metabolic effects have been reported for Rib at the 
concentration used, however a G0-protein coupled adenine receptor has been 
described and cloned recently (Bender et al., 2002; von Kugelgen et al., 2008). 
Therefore, to test whether Ade or Rib/Ade had any effects on the presynaptic release 
probability, via activation of adenine P0 receptors, I compared paired pulse ratios of 
slices incubated in standard aCSF before and after 10 min application of Ade or 
Rib/Ade. As shown in Figure 5.4 acute application of 50 μM Ade (Figure 5.4 A, N = 
4) on its own or in combination with 1 mM Rib (Figure 5.4 B, N = 5) did not change 
paired-pulse ratios when applied acutely to slices. Furthermore I did not observe any 
effects on the fEPSP baseline (105.7 ± 2 % after 10 min application of Rib/Ade). 
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These results show that the adenine receptor, if present in the hippocampus, does not 
have any presynaptic effects on neurotransmitter release.   
 
To study the effect of Rib/Ade application after slice cutting on the recovery of 
synaptic transmission, freshly cut slices were immediately transferred to a recording 
chamber submerged in aCSF at 33.4 ± 0.3°C. The stimulation strength was adjusted 
to obtain a fiber volley amplitude of -0.12 – -0.16 mV and the recovery of fEPSPs 
were monitored for 1 h in slices perfused with standard aCSF or Rib/Ade 
supplemented aCSF.  
 
The recovery of synaptic transmission after slice cutting was not different between 
control and Rib/Ade-treated slices (Figure 5.5). Within one hour after slice cutting 
fEPSP slopes recovered to -0.7 ± 0.1 mV/ms in slices incubated in standard aCSF  
and to -0.8 ± 0.1 mV/ms in slices incubated in Rib/Ade-supplemented aCSF (N = 5; 
p > 0.05, unpaired t-test). In two experiments the fEPSPs were monitored for ≥ 2 hrs, 
with no further substantial increase in slope or fEPSP amplitude. 
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Figure 5.4:  Acute application of Ade and Rib/Ade does not change presynaptic 
release probability. Paired pulse ratios for slices incubated in standard aCSF before 
(black circles) and after 10 min acute application of A 50 μM Ade (open green 
circles, N = 4) or B 50 μM Ade and 1 mM Rib (green circles, N = 5). Insets are 
representative fEPSPs at 50 ms interpulse interval before (black trace) and after 
(green trace) application of Ade or Rib/Ade. All recordings were performed at 33.4 
± 0.2 °C at a flow rate of 7 – 8 ml/min after a ≥ 3 h recovery period from slice 
cutting.   
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Figure 5.5: 1 mM Ribose (Rib) and 50 μM adenine (Ade) do not affect the time-
course of recovery of the fEPSP after slice cutting. Slices were removed from the 
vibratome upon cutting and immediately placed into the recording chamber. 
Stimulating and recording electrodes were inserted into stratum radiatum of area 
CA1 and the afferent Schaffer pathway stimulated to evoke a fiber volley of -0.12 to -
0.16 mV as seen in A. The delay between slice cutting and evoking a fiber volley was 
typically ~ 2 min. B The growth of the fEPSP at a fixed stimulation strength was 
monitored for 60 min until it stabilised. Insets are fEPSPs taken at the time points 
indicated. There was no appreciable difference between control slices in standard 
aCSF (black dots, black traces) and slices perfused with Rib/Ade (green dots, green 
traces). 
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5.3 Discussion 
 
The results of this Chapter show that brain slices have the capacity through the 
purine salvage pathway to restore their intracellular ATP pool in the viable core 
tissue to levels close to the in vivo brain if incubated with Rib and the purine base 
Ade.  
 
Rib on its own was not sufficient to cause a significant increase in basal ATP levels 
during a 3 h treatment period. The reason for this could be that after slice cutting the 
capacity of the purine salvage pathway is mostly limited by the loss of purine 
metabolites (see Chapter 4, Table 4.1). However, brain slices treated with 10 mM 
Rib had significantly elevated IMP levels. Therefore the accumulated PRPP might be 
mainly used for purine de novo synthesis, which is not sufficiently fast to increase 
tissue ATP levels during that short reperfusion period (Gerlach et al., 1971; Kleihues 
et al., 1974). Likewise a 3 h incubation with Ade on its own did not result in a 
significant elevation of basal ATP levels. This is in agreement with previous in vivo 
studies in rat heart, where for a significant increase of postischemic ATP levels 
during a 5 h reperfusion period only the combination of Rib and Ade was found to 
be effective (Zimmer, 1996). In myocytes the incorporation of HX and Ade into the 
adenine nucleotide pool is enhanced in the presence of Rib (Brown et al., 1985) and 
the authors found a maximal salvage of HX or Ade in the presence of 1 mM Rib (at a 
range of 10 µM – 10 mM Rib). In the same report, Rib/HX seemed to be less 
efficiently incorporated into the adenine nucleotide pool compared to Rib/Ade, 
which is in agreement with my own results (Table 5.1). However, tissue IMP levels 
of brain slices were elevated after 3 h Rib/HX incubation, suggesting that HX is 
efficiently salvaged by HGPRT. Compared to Ade the incorporation of HX into the 
adenine nucleotide pool is more complex since IMP can be converted to AMP or 
guanosine monophosphate (GMP), via different intermediates. Therefore the 
conversion of IMP to AMP also depends on the activity of the two enzymes 
adenylosuccinate synthetase and adenylosuccinate lyase and in myocytes the 
incorporation of HX into the ATP pool has been shown to be limited by the slow rate 
of catalysis by adenylosuccinate synthetase (Brown et al., 1985). That might explain 
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why Rib/HX treatment results in elevated IMP in brain slices but is still less 
effective in increasing ATP or TAN levels compared to Rib/Ade treatment. Thus I 
mainly focused on Rib/Ade supplementation since these metabolites are directly 
converted to AMP and since a 2 - 3 h incubation period resulted in a significant 
increase of basal ATP levels. Furthermore both substances are (i) known to be 
tolerated in humans, as discussed below and (ii) can cross the blood brain barrier, as 
discussed later. 
 
The metabolism of orally and intravenously administered Rib has been extensively 
studied in humans (Segal and Foley, 1958; Gross and Zollner, 1991; Seifert et al., 
2008) and the only side effect observed was mild hypoglycemia, the reason for 
which has not been found yet. At very high concentrations (1M) Rib has been shown 
to result in glycolation of tau and α-synuclein in vitro (Chen et al., 2009; Wei et al., 
2009; Chen et al., 2010a). However, these concentrations are not physiological, with 
the normal Rib blood concentration being around 0.1-0.5 mM and blood levels 
reaching a maximum of about 5 - 6 mM (Gross and Zollner, 1991) after intravenous 
Rib infusion. Rib has been given successfully given to patients suffering from a 
variety of conditions such as congestive heart failure (Omran et al., 2003), coronary 
artery disease (Pliml et al., 1992), AMP deaminase deficiency (Gross et al., 1989) or 
fibromyalgia (Gebhart and Jorgenson, 2004).  
 
Likewise Ade has been given to humans. However, it has been shown that Ade can 
be metabolised by xanthine oxidase to 2,8-dihydroxy-adenine (Bendich et al., 1950). 
This metabolite per se is not toxic but due to its insolubility in water 2,8-dihydroxy-
adenine precipitates in the kidneys and can result in formation of kidney stones, as 
seen in patients suffering from APRT deficiency (Van Acker et al., 1977). To avoid 
this side effect Ade has to be applied with the xanthine oxidase inhibitor allopurinol 
(Greenwood et al., 1982; Simmonds, 1986). Ade/Allopurinol has been given to 
patients suffering from Lesch-Nyhan syndrome (Schulman et al., 1971; Benke et al., 
1973; Watts et al., 1974) and adenylosuccinate lyase deficiency (Jaeken et al., 1988). 
Despite the fact that adenine therapy was not successful in preventing the 
neurological damage or improving the neurological outcome in these patients, no 
adverse effects of adenine administration have been reported in these studies. In in 
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vitro studies Ade has been shown to have neurotrophic effects in cerebellar purkinje 
cells (Yoshimi et al., 2003). Furthermore a Gi-protein coupled adenine P0 receptor 
has been described (Bender et al., 2002) and cloned recently (von Kugelgen et al., 
2008) and Ade has been suggested to have a pronociceptive role in nociceptive 
sensory transmission (Matthews and Dickenson, 2004). Quantitative reverse 
transcriptase–PCR analyses of rat adenine receptor transcripts showed the highest 
expression levels in dorsal root ganglia, moderate expression in hypothalamus and 
very low expression levels in the other brain regions, including the hippocampus 
(Bender et al., 2002). I did not observe any effects of acute Ade or Rib/Ade 
application on paired pulse ratios or fEPSP baseline in brain slices, suggesting that 
the P0 receptor, if present in the hippocampus, does not have any presynaptic effects 
on neurotransmitter release.  
 
Ade is taken up by the brain by a transport mechanism shared with HX (Betz, 1985; 
Spector, 1989; Redzic et al., 2001) and the  Km value of adenine transport across the 
blood brain barrier was estimated to be 27 µM (Cornford and Oldendorf, 1975). Cell 
membranes are highly permeable to Rib (Sacerdote and Szostak, 2005) and it has 
been shown that Rib can cross the in vitro choroid plexus from the frog to the blood 
(Prather and Wright, 1970) and that its uptake competes with that of glucose (Betz et 
al., 1975). This may explain why in one study the presence of glucose may have 
affected Rib uptake (Agnew and Crone, 1967). Furthermore Rib is converted to 
PRPP in heart (Zimmer, 1998) and in brain extracts (Barsotti and Ipata, 2002), which 
might underestimate its uptake and may explain the low levels of Rib detected in 
both brain and heart in another study (Park et al., 1957). Administration of Rib to a 
patient suffering from adenylosuccinate lyase deficiency has been shown to reduce 
seizure frequency (Salerno et al., 1999), suggesting that Rib is taken up by human 
brain. However, this was not replicated in another study (Jurecka et al., 2008), which 
may reflect differences in dosing and dietary regime. These studies indicate that both 
Rib and Ade can enter the brain from the periphery, which may be exaggerated after 
injury, such as stroke, when the BBB may is compromised for several weeks 
(Strbian et al., 2008). 
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In summary this chapter shows that enhancing the purine salvage pathway with 
Rib/Ade is an effective strategy to improve the recovery of ATP levels in brain tissue 
after an ischemic insult. Furthermore my results demonstrate that brain slices have 
the capacity to increase their ATP levels close to in vivo values, which shows that the 
traditionally reported lower ATP levels (see Chapter 4 and Appendix 3) are due to a 
loss and lack of ATP precursors and not a generally compromised energetic state of 
the tissue. Therefore in the next chapter I investigated whether the increased ATP 
content of brain slices had any consequences on the electrophysiological properties 
of the tissue, before studying the effect of Rib/Ade application in in vitro ischemia 
models. 
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6 Influence of 
elevated tissue ATP 
levels on synaptic 
transmission 
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6.1 Introduction 
 
The findings of the previous chapters provide new insights into the energetic status 
of brain slices. They show that the loss of ATP precursors is responsible for the 
decreased ATP content of brain slices, and by supplementing the aCSF with adenine 
and D-Ribose, the recovery of tissue ATP levels can be improved. Since I have 
shown that neither Ade nor the combination of Rib/Ade had any appreciable effects 
on basic electrophysiological properties I further wanted to test whether the elevated 
tissue ATP levels had measurable consequences on synaptic transmission. Both ATP 
and its degradation metabolite adenosine can participate in regulation of synaptic 
transmission via activation of P1 receptors by adenosine and P2 receptors by ATP 
and other nucleotides (Cunha, 2001; Burnstock, 2006).  
 
In the CNS ATP acts as a sole neurotransmitter or as a cotransmitter, such as with 
GABA or glutamate (Pankratov et al., 2009). There are seven characterised 
ionotropic P2X receptors forming homo or heteromers and eight metabotropic P2Y 
receptors (Burnstock, 2006) and many of these receptor subtypes have been shown 
to be widely expressed in neurons and glial cells. Purinergic signalling is involved in 
neurotransmission and modulation as well as neuron-glial and glial-glial signalling 
(Fields and Burnstock, 2006). Activation of P2X receptors allows the passage of 
sodium, potassium and calcium ions and is responsible for fast excitatory purinergic 
neurotransmission (Pankratov et al., 2009). Activation of P2Y receptors can release 
calcium from intracellular stores or inhibit adenylyl cyclase activity and modulate 
ion channels (Abbracchio et al., 2009). Functional studies in hippocampal 
synaptosomes showed that ATP can modulate glutamate release via facilitation by 
P2X(1,2/3,3) receptor activation as well as inhibition by P2Y(1,2,4) receptor activation 
(Rodrigues et al., 2005). Furthermore ATP release has been implicated in 
hippocampal long term potentiation (LTP) (Wieraszko and Ehrlich, 1994), the 
electrophysiological correlate of learning and memory. However, the exact 
mechanism by which ATP influences synaptic plasticity is controversial since P2X 
receptor activation has been reported to facilitate (Almeida et al., 2003) and inhibit 
(Pankratov et al., 2002) LTP, which might reflect the complex nature of LTP 
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induction and maintenance, which is sensitive to cytosolic calcium levels (Abraham 
and Williams, 2003; Abbracchio et al., 2009). 
 
Additionally ATP can modulate synaptic transmission via its extracellular 
degradation to adenosine (see Chapter 14.3.3). A2A and A2B receptors generally 
mediate excitatory actions in the central nervous system. Activation of A2 receptors 
has been shown to result in increased acetylcholine and glutamate release as well as 
A1 receptor desensitisation (Lopes et al., 2002; Pedata et al., 2007). Likewise A3 
receptors can inhibit the action of A1 receptors resulting in enhanced 
neurotransmission (Dunwiddie et al., 1997; Pedata et al., 2007). A2A and A3 receptor 
activation can exert excitatory effects on hippocampal LTP (Costenla et al., 2001; 
Almeida et al., 2003). Despite this, the main role of adenosine in the CNS is 
inhibitory via activation of A1 receptors, which results in combined postsynaptic 
hyperpolarisation due to activation of potassium conductance and presynaptic 
inhibition of neurotransmitter release (Dunwiddie and Masino, 2001). In 
hippocampal brain slices there is a low inhibitory adenosine tone in the extracellular 
space (Dunwiddie and Diao, 1994). Furthermore adenosine release has been shown 
to modulate synaptic plasticity, such as paired pulse facilitation, long term 
depression (LTD) and LTP via A1 receptor activation (de Mendonca and Ribeiro, 
1997).  
 
Considering the above actions of ATP and adenosine, the main aim of this chapter 
was to test whether the elevated tissue ATP levels in Rib/Ade-treated hippocampal 
brain slices had any measurable consequences on basal synaptic transmission as well 
as LTP via increased ATP and/or adenosine release. 
 
I will show that the elevation of tissue ATP levels, by Rib/Ade treatment, results in 
greater activity-dependent release of adenosine and, via activation of adenosine A1 
receptors, leads to the raising of the threshold for the induction of LTP. I further 
confirmed the greater adenosine release during LTP induction in Rib/Ade-treated 
slices by measurements with adenosine biosensors and tried to determine the 
mechanism of release by using inhibitors of extracellular nucleotidases and 
equilibrative adenosine transporters.  
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6.2 Results 
 
6.2.1 Electrophysiological properties of slices incubated in Rib/Ade 
 
To establish whether the higher ATP and TAN levels in slices incubated in Rib/Ade 
would alter the electrophysiological properties of brain slices I performed 
extracellular recordings from the CA1 region of hippocampal slices. For this purpose 
input-output curves, paired-pulse facilitation and long-term potentiation (LTP) were 
compared between slices incubated for 3 - 8 h in standard aCSF, and slices incubated 
for 2 h in 1 mM Rib and 50 μM Ade then for 1 - 6 h in standard aCSF, to wash these 
agents out of the tissue. A 2 h incubation period in Rib/Ade was chosen, since slice 
TAN levels reached an asymptotic value at that time (Chapter 5, Figure 5.3). 
 
6.2.1.1 Basal synaptic transmission is normal in Rib/Ade-treated slices 
  
There was no significant difference in input-output curves (Figure 6.1 A; N = 15 - 
16) and paired-pulse ratios (Figure 6.1 B; N = 18 - 22) between the two set of slices 
(p > 0.05, one way ANOVA). This suggests that under conditions of low-frequency 
stimulation of afferent fibers, the enhanced tissue ATP levels in Rib/Ade-treated 
slices is not being released to form adenosine in the extracellular space which would, 
via inhibitory adenosine A1 receptors (A1R), inhibit glutamate release and raise the 
paired-pulse facilitation ratio.  
 
To further exclude possible differences in A1R sensitivity or adenosine uptake 
caused by treatment with Rib/Ade, I applied the selective A1R agonist N
6
-
cyclopentyladenosine (N
6
-CPA, 10 nM) (Gadalla et al., 2004) and the adenosine 
uptake inhibitors nitrobenzylthioinosine (NBTI, 5 μM)/dipyridamole (DIPY, 10 μM) 
(Frenguelli et al., 2007; Etherington et al., 2009) to both sets of slices (Figure 6.1 
CD). The concentrations chosen were submaximal for complete depression of the 
fEPSP to avoid a “floor effect” obscuring potential differences between the two sets 
of slices. Furthermore, it has been previously shown that NBTI/DIPY caused a 
depression of the fEPSP which is caused by an increased accumulation of 
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extracellular adenosine (Frenguelli et al., 2007; Etherington et al., 2009) and which 
can be reversed with A1R antagonists (Pearson et al., 2001).  
 
The rate and extent of fEPSP depression after a 15 min application of N
6
-CPA was 
the same in control (50.0 ± 1.6 %; N = 5) and Rib/Ade-treated slices (50.4 ± 1.6 %; 
N = 5; p > 0.05, unpaired t-test, Figure 6.1 C). Likewise, application NBTI/DIPY for 
40 min resulted in the same rate and amount of depression in both sets of slices (40 ± 
5.9 % for standard slices; 43 ± 3.3 % for Rib/Ade treated slices; N = 4; p > 0.05, 
unpaired t-test, Figure 6.1 D). These data suggest that Rib/Ade pre-treatment and/or 
increased tissue ATP levels do not influence the sensitivity of the A1R to agonists 
nor the activity of equilibrative adenosine transporters.  
 
To further exclude the possibility of differences in adenylyl cyclase activation and 
cAMP formation, due to adenine exposure and potential activation of the adenine P0 
receptor (Bender et al., 2002) between Rib/Ade-treated slices and slices incubated in 
standard aCSF, I applied 50 μM forskolin, an adenylyl cylcase activator, to both sets 
of slices and compared the increase in fEPSP slopes. There was no significant 
difference in forskolin-induced potentiation between Rib/Ade-treated slices and 
slices incubated in standard aCSF (Figure 6.1 E; 147.4 ± 9.8 % in standard slices and 
159.1 ± 12.9 % in Rib/Ade-treated slices; N = 3 - 4; p < 0.05 compared to baseline 
prior to application of forskolin, p > 0.05 between standard slices and Rib/Ade-
treated slices at 20 min after application of forskolin, one way ANOVA). Paired-
pulse facilitation was similarly affected by forskolin in standard slices and Rib/Ade-
treated slices (Figure 6.1 F; N = 3 - 4, p > 0.05 between standard slices and Rib/Ade-
treated slices, unpaired t-test). This suggests that adenylyl cyclase activation and 
cAMP production is not impaired in Rib/Ade-treated slices.  
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Figure 6.1: Basal synaptic transmission is not different between slices incubated 
in standard aCSF and slices treated for 2 h in 1mM D-Ribose (Rib) and 50 μM 
Adenine (Ade). A Input-output curves (N = 15 - 16) and B paired-pulse ratios (N = 
18 - 22) for slices incubated in standard aCSF (black dots) and slices treated for 2 h 
with Rib/Ade supplemented aCSF (green dots). Insets are representative fEPSPs 
from 10 – 300 A (A) and at 50 ms interpulse intervals (B) for control (black traces) 
and Rib/Ade treated slices (green traces). C There was no difference in the rate or 
magnitude of fEPSP depression in response to the selective A1R agonist N
6
-
cyclopentyladenosine (N
6
-CPA, 10 nM; N = 5) or D the combination of the 
adenosine uptake inhibitors nitrobenzylthioinosine (NBTI, 5 μM)/dipyridamole 
(DIPY, 10 μM; N = 4) in standard slices (black dots) or Rib/Ade-treated slices 
(green dots). E Likewise forskolin-induced potentiation (50 μM) in standard slices 
(black dots) and Rib/Ade treated slices (green dots) was not different  (N = 3 - 4) 
and F the decrease in paired-pulse facilitation (N = 3 - 4) was similar in both sets of 
slices. Recordings were performed at 33.4 ± 0.2 °C at a flow rate of 7 - 8 ml/min 
after a ≥ 3 h recovery period from slice cutting. All values are presented as mean ± 
S.E.M. No significant differences observed between standard and Rib/Ade-treated 
slices with unpaired t-tests or one way ANOVA with Bonferroni’s multiple 
comparison test. Where no error bars can be seen they are smaller than the symbol. 
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6.2.1.2 Long-term potentiation is impaired in Rib/Ade-treated slices 
 
Slices incubated in standard aCSF showed robust LTP 55 - 60 min after tetanic 
stimulation (1 train of 100 shocks at 100 Hz; Figure 6.2 A; 135 ± 5.8 % of baseline; 
N = 9; p < 0.001 compared to 5 min baseline prior to tetanic stimulation, one way 
ANOVA). However, LTP in slices incubated for 2 h in 1 mM Rib and 50 μM Ade 
decayed back to baseline 60 min after tetanic stimulation, (108 ± 4.9 % of baseline; 
N = 11; p > 0.05 compared to 5 min baseline prior to tetanic stimulation, one way 
ANOVA), and was significantly lower in amplitude than LTP in control slices 
incubated in standard aCSF (Figure 6.2 B, p < 0.001 from 55 – 60 min after LTP 
induction, one way ANOVA).  
 
 
 
Figure 6.2: LTP induction with tetanic stimulation is impaired in slices treated for 
2 h in 1 mM D-Ribose (Rib) and 50 μM Adenine (Ade) A LTP after tetanic 
stimulation (1 x 100 stimuli at 100 Hz) in slices incubated in standard aCSF (black 
dots, N = 9) and slices incubated for 2 h in Rib/Ade-supplemented aCSF (green dots 
, N = 11). B Comparison of the last five minutes of LTP in each set of slices. Insets 
are representative of fEPSPs before (solid lines) and 60 min after the induction of 
LTP (dashed lines). Recordings were performed at 33.4 ± 0.2 °C at a flow rate of 7 - 
8 ml/min after a ≥ 3 h recovery period from slice cutting. All values are presented as 
mean ± S.E.M. (***) p < 0.001, one way ANOVA. 
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The fact that stable recordings could be achieved in Rib/Ade-treated slices over the 
same time period (Figure 6.3 A) argues against baseline drift as being the cause for 
the observed decay in LTP. Furthermore acute application of Ade (Figure 6.3 B) or 
Rib (Figure 6.3 C) alone, or both in combination (Figure 6.3 C) did not impair 
tetanus-induced LTP implying a requirement for uptake and intracellular conversion 
to adenine nucleotides. 
 
 
 
Figure 6.3: A Baseline stability in electrophysiological recordings of slices treated 
with 1 mM D-Ribose and 50 μM Adenine for 2 h over the time course of LTP 
experiments, N = 4. Acute application for 10 min of B 50 μM Adenine (Ade), C 1 
mM Ribose (Rib) or D both in combination, does not prevent a stable induction of 
tetanus-induced LTP (1 train of 100 pulses at 100 Hz). Recordings were performed 
at 33.4 ± 0.2 °C at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from 
slice cutting. All experiments were performed interleaved over the same time period, 
however for the presentation of the data the different treatments were split up in 
Figure 6.3 BCD with the control values being the same in all three figures. For 
statistical tests all values were compared simultaneously. Values are expressed as 
mean ± S.E.M, N = 4 - 5. No statistical differences between groups were observed 
with one way ANOVA and Bonferroni’s multiple comparison test. 
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A potential reason for the impaired LTP stabilisation in Rib/Ade-treated slices might 
be that, due to the higher TAN pool, enhanced synaptic activity during tetanic 
stimulation causes the activity-dependent release of ATP and/or its metabolite 
adenosine. To test this I incubated slices in the ATP P2 receptor antagonist PPADS 
(10 μM) and A1R antagonist 8-CPT (1 μM) prior to the induction of LTP.  
 
Pre-incubation with PPADS did not prevent the decay of LTP in Rib/Ade-treated 
slices (Figure 6.4; N = 4). These observations suggest that if ATP is being released 
during tetanic stimulation it is not directly responsible via P2 receptors for the 
impairment of LTP. 
 
 
Figure 6.4: 10 μM PPADS applied for 10 min prior to tetanic stimulation (1 train of 
100 pulses at 100 Hz) in slices treated with 1 mM D-Ribose and 50 μM Adenine for 2 
h does not prevent the impairment of LTP. Recordings were performed at 33.4 ± 0.2 
°C at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from slice cutting. 
Values are expressed as mean ± S.E.M, N = 4. 
 
 
To test for a role for adenosine A1 receptors, I applied 8-CPT (1 μM), a selective 
A1R antagonist, to slices which had either been pre-treated with Rib/Ade or 
incubated in standard aCSF. Ten minutes after acute application of 8-CPT fEPSPs 
increased to 121.4 ± 0.7 % in standard slices (N = 6; data not shown) and to 124.1 ± 
0.5 % in Rib/Ade-treated slices (N = 8) and was associated with a similar decrease in 
PPF in both (7.5 %). Both these changes in synaptic transmission are indicative of 
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the removal of a basal adenosine A1R-dependent inhibitory tone. The fact that the 
changes were similar between the two conditions argues against the possibility of an 
increased basal adenosine tone in Rib/Ade-treated slices. This is consistent with 
observations of similar tissue adenosine levels in both sets of slices after a 3 h 
incubation (see next chapter Figure 7.6 E, standard slices: 0.05 ± 0.004 nmol/mg 
protein; N = 3; Rib/Ade-treated slices: 0.04 ± 0.002 nmol/mg protein; N = 3; p > 
0.05, unpaired t-test), and of normal basal transmission and paired-pulse facilitation 
in Rib/Ade-treated slices (Figure 6.1).  
 
Having established that the basal handling and effects of adenosine were similar in 
control and Rib/Ade-treated slices I next examined the effect of the A1R antagonist 
on tetanus-induced LTP with or without prior Rib/Ade-treatment. LTP was induced 
when a stable fEPSP baseline of 15 min was collected, approximately 30 - 40 min 
after application of 8-CPT. Both sets of slices showed robust LTP in the presence of 
8-CPT 55 - 60 min after tetanic stimulation (Figure 6.5 AB, 143 ± 6.0 % in standard 
slices and 154 ± 6.7 % in Rib/Ade-treated slices; N = 5 - 6; p < 0.001 compared to 5 
min baseline prior to tetanic stimulation, p > 0.05 between standard slices and 
Rib/Ade-treated slices 55 - 60 min after tetanic stimulation, one way ANOVA). This 
suggests that the activity-dependent accumulation of extracellular adenosine 
contributes to the impairment of LTP induction in Rib/Ade-treated slices.  
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Figure 6.5: A LTP after tetanic stimulation and in the presence of 8-CPT in slices 
incubated for 2 h in Rib/Ade-supplemented aCSF (grey circles, N = 6) and slices 
incubated in standard aCSF (black circles, N = 5). B Comparison of the last five 
minutes of LTP in each set of slices. Insets are representative of fEPSPs before (solid 
lines) and 60 min after the induction of LTP (dashed lines). Recordings were 
performed at 33.4 ± 0.2 °C at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery 
period from slice cutting. All values are presented as mean ± S.E.M. (***) p < 0.001 
compared to 5 min baseline prior to LTP induction, one way ANOVA. 
 
 
The deficit in LTP induction upon tetanic stimulation in Rib/Ade treated slices might 
represent a raising of the threshold for LTP by the activity-dependent accumulation 
of extracellular adenosine and activation of inhibitory A1Rs. This hypothesis predicts 
that stronger activation of postsynaptic neurons should overcome this threshold. 
Accordingly, I utilised a theta-burst stimulation (TBS) LTP induction protocol 
(Larson et al., 1986), which is known to deliver sustained glutamatergic excitation 
whilst causing fatigue of GABA-mediated inhibition and hence greater activation of 
NMDA receptors (Chen et al., 2010b). 
 
Control and Rib/Ade-treated slices were stimulated with two TBS at 5 min intervals 
(2 x 10 trains of 4 pulses at 100 Hz with 200 ms intervals, ie 80 pulses in total). This 
protocol resulted in robust LTP in both standard and Rib/Ade-treated slices 55 - 60 
min after TBS (Figure 6.6 A; 150.2 ± 7.6 % in standard slices and 140.0 ± 7.1 % in 
Rib/Ade-treated slices; N = 6 - 7; p < 0.001 compared to 5 min baseline prior to 
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TBS, p > 0.05 between standard slices and Rib/Ade-treated slices at 55 - 60 min after 
TBS, one way ANOVA). One TBS (40 pulses) resulted in smaller LTP 55 - 60 min 
after TBS and showed little difference between standard and Rib/Ade-treated slices 
(Figure 6.6 B; 137.7 ± 9.5 % in standard slices and 126.2 ± 5.0 % in Rib/Ade-treated 
slices; N = 6; p < 0.01 for standard slices and p < 0.05 for Rib/Ade treated slices 
compared to 5 min baseline prior to TBS, p > 0.05 between standard slices and 
Rib/Ade-treated slices at 55 - 60 min after TBS, one way ANOVA). However, 20 
pulses (5 x 4 pulses at 100 Hz, 200 ms apart) resulted in significant LTP in standard 
slices, but not in Rib/Ade-treated slices 55 - 60 min after TBS (Figure 6.6 C; 131.6 ± 
2 % in standard slices and 117.8 ± 6.6 % in Rib/Ade-treated slices; N = 3 - 4; p < 
0.01 for standard slices and p > 0.05 for Rib/Ade treated slices compared to 5 min 
baseline prior to TBS, one way ANOVA). A comparison of the magnitude of LTP vs 
the number of TBS pulses (Figure 6.6 D) reveals a consistent inhibitory influence of 
Rib/Ade treatment on the magnitude of LTP.  
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Figure 6.6: LTP is not different in slices incubated for 2 h in Rib/Ade-supplemented 
aCSF (green circles) and standard aCSF (black circles) when either two (A; 10 
trains of 4 pulses delivered at 100 Hz and  at 200 ms interval, 5 min apart; 80 pulses 
in total; N = 6 - 7) or one (B; 40 pulses in total; N = 6 for both) theta-burst 
stimulation (TBS) are delivered. C In contrast, a briefer TBS (5 trains of 4 pulses, 20 
pulses in total) resulted in significant LTP in standard slices 55 - 60 min after TBS 
(black circles, N = 3 from 2 animals), but not Rib/Ade-treated slices (green circles, 
N = 4 from 3 animals). D Plot of pulse number versus magnitude of LTP 55 - 60 min 
(20, 40, 80 pulses) or 30 min (120 pulses) after induction in standard and Rib/Ade-
treated slices. Note that throughout the pulse number range Rib/Ade-treated slices 
give rise to lower LTP, which falls below significant LTP induction threshold at 20 
pulses. Data for 120 pulses is obtained from Figure 6.9 A with 120 pulses delivered 
via 3 x 40 pulse theta trains at 10 s intervals with LTP measured after 30 min. All 
insets are representative of fEPSPs before (solid lines) and 60 min after the 
induction of LTP (dashed lines). Recordings were performed at 33.4 ± 0.2 °C at a 
flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from slice cutting. All values 
are presented as mean ± S.E.M. 
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To confirm that TBS resulted in greater depolarisation compared to tetanic 
stimulation, I measured the area associated with each pulse induced by tetanic 
stimulation (100 pulses) and TBS (40 pulses) in a manner similar to that recently 
described (Chen et al., 2010b). In accordance with the authors findings, a 
comparison of the normalized cumulative area evoked by each pulse in a tetanus and 
TBS (Figure 6.7) revealed a dramatic difference between the two: during a tetanus, 
most of the depolarisation had occurred within the first 20 pulses, whereas during 
TBS the depolarisation increased almost linearly during the 40 pulse train. 
 
Furthermore, during a tetanus, there was evidence of a fatigue of transmission in 
Rib/Ade-treated slices occurring at the later stages of the train (> 20 pulses; Figure 
6.7 A). This was prevented in slices treated with 8-CPT (Figure 6.7 B) and is 
consistent with a gradual synaptic accumulation of adenosine. Indeed, the apparent 
enhancement in CPT/Rib/Ade-treated slices may reflect an action of adenosine on 
facilitatory adenosine A2 (Kessey and Mogul, 1998; Fujii et al., 1999; Almeida et al., 
2003) or A3 receptors (Costenla et al., 2001). In contrast, this Rib/Ade-induced 
fatigue was hardly present during 1 TBS (Figure 6.7 A), 2 TBS given 5 min apart 
(Figure 6.7 C), or 3 TBS given 10 seconds apart (Figure 6.7 D/E) suggesting rapid 
clearance of adenosine in the 200 ms between each 4 x 100 Hz stimuli. An 
examination of the cumulative depolarisation evoked by tetanic stimulation (Figure 
6.7 A) predicted that around 20 pulses was the threshold for Rib/Ade-treated slices to 
inhibit the induction of TBS LTP since this was the exactly the point at which 
cumulative tetanic depolarisations diverged between standard and Rib/Ade treated 
slices and also equivalent to the number of TBS pulses required to evoke the 
maximal tetanic depolarisation in Rib/Ade. Interestingly, as shown before this theta-
burst induction protocol (20 pulses) resulted in significant LTP in standard slices but 
not in Rib/Ade treated slices (Figure 6.6 E).  
 
These data point to the release of either ATP or adenosine upon electrical 
stimulation, which, via adenosine A1Rs, inhibits the induction of LTP in response to 
tetanic stimulation in Rib/Ade treated slices. Importantly, this impairment can be 
overcome by additional stimulation suggesting that the elevated levels of tissue ATP 
translate into raising the threshold for LTP induction. 
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Figure 6.7: Theta-burst stimulation (TBS) results in stronger depolarisation than 
tetanic stimulation. A The cumulative pulse area (mV*ms) from the data from 
Figure 6.2 A and Figure 6.6 B is expressed as the fold increase of the first pulse area 
for tetanic stimulation (100 pulses, 100 Hz) and TBS (10 trains of 4 pulses, 200 ms 
apart, 100 Hz) in both standard slices (black dots) and slices pre-treated with 1 mM 
D-Ribose (Rib)/ 50 μM adenine (Ade) for 2 h (green dots). TBS stimulation resulted 
in significantly greater depolarisation than tetanic stimulation in both sets of slices. 
Furthermore, during a tetanus, there was evidence of an influence of Rib/Ade in 
causing fatigue of transmission during the later stages of the train (> 20 pulses), 
which is consistent with a gradual synaptic accumulation of adenosine. B A similar 
analysis of the tetanus train files of standard and Rib/Ade slices in the presence of 8-
CPT (Figure 6.5 A) shows that the fatigue observed in Rib/Ade slices is prevented 
and may reflect an action of adenosine on facilitatory adenosine A2A or A3 receptors. 
N = 6. The Rib/Ade-induced fatigue was not obvious during A 1 TBS C 2 TBS given 
5 min apart (Figure 6.6 A) or D/E 3 TBS given 10 seconds apart (Figure 6.8 A). 
Cumulative pulse areas were expressed as fold increase from the first pulse area in 
each train. N = 4 – 7;  All values are presented as mean ± S.E.M.  
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6.2.2 Real time measurement of adenosine release during LTP induction 
 
To further test whether the higher TAN levels in Rib/Ade-treated slices results in a 
greater accumulation of extracellular adenosine during periods of electrical 
stimulation of afferent fibers I used adenosine biosensors (Frenguelli et al., 2003) to 
measure the real-time release of adenosine during TBS stimulation and LTP 
induction. The sensors (adenosine and null sensors) were placed in stratum radiatum 
of the CA1 region of hippocampal slices between the recording and stimulating 
electrodes.  
 
I could not detect any measurable release of adenosine during tetanic stimulation 
(100 Hz, 1 s, Figure 6.8) or consistently with one TBS, presumably because the 
released adenosine is below the limit of detection for adenosine biosensors (50 nM) 
or because the released adenosine remained close to the side of release unavailable to 
the enzymes in the sensor.  
 
 
 
Figure 6.8: LTP induction using tetanic stimulation does not result in adenosine 
release. Shown is an example trace for a Rib/Ade treated slice with the null sensor 
(Null, upper trace) and adenosine biosensor trace (Ado, lower trace). The traces 
were not subtracted and the baseline is shown by the dashed black line in the 
adenosine sensor trace. 
 
For this reason I used a more intense protocol that would be more likely to result in 
greater adenosine release and sufficient spill-over of adenosine to be detected by the 
sensors. Accordingly, with a multiple TBS stimulation protocol (10 trains of 4 pulses 
at 100 Hz, 200 ms apart, repeated 3 times at 10 s intervals; Figure 6.9 A) I was able 
to detect a rise in extracellular adenosine in slices incubated in standard aCSF and 
slices treated with Rib/Ade (Figure 6.9 B).  
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Rib/Ade-treated slices released significantly more adenosine during TBS stimulation 
as measured by integrating the area under the adenosine signal at the start of TBS 
stimulation to 5 min after stimulation (Figure 6.9 B; 0.64 ± 0.1 μM’*min in slices 
incubated in standard aCSF and 1.98 ± 0.1 μM’*min in Rib/Ade-treated slices; N = 
3; p < 0.01, unpaired t-test). Despite this greater release of adenosine I did not 
observe any differences in LTP (Figure 6.9 A) between the 2 sets of slices. This is 
likely due to the fact that the strong stimulation protocol (Figure 6.7 DE) overcame 
the inhibitory effects of A1R.  
 
These results suggest that higher intracellular TAN/ATP levels result in increased 
activity-dependent adenosine release during periods of strong electrical stimulation, 
which can modulate the induction threshold for LTP.  
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Figure 6.9: Real time measurement of adenosine release during LTP induction 
reveals significantly higher adenosine release in slices treated for 2 h in 1mM D-
Ribose (Rib) and 50 μM Adenine (Ade). A fEPSP slopes after LTP induction with 
TBS (10 trains of 4 pulses, at 100 Hz 200 ms apart, applied 3 times with 10 s 
intervals) are not different in slices incubated for 2 h in Rib/Ade-supplemented aCSF 
(green dots, N = 4) and slices incubated in standard aCSF (black dots, N = 5). B 
fEPSP slopes and adenosine sensor traces from 1 min before and 5 min after TBS, as 
shown by the grey dotted lines in A. Adenosine sensor traces show pooled traces of 
all experiments for standard slices (black line with green area for mean ± S.E.M., 
respectively, N = 3) and Rib/Ade treated slices (white line with black area for mean 
± S.E.M., respectively, N = 3). Adenosine sensors placed between the recording and 
stimulating electrodes show significantly higher adenosine release in Rib/Ade-
treated slices during LTP induction. C Expanded time scale of the adenosine sensor 
trace during TBS, as shown in the dashed rectangle in D. All values are presented as 
mean ± S.E.M. 
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6.2.2.1 Mechanism of theta-burst induced adenosine release 
 
To establish whether the released adenosine arose from direct release of adenosine or 
from extracellular degradation of ATP, I used adenosine uptake inhibitors 
(NBTI/DIPY) and sodium polyoxotungstate (POM-1), a non-competitive inhibitor of 
ectonucleotidases (Müller et al., 2006; Wall et al., 2008). To assess the effect of 
these drugs on adenosine release, TBS-induced adenosine release was evoked twice 
(45 - 60 min apart). The first TBS stimulation was in control aCSF (in either 
standard slices or Rib/Ade-treated slices) and the second was in the presence of 
NBTI (5 μM)/DIPY (10 μM) or POM-1 (100 μM), which were applied 30 min after 
the initial TBS stimulation. Repeating TBS twice within 45 - 60 min did not affect 
adenosine release (see Figure 6.10 A). If adenosine was released directly one would 
expect the transport inhibitors to reduce TBS-induced adenosine accumulation as 
they represent a major efflux pathway for adenosine into the extracellular space 
(Baldwin et al., 2004). If extracellular adenosine arose from the metabolism of ATP, 
POM-1 should reduce TBS-induced adenosine release. 
 
The effectiveness of POM-1 to inhibit ATP breakdown in hippocampal brain slices 
was assessed by inserting adenosine biosensors into slices and measuring adenosine 
production following exogenous ATP application in the presence and absence of 
POM-1 (Wall et al., 2008). In the absence of POM-1 50 μM ATP yielded 3.5 ± 0.2 
μM’ adenosine. After POM-1 application for 5 min ATP breakdown was inhibited 
by 30 ± 3 % (2.5 ± 0.1 μM’; N = 3; p > 0.05 compared to initial response, one-way 
ANOVA) and after 15 min application by 42 ± 2 % (2 ± 0.2 μM’; N = 3; p < 0.05 
compared to initial response, one-way ANOVA; Figure 6.10 BC), which was 
reversible after 10 min washout. I therefore decided to wait 15 min after POM-1 
application to study the effect of POM-1 on TBS-induced adenosine release.  
 
In the presence of POM-1 TBS-induced adenosine release was variable but showed 
no evidence of inhibition of adenosine release. In fact the reverse was observed: 
POM-1 seemed to increase TBS-induced adenosine release in both standard and 
Rib/Ade slices (Figure 6.10 A). This could represent an off-target effect, as has been 
suggested exist in the use of POM-1 (Wall et al., 2008), or could reflect a previously 
Chapter 6 
141 
 
described ATP-mediated facilitation of adenosine release via the activation of ATP 
P2 receptors (Almeida et al., 2003). To address this I incubated Rib/Ade-treated 
slices with the P2 Receptor antagonist PPADS (10 μM) for 10 min before TBS 
stimulation. PPADS had no significant effect on adenosine release in Rib/Ade-
treated slices (2.0 ± 0.41 μM’*min for Rib/Ade treated slices; N = 10; and 2.0 ± 0.61 
μM’*min for Rib/Ade-treated slices in the presence of PPADS; N = 3; p > 0.05, one 
way ANOVA) and indeed did not affect the increased TBS-induced adenosine 
release in the presence of POM-1 (2.8 ± 0.45 μM’*min for Rib/Ade-treated slices 
after POM-1 application; N = 4, and 2.3 and 3.3 μM’*min in two Rib/Ade-treated 
slices in the presence of POM-1 and PPADS; Figure 6.10 A). These negative results 
with the ectonucleotidase inhibitor POM-1 argue against an appreciable release of 
ATP and extracellular conversion to adenosine. 
 
In contrast, application of NBTI/DIPY for 30 min resulted in a 50 % reduction in 
TBS-induced adenosine release in both sets of slices (Figure 6.10 A, 50.3 ± 17.0 % 
for control slices; N = 4; p = 0.06; 49.2 ± 11.0 % for Rib/Ade-treated slices; N = 3; p 
= 0.04, paired t-test), suggesting a role of equilibrative adenosine transporters in the 
release of adenosine in response to high-frequency stimulation of afferent fibers. 
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Figure 6.10: Effect of adenosine uptake and ectonucleotidase inhibitors on 
adenosine release upon TBS (10 trains, 4 pulses, 100 Hz, 200 ms apart, repeated 3 
times with 10 s intervals) in standard slices (black bars) and slices pre-treated with 
1 mM D-Ribose (Rib)/50 μM adenine (Ade) (green bars). A Adenosine release was 
measured by integrating the area under the adenosine signal from the start of TBS to 
5 min after stimulation. Rib/Ade-treated slices release significantly more adenosine 
in response to the first TBS than standard slices (N = 8 - 13; p < 0.01, one-way 
ANOVA with Bonferroni’s multiple comparison test). To assess the effect of the 
above mentioned drugs on adenosine release, TBS-induced adenosine release was 
evoked twice. The first TBS was in standard aCSF (first release), whereas the second 
one was either in standard aCSF (second release, 45 - 60 min later) or in the 
presence of adenosine uptake inhibitors nitrobenzylthioinosine (NBTI, 5 μM) and 
dipyridamole (DIPY, 10 μM), or the ectonucleotidase inhibitor sodium 
polyoxotungstate (POM-1, 100 μM). Both drugs were applied 30 min after LTP 
induction, and NBTI/DIPY was washed on for 30 min, whereas POM-1 was washed 
on for 15 min before the second TBS. The effect of PPADS was only tested in 
Rib/Ade-treated slices and the first release was induced after 10 min application of 
10 μM PPADS, whereas the second release was induced 45 min later after 15 min 
application of POM-1 in the continuous presence of PPADS (N = 2). NBTI/DIPY 
resulted in a consistent 50 % reduction in adenosine release in both sets of slices (N 
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= 3 - 4), whereas POM-1 resulted in a variable increase of adenosine release (N = 4 
- 5). All values are presented as mean ± S.E.M. B POM-1-mediated inhibition of 
ATP breakdown in hippocampal brain slices was assessed by inserting adenosine 
biosensors in slices and measuring the adenosine production following ATP 
application (50 μM), under control conditions (black bar, control) and after 
application of POM-1 for 5 min (red bar) or 15 min (orange bar), as well as after 
washout of POM-1 for 10 min (black bar, washout). The adenosine production 
induced by ATP breakdown was reduced by 41 % after 15 min application of POM-
1, which reversed on POM-1 removal (N = 3; p < 0.05, one-way ANOVA with 
Bonferroni’s multiple comparison test.). All values are presented as mean ± S.E.M. 
C An example of unprocessed traces obtained from null and adenosine (ado) 
biosensors in parallel with continuous extracellular field recordings (fEPSP) 
showing the effects of POM-1. Periodic deflections reflect fEPSPs evoked at 15 s 
intervals.  
 
 
 
6.3 Discussion 
 
As shown in the previous chapter Rib/Ade-treatment is an effective intervention to 
restore tissue nucleotide levels close to those observed in vivo. Results from this 
chapter show that this does not have a bearing on basal synaptic transmission, 
paired-pulse facilitation, or the tonic handling and effects of extracellular adenosine 
in terms of sensitivity to an agonist (N
6
-CPA), antagonist (8-CPT) or uptake 
inhibition (DIPY/NBTI). Instead, I observed a slow decline of LTP after tetanic and 
weak TBS in Rib/Ade-treated slices. A likely explanation for this is that the higher 
TAN levels resulted in greater activity-dependent adenosine release, thereby 
preventing a stable expression of LTP in an A1R-dependent manner. This is further 
emphasised by the analysis of the individual responses during the tetanus, which 
were consistently lower in Rib/Ade-treated slices than in control slices. Additionally, 
the application of the A1R antagonist rescued the decline of tetanus-induced LTP in 
Rib/Ade-treated slices and reversed the fatigue of the fEPSP during the tetanus. This 
latter observation may reflect a facilitatory action on the fEPSP by adenosine acting 
on A2 or A3 receptors (Kessey and Mogul, 1998; Fujii et al., 1999; Costenla et al., 
2001; Almeida et al., 2003). 
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It is known that activity-dependent adenosine release regulates synaptic transmission 
(Mitchell et al., 1993; Manzoni et al., 1994; Wall and Dale, 2008). Indeed, the use of 
A1R antagonists facilitate LTP, suggesting that endogenous adenosine exerts an 
inhibitory influence on LTP induction (de Mendonca and Ribeiro, 1994; Forghani 
and Krnjevic, 1995; Fujii et al., 2000; Rex et al., 2005), especially when used with 
weak stimulation protocols (Arai and Lynch, 1992; de Mendonca and Ribeiro, 
2000). Interestingly, the threshold for adenosine-dependent regulation of TBS, based 
on the facilitatory actions of an A1R antagonist, was 20 pulses (Arai and Lynch, 
1992; de Mendonca and Ribeiro, 2000), consistent with my predictions based on 
tetanic and TBS cumulative depolarisations, and experiments with Rib/Ade-treated 
slices. These observations and my own results point towards an adenosine A1R-
dependent regulation of LTP, which is influenced by the levels of intracellular 
adenine nucleotides. 
 
The inhibitory effect of A1R activation on LTP induction in Rib/Ade-treated slices 
could be overcome by using stronger TBS protocols (40, 80 or 120 pulses). This 
likely arises through greater postsynaptic depolarisation across the duration of the 
train compared to tetanic stimulation, allowing more effective engagement of 
NMDA receptors (Chen et al., 2010b). My analysis of the stimulus trains provides a 
potential additional mechanism: the adenosine A1R-dependent fatigue of the fEPSP 
during a tetanus was not observed during TBS. This may reflect the fact that the 200 
ms burst spacing may allow time for the removal of extracellular adenosine between 
stimulus trains either through reuptake, metabolism or diffusion. Thus, to the two 
known actions of TBS that make it an effective and naturalistic stimulus for LTP 
induction, postsynaptic depolarisation and GABA-ergic fatigue, my results may now 
potentially add a third: minimising the intraburst synaptic accumulation of 
extracellular adenosine. 
 
Earlier studies using HPLC have shown increased adenosine release during 
prolonged electrical stimulation (Lloyd et al., 1993; Sciotti et al., 1993; Cunha et al., 
1996). In the present study I was able to detect in real time the release of adenosine 
during TBS, effectively ~ 6 s of stimulation. Rib/Ade-treated slices released 
significantly more adenosine, consistent with the availability of a greater precursor 
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pool of ATP. My attempts to establish whether ATP or adenosine was released in 
response to high-frequency stimulation were made using an ectonucleotidase 
inhibitor, POM-1 (Müller et al., 2006; Wall et al., 2008) and the equilibrative 
nucleoside transporter (ENT) inhibitors DIPY/NBTI (Dunwiddie and Diao, 1994; 
Frenguelli et al., 2007; Etherington et al., 2009). As described previously (Wall et 
al., 2008), POM-1 is an effective inhibitor of ATP breakdown in slices, but failed to 
reduce, and indeed facilitated, TBS-induced adenosine release. This is unlikely to be 
due to ATP P2 receptor-mediated facilitation of adenosine release reported by others 
(Almeida et al., 2003) since the facilitation was not affected by the P2 antagonist 
PPADS. Instead, this facilitation may involve non-specific actions of POM-1 (Wall 
et al., 2008) or could potentially involve ATP heteroexchange with adenosine 
(Sperlagh et al., 2003), which is insensitive to P2 receptor antagonists, but sensitive 
to ENT inhibition. Accordingly, my observations of a 50 % reduction in TBS-
induced adenosine release by DIPY/NBTI are consistent with the direct release of 
adenosine during high-frequency stimulation. 
 
In summary the data presented here and in a recent publication (Zur Nedden et at., 
2011) shows that the physiological consequences of elevated tissue ATP levels are in 
the greater activity-dependent release of adenosine and the subsequent inhibition of 
LTP upon tetanic or weak theta-burst stimulation of afferent fibers.  
 
In a wider context, the reduced tissue ATP levels observed in vivo after cerebral 
ischemia may, via reduced extracellular adenosine and reduced activation of the 
inhibitory A1R may contribute to a further loss of neurons due to imbalances of their 
energy metabolism. Accordingly, elevation of tissue ATP levels with Rib/Ade may 
be of value in the post-ischemic brain, in vitro, in vivo, and potentially in humans. As 
described in the previous chapter both, Rib and Ade/Allopurinol have been given to 
humans. Allopurinol may itself be beneficial (Phillis et al., 1995) as it would prevent 
the metabolism of salvageable hypoxanthine to non-salvageable xanthine thereby 
providing greater substrates for the purine salvage pathway in the post-ischemic 
brain. Therefore in the next chapter I investigated the effect of Rib, Ade and 
Allopurinol on the recovery of postischemic ATP levels, the electrophysiological 
consequences, as well the effect on cell viability.  
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7.1 Introduction 
 
The brain’s energy stores are limited and therefore it relies on a constant supply of 
oxygen and glucose to maintain high intracellular levels of ATP. The depletion of 
ATP levels during periods of ischemia, as occurs during stroke, results in a loss of 
neuronal function and viability (Lipton, 1999).  Furthermore, the complete recovery 
of post-ischemic ATP levels may take up to 24 hours (Kleihues et al., 1974; Phillis et 
al., 1996) thereby prolonging the period of energy depletion and leaving the brain 
less able to deploy reparative mechanisms as well as more vulnerable to secondary 
insults. The brain mainly relies on the purine salvage pathway to restore its ATP 
levels (Gerlach et al., 1971; Mascia et al., 2000) and the reduction and incomplete 
recovery of post-ischemic ATP levels is due to a loss of salvageable ATP 
degradation metabolites, such as adenosine, inosine or hypoxanthine (Hillered et al., 
1989; Kobayashi et al., 1998; Valtysson et al., 1998; Weigand et al., 1999) as well as 
the production of the unsalvageable metabolites xanthine and uric acid by xanthine 
oxidase (Kanemitsu et al., 1988; Stover et al., 1997) (see Figure 7.1). 
 
However, as explained in the Introduction (Chapter 1 section 1.4.3) the release of 
purine metabolites is important since for example the purine nucleoside adenosine is 
known to be neuroprotective during ischemia. Adenosine, via activation of A1 
receptors reduces synaptic transmission and thereby helps cells to preserve their 
energy homeostasis during short ischemic periods (Rudolphi et al., 1992; Dunwiddie 
and Masino, 2001; Ribeiro et al., 2003). Additionally adenosine can activate A2 
receptors in cerebral blood vessels and thereby increase cerebral blood flow (Phillis, 
1989; Soricelli et al., 1995). 
 
Considering the importance of ATP in maintaining cerebral function and the 
neuroprotective role of adenosine, there are two scenarios which might improve cell 
viability and function after ischemia: pre-treatment of brain tissue with substances, 
that can either (i) increase the release of adenosine during ischemia or (ii) delay the 
degradation of ATP, or treatment of brain tissue after the ischemic insult with 
substances that help to improve the post-ischemic recovery of ATP, thereby helping 
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the brain to restore the balance of its energy metabolism. The first scenario might be 
useful for high risk stroke patients, whereas the second scenario is more useful for 
acute stroke patients. 
 
The aim of this chapter was to manipulate the decline and recovery of intracellular 
ATP levels during in vitro ischemia by (i) enhancing the purine salvage pathway 
and/or (ii) delaying the degradation of ATP during ischemia and to study the effect 
on intracellular adenine nucleotides, synaptic transmission and adenosine release. 
 
This was achieved by (i) increasing basal ATP levels with D-Ribose and Adenine 
(Rib/Ade, see Chapter 5) and/or inhibiting xanthine oxidase with allopurinol (see 
Figure 7.1). Due to the greater ATP pool in Rib/Ade-treated slices there might be a 
greater adenosine release during ischemia and additionally Rib/Ade might be useful 
in restoring post-ischemic ATP levels. Likewise pre-treatment with allopurinol has 
been shown to increase hypoxic adenosine levels in the in vivo brain (Marro et al., 
2006) and enhance the recovery of post-ischemic ATP levels (Phillis et al., 1995). 
 (ii) On the other hand I aimed to delay the degradation of ATP during ischemia 
upon incubation with creatine, which is converted to the high energy phosphate 
phosphocreatine in a reversible reaction catalyzed by creatine kinase (see Chapter 1 
section 1.4.2.1). Creatine kinase can then delay the degradation of ATP even in the 
absence of oxygen and glucose, by transferring the phosphate group from 
phosphocreatine back to ADP (see Figure 7.1). This is shown in the fact that the 
decline of neuronal phosphocreatine levels during ischemia precedes the decline in 
ATP (Lipton and Whittingham, 1982).  
 
Pre-treatment of brain tissue with allopurinol (Lin and Phillis, 1991, 1992; Phillis et 
al., 1995; Marro et al., 2006) or creatine (Whittingham and Lipton, 1981; Balestrino 
et al., 2002; Berger et al., 2004; Zhu et al., 2004) has been shown to have a 
neuroprotective effect in various in vitro and in vivo models of cerebral ischemia. As 
discussed before Rib/Ade or Rib on its own has been successfully used in various in 
vitro and in vivo models of myocardial ischemia (Zimmer, 1992, 1996).  
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Allopurinol is widely used in the treatment of gout (Smalley et al., 2000; Terkeltaub, 
2003; Pea, 2005) and leukaemia (Sahasranaman et al., 2008). Likewise creatine is 
known to be tolerated in humans (Kim et al., 2011) and is used as a performance 
enhancing supplement for athletes (Williams and Branch, 1998). Additionally 
therapeutic effects on myopathies and neurodegenerative diseases have been 
reported (Gualano et al., 2011). 
 
 
 
Figure 7.1: Degradation and restoration of ATP levels. Adenine nucleotides (ATP, 
ADP and AMP) are degraded to adenine nucleosides (adenosine and inosine), 
purine bases (hypoxanthine and xanthine) and uric acid. Substances indicated with 
an arrowhead can be released from the cell and lost to the systemic circulation. In 
the purine salvage pathways (shown in blue) the free purine bases hypoxanthine or 
adenine are combined with the activated sugar donor 5-phosphoribosyl-1-
pyrophosphate (PRPP) to build up the respective purine nucleotide IMP via 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT) or AMP via adenine 
phosphoribosyl transferase (APRT). D-Ribose and Adenine can be used to increase 
basal ATP levels via the activity of APRT. Allopurinol is a xanthine oxidase 
inhibitor, that can be used to prevent the degradation of hypoxanthine to xanthine 
and uric acid. ATP levels can be maintained through the action of creatine kinase 
(CK) by transferring a phosphate group from phosphocreatine (PCr) to ADP 
generating ATP and Creatine (Cr).  
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In this chapter I will show that it is possible to influence the decline and recovery of 
synaptic transmission as well the amount and pattern of adenosine release during 
ischemia by modulation of intracellular high energy phosphate levels with 
substances that are known to be tolerated in humans.  
 
 
7.2 Results 
 
7.2.1 Oxygen/glucose deprivation as an in vitro model for cerebral ischemia 
 
In order to test the effect of these various intereventions on the post-ischemic 
energetic and functional recovery, I first wanted to establish an in vitro ischemia 
protocol in hippocampal brain slices that would result in partial reduction of the 
tissue ATP and TAN levels as well as partial recovery of synaptic transmission. 
Oxygen/glucose deprivation (OGD), which is a commonl-used  in vitro model of 
cerebral ischemia, was induced by exposing slices to aCSF devoid of glucose and 
bubbled with 95% N2/5% CO2. The glucose in the aCSF was substituted with an 
equimolar amount of sucrose. For reperfusion (rep) studies slices were transferred 
back to standard aCSF bubbled with 95% O2/5%CO2. 
 
7.2.1.1 Effect of OGD on adenine nucleotide levels and energetic parameters 
 
7.2.1.1.1 Adenine nucleotide levels 
 
Representative HPLC traces of brain slices exposed to 5 or 10 min OGD and 
subsequent reperfusion are shown in Figure 7.2.  As seen in the individual peaks, the 
extent of the decrease of ATP levels upon OGD and the recovery during reperfusion 
depends on the duration of the ischemic insult. The decline in ATP levels is 
accompanied by a significant rise in AMP levels and other ATP degradation 
metabolites, such as adenosine and IMP.  
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Figure 7.2: Representative HPLC traces of slices exposed to oxygen/glucose 
deprivation (OGD) and subsequent reperfusion. After a 3 h recovery period from 
slice cutting (A) slices were exposed to B 5 min OGD or C 10 min OGD. Dashed 
rectangle is shown enlarged next to the traces. D 5 min OGD and subsequent 10 min 
reperfusion and  E 10 min OGD and subsequent 60 min reperfusion. Note the 
incomplete recovery of ATP after 10 min OGD. Numbers on traces refer to the 
following compounds: 1 GMP, 2 IMP, 3 Inosine (Ino) and 4 Adenosine (Ado). All 
these metabolites are elevated during OGD and decline during reperfusion. 
Bidirectional arrowheads indicate 100 milli absorbance units.  
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The changes in individual adenine nucleotide and adenosine levels are summarised 
in Figure 7.3. ATP levels decreased approximately 71 % after 5 min OGD and 93 % 
after 10 min OGD (Figure 7.3 A; from  14.0 ± 1.1 to 4.0 ± 0.9 and 0.9 ± 0.1 
nmol/mg protein respectively, N = 6 - 8, p < 0.001, one way ANOVA).  ADP 
showed an initial 2.7 fold increase after 5 min of OGD (Figure 7.3 B, from 1.3 ± 0.2 
nmol/mg protein to 3.6 ± 0.5 nmol/mg protein, N = 6 - 8, p < 0.001, one way 
ANOVA) but decreased back to pre-ischemic levels after 10 min OGD (1.2 ± 0.2 
nmol/mg protein, N = 6, p > 0.05 compared to pre-ischemic values, one way 
ANOVA). This observation has been made before in vitro (Mitani et al., 1994) as 
well as in vivo brain during global ischemia (Hertz, 2008). AMP levels increased 38-
fold after 5 min OGD and 46-fold after 10 min OGD (Figure 7.3 C; from 0.2 ± 0.02 
to 7.5  ± 0.7 and 9.1 ± 0.5 nmol/mg protein respectively, N = 6 - 8, p < 0.001, one 
way ANOVA). Likewise adenosine levels, showed a significant increase after 5 and 
10 min OGD (Figure 7.2 D; from 0.02 ± 0.005 to 0.25 ± 0.05 and 0.5 ± 0.03 
nmol/mg protein respectively, N = 5 - 8, p < 0.001, one way ANOVA). Due to 
degradation of AMP the total adenine nucleotide (TAN) pool, composed of ATP, 
ADP and AMP, declined up to 23 % after 10 min OGD (Figure 7.3 E, from 15.1 ± 
1.2 to 11.5 ± 0.7 nmol/mg protein, N = 6 - 8, p > 0.05 compared to pre-ischemic 
levels, one way ANOVA)  
 
Upon the reperfusion time points tested, there was a trend towards recovery to pre-
ischemic values for all metabolites. However, the extent of the recovery was delayed 
after 10 min OGD compared to 5 min OGD, as seen in the still significant elevation 
of AMP levels after 10 min OGD and 10 min reperfusion (Figure 7.3 C, 2.3 ± 0.24 
nmol/mg protein, N = 5, p < 0.05 compared to pre-ischemic values, one way 
ANOVA). Likewise TAN levels remained significantly reduced by about 33 % after 
10 min OGD and 10 min reperfusion (Figure 7.2 D, 10.3 ± 1  nmol/mg protein, N = 
4, p < 0.05 compared to pre-ischemic values, one way ANOVA), with no improved 
recovery after 60 min reperfusion (10 ± 0.4 nmol/mg protein, N = 4). The reduced 
TAN pool limits the potential recovery of ATP and accordingly ATP levels only 
recovered to 61 % of pre-ischemic levels after 10 min OGD and 60 min reperfusion 
(8.6 ± 0.4 nmol/mg protein, N = 4, p < 0.01, one way ANOVA).  
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Longer reperfusion periods (6 h) did not result in complete recovery of TAN levels 
(data not shown), however after 9 h incubation a ~ 20 % drop in TAN could be 
observed in time control slices (see Appendix 4, Figure 13.1), suggesting a slow 
deterioration of brain slices after prolonged incubation periods. 
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Figure 7.3: Effect of oxygen/glucose deprivation (OGD) and reperfusion (Rep) on 
tissue adenine nucleotide and adenosine levels: A ATP, B ADP, C AMP, D 
adenosine and E total adenine nucleotide (TAN) levels. Symbols refer to pre-
ischemic values (Control, 3 h recovery after slice cutting, black dots), 5 min OGD 
and subsequent 10 min reperfusion (open circles) and 10 min OGD and subsequent 
10 and 60 min reperfusion (open squares). 10 min OGD and 10 min reperfusion 
resulted in a significant reduction of the TAN pool, indicating a loss of ATP 
degradation metabolites and limiting the potential recovery of ATP upon 
reperfusion. All values are expressed as mean ± S.E.M. N = 4 - 8, (*) p < 0.05, (**) 
p < 0.01, (***) p < 0.001 between indicated groups, one way ANOVA with 
Bonferroni’s multiple comparison test. Where no error bars can be seen they are 
smaller than the symbol. All incubations were done at 34°C. 
Chapter 7 
155 
 
7.2.1.1.2 Energetic parameters 
 
The energy charge (EC) decreased to 0.14 ± 0.02 after 10 min OGD (Figure 7.4 A). 
Upon reperfusion, aerobic energy metabolism is resumed and cellular EC recovers, 
despite a decreased TAN and ATP pool (Ljunggren et al., 1974). However, pre-
ischemic EC values are not completely restored, due to the decreased ATP and still 
elevated AMP levels. Accordingly, values returned close (0.91 ± 0.01 after 5 min 
OGD 10 min reperfusion and 0.90 ± 0.005 after 10 min OGD and 60 min 
reperfusion, N = 6 - 8, p > 0.05 compared to pre-ischemic values, one way ANOVA) 
but not completely to pre-ischemic values (0.95 ± 0.001) during reperfusion. 
Furthermore the energy metabolism in slices exposed to 10 min OGD showed a 
more severe disturbance, as indicated by the slower recovery of the EC.  
 
As explained in Chapter 4, a more sensitive parameter of the energetic state of the 
tissue is the ATP/AMP ratio. Like the EC this ratio severely declined during OGD 
(Figure 7.4 B, from 70 ± 6 to 0.63 ± 0.2 after 5 min OGD and to 0.1 ± 0.01 after 10 
min OGD, N = 6 - 8, p < 0.001, one way ANOVA). Furthermore the ATP/AMP ratio 
remained significantly reduced and never reached pre-ischemic values upon the 
reperfusion time points tested (22 ± 5 after 5 min OGD and 10 min reperfusion and 
14 ± 1.1 after 10 min OGD and 60 min reperfusion, N = 4 - 5, p < 0.001 compared to 
preischemic values), suggesting a severe disturbance of the energy metabolism. 
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Figure 7.4: Effect of oxygen/glucose deprivation (OGD) and reperfusion (Rep) on 
energetic parameters: A Energy charge and B ATP/AMP ratio. Symbols refer to 
pre-ischemic values (Control, 3 h recovery after slice cutting, black dots), 5 min 
OGD and subsequent 10 min reperfusion (open circles) and 10 min OGD and 
subsequent 10 and 60 min reperfusion (open squares). Note the incomplete recovery 
of the ATP/AMP ratio after OGD. All values are expressed as mean ± S.E.M. N = 4 - 
8 , (**) p < 0.01, (***) p < 0.001 between indicated groups, one way ANOVA with 
Bonferroni’s multiple comparison test. Where no error bars can be seen they are 
smaller than the symbol. All incubations were done at 34°C. 
 
 
These results show that ATP and TAN concentrations decrease progressively with 
the duration of ischemia and that the severity of the ischemic insult negatively 
affects the recovery of ATP upon reperfusion. This is due to a reduction of the TAN 
pool, caused by a loss of ATP degradation metabolites such as adenosine. 
Furthermore the severe disruption of the energy metabolism is reflected in an 
incomplete recovery of energetic parameters upon reperfusion. 
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7.2.1.2 Effect of OGD on synaptic transmission 
 
To study the effect of OGD on synaptic transmission I performed extracellular field 
recordings in hippocampal brain slices and exposed them to 5 or 10 min OGD and 
subsequent reperfusion, similar to previous HPLC studies.  
 
As shown in Figure 7.5 synaptic transmission declined very rapidly upon exposure to 
OGD, which is mainly mediated by release of adenosine and subsequent A1 receptor 
activation (Pearson et al., 2006; Dale and Frenguelli, 2009). After 5 min OGD and 
30 min reperfusion there was a nearly complete, but still significantly reduced 
recovery of synaptic transmission (92 ± 2 % of pre-ischemic baseline, N = 4, p < 
0.01, paired t-test). However after 10 min OGD there was no recovery of synaptic 
transmission in the two slices tested (Figure 7.5 B). This is due to the fact that the 
anoxic depolarisation (AD) occurred in those slices. AD is caused by a complete loss 
of ion homeostasis, due to functional inactivation of the Na
+
/K
+
 ATPase (Somjen, 
2002), and if the AD is prolonged beyond a critical time point there is no recovery of 
electrophysiological activity in brain tissue. The occurrence of AD is marked by a 
disappearance of the presynaptic fibre volley (Frenguelli et al., 2007) (as shown by 
the arrowhead in Figure 7.5 B). The mean time to AD in control slices was 7.2 ± 0.2 
min (see Figure 7.10 C). 
 
In order to achieve a partial recovery of synaptic transmission in combination with a 
partial reduction of the total adenine nucleotide pool for studies on interventions of 
the purine salvage pathway, I choose to adjust the OGD exposure period for HPLC 
analyses to the value for the 75 % percentile of the mean time to AD in control 
slices, which was 8 min. 
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Figure 7.5: Effect of oxygen/glucose deprivation (OGD) and reperfusion on 
synaptic transmission: Brain slices were exposed to either A 5 min (N = 4) or B 10 
min OGD (N = 2) and subsequent reperfusion. Whereas 5 min OGD resulted in a 
nearly complete recovery of synaptic transmission there was no recovery of synaptic 
transmission after 10 min OGD. Arrowhead in B indicates the disappearance of the 
presynaptic fiber volley, which marks the time of anoxic depolarisation observed 
during 10 min OGD. Values in A are expressed as mean ± S.E.M. and values in B 
are expressed as mean only. Insets are fEPSP traces taken from the indicated 
timepoints. Recordings were performed at a flow rate of 6 – 7 ml/min, at 33.4 ± 1°C 
and after a ≥ 3 h recovery period from slice cutting. 
 
 
 
7.2.2 Modulation of intracellular high energy phosphate levels with Rib/Ade 
Creatine and Allopurinol – Effect on adenine nucleotide levels and ratios 
 
 
I next wanted to test the effect of manipulations of intracellular ATP and 
phosphocreatine levels on the decline and recovery of adenine nucleotides and 
energetic parameters in brain slices during OGD. The interventions were (1) pre-
treatment with 1 mM D-Ribose/50 µM Adenine (Rib/Ade) to increase basal ATP 
and TAN levels, (2) pre-treatment with 10 µM allopurinol to inhibit xanthine oxidase 
and the production of unsalvageable ATP degradation metabolites, and (3) pre-
treatment with 1 mM creatine to increase phosphocreatine levels and buffer the 
initial decline of ATP upon energy shortage. Brain slices were treated with these 
Chapter 7 
159 
 
metabolites immediately after slice cutting at 34 °C. After 3 h slices were exposed to 
8 min OGD and transferred back to the supplemented aCSF for 1 h reperfusion.  
 
The concentration of Rib/Ade (1 mM/50 µM) is based on results of Chapter 5, 
creatine was used at an equimolar concentration to Rib (1 mM) and allopurinol has 
been shown to inhibit xanthine oxidase at 10 µM in cerebellar granule cells (Atlante 
et al., 1997). The effectiveness of 10 µM allopurinol was further tested on adenosine 
biosensors, since xanthine oxidase is part of the enzyme complex (see Appendix 4, 
Figure 13.2). Allopurinol is converted to oxypurinol, the active inhibitor (Lin and 
Phillis, 1991), by xanthine oxidase itself. Therefore allopurinol gives a signal on the 
adenosine sensor trace, which gradually decreases over time due to inhibition of 
xanthine oxidase. There was a time-dependent inhibition of the initial adenosine 
response in sensors treated with allopurinol, and the response was reduced by about 
96 % after 3 h.  
 
7.2.2.1 Effect of Rib/Ade, creatine and allopurinol on pre- and post-ischemic 
adenine nucleotide levels  
 
The changes observed in individual adenine nucleotide, adenosine and IMP levels in 
slices pre-treated with Rib/Ade, creatine and allopurinol are shown in Figure 7.6. It 
was difficult to measure phosphocreatine and creatine levels with this HPLC method 
since the retention time was very close to the void volume of the column (~ 1. 5 min) 
and was contaminated by other unretained materials. However, it has been shown 
that treatment of brain slices with 1 mM creatine increases basal phoshocreatine 
levels upon a 2 h treatment period (Balestrino et al., 1999). 
 
As shown before (Chapter 5) Rib/Ade treatment results in significant elevation of 
basal ATP levels (Figure 7.6 A, 24.0 ± 1.3 nmol/mg protein compared to 18.8 ± 0.4 
nmol/mg protein in control slices, N = 5, p < 0.01, one way ANOVA), while having 
no effect on basal adenosine levels (Figure 7.6 E, 0.04 ± 0.002 nmol/mg protein 
compared to 0.05 ± 0.002 nmol/mg protein in control slices, N = 4, p > 0.05, one 
way ANOVA). Creatine and allopurinol did not change any of the metabolites tested 
under control conditions, although I observed a slight but insignificant elevation of 
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basal adenosine levels in allopurinol-treated slices (Figure 7.6 E, 0.07 ± 0.02 
nmol/mg protein, N = 4, p > 0.05 compared to control slices, one way ANOVA).  
 
As shown in Figure 7.3, upon exposure to OGD (8 min, 75 % percentile of the time 
to AD in control slices) I observed significant a decline in ATP levels (Figure 7.6 A), 
a significant rise in ADP (Figure 7.6 B), AMP (Figure 7.6 C), adenosine (Figure 7.6 
E) and IMP levels (Figure 7.6 F) upon all conditions tested.  
Interestingly, there were differences in adenosine and IMP levels (Figure 7.6 EF) in 
Rib/Ade and creatine pre-treated slices. Rib/Ade treatment resulted in significantly 
higher adenosine levels during OGD (Figure 7.6 E, 1.1 ± 0.08 nmol/mg protein in 
Rib/Ade treated slices compared to 0.8 ± 0.08 nmol/mg protein in control slices, N = 
4, p < 0.01, one way ANOVA), suggesting that the greater ATP pool results in 
greater production of adenosine upon energy shortage. Although allopurinol-treated 
slices also had elevated adenosine levels during OGD, this did not reach statistical 
significance (Figure 7.6 D, 1.0 ± 0.1, N = 3, p > 0.05 compared to control slices, one 
way ANOVA). Creatine-treated slices had significantly reduced adenosine levels 
during OGD (0.5 ± 0.03 nmol/mg protein, p < 0.05 compared to control slices, p < 
0.001 compared to Rib/Ade treated slices, N = 4, one way ANOVA), due to 
increased buffering capacity of the phosphocreatine pool and the delayed 
degradation of ATP. This is also supported by the slightly elevated ADP levels 
during OGD (Figure 7.6 B, 4.0 ± 0.6 for creatine treated slices compared to 2.6 ± 0.1 
for control slices, N = 4, p > 0.05, one way ANOVA). 
 
IMP levels were significantly higher in Rib/Ade-treated slices compared to control 
slices (Figure 7.6 F, 6.3 ± 0.2 for Rib/Ade treated slices compared to 3.6 ± 0.3 
nmol/mg protein for control slices, N = 4, p < 0.001, one way ANOVA). This 
suggests either increased degradation of AMP due to the higher ATP levels and/or 
increased salvage of accumulated hypoxanthine and/or Ade via the purine salvage 
pathway. The latter hypothesis is supported by the fact that incubation of brain slices 
with high Rib concentrations alone, which does not affect pre-ischemic ATP levels, 
also resulted in increased production of IMP during OGD (see Appendix 4, Figure 
13.3 C). In contrast, creatine-treated slices had significantly lower IMP levels (0.5 ± 
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0.03 for creatine-treated slices, N = 4, p < 0.05 compared to control slices, p < 0.001 
compared to Rib/Ade-treated slices, one way ANOVA). 
 
Upon reperfusion Rib/Ade treatment resulted in significantly better recovery of ATP 
(Figure 7.6 A, 21.8 ± 0.4 nmol/mg protein for Rib/Ade treated slices compared to 
15.3 ± 0.9 nmol/mg protein for control slices, N = 4, p < 0.001, one way ANOVA) 
and TAN levels (Figure 7.6 D, 22.0 ± 1.2 nmol/mg protein for Rib/Ade treated slices 
compared to 17.0 ± 0.9 nmol/mg protein, N = 4, p < 0.05, one way ANOVA). 
Despite the improved recovery of ATP in Rib/Ade treated slices there was still a 14 
% reduction of the TAN pool upon reperfusion, which is similar to that observed for 
control slices. In contrast, creatine treatment prevented the reduction of TAN levels 
upon reperfusion (18.9 ± 1.4 nmol/mg protein for pre-ischemic TAN levels and 19.2 
± 1.0 upon 1 h reperfusion).  
 
These results show that it is possible, by Rib/Ade or creatine pre-treatment to 
modulate the decline and recovery of intracellular adenine nucleotide levels as well 
as the production of ATP degradation and precursor metabolites, such as adenosine 
and IMP during OGD. Interestingly, allopurinol did not have a significant effect on 
any of the metabolites tested, potentially suggesting that the concentration used was 
too low. 
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Figure 7.6: Effect of Ribose/Adenine (Rib/Ade), creatine and allopurinol on the 
decline and recovery of adenine nucleotide, adenosine and IMP levels upon 
oxygen/glucose deprivation (OGD) and reperfusion (Rep). Brain slices were 
incubated in standard aCSF (black bars) or pre-treated with Rib/Ade (green bars, 1 
mM/50 µM), creatine (red bars, 1 mM) or allopurinol (blue bars, 10 µM) for 3 h at 
34°C before being exposed to 8 min OGD. For reperfusion, slices were transferred 
back to control aCSF or aCSF supplemented with these substances. HPLC analysis 
was performed immediately and A ATP, B ADP, C AMP, D total adenine 
nucleotides (TAN) as well as E adenosine and F IMP levels were measured. All 
values are expressed as mean ± S.E.M. N = 3 - 5 , (*) p < 0.05, (**) p < 0.01, (***) 
p < 0.001 between indicated groups, one way ANOVA with Bonferroni’s multiple 
comparison test.  
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7.2.2.2 Effect of Rib/Ade, creatine and allopurinol on pre- and post-ischemic 
energetic parameters 
 
As seen in Figure 7.7 none of the treatments tested had any significant effects on the 
basal EC values or the ATP/AMP ratio, although a consistently lower ATP/AMP 
ratio, due to slightly elevated AMP levels (Figure 7.6 C) was observed in 
allopurinol-treated slices (74.5 ± 8 for allopurinol treated slices compared to 125 ± 
16 for control slices, N = 4 - 5, p > 0.05, one way ANOVA).  
 
During OGD creatine-treated slices had significantly higher EC values compared to 
all other conditions (Figure 7.7 A, 0.3 ± 0.03 for creatine-treated slices compared to 
0.01 ± 0.001 for control and Rib/Ade-treated slices and 0.01 ± 0.004 for allopurinol-
treated slices, N = 3 - 4, p < 0.001, one way ANOVA), due to a better preservation of 
ATP and ADP levels as seen in Figure 7.6 AB. During reperfusion EC recovered 
nearly completely and there was no difference in any of the conditions. 
 
The ATP/AMP ratio (Figure 7.7 B) was significantly reduced upon reperfusion in 
control (38 ± 11 after 1 h reperfusion compared to a pre-ischemic value of 125 ± 16, 
N = 4 – 5, p < 0.001, one way ANOVA) and Rib/Ade-treated slices (58 ± 8 after 1 h 
reperfusion compared to a pre-ischemic value of 125 ± 20, N = 4 - 5, p < 0.01, one 
way ANOVA), but was not different in creatine- and allopurinol-treated slices. The 
reason for the first observation might be that due to the better preservation of post-
ischemic ATP and TAN levels, there was a better recovery of the energetic 
metabolism. However, the reason for the latter observation might be that the basal 
ATP/AMP ratio of allopurinol-treated slices was lower under control conditions. 
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Figure 7.7: Effect of Ribose/Adenine (Rib/Ade), creatine and allopurinol on the 
decline and recovery of energetic parameters upon oxygen/glucose deprivation 
(OGD) and reperfusion (Rep): Brain slices were incubated in standard aCSF (black 
bars) or pre-treated with Rib/Ade (green bars, 1 mM/50 µM), creatine (red bars, 1 
mM) or Allopurinol (blue bars, 10 µM) for 3 h at 34°C before being exposed to 8 
min OGD. For reperfusion, slices were transferred back to control aCSF or aCSF 
supplemented with these substances. HPLC analysis was performed immediately and 
A the energy charge (EC = (ATP + 0.5ADP)/TAN) as well as B the ATP/AMP ratio 
were determined. All values are expressed as mean ± S.E.M. N = 3 - 5 , (**) p < 
0.01, (***) p < 0.001 between indicated groups, one way ANOVA with Bonferroni’s 
multiple comparison test. Where no error bars can be seen they are smaller than the 
symbol. 
 
 
In summary these data show that creatine pre-treatment effectively preserves pre-
ischemic adenine nucleotide levels and energetic parameters upon reperfusion. 
Despite the fact that Rib/Ade increased both, pre- and post-ischemic ATP levels, 
there was still a reduction of the TAN pool by 14 % and a decreased ATP/AMP ratio 
upon 1 h reperfusion. Furthermore I observed differences in tissue adenosine levels 
during OGD upon the conditions tested. Therefore I next wanted to test the 
electrophysiological consequences of the modulation of tissue ATP and adenosine 
levels during OGD in Rib/Ade, creatine and allopurinol treated slices. 
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7.2.3 Modulation of intracellular high energy phosphate levels by Rib/Ade 
Creatine and Allopurinol – Effect on synaptic transmission 
 
 
7.2.3.1  Effect of creatine and allopurinol on basic synaptic transmission 
 
In the previous chapters I have shown that Rib/Ade had no effect on input-output 
curves or paired pulse ratios. I further wanted to test whether creatine or allopurinol 
had any effect on basic synaptic transmission. I therefore compared input-output 
curves (Figure 7.8 A) and paired pulse ratios (Figure 7.8 B) of brain slices incubated 
for 3 - 6 hrs in creatine, allopurinol or Rib/Ade + creatine and Rib/Ade + allopurinol 
with control slices. I did not observe any significant differences between any of the 
treatments tested, although a slightly elevated output was observed for Rib/Ade + 
creatine treated slices. Likewise a consistently higher paired pulse ratio was observed 
in allopurinol and Rib/Ade + allopurinol treated slices, which might reflect the 
slightly elevated basal tissue adenosine levels observed upon allopurinol treatment 
(see Figure 7.6 E). 
 
Chapter 7 
166 
 
 
Figure 7.8: A input/output curves and B paired pulse ratios for slices incubated in 
standard aCSF (black dots, N = 6), or in the continuous presence of creatine (red 
dots, 1 mM, N = 6), allopurinol (blue dots, 10 µM, N = 3), creatine + 
Ribose/Adenine (1 mM Rib/ 50 µM Ade, pink dots, N = 3) and allopurinol + Rib/Ade 
(green dots, N = 3). All values are presented as mean ± S.E.M. No significant 
differences observed between standard and Rib/Ade-treated slices with one way 
ANOVA with Bonferroni’s multiple comparison test. Where no error bars can be 
seen they are smaller than the symbol. Recordings were performed at 33.4 ± 0.2 °C 
at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from slice cutting. 
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7.2.3.2 Effect of Rib/Ade, creatine and allopurinol on the decline of synaptic 
transmission during OGD 
 
Brain slices were incubated for ≥ 3 h in Rib/Ade, creatine, allopurinol or indicated 
combinations. After a stable baseline of 20 min was collected in the continuous 
presence of these substances, slices were perfused with oxygen and glucose-free 
aCSF. The decline of synaptic transmission, which is primarily mediated by the 
release of adenosine and the activation of A1 receptors (Pearson et al., 2006; Dale 
and Frenguelli, 2009), and the time to 50 % inhibition of the initial fEPSP response 
is shown in Figure 7.9. 
 
Rib/Ade significantly accelerated the time to 50 % inhibition of fEPSP upon onset of 
OGD (Figure 7.9 B, 106 ± 2.5 seconds for Rib/Ade treated slices compared to 128 ± 
2.7 seconds for control slices, N = 10 - 12, p < 0.001, one way ANOVA) whereas 
creatine had the opposite effect (168 ± 7 seconds, N = 8, p < 0.001 compared to 
control slices, one way ANOVA), reflecting potential differences in adenosine 
release. Allopurinol on its own did not affect the time to 50 % inhibition (129 ± 9.5 
seconds, N = 5, p > 0.05 compared to control slices, one way ANOVA). I further 
studied the effect of combined treatment with allopurinol + Rib/Ade, since Ade has 
to be applied with allopurinol to prevent its degradation to the nephrotoxic 
metabolite 2,8-dihydroxy-adenine (see Chapter 5). Interestingly, this combination 
further accelerated the time to 50 % inhibition of fEPSPs during OGD (96 ± 5.2 
seconds, N = 6, p < 0.001 compared to control slices, one way ANOVA). This 
suggests that xanthine oxidase inhibition can influence the adenosine release during 
OGD, which becomes more obvious if the adenosine production is enhanced by 
Rib/Ade supplementation and is consistent with slightly elevated tissue adenosine 
levels during OGD in allopurinol treated slices (Figure 7.6 E). The combination of 
Rib/Ade and creatine, which would result in both increased ATP and 
phosphocreatine levels, thereby potentially counteracting each other, resulted in 
similar decline of fEPSPs as in control slices (133 ± 5 seconds, p > 0.05 compared to 
control slices, one way ANOVA). 
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Figure 7.9: Decline of synaptic transmission during OGD in Ribose/Adenine 
(Rib/Ade), creatine and allopurinol treated slices: The decline of fEPSP traces 
during the first 5 min of OGD is shown in A and the time to 50 % inhibition of the 
initial response, as calculated by fitting a Boltzmann sigmoidal curve to each 
individual experiment is shown in a scatter plot in B. Symbols refer to: Control 
slices (black dots, N =12) and slices treated with Rib/Ade (green dots, 1 mM/50 µM, 
N = 10), creatine (red dots, 1 mM, N = 8), allopurinol (blue dots, 10 µM, N = 5), 
Rib/Ade + Creatine (orange dots, N = 6) and Rib/Ade + Allopurinol (pink dots, N = 
6). Recordings were performed at 33.4 ± 0.2 °C at a flow rate of 7 - 8 ml/min after a 
≥ 3 h recovery period from slice cutting. Values in A are presented as mean ± S.E.M 
and values in B as individual experiments with the mean shown as black horizontal 
line. (**) p < 0.01, (***) p < 0.001, one way ANOVA with Bonferroni’s multiple 
comparison test. 
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7.2.3.3 Effect of Rib/Ade, creatine and allopurinol on the time to anoxic 
depolarisation 
 
 
As explained above, the anoxic depolarisation (AD) marks the time of a complete 
loss of ion homeostasis. If the duration of AD is prolonged beyond a critical point 
there is an irreversible loss of synaptic transmission (Frenguelli, 1997; Balestrino et 
al., 2002; Somjen, 2002; Frenguelli et al., 2007). In order to test whether any of the 
treatments prolonged the time to AD, brain slices were exposed to OGD until the AD 
occurred, as measured by the disappearance of the presynaptic fibre volley.  
 
In order to make sure that the age of the animal, as well as the age of the slice did not 
affect the time to AD, I have plotted the data obtained for control slices from 
different aged animals and slices against the time to AD (Figure 7.10). Neither the 
age of the animal (Figure 7.10 A) nor the age of the slice (Figure 7.10 B) had an 
effect on the time to AD. However, I have tried to avoid using animals younger than 
P 20 and older than P 26 and most slices were between 3 and 7 h old. 
 
The time to AD was not different between control (N = 18), Rib/Ade (N = 7), 
allopurinol (N = 5) or Rib/Ade + allopurinol (N = 5) treated slices (Figure 7.10 C, 
values are given in the bar graphs, p > 0.05, one way ANOVA). However creatine 
(N = 4) as well as Rib/Ade + creatine (N = 4
6
) significantly delayed the occurrence 
of AD (p < 0.001 compared to other groups, one way ANOVA). Interestingly, in 3 
out of 4 slices treated with creatine and in 4 out of 4 slices treated with Rib/Ade + 
Creatine, I observed epileptiform activity during OGD, which occurred about 1 min 
before AD.  Furthermore in one experiment of Rib/Ade + Creatine treated slices the 
time to AD was delayed by 18.25 min, and this experiment was not included in the 
main data set since the time to AD was longer than twice the standard deviation of 
the mean time to AD. This slice had strong epileptiform activity for about 5 min. 
 
                                                 
6
 One experiment was excluded since the time to AD was longer than double the standard deviation.  
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These results show that increasing pre-ischemic ATP levels, or increasing adenosine 
levels during OGD does not affect the time to AD, whereas, in agreement with 
previous reports (Balestrino et al., 1999), delaying the degradation of ATP by 
creatine supplementation delays the time to AD by 60 %. These results further show 
that even if the pre-ischemic ATP levels are increased by Rib/Ade supplementation 
the combined treatment with creatine is still effective in delaying the time to AD. 
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Figure 7.10: The time to Anoxic depolarisation (AD) in Ribose/Adenine (Rib/Ade), 
creatine and allopurinol treated slices: Brain slices were exposed to OGD until the 
presynaptic fibre volley disappeard, which marks the time of AD. Neither the age (P 
postnatal) of the animals as shown in the scatter plot in A nor the age of the slices as 
shown in B seemed to influence the time to AD in control slices. For most 
experiments the animals were P 20 – P 26, and the slices were between 3 and 7 h 
old. C Time to AD in control slices (black bars, N = 18), slices pre-treated with 
Ribose and Adenine (Rib/Ade, 1 mM/ 50 µM, green bar, N = 7), allopurinol (blue 
bar, 10 µM, N = 5), Rib/Ade + allopurinol (pink bar, N = 7), creatine  (red bar, 1 
mM, N = 4) or Rib/Ade + creatine (orange bar, N = 4). Creatine as well as Rib/Ade 
+ creatine significantly delayed the time to AD. Recordings were performed at 33.4 
± 0.2 °C at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from slice 
cutting. Values in A and B are presented as individual experiments with the mean 
shown as horizontal line and values in C are shown as mean ± S.E.M. (***) p < 
0.001, one way ANOVA with Bonferroni’s multiple comparison test. 
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7.2.3.4 Effect of Rib/Ade, creatine and allopurinol on the recovery of synaptic 
transmission after OGD 
 
I further aimed to study the effect of Rib/Ade, creatine and allopurinol on the 
recovery of synaptic transmission after OGD. Therefore pre-treated slices were 
exposed to OGD until the AD occurred (mean times are shown in Figure 7.10 C) and 
then super-fused again for 1 h with aCSF supplemented with the previous treatment 
(Figure 7.11). 
 
The recovery of synaptic transmission 1 h after the ischemic insult was not different 
between control (Figure 7.11 A, 21 ± 7.6 % of the intial fEPSP baseline), Rib/Ade 
(27 ± 5.6 %) or allopurinol treated slices (42 ± 10 %, p > 0.05 compared to control 
slices, one way ANOVA). Surprisingly creatine and Rib/Ade + creatine treated slices 
showed a nearly complete recovery of synaptic transmission (92 ± 3.2 % for creatine 
treated slices and 94 ± 2 % in Rib/Ade + creatine  treated slices, p < 0.001 compared 
to all other groups, one way ANOVA).  
 
In three experiments I applied 8-CPT after 1 h reperfusion to Rib/Ade treated slices, 
to test whether the incomplete recovery was due to increased adenosine levels 
(Appendix 4, Figure 13.4). In one slice the baseline increased by 250 %, however in 
the other two the baseline increased by 28 %, which is slightly higher but still close 
to the effect of 8-CPT on pre-ischemic baseline in control slices (see Chapter 6, 21 % 
increase). This suggests that extracellular adenosine levels might be slightly elevated 
after 1 h reperfusion in Rib/Ade slices, but do not alone account for the incomplete 
recovery of synaptic transmission. 
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Figure 7.11: Recovery of synaptic transmissionin Ribose/Adenine (Rib/Ade), 
creatine and allopurinol treated slices: Slices were exposed to OGD until AD 
occurred and reperfusion was induced as soon as the presynaptic fiber volley 
disappeared. It took ~ 1 min until the fibre volley appeared again. Slices were 
reperfused with the treatment they obtained before, which was either standard aCSF 
(black dots, N = 5), or aCSF supplemented with Ribose and Adenine (Rib/Ade, 1 
mM/ 50 µM, N = 5), creatine (1 mM, N = 4), allopurinol (10 µM, N = 5), Rib/Ade + 
creatine (N = 5) or Rib/Ade + allopurinol (N = 6). The recovery of fEPSP traces 
during 1 h of reperfusion is shown in A and a scatter plot of the degree of recovery 
for individual treatments 60 min after OGD, expressed as a percentage of the pre-
ischemic fEPSP baseline is shown in B. Recordings were performed at 33.4 ± 0.2 °C 
at a flow rate of 7 - 8 ml/min after a ≥ 3 h recovery period from slice cutting. Values 
in A are presented as mean ± S.E.M and values in B as individual experiments with 
the mean shown as horizontal line. (***) p < 0.001, one way ANOVA with 
Bonferroni’s multiple comparison test. 
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The creatine concentrations used in other in vitro studies (Whittingham and Lipton, 
1981; Lipton and Whittingham, 1982) were higher (5 – 25 mM) than 1 mM, and a 
dose dependent increase in the phosphocreatine content between 1 and 10 mM 
creatine upon a 2 h incubation period has been described (Balestrino et al., 1999). I 
did not observe any differences in the decline of synaptic transmission during OGD 
in two slices treated with 5 mM Creatine compared to 1 mM Creatine (see Appendix 
4 Figure 13.5 A). The mean time to AD in 5 mM Creatine-treated slices was slightly 
longer at 13.25 (compared to 11.5 min in 1 mM Creatine treated slices). However in 
1 slice treated with 10 mM creatine the AD occurred after 10.25 min (data not 
shown), which is similar to slices treated with 1 mM Creatine, suggesting that during 
this long incubation period (≥ 3 h) the phosphocreatine content of slices is saturated 
with 1 mM Creatine exposure.  
 
In a few experiments (N = 2 – 4) I exposed control slices to OGD and then 
reperfused them with Rib/Ade or creatine (Appendix 4 Figure 13.6) and measured 
the functional recovery over a 3 h reperfusion period. However, I obtained very 
variable results, although a trend towards better recovery was seen in Rib/Ade and 
creatine treated slices.  
 
 
 
7.2.4 Modulation of intracellular high energy phosphate levels by Rib/Ade 
creatine and allopurinol – Effect on adenosine release 
 
Since I observed differences in the decline of synaptic transmission during OGD I 
next wanted to measure the real time release of adenosine with biosensors in 
Rib/Ade and creatine treated slices. Slice were treated for 3 - 6 hrs with Rib/Ade or 
creatine and these substances were washed out in standard aCSF for 30 min before 
slices were transferred into the recording chamber. I have shown before that adenine 
levels decline back to baseline within 1 h washout (see Chapter 5, Figure 5.5) 
therefore tissue adenine levels did not interfere with the adenosine signal. I did not 
test allopurinol treated slices since xanthine oxidase is part of the enzyme complex in 
the adenosine biosensor, and allopurinol interferes with the adenosine signal (see 
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Appendix 4, Figure 13.1). 45 min after insertion of the sensors, fEPSPs were 
recorded for 20 - 30 min and then slices were exposed to 5 min OGD, to avoid the 
occurrence of AD, and subsequent reperfusion in standard aCSF. fEPSPs and 
adenosine sensor traces were recorded simultaneously (Figure 7.12).  
 
As reflected in the faster decline of synaptic transmission and the increased tissue 
adenosine levels during OGD, Rib/Ade treated slices released significantly more 
adenosine during OGD and upon reperfusion (Figure 7.12 AB, 16 ± 1.3 µM’ 
compared to 11 ± 0.4 µM’ in control slices, N = 4, p < 0.05, one way ANOVA), 
whereas creatine treated slices released significantly less adenosine (5 ± 0.5 µM’, N 
= 3, p < 0.01 compared to control slices, one way ANOVA) as measured by the peak 
during the post-ischemic purine efflux (Frenguelli et al., 2003). This correlates with 
a delayed recovery of synaptic transmission in Rib/Ade treated slices, due to 
increased extracelluar adenosine levels (Figure 7.12 AD).  Furthermore, Rib/Ade and 
standard slices showed the same pattern of adenosine release, whereas creatine 
treated slices seemed to differ (Figure 7.12 A), by showing a peak and then a plateau 
at an elevated level.  The full time course of adenosine release and fEPSP traces, for 
Rib/Ade, creatine and Rib/Ade + creatine treated slices is shown in Appendix 4, 
Figure 13.7. Interestingly the adenosine release in Rib/Ade + Creatine treated slices 
was more similar to the trace observed for creatine treated slices than to Rib/Ade 
treated slices. This further shows that the intracellular phosphocreatine levels can 
still buffer the decline of the higher ATP levels and hence the production of 
adenosine in Rib/Ade treated slices and is in agreement with the similar time to AD 
in creatine and Rib/Ade + creatine treated slices (Figure 7.10 C). 
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Figure 7.12: Modulation of intracellular adenine nucleotides with Ribose/Adenine 
(Rib/Ade) or creatine influences adenosine release during OGD: A mean traces for 
adenosine sensor recordings of control slices (black trace, N = 4), slices pre-treated 
with Ribose and Adenine (Rib/Ade, green trace, N = 4) or Creatine (red trace, N = 
3). B The peak height during the postischemic purine efflux was calculated and 
expressed as µM’ Adenosine. Simultaneously to sensor traces fEPSPs were recorded 
as shown in C and D. C Decline of synaptic transmission during the first 3 min of 
OGD and D recovery of synaptic transmission after OGD. Note the accelerated 
decline and delayed recovery of fEPSPs in Rib/Ade treated slices, which reflects the 
increased extracellular adenosine levels. Values in A are expressed as mean and 
values in BCD are expressed as mean ± S.E.M. (*) p < 0.05, (**) p < 0.01, (***) p 
< 0.001, one way ANOVA with Bonferroni’s multiple comparison test. 
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I further wanted to study the effect of two brief ischemic periods on adenosine 
release, to test whether Rib/Ade could replenish the reduced adenosine release 
observed during subsequent ischemic periods in vitro (Pearson et al., 2001) and in 
vivo (Valtysson et al., 1998). Therefore I wanted to find a protocol, which would 
result in partial recovery of synaptic transmission during the first ischemic period 
and accelerated recovery of synaptic transmission during the second ischemic period 
of the same duration, as shown before (Pearson et al., 2001). However, I was not 
able to establish an appropriate protocol due to very inconsistent results (see 
Appendix 4, Figure 13.8). In slices exposed to 6.25 or 6 min OGD (Pearson et al., 
2001), I sometimes observed a complete recovery of synaptic transmission during 
the first and second ischemic period, and sometimes the AD occurred during the 
second ischemic insult resulting in delayed and incomplete recovery of synaptic 
transmission. Shorter ischemic periods (5 min) always resulted in complete recovery 
of synaptic transmission and longer ischemic period (6.5 min or 7 min, data not 
shown) always resulted in the occurrence of AD during the second ischemic insult. 
This might be due to different age of the animals since it has been shown that the AD 
in older animals (P 20) occurs faster than in younger animals (P 12) (Madry et al., 
2010) and the animals in (Pearson et al., 2001) were P 12 – P 24, as opposed to P 20 
– P 26 in this study.  
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7.3 Discussion 
 
In summary these data show that it is possible to modulate the decline and recovery 
of intracellular ATP levels, by increasing the pre-ischemic tissue ATP content with 
Rib/Ade or the tissue phosphocreatine content with creatine. This has measurable 
consequences on the decline and recovery of synaptic transmission and release of 
neuroprotective adenosine during OGD.  
 
7.3.1 Effect of OGD on adenine nucleotide levels and synaptic transmission 
 
Data in the literature (Whittingham et al., 1984a; Milusheva et al., 1996; Newman et 
al., 1998) and my own results show that brain slices behave in the same way as the in 
vivo brain with respect to the rapid deline and incomplete recovery of ATP levels 
and synaptic transmission (Schurr and Rigor, 1989). That is that ATP and TAN 
concentrations decrease progressively with the duration of ischemia which 
negatively affects the recovery of ATP, due to a reduction in the TAN pool. 
Likewise the decline and recovery of synaptic transmission in hippocampal brain 
slices reflects observations reported for in vivo brain, showing that if the ischemic 
period is prolonged beyond a critical point there is no recovery of synaptic 
transmission (Somjen, 2002; Krnjevic, 2008). Therefore, by establishing a protocol 
which results in incomplete recovery of TAN levels as well as synaptic transmission, 
brain slices can be easily used to screen for the effect of potential neuroprotective 
interventions on energetic and functional recovery from ischemic insults. 
 
7.3.2 Manipulations of intracellular high energy phosphate levels 
 
The approach of pre-treating brain tissue with neuroprotective substances might be 
useful for clinical interventions, where a known risk of global or cerebral ischemia 
exists, such as operations on the open heart, atherectomy of carotid arteries or high 
stroke risk patients. From the manipulations tested in this chapter (Rib/Ade, creatine, 
allopurinol) the most effective ones were Rib/Ade and creatine. Rib/Ade-treatment 
results in increased tissue ATP levels, increased adenosine release and improved 
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recovery of post-ischemic ATP levels. Creatine treatment on the other hand delays 
the degradation of ATP during ischemia, improves the EC during ischemic periods, 
helps to maintain post-ischemic ATP levels, and results in a nearly complete 
recovery of synaptic transmission after OGD.  
 
7.3.2.1 Pre-treatment with Rib/Ade to increase adenosine release and improve 
post-ischemic ATP recovery 
 
To my knowledge there is one report, where the recovery of post-ischemic ATP 
levels in brain slices was improved upon addition of 1 mM Ade (Newman et al., 
1998). However, despite this study, pre- or post-ischemic Rib/Ade or Ade 
administration has not been studied in brain tissue. In contrast, the positive effect of 
Rib or Rib/Ade on the recovery of post-ischemic myocardial ATP and TAN levels in 
in vitro and in vivo preparations is well documented (Zimmer, 1982; Mauser et al., 
1985; Zimmer et al., 1989; Zimmer, 1996; Muller et al., 1998; Smolenski et al., 
1998; Perkowski et al., 2007). The improved post-ischemic ATP recovery has been 
linked to an enhanced functional recovery of the heart, as seen in improved cardiac 
contractility (Pasque and Wechsler, 1984; Lamberts et al., 2007; Schneider et al., 
2007). Rib was also effective in improving renal ischemic injury (Nishiyama et al., 
2009; Sato et al., 2009). Likewise administration of Rib to patients suffering from 
congestive heart failure (Pliml et al., 1992; Omran et al., 2003; Omran et al., 2004; 
Maccarter et al., 2008) has been shown to have beneficial effects on cardiac function. 
Hence, Rib has been suggested as a supplement to improve cardiac energy 
metabolism (Pauly and Pepine, 2000; Shecterle et al., 2010). However, despite the 
improved recovery of post-ischemic ATP levels in Rib/Ade-treated slices, I did not 
observe any positive effect on the functional recovery in brain slices. This might be 
due to the fact that, despite the higher post-ischemic ATP levels in Rib/Ade slices, 
the reduction compared to pre-ischemic values (14 %) was similar to that in control 
slices, and that the ATP/AMP ratio has not completely recovered during 1 h 
reperfusion. Most of these studies, cited above, were done over a reperfusion period 
of minimally 5 h and up to 24 h. Even for combined administration of Rib/Ade a 5 h 
reperfusion period was chosen (Zimmer, 1998). Therefore the lack of any effect on 
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Rib/Ade supplementation on the functional recovery of brain slices in this chapter 
might be due to a too short reperfusion period.  
 
However, Rib/Ade treated slices released significantly more adenosine during 
ischemia, which might have protective effects in the in vivo ischemic brain. It has 
been shown that pre-ischemic administration of adenosine deaminase inhibitors 
increases adenosine release from rat brain during ischemia (Phillis et al., 1991). 
Adenosine can via activation of A2 receptors enhance cerebral blood flow (Phillis et 
al., 1985; Phillis, 1989) which would improve the oxygen and glucose supply to 
hypoperfused areas. Accordingly pre-ischemic administration of the adenosine 
deaminase inhibitor deoxycoformycin has been shown to protect the in vivo brain 
from ischemic brain injury (Phillis and O'Regan, 1989; Lin and Phillis, 1992). 
Furthermore the reduced tissue ATP levels observed in vivo after cerebral ischemia 
may via reduced extracellular adenosine and reduced activation of the anticonvulsant 
A1R (Boison and Stewart, 2009; Dale and Frenguelli, 2009) contribute to the 
development of post-ischemic epilepsy (Camilo and Goldstein, 2004; Kadam et al., 
2010). The influence of intracellular ATP on extracellular adenosine and neuronal 
excitability has recently been described (Kawamura et al., 2010), and an increase in 
intracellular ATP with a concomitant increase in extracellular adenosine has been 
proposed of being the basis for reduced incidence of seizures during a ketogenic diet 
(Masino and Geiger, 2008). Therefore Rib/Ade treatment and increased adenosine 
release during periods of energy depletion might be useful to enhance cerebral blood 
flow through A2 receptor activation and inhibit post-ischemic seizure activity 
through greater activation of the anticonvulsant adenosine A1 receptor. 
 
7.3.2.2 Pre-treatment with Creatine to delay the degradation of ATP 
 
The alternative approach of delaying the degradation of ATP by pre-incubation with 
creatine proved more effective in terms of delaying the time to AD and improving 
the functional recovery during the short reperfusion period tested. The protective 
effect of creatine pre-treatment by delaying the time to AD in ischemic brain slices 
(Kass and Lipton, 1982; Lipton and Whittingham, 1982; Balestrino et al., 1999) and 
improving the anoxia-induced impairment of protein synthesis (Carter et al., 1995) 
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has been reported earlier. Furthermore it has been shown that pre-ischemic 
administration of creatine and Rib was effective in preserving cell viability of 
myocytes (Caretti et al., 2010). Since creatine is well tolerated in humans, the 
approach of treating high stroke risk patients with creatine supplementation has been 
suggested (Zhu et al., 2004; Gualano et al., 2011). 
 
Creatine can enter the cells through creatine transporters and an increased 
phosphocreatine content in in vivo rat brain has been shown after 
intracerebroventricular creatine application (Rebaudo et al., 2000). However after a 
single bolus intraperitoneal administration with a high creatine dose (160 mg/kg at 
its solubility limit) brain creatine levels only increased by 70 µM, which is a minor 
amount compared to the total cellular creatine and phosphocreatine pool of about 10 
mM (Balestrino et al., 2002; Perasso et al., 2003). This suggests a weak blood-brain 
permeability of creatine through the creatine transporter, and it has been shown that 
prolonged continuous oral administration of creatine (weeks) is required to raise 
brain creatine levels of healthy human subjects , and even then only by 10 % 
(Dechent et al., 1999; Lyoo et al., 2003).  Accordingly prophylactic creatine 
administration for 1 month is effective in reducing the post-ischemic caspase-cell 
death cascades in mice and thereby preserving cell viability (Zhu et al., 2004). 
Creatine has also been shown to improve hypoxic/ischemic damage in neonatal rats 
at even shorter pre-treatment periods (days) (Berger et al., 2004). Shorter pre-
treatment periods in adult animals (1 week) (Zhu et al., 2004) or addition of creatine 
after the ischemic insult (Berger et al., 2004) were not protective. However, a novel 
Phosphocreatine-Mg-acetate complex has been developed which can cross the 
blood-brain barrier independently of the creatine transporter. This complex increases 
cerebral phosphocreatine levels and has been shown to be neuroprotective even if 
given 30 or 60 min prior to ischemic insults in mice (Perasso et al., 2009). 
Interestingly, another study showed that the reduced infarct volume in mice which 
were pre-treated that creatine was not linked to increased cerebral phosphocreatine 
levels but to improved cerebrovascular protection (Prass et al., 2007).  
 
Slices in this report were exposed to OGD until the AD occurred, so the severity of 
the ischemic insult was the same in all conditions. Nevertheless, creatine was still 
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effective in improving the post-ischemic recovery of synaptic transmission, which 
might not be solely linked to increased phosphocreatine levels. For example creatine 
itself has been shown to have mild antioxidant effects, primarily against free radical 
ions (Lawler et al., 2002; Sestili et al., 2006). During both ischemia and reperfusion, 
neuronal injury is worsened by the generation of oxygen radicals which damage 
essential cellular components and activate apoptotic signalling mechanism 
(Schmidley, 1990; Doyle et al., 2008). Radical scavengers improve cell viability 
(Ginsberg, 2008), and this effect does not depend upon pre-incubation and might 
therefore explain why the continuous presence of creatine upon reperfusion might 
further improve functional recovery. 
 
However the fact that creatine pre-treated slices exposed to OGD undergo a short 
epileptiform activity before occurrence of the AD, has to be considered. This might 
be caused by the fact that adenosine levels are lower, and therefore the high 
extracellular potassium concentrations during ischemia (Dirnagl et al., 1999) might 
shift the brain slice towards epileptiform activity. Nevertheless, from all treatments 
tested creatine was the most effective intervention in terms of improving functional 
recovery. 
 
7.3.2.3 Pre-treatment with allopurinol to inhibit production of unsalvageable 
metabolites 
 
Unlike Rib/Ade or creatine pre-treatment of brain slices, allopurinol had no 
measurable effects on the recovery of adenine nucleotides or synaptic transmission. 
However, I did observe slightly elevated tissue adenosine levels under control and 
ischemic conditions. This effect has been reported in vivo as well, and was linked to 
the antinociceptive role of allopurinol administration (Schmidt et al., 2009). The fact 
that xanthine oxidase inhibition can influence adenosine levels is further emphasised 
by an increased decline of synaptic transmission during OGD in Rib/Ade + 
allopurinol treated slices. In agreement with these results pre-treatment of newborn 
piglets with allopurinol increased adenosine and inosine levels in cerebral cortex 
during hypoxia (Marro et al., 2006).  
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Pre-treatment with oxypurinol, the active xanthine oxidase inhibitor, enhanced 
postischemic recovery of adenine nucleotide levels (Phillis et al., 1995) and helped 
to reduce the cerebral infarct zone in the ischemic rat brain (Lin and Phillis, 1991, 
1992). Interestingly the neuroprotective effect was still evident when allopurinol or 
oxypurinol was administered after the ischemic insult (Lin and Phillis, 1992; Palmer 
et al., 1993) and the authors proposed that this effect is not likely linked to increased 
adenosine levels, since at that time adenosine levels have fallen back to baseline 
values. In addition to enhancing the purine salvage pathway, allopurinol has been 
shown to act as a scavenger of free radicals (Das et al., 1987), which as explained 
above can improve cell viability and function. Therefore, it has been suggested that 
the protective effect of oxypurinol on post-stroke treatment might be linked to its 
radical scavenging action (Phillis and Sen, 1993) as well as inhibition of further 
degradation of hypoxanthine levels (Lin and Phillis, 1992), which are elevated for up 
to several hours after ischemia (Hillered et al., 1989).   
 
In summary these results show that it is possible to modulate ATP levels using 
compounds safe for use by humans and they have the expected effects on the release 
of adenosine and the energetic recovery of the tissue.  
 
The brain slice is a good model system to study neuroprotective interventions, and 
establish their short term effect on a variety of functional and metabolic conditions. 
However, in order to study long term reperfusion acute brain slices are not suited 
since they can only be maintained for ≤ 9 h incubation period (see Appendix 4, 
Figure 13.1). The limitations of brain slices required me to move to long term 
reperfusion in vitro model of cerebral ischemia. Hence, in order to establish the 
effect of Rib/Ade on cell viability if added after the ischemic insult andfor longer 
reperfusion studies (12 – 14 h) I used a primary neuronal cell culture. Therefore in 
the next chapter I will present data obtained from cerebellar granule cells, pre- or 
post-treated with various combinations of Rib and/or Ade. 
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8.1 Introduction 
 
As shown in Appendix 4, Figure 13.1 the metabolic integrity of slices is limited, and 
I observed a 20 % reduction of TAN levels after 9 h incubation. In an earlier report 
brain slice TAN levels have been shown to be stable for 8 h (Whittingham et al., 
1984b), therefore the experimental window in brain slices (after a 3 h recovery 
period) is limited. Hence, in order to test the effect of Rib/Ade on cell viability 
during prolonged reperfusion periods I used cerebellar granule cells. 
 
In addition to the incomplete recovery of post-ischemic ATP levels observed in in 
vivo models of stroke (Kleihues et al., 1975; Levy and Duffy, 1977) and as seen in 
the previous chapter in hippocampal brain slices, a secondary deterioration of ATP 
and phosphocreatine levels can be observed during prolonged reperfusion (Hata et 
al., 2000a), suggesting marked imbalances between energy use and production 
(Schaller and Graf, 2004). At the cellular level reperfusion injury involves a 
reduction in the mitochondrial respiratory chain, increased production of reactive 
oxygen species, transient but large imbalances in mitochondrial Ca
2+ 
homeostasis, 
suppression of protein synthesis, as well as activation of deleterious signalling 
cascades. This eventually leads to cell death via necrosis and apoptosis (Schaller and 
Graf, 2004). It has therefore been suggested that the compromised ATP levels might 
contribute to the ongoing loss of tissue upon reperfusion (Hashimoto et al., 1992; 
Lust et al., 2002). 
 
Prophylactic treatment of brain tissue with substances that can delay the degradation 
of ATP, such as creatine (Berger et al., 2004; Perasso et al., 2009), or improve the 
post-ischemic recovery of ATP, such as allopurinol (Lin and Phillis, 1991; Phillis et 
al., 1995), have been shown to be neuroprotective in the in vivo ischemic brain. In 
agreement with these reports, results from the previous chapter show that creatine 
pre-treatment significantly delays the time to anoxic depolarisation and helps to 
improve the functional recovery after ischemia. However, an intervention that could 
improve cell viability and function if given after the ischemic insult would be more 
helpful for acute stroke patients. 
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Therefore the aim of this chapter was to test whether Rib and/or Ade administration, 
which increase post-ischemic ATP levels in hippocampal brain slices, is an effective 
intervention to improve cell viability after OGD in a long term model of reperfusion. 
As an in vitro model for these studies I used cultures of cerebellar granule cells 
(CGC), since they are reported to contain 95% neurons (Thangnipon et al., 1983) and 
are therefore a good model system to study  in a relatively pure neuronal population.  
 
In this chapter I will show that the combined treatment of post-ischemic neurons 
with Rib/Ade helps to preserve cell viability during prolonged reperfusion periods. 
 
 
 
8.2 Results 
 
8.2.1 Effect of various D-Ribose concentrations on basal cell viability  
 
In a first set of experiments I studied the effect of various Rib concentrations on cell 
viability in CGC. Neurons were cultured with 2.5 – 50 mM Rib for 2 days and cell 
viability was assessed with Hoechst (stains all cells, blue) and propidium iodide 
(stains dead cells, red). As seen in Figure 8.1, Rib at concentrations from 2.5 - 10 
mM had no adverse effects on cell viability. These concentrations were also used in 
myocardial cell cultures (Kalsi et al., 1998; Smolenski et al., 1998) and blood Rib 
concentrations up to 6 mM has been shown to be well tolerated in humans (Salerno 
et al., 1999). However, incubating cells with 50 mM Rib led to a nearly complete 
loss of all neurons (Figure 8.1 A). This might be either caused by osmotic stress or 
impurities of the drug. In addition  recent publications, have shown that Rib, at high 
concentrations (1 M), can result in non-enzymatic ribosylation of α-synuclein (Chen 
et al., 2010a) and tau (Chen et al., 2009). These ribosylated proteins aggregate and 
exert cytotoxic effects. However, this effect was only observed with 1 M Rib and 
after a ≥ 24 h incubation of the pure protein.  
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Figure 8.1: Effect of Ribose on cell viability: After 6 - 7 days in vitro cells were 
incubated with various Ribose concentrations (2.5 - 50 mM) and were stained for 
cell death 48 h later with Hoechst (blue stain, all cells) and propidium iodide (red 
stain, dead cells). A Representative images showing the merged bright 
field/Hoecht/propidium iodide staining. All pink cells are dead cells. Scale bar 
represents 20µm. B The percentage of dead cells was calculated ((propidium 
positive cells x 100)/Hoechst positive cells).  There was no difference between 
control cells or cells treated with 2.5, 5 or 10 mM Ribose (N = 4). However most 
cells maintained in 50 mM Ribose were dead (N = 2), potentially due to osmotic 
stress or due to the ribosylation and aggregation of cellular proteins. All values are 
presented as mean ± S.E.M. No statistical differences were observed with one way 
ANOVA and Bonferroni’s multiple comparison test for control cells versus Rib-
treated cells (2.5 – 10 mM). 
 
 
I further wanted to establish the effect of various Rib concentrations on the energy 
charge (EC) of CGC (Figure 8.2). The EC for cells cultured in Rib was not different 
from control cells. However, the measured EC values were very low (~0.79, Figure 
8.2 A) as compared to the values obtained in brain slices (~0.96) (see previous 
chapters). This might be due to the fact that extracts were kept at -20°C for at least 1 
month before analysis, possibly resulting in degradation of ATP (see Chapter 3) (Zur 
Nedden et al., 2009), as seen in the high AMP levels (Figure 8.2 B). Therefore for 
further analysis of intracellular nucleotides CGC cell extracts were maintained over 
night at -20°C. 
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Figure 8.2: Effect of various Ribose concentrations on the cellular energy charge: 
After 6 - 7 days in vitro cells were incubated with various Ribose concentrations (2.5 
- 10 mM) for 2 days. Cell extracts were prepared and maintained at - 20°C for ≥ 1 
month. A Energy charge values (EC = (ATP+0.5ADP)/TAN) from cell nucleotide 
extracts, N = 3. B Representative HPLC trace obtained from control cells. Note the 
very high AMP and ADP concentrations, potentially reflecting partial degradation 
of ATP upon prolonged storage at -20°C. All values are presented as mean ± S.E.M. 
No statistical differences were observed with one way ANOVA and Bonferroni’s 
multiple comparison test.  
 
8.2.2 Development of an OGD model in cerebellar granule cells  
 
For OGD in CGC the culture medium was exchanged for glucose-free PBS (Wise-
Faberowski et al., 2001)(supplemented with glutamine, Pen/Strep, KCl and B27 and 
equilibrated with 95 % N2/5 % CO2), and cells were kept for 3 - 14 h in an air-tight 
chamber equilibrated with 95 % N2/5 % CO2 (Figure 8.3). 3 h OGD did not result in 
increased cell death (25 %, N = 2 compared to 25 ± 5 % in control slices, N = 5). 
However, 6h OGD resulted in significantly increased cell death (Figure 8.3 B, 59.5 ± 
6.3 %, N = 5, p < 0.001, one way ANOVA). Therefore 6h OGD was chosen for all 
future experiments. 
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Figure 8.3: Effect of various durations of OGD on cell viability in cerebellar 
granule cells. After 7 - 8 days in culture, cells were incubated in PBS (supplemented 
with glutamine, Pen/Strep, KCl and B27 and equilibrated for 3 h with 95 % N2/5 % 
CO2) in an airtight chamber, equilibrated with 95 % N2/5 % CO2. Control (Co) cells 
were incubated in supplemented Neurobasal medium.  A Cell death was analysed by 
Hoechst (blue, all cells) and propidium iodide (red, dead cells) staining. All pink 
cells are dead cells. Scale bar refers to 20μm. B The percentage of dead cells was 
calculated: ((propidium iodide positive cells x 100)/ Hoechst positive cells); Values 
for Co, 6 h OGD and 12 h OGD are expressed as mean ±  S.E.M.;  N = 3 – 5. Values 
for 3 h OGD are presented as mean (N = 2); (***) p < 0.001 compared to Co, one 
way ANOVA, Bonferroni’s multiple comparison test. 
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8.2.3 Effect of D-Ribose and adenine on cell viability in CGC if added before 
the ischemic insult 
 
In a first set of experiments I studied the effect of prophylactic administration of 
various Rib and/or Ade concentrations on post-ischemic cell viability in CGC. Cells 
were pre-treated for 3 h with various Rib and/or Ade concentrations and 
subsequently exposed to 6 h OGD. Cell death was assessed immediately afterwards. 
Control cells were incubated with Neurobasal medium (Co NB) or in PBS 
supplemented with glucose (equimolar to NB medium) for the same time period. 
 
As seen in Figure 8.4 the amount of cell death in cells exposed to 6 h OGD (58 ± 5 
%, N = 7) was significantly higher compared to cells incubated in Neurobasal 
medium (27 ± 4 %, N = 6, p < 0.001, one way ANOVA) as well as cells incubated 
for 6 h in glucose-supplemented PBS (22 ± 4 %, N = 3, p < 0.001, one way 
ANOVA). Furthermore there was a significant increase in cell death between cells 
incubated in glucose-free PBS but under normoxic conditions (36 ± 5 %, N = 5) and 
cells incubated in OGD (p < 0.05, one way ANOVA), showing that the lack of 
oxygen further contributes to a loss of neurons.  
 
Rib seemed to preserve cell viability in a concentration-dependent manner, with 10 
mM Rib being most effective (37 ± 2 %, N = 6, p < 0.05 compared to 6 h OGD, p > 
0.05 compared to Co NB and PBS + Glucose, one way ANOVA). Ade on its own 
had a similar effect to 1 mM Rib on its own (48 ± 5 %  for both conditions, N = 4 – 
5) and the combination of Rib and Ade did not further improve the cell viability 
compared to Rib alone. 
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Figure 8.4: Cell death after 6 h OGD in cells pre-treated for 3 h with or without D-
ribose (Rib) and/or adenine (Ade). For control experiments cells were: (i) incubated 
in Neurobasal medium (Co NB), in (ii) glucose supplemented PBS  (PBS + Glucose) 
or in (iii) glucose-free PBS but under normoxic conditions (PBS – Glucose). A Cell 
death was analysed by Hoechst (blue, all cells) and propidium iodide (red, dead 
cells) staining immediately after 6 h OGD. All pink cells are dead cells. Scale bar 
refers to 20μm. B The percentage of cell death calculated: ((propidium iodide 
positive cells x 100)/ Hoechst positive cells). All values are expressed as mean ± 
S.E.M; N = 3 - 6; (***) p < 0.001, (**) p < 0.01, (*) p < 0.05, one way ANOVA with 
Bonferroni’s multiple comparison test. 
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8.2.4 Effect of D-Ribose on TAN levels in CGC before and after ischemia 
 
To investigate whether the improved cell viability after OGD in Rib pre-treated cells 
was due to a better preservation of ATP levels or energetic parameters, HPLC 
analysis was performed immediately after OGD. In order to prevent adenine 
nucleotide degradation seen in Figure 8.2, the cell extracts were stored over night at -
20 °C and analysed on the next day.  
 
However, as seen in Figure 8.5 no difference was observed in TAN, energy charge 
or ATP/AMP ratio levels between Rib-treated cells and control cells exposed to 6 h 
OGD. I further performed a nucleotide extraction after 3 h OGD, to investigate 
whether Rib helps cells to maintain higher ATP levels for a longer period. 
Preliminary results suggest that there is no change in TAN levels (Figure 8.5 E, N = 
1). Further experiments, looking at pre-ischemic TAN levels and earlier time points 
during OGD in Rib-treated cells, will give a better idea as to how ribose and/or 
adenine may improve cell viability after OGD. However, there was not enough time 
to finish these experiments.  
 
Interestingly the basal EC (0.98 ± 0.001) and ATP/AMP ratio values (311 ± 19) in 
cells were higher than in slices (EC ~ 0.96, ATP/AMP ratio ~ 100, see Chapter 4, 5 
and 7). This might be due to a higher incubation temperature (37°C as compared to 
34°C), since I have shown before that the ATP/AMP ratio is temperature-dependent. 
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Figure 8.5: HPLC analysis of CGC extracts after 6 h OGD. A Representative 
HPLC traces obtained from CGC extracts under control conditions in Neurobasal 
medium (Co NB), after 6 h incubation in PBS + Glucose, as well as after 3 or 6 h 
OGD. B TAN and C energy charge (EC) and D ATP/AMP ratio values obtained for 
CGC before and after 6h OGD and with or without prophylactic treatment (3 h) with 
1 - 10 mM Ribose (Rib). B-D: All values are expressed as mean ± S.E.M; N = 4 - 5. 
(**) p < 0.01, (***) p < 0.001, one way ANOVA with Bonferroni’s multiple 
comparison test.  
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8.2.5 Effect of D-Ribose and adenine on cell viability in CGC after OGD for 
12 – 14 h reperfusion 
 
Having established, that Rib/Ade was beneficial if given before OGD, I further 
aimed to test the effect of Rib and/or Ade on cell viability, if added after the 
ischemic insult for prolonged reperfusion periods (12 – 14 h). Cells were therefore 
exposed to 6 OGD (or 6 h PBS + Glucose) and thereafter the OGD medium was 
replaced by the previous Neurobasal culture medium, which was supplemented with 
or without Rib and/or Ade.  Rib and Ade had no adverse effects on cell viability, 
when added for 24 h (Figure 8.6) and there was no significant difference between 
control cells, cells treated with 10 mM Rib, 50 or 100 µM Ade or the combination of 
Rib/Ade (p > 0.05, one way ANOVA). 
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Figure 8.6: Effect of adenine (Ade) and/or Ribose (Rib) on cell viability: After 6 - 7 
days in vitro cells were incubated with Rib and/or various Ade concentrations for 24 
h and stained for cell death with Hoechst and propidium. Values for control cells 
incubated in standard Neurobasal medium (Co NB) or cells incubated in 10 mM Rib, 
100 µM Ade and 10 mM Rib + 50 µM Ade are expressed as mean ±  S.E.M.;  N = 3 - 
5. Values for 50 µM Ade are presented as mean (N = 2). No statistical differences 
were observed with one way ANOVA and Bonferroni’s multiple comparison test.  
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After 12 - 14 h reperfusion there was no significant difference between cells that 
were continuously cultured in Neurobasal medium (Figure 8.7, Co NB, 30 ± 4 %, N 
= 4) and cells that were exposed to 6 h PBS + glucose and subsequent 12 -14 h 
reperfusion in Neurobasal medium (PBS + Glucose, 25 ± 9 %, N = 3, p > 0.05, one 
way ANOVA). However there was a significant amount of cell death in cells that 
were exposed to 6 h OGD and subsequent 12 - 14 h reperfusion (83 ± 7 %, p < 0.001 
compared to Co NB and 6 h PBS + Glucose, one way ANOVA). Likewise cells that 
were treated with 1 - 5 mM Rib (N = 3) or 50 µM Ade (N = 2) after OGD showed 
the same amount of cell death (p < 0.01 compared to Co NB , p < 0.001 compared 
and Glucose + PBS, one way ANOVA). However, a trend could be seen towards 
better cell survival in cells pre-treated with 10 mM Rib (60 ± 10 %, N = 3, p > 0.05 
compared to control cells, one way ANOVA). Interestingly, the combination of Rib 
and Ade was effective in preserving cell viability at even lower Rib concentrations 
(57 ± 9 % for cells which were treated with 1 mM Rib/50 µM Ade, N = 3, p > 0.05 
compared to Co NB and PBS + Glucose, one way ANOVA) and there was no further 
improvement upon higher Rib concentrations.  
 
This suggests that the approach of enhancing the recovery of post-ischemic ATP 
levels with Rib/Ade administration (as shown in hippocampal brain slices, see 
Chapter 7) can improve cell viability. Further experiments looking at the intracellular 
ATP levels after 12 – 14 h reperfusion could have clarified this point. However, this 
was beyond the scope of this study. 
 
The major disadvantage of propidium iodide staining is that it only stains cells with 
broken membranes, which does not necessarily imply that all propidium negative 
cells are still viable. To complement findings of cell death assays in CGC, I wanted 
to use an XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide inner salt)-based cell viability assay. In this assay cell viability is 
assessed by measuring the activity of mitochondrial dehydrogenases, which convert 
the yellow tetrazolium salt to orange formazan. Furthermore, the results of an XTT 
assay are analysed by a spectrophotometer reading, which is a more un-biased way 
of analysis than manually counting propidium iodide positive cells. 
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Figure 8.7: Cell death after 6 h OGD and 12 - 14 h reperfusion in cells that were 
treated with/without D-ribose (Rib) and/or adenine (Ade) after the ischemic insult. 
CGC were exposed to 6 h OGD an 12 – 14 h reperfusion in Neurobasal medium 
supplemented with/without Rib and/or Ade. A Cell death was analysed by Hoechst 
(blue, all cells) and propidium iodide (red, dead cells) staining after a 12 – 14 h 
reperfusion period. All pink cells are dead cells. Scale bar refers to 20μm. B The 
percentage of cell death calculated: ((propidium iodide positive cells x 100)/ 
Hoechst positive cells). All values are expressed as mean ± S.E.M; N = 2 - 6; (***) p 
< 0.001, (**) p < 0.01, (*) p < 0.05, one way ANOVA with Bonferroni’s multiple 
comparison test. 
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Holly Baum, a project student in the lab under my supervision, used the XTT assay 
and was able to detect a significant decrease in cell viability after 3 h OGD (at which 
time Hoechst/propidium iodide staining did not show an increased cell death, see 
Figure 8.3), which correlates with previous results showing that following 3 h OGD, 
there was an appreciable reduction in the total adenine nucleotide pool (Figure 8.5 
E). Therefore the results obtained from cell death assays with Hoechst/propidium 
iodide could be confirmed with this more sensitive way of assessing the cell 
viability. However, there was not enough time to finish these experiments.  
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Figure 8.8: Exposing CGC to 3 h OGD results in a significant reduction of cell 
viability as assessed with the XTT cell viability assay. After 7 - 8 days in culture, 
cells were incubated in PBS (supplemented with glutamine, Pen/Strep, KCl and B27 
and equilibrated for 3 h with 95 % N2/5 % CO2) in an airtight chamber, equilibrated 
with 95 % N2/5 % CO2, for 1 or 3 h. Control (Co) cells were incubated in 
supplemented Neurobasal medium. Cells were then washed with PBS and exposed to 
PBS containing the XTT reagents for 4 h. Thereafter the optical density was 
measured on a plate reader at a wavelength of 450 nm with a reference wavelength 
of 690 nm. Values were normalised to the control values (fold of control) and are 
expressed as mean ± S.E.M. (**) p < 0.01, one way ANOVA with Bonferroni’s 
multiple comparison test. 
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8.3 Discussion 
 
8.3.1 Effect of D-Ribose and Adenine on basal cell viability 
 
Prolonged exposure of cells to Rib or Ade had no adverse effect on cell viability. 
Only at high Rib concentrations (50 mM) did I observe increased cell death. 
Treatment of quiescent human peripheral blood mononuclear cells with 50 mM Rib 
has also been shown to induce apoptosis after 2 days exposure (Barbieri et al., 1994). 
As explained above, this is likely due to osmotic stress and could have been 
confirmed upon 50 mM sucrose administration. However, the involvement of Rib in 
the production of advanced glycation end products (AGE) cannot be excluded. AGEs 
are formed by non-enzymatic reaction of reducing sugars with free aminogroups of 
lipids, proteins or nucleic acids with subsequent oxidation, fragmentation and cross-
linking. AGEs are formed at a slow and constant rate in the body, but their 
generation is for example enhanced in diabetics (Peppa et al., 2003). Ribosylation of 
tau (Chen et al., 2009), α-synuclein (Chen et al., 2010a) and BSA (Wei et al., 2009) 
has been shown to induce misfolding into globular aggregates with high cytotoxic 
effects. However, in all these studies the pure protein was incubated with 1 M Rib 
over a prolonged incubation period (≥ 24 h) and the role of Rib in production of 
AGEs in vivo has not been studied yet. Oral administration of Rib (13 weeks, 15 
g/kg bodyweight/day) to rats revealed no microscopic histopathology that could be 
attributed to Rib (Griffiths et al., 2007) and haematological and biochemical 
parameters in healthy human volunteers were not changed over a period of 2 weeks 
(Seifert et al., 2008). Furthermore Rib has been administered to patients over a 
prolonged period (several months - 1 year) without any toxic side effects (Salerno et 
al., 1999; Jurecka et al., 2008). Hence, Rib at concentrations as low as 1 mM is 
unlikely to negatively affect cell viability over prolonged incubation/treatment 
periods.  
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8.3.2 Effect of D-Ribose and Adenine on post-ischemic cell viability 
 
Prophylactic administration of Rib for 3 h prior to the ischemic insult seemed to 
preserve cell viability in a concentration-dependent manner. However, analysis of 
the total adenine nucleotide content did not reveal  better preservation of TAN levels 
or energetic parameters immediately after OGD. Nevertheless, Rib might help the 
cells to preserve the TAN levels for a longer period compared to control cells. 
Therefore further analysis of TAN levels after 1 or 3 h OGD (Figure 8.5 E) could 
clarify the mechanism by which Rib helps to improve cell survival.  
 
The protective effect of prophylactic Rib administration may also be mediated by 
increasing glycogen stores in CGC. Rib can be converted to fructose-6-phosphate via 
metabolism in the non-oxidative branch of the pentose phosphate pathway (see 
Introduction). Indeed treatment of myocardial tissue with Rib under control 
conditions has been shown to increase glycogen stores and the tolerance to ischemic 
insults (Wallen et al., 2003). This might also explain why Rib in combination with 
Ade did not further improve cell viability compared to Rib alone. 
 
Following 12 - 14 h reperfusion the percentage of dead cells increased to 80 %, 
showing that there is a further loss of neurons during reperfusion (White et al., 
2000). Neither administration of 1 mM Rib nor administration of 50 µM Ade on its 
own for the duration of reperfusion seemed to improve cell viability. However, 
treatment of cells after OGD with the combination of Rib/Ade (1 mM/50 µM) was 
effective in preserving cell viability (~ 50 % cell death, ~ 37 % improved cell 
survival). It is reasonable to assume that this protective effect is linked to improved 
recovery of post-ischemic ATP levels, as has been shown in many times in 
myocardial tissue (Zimmer, 1992, 1998) and in hippocampal tissue in the previous 
chapter. These results are important as it provides evidence that Rib/Ade may be 
useful when given after a stroke. Additionally the fact that Rib/Ade has to be applied 
with allopurinol may further enhance this protective effect, since xanthine oxidase 
inhibition would increase salvage of accumulated hypoxanthine as well as reduce the 
generation of reactive oxygen radicals (Atlante et al., 1997). 
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As explained in the introduction (Chapter 1, section 1.1.1.1) the main current 
treatment for acute ischemic stroke patients target the restoration of the blood supply 
to the affected brain area. Despite this being important, it does not improve post-
ischemic ATP levels, as seen in in vivo models of ischemia. Additionally the 
occurrence of peri-infarct depolarisations (see Chapter 1, section 1.3.2), further 
challenge hypoperfused brain areas energetically (Somjen, 2002; Dohmen et al., 
2008; Doyle et al., 2008). Therefore addition of supplements such as Rib/Ade might 
be a usefull additional strategy to help the brain to restore the balance of its energy 
metabolism.  
 
Therefore both strategies: delaying the degradation of ATP during ischemia, with 
creatine (see previous chapter) and improving the recovery of post-ischemic ATP 
levels with Rib/Ade are effective strategies for improving neuronal function and 
viability. In summary these results show that manipulating both, the decline and 
incomplete recovery of ATP during ischemia and reperfusion with substances that 
are known to be tolerated in humans exerts promising neuroprotective effects in in 
vitro models of cerebral ischemia. Therefore these results provide good evidence for 
the initiation of in vivo animal studies as well as small-scale, low risk clinical trials 
with Rib/Ade in patients having suffered stroke or head injury.  
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9 Future directions 
and possible 
translation into 
clinical trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 
202 
 
9.1 Future directions 
 
In line with previous reports (Gerlach et al., 1971; Allsop and Watts, 1980; Mascia et 
al., 2000) my data show that the brain has a strong capacity through the purine 
salvage pathway, and especially APRT, to restore its ATP levels when supplied with 
the precursors Rib/Ade.  
 
Another possibility to prove the importance of purine salvage in the brain for the 
restoration of post-ischemic ATP levels and cell viability would have been to inhibit 
HGPRT or purine nucleoside phosphorylase, both of which should reduce post-
ischemic ATP recovery and exacerbate ischemic damage. However, difficulties in 
obtaining the inhibitor of purine nucleoside phosphorylase immucillin-H (Kicska et 
al., 2001) and the inhibitor of HGRPT carbocylcic GMP (Bennett et al., 1985), plus 
the fact that I wanted to restrict studies to chemicals already in use by patients, meant 
that I did not use these drugs.  
 
The fact that Rib/Ade or high Rib concentrations improve cell viability after OGD 
strongly suggests that the approach of enhancing the purine salvage pathway after 
OGD is neuroprotective, providing hope that this could be effective in the injured 
human brain. Furthermore, I have shown that adenosine release during ischemic 
periods can be enhanced upon Rib/Ade and decreased upon creatine pre-treatment. 
These strategies open up new possibilities for manipulating adenosine release during 
various physiological or pathophysiological conditions, where it is known to play a 
major role. For example during epileptic seizures, enhanced adenosine release and 
subsequent A1 receptor activation might shorten the seizure duration and intensity 
(Etherington and Frenguelli, 2004).  
 
Therefore there are two future directions that can be pursued based on the results of 
my thesis:  
 
- Epilepsy: It would be interesting to investigate whether boosting cellular ATP 
levels by Rib/Ade would inhibit in vitro seizure activity, duration or intensity 
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via enhanced release of the anticonvulsant adenosine (see Discussion, chapter 
6). 
 
- Stroke: My results provide good evidence for studying the effects of Rib/Ade 
administration in in vivo animal models of stroke and even for the initiation of a 
small-scale, low risk clinical trial. However, since so many clinical trials with 
neuroprotective agents failed to show a beneficial effect, care has to be taken by 
the translation of preclinical studies into clinical trials (Gladstone et al., 2002; 
Ginsberg, 2008).  
 
 
9.2 Translation of in vitro and in vivo neuroprotection 
studies into clinical trials 
 
As mentioned in the introduction, a major disadvantage of in vitro models is the lack 
of blood borne components, severed input and output connections as well as the lack 
of a behavioural output. Therefore in vitro studies, including this thesis, mainly help 
to dissect the biochemical and physiological mechanisms of neuroprotection in 
isolated brain tissue, but have to be put in context with pre-clinical in vivo studies 
and subsequently clinical trials. 
 
 It is however, encouraging that  the effect of Rib has been first established in in vitro 
(Kalsi et al., 1998; Smolenski et al., 1998) and in vivo animal models of myocardial 
ischemia (Zimmer, 1982, 1983; Zimmer and Ibel, 1984; Mauser et al., 1985; St Cyr 
et al., 1989; Zimmer et al., 1989; Muller et al., 1998) and has then been successfully 
translated into clinical trials (Pliml et al., 1992; Omran et al., 2003; Perkowski et al., 
2007; Maccarter et al., 2008). This shows, as reported before, that  the effect of Rib 
is not species-specific (Zimmer et al., 1984) and that it is a metabolic substrate for 
ATP synthesis in rodents and in humans, which is also true for adenine (Ayvazian 
and Skupp, 1965). To date many reviews have been published on “the benefits of D-
Ribose in cardiovascular disease” (Pauly and Pepine, 2000; Pauly et al., 2003; 
Omran et al., 2004; Parang et al., 2005; Shecterle et al., 2010). Considering the 
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similarity of the heart and the brain with respect to their dependence on the salvage 
pathway, the weak capacity of purine de novo synthesis and the beneficial effect of 
Rib/Ade on post-ischemic ATP recovery and cell viability, it is reasonable to assume 
that the post-ischemic human brain might equally benefit from Rib or 
Rib/Ade/allopurinol. Additionally Rib is commercially available as a dietary 
supplement and allopurinol is a widely used treatment for gout, hence there is 
relatively little cost associated with the production of these substances. Likewise 
adenine is available at a high purity, which can be used for human studies (see 
(Schulman et al., 1971; Benke et al., 1973)). 
 
Nevertheless, in vivo stroke studies could clarify whether Rib/Ade/allopurinol is 
neuroprotective, in terms of reducing brain infarct size and improving behavioural 
outcome as well as help to determine the effective concentrations and drug 
administration regimes, and therefore provide additional support and evidence for 
the initiation of clinical stroke trials. 
 
9.2.1 Effective concentration of Rib/Ade/allopurinol administration 
 
From my in vitro studies the exact plasma concentration of Rib/Ade needed to 
increase brain levels to ~ 1 mM/~ 50 µM, respectively, cannot be predicted. For that 
purpose in vivo animal studies would be useful in order to establish a dose-response 
curve to determine the minimal effective concentration upon intravenous infusion 
and/or oral supplementation. This is important for the translation into clinical trials, 
since it has been suggested that drug doses chosen in clinical trials may not be 
sufficiently high to increase CNS levels of the neuroprotectant used (Dorman and 
Sandercock, 1996; Ginsberg, 2008).  
 
Serum Rib concentrations in humans can be increased up to 5.5 mM upon 
intravenous administration of 222 mg/kg/h Rib over 5 hours, and this concentration 
has been shown to be well tolerated  (Gross et al., 1989). In rats adenine can be given 
in combination with 10 mg/kg/day allopurinol at a dose of 70 mg/kg/day without 
formation of kidney stones and oral administration of 60 mg/kg/day Ade in 
combination with 10 mg/kg/day allopurinol was well tolerated for 8 months 
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(Schulman et al., 1971). However, the corresponding blood Ade/allopurinol 
concentrations have not been reported, hence it is difficult to estimate whether this 
concentration is sufficiently high to increase brain Ade levels. At a lower dose of 10 
mg adenine/kg/day only little orally administered adenine may reach the brain, since 
it is converted to AMP in the intestines (Benke et al., 1973). Nevertheless, these 
studies provide a good starting point for the choice of Rib/Ade/allopurinol 
concentrations for in vivo studies and potential clinical trials.  
 
9.2.2 Therapeutic window of Rib/Ade/allopurinol administration 
 
Most in vivo and in vitro studies, including my work, tested the neuroprotective 
effects of drug administration either in advance or soon after the ischemic insult. 
However, the therapeutic window for acute stroke patients is longer and much more 
variable, since they are often hospitalised several hours after onset of stroke. 
Accordingly it has been suggested that another pitfall in the translation of preclinical 
animal studies into clinical trials, is the time window at which the drug is applied 
(median time to treatment in clinical trials is ~ 14 h in studies published between 
1995 and 1999) (Gladstone et al., 2002). Therefore it would be interesting to study 
whether Rib/Ade would still be neuroprotective in vitro and in vivo models if added 
several hours after the ischemic insult.  
 
9.2.3 Optimal Duration of Rib/Ade/allopurinol administration 
 
Another disadvantage of in vitro models is the limited time scale for which they can 
be used. Therefore the optimal duration of Rib/Ade/allopurinol administration (days, 
weeks, months?) can only be established in in vivo models. It is however 
encouraging that long term administration of Rib (> 12 month) (Salerno et al., 1999; 
Jurecka et al., 2008) as well as Ade/allopurinol (> 8 month) (Schulman et al., 1971) 
is well tolerated by humans.  
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9.2.4 Patient selection 
 
Another important criteria for the translation of preclinical studies (based on a 
homogenous population) into clinical trials (dealing with a heterogenous population) 
is the appropriate patient selection.  
 
Since neuroprotective strategies target the penumbra, patients with no evidence of 
penumbral tissue (as determined by PET or MRI scans) should not be included in the 
clinical trials or posthoc analysis (Gladstone et al., 2002; Muir, 2002).  Therefore a 
better selection of patient eligibility might not only reduce the sample sizes needed 
but also reveal a neuroprotective effect of the substances tested, in those who have 
tissue left to salvage.  
 
Additionally, preclinical studies mainly use one in vivo stroke model, such as middle 
cerebral artery occlusion, whereas clinical trials allow the entry of many different 
stroke types, such as haemorrhagic and ischemic strokes.  The population 
heterogeneity alone with accordingly too small sample sizes may be sufficient to 
explain the negative results of neuroprotective trials  (Dorman and Sandercock, 
1996; Muir, 2002).  
 
In that respect one advantage of Rib/Ade/allopurinol is that it is a metabolic 
intervention that does not, unlike other neuroprotective strategies, target a specific 
receptor or pathway which may play distinct roles in the different types and 
severities of stroke. Instead it addresses the energetic state of the tissue, which is 
generally challenged by ischemia. In fact the incomplete recovery of ATP has been 
shown to occur after transient ischemia, induced by uni- or bilateral cerebral artery 
occlusion (Kobayashi et al., 1977; Levy and Duffy, 1977; Welsh et al., 1982; 
Onodera et al., 1986; Hashimoto et al., 1992; Phillis et al., 1996; Folbergrova et al., 
1997) as well as after cardiac arrest (Kleihues et al., 1974; Kleihues et al., 1975; 
Hoxworth et al., 1999) in rats, gerbils, cats and monkeys, showing that this is 
common to different types of strokes in different species. Hence the improved 
recovery of ATP by Rib/Ade/allopurinol suplementation is a metabolic intervention 
that might prove beneficial for different types of stroke.
 207 
 
10 Appendix 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 10 
208 
 
10.1 Solutions for cerebellar granule cell culture 
 
10 x Krebssolution  250 ml 
pH was adjusted with 5 M 
NaOH to pH 7,4 
The solution was steril 
filtered and stored at 4°C 
NaCl 18.13 g 
KCl 1.00 g 
NaH2PO4H2O 0.35 g 
D-Glucose 6.50 g 
Phenol-Red 0.025 g 
HEPES 14.85 g 
H2O 250 ml 
 
3,82 % MgSO4 H2O 100 ml 
Steril filtered, stored at RT MgSO4 3,82 g 
1,2 % CaCl2 H2O 100 ml 
Steril filtered, stored at RT CaCl2 1,2 g 
DNase 
10 mg/ml H2O Aliquots stored at - 20°C 
Trypsin Inhibitor 
31 mg in 600 µl Solution 1 oder PBS 
Aliquots stored at - 20°C 
1 M KCl 0.7 g/in 10 ml Neurobasal medium or PBS 
 
1 x Krebs solution 100 ml 
Steril filtered and used  10 x Krebssolution 10 ml 
within 2 weeks BSA 0,3 g 
 3,82 % MgSO4 800 µl 
 H2O 90 ml 
 
Solution 3  10 ml 
Freshly prepared  1 x Krebs solution 10 ml 
 DNAseI 100 µl 
 Trypsin Inhibitor 100 µl 
 3,82 % MgSO4 100 µl 
 
Solution 5 10 ml 
Freshly prepared  1 x Krebs solution 10 ml 
 1,2 % CaCl2 12 µl 
 3,82 % MgSO4 83 µl 
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Neurobasal medium 20 ml 
Stored at 4°C  and used  Neurobasal 20 ml 
within 2 weeks Glutamine 200 µl 
 Pen/Strep 20 µl 
 B-27 Supplement 400 µl 
*Not added for pre-plating  
step 
1 M KCl* 20 µl 
 
Supplemented PBS 20 ml 
Stored at 4°C  and used  PBS 20 ml 
within 2 weeks D-Glucose 90 mg 
 Glutamine 200 µl 
 Pen/Strep 20 µl 
 B-27 Supplement 400 µl 
* made up in PBS 1 M KCl* 20 µl 
 
10.2 Solutions for acute hippocampal brain slices 
 
10 x aCSF 1 L 
Stored at 4°C NaCl 72.5 g 
 NaHCO3 21.8 g 
 NaH2PO42H2O 1.92 g 
 KCl 2.2 g 
 H2O 1 L 
 
1 x aCSF 1 L 
Freshly prepared; 10 x aCSF 100 ml 
CaCl2 was added after 10  D-Glucose 1.8 g 
min bubbling with 95%  1M CaCl2 2 ml 
O2/5% CO2 1M MgSO4 1 ml 
 H2O 900 ml 
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OGD aCSF 500 ml 
Freshly prepared; 10 x aCSF 50 ml 
CaCl2 was added after 10 Sucrose 1.71 g 
min bubbling with 95%  1M CaCl2 1 ml 
N2/5% CO2 1M MgSO4 0.5 ml 
 H2O 450 ml 
 
10.3 Solutions for High performance liquid 
chromatography 
 
1 M HPLC phosphate buffer 500 ml 
Stored at 4°C K2HPO4 52.254 g  
 KH2PO4 27.218 g  
 
10.3.1 Solutions for ion-pairing HPLC 
 
Buffer A 500 ml 
Freshly prepared/ 10 x HPLC phosphate buffer 24.382 ml 
Stored at 4°C for  < 2  TBAHS 0.5085 g 
days, filtered before 
use 
H2O 350.61 ml 
 
Buffer B 250 ml 
Freshly prepared/ 10 x HPLC phosphate buffer 16.25 ml 
Stored at 4°C for < 2  H2O 171.25 ml 
days, filtered before 
use 
HPLC grade Methanol 62.5 ml 
 
10.3.2 Solutions for reverse phase HPLC with fluorescence detection 
 
Buffer A 500 ml 
Freshly prepared/ 10 x HPLC phosphate buffer 10 ml 
Stored at 4°C for < 2 
days, filtered before 
use 
H2O 490 ml 
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Buffer B 500 ml 
Freshly prepared/ 10 x HPLC phosphate buffer 10 ml 
Stored at 4°C for < 2  H2O 365 ml 
days, filtered before 
use 
HPLC grade Methanol 125 ml 
 
10.4 Solutions for cell viability assays 
 
Propidium iodide solution 50 ml 
Stored at 4°C and used at 
100 μl/ml 
Propidium iodide 2.5 mg 
 Sodium citrate 50 mg 
 H2O 50 ml 
Hoechst 
8 mM in PBS  or Solution 1 Aliquots stored at -20°C, 
diluted 1:10 in PBS and 
used at 10 μl/ml 
 
XTT assay 10 ml 
Freshly prepared XTT 10 mg 
 1.25 mM PMS in PBS 0.2 ml 
 Supplemented PBS 10 ml 
 
 
10.5 Chemicals and stock solutions 
 
Cell culture chemicals Supplier Storage 
B27 Invitrogen Lightsensitive, -20°C 
DNAse Roche -20°C 
Glutamine  From media prep -20°C 
Pen/Strep From media prep -20°C 
Phenolred Sigma Aldrich RT 
Trypsin From media prep -20°C 
Trypsin Inhibitor (Soy 
bean) 
Invitrogen  -20°C 
Neurobasal medium Invitrogen;                     
Cat No.: 21103 
4°C 
Phenol Red Sigma RT 
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HPLC chemicals Supplier Storage 
1,1,2-Trichloro-1,2,2-
trifluoro-ethane 
CHROMASOLV® 
Sigma Aldrich 4°C 
Dipotassium hydrogen 
phosphate 
Fisher Scientific RT 
HPLC grade Acetonitril Sigma Aldrich RT 
HPLC grade Methanol Sigma Aldrich RT 
Orthophosphoric acid Fisher Scientific RT 
Perchloric acid 70% Fisher Scientific RT/light sensitive 
Potassium dihydrogen 
phosphate 
Fisher Scientific RT 
Tetrabutylammonium 
hydrogen sulphate 
(TBAHS) 
Sigma Aldrich RT 
Tetrahydrofuran Sigma Aldrich RT 
Tri-n-octylamine Sigma Aldrich RT 
 
Drugs Supplier Stock solutions 
8-CPT Sigma Aldrich 10 mM in 1N NaOH/       
1 mM in H2O 
Adenine Sigma Aldrich 100 mM in 1N NaOH 
Adenosine Sigma Aldrich 1 mM/10 mM in H2O 
ADP Sigma Aldrich 10 mM in H2O 
Allopurinol Sigma Aldrich 100 mM in 1N NaoH 
AMP Sigma Aldrich 1 mM in H2O/10 mM in 
1N NaOH 
ATP Sigma Aldrich 10 mM/1 mM in H2O 
Creatine Sigma Aldrich Endconcentration in aCSF 
D-Ribose Sigma Aldrich 1 M in aCSF/ Neurobasal 
Forskolin Acent 10 mM in DMSO 
GDP Sigma Aldrich 1 mM in H2O 
GMP Sigma Aldrich 10 mM in H2O 
GTP Sigma Aldrich 1 mM in H2O 
Guanosine Sigma Aldrich 10 mM in 1N NaOH 
Hypoxanthine Sigma Aldrich 100 mM in 1N NaOH 
IMP Sigma Aldrich 10 mM in H2O 
Inosine Sigma Aldrich 10 mM in H2O 
NADH Sigma Aldrich 10 mM in H2O 
PPADS Tocris 10 mM in H2O 
Rotenone Sigma Aldrich 10 mM in DMSO 
Serotonin Sigma Aldrich 10 mM in H2O 
Xanthine Sigma Aldrich 100 mM in 1N NaOH 
Hoechst Sigma Aldrich 80 mM in PBS 
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11.1 Factors that determine the separation process in 
reverse phase HPLC 
 
There are numerous parameters that influence the separation of sample compounds 
in reverse phase HPLC, some of which are shown in Table 11.1. Commonly used 
terms to describe the properties of a HPLC method are the: 
 
 retention times of analytes (TR), which describes the time from injection of 
the sample to the appearance of the peak maximum in the detector  
 selectivity (separation factor) describes the relative TR of two compounds 
with respect to each other (TR2/TR1)  
 resolution of peaks (RS) takes the width of peaks into account and describes 
the degree of separation of two peak maxima (RS = TR1 – TR2 / average peak 
width)  
 column efficiency is expressed as the number of theoretical plates (N, 
dimensionless) and determines the sharpness of the peaks and hence the RS, 
which increases with increasing N.  
 
Although changes to both phases will affect most parameters, they exert these effects 
via different mechanisms, as summarised in Table 11.1. 
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Chromatographic 
conditions 
Mechanism 
Temperature Viscosity of mobile phase decreases with increasing 
temperature, resulting in improved mass transfer analytes 
between mobile and stationary phase  
Flow rate Determines the longitudinal diffusion of analytes, which 
affects the ability of the reverse phase medium to absorb 
sample compounds 
Mobile phase  Mechanism 
pH  The ionisation of acidic and basic residues depends on 
the pH. pH should be adjusted to suppress ionisation in 
order to allow sufficient interaction with the stationary 
phase 
Type and percentage of 
organic modifier 
The lower the polarity of the mobile phase the higher its 
elutive capacity, with water being the most polar eluent 
(water>methanol>acetonitrile>tetrahydrofuran).  
Gradient/Isocratic 
elution 
The gradient profile and/or the parameters of an isocratic 
elution affect the elution time of compounds 
Ionic strength  Higher salt concentrations of the buffer can help to 
reduce residual silanol (SiOH) and sample ionisation as 
well as electrostatic repulsion between them, however 
high buffer concentrations lead to salt precipitates in the 
HPLC system 
Ion pairing agents Improves retention of charged analytes 
Stationary phase  Mechanism 
Column length Increasing column length will increase the number of 
theoretical plates (N), however so will the runtime and 
the backpressure 
Alkyl chain length Longer alkyl chains will increase the hydrophobic 
properties of the stationary phase (C18>C8>C4>C3) 
Particle size  Efficiency increases with increasing particle size, 
however so will the runtime and the backpressure  
 
Table 11.1: Factors of a reverse phase HPLC system, that determine the 
separation process. 
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Table 11.2 summarises all the changes to the mobile and stationary phases of the 
reverse phase system, which I have tried to improve the separation of 
purine/pyrimidine metabolites. However, none of these parameters resulted in a 
sufficient resolution of ATP/GMP and/or IMP as well as 
AMP/hypoxanthine/xanthine.  
 
Mobile phase   Coeluting 
compounds 
Gradient profile 
pH 7 
20 mM phosphate buffer 
 
pH 6.5 
20 mM phosphate buffer 
 
pH 6 
20 mM phosphate buffer 
 
pH 5.5  
20 mM acetate buffer 
 
pH 5 
20 mM acetate buffer 
HX/X/AMP 
ATP/IMP/GMP 
 
X/AMP 
GMP/ATP 
 
HX/X 
ATP/IMP/GMP 
 
HX/X/AMP 
 
 
HX/X/AMP 
IMP/GMP 
Linear gradient to 25 % 
MetOH 
 
 
 
 
Gradient profile does not 
improve resolution 
 
 
 
 
Gradient profile does not 
improve resolution 
Stationary phase factor  Comments 
Two C8, 5 µm, 150 mm columns 
in series 
 
C18, 3 µm, 150 mm  
Increased TR but no sufficiently improved RS or 
selectivity  
 
Improved efficiency, increased TR, but no 
sufficiently improved RS or selectivity 
 
Table 11.2: Effect of changing several mobile phase and/or stationary phase 
parameters on the separation of standard compounds: The resolution of ATP/IMP 
and/or GMP as well as AMP/ xanthine (X) and/or hypoxanthine (HX) could not be 
improved by various adjustments of the mobile phase (pH and buffer) or stationary 
phase (column). 
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The following tables summarise reported adenine nucleotide levels of in vivo rat 
brain (Table 12.1) or in vitro brain slices (Table 12.2). Since not all of the reported 
values are given in concentrations per mg protein, values reported per mg wet weight 
and or mg dry weight were converted to mg protein, following a wet weight to 
protein ratio of 1: 10 obtained from my own data and published reports 
(Whittingham and Lipton, 1981) and a wwt/dwt ratio of 1:5  (Xu et al., 2006). 
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species Age/weight Detection Brain region ATP ADP AMP EC 
TAN 
[nmol/mg 
protein] 
(estimated) 
Reference 
SD  E18 In situ freezing  
Fluorimetric/enzymatic 
[nmol/mg dwt] 
Cortex 
 
Hippocampus 
 
Cerebellum 
20.5±3.4 
 
18.4±3.3 
 
19.1±2.4 
 
    (Pundik et al., 2006) 
Wistar  P7 Whole animal freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
 
Whole brain 2.4±0.08 0.27±0.03 0.03±0.02  27 (Vannucci et al., 1996) 
SD  145-160 g Microwave irradiation 
HPLC 
 
[µmol/g wwt] 
Cortex 2.49±0.07 0.82±0.045 0.176±0.011 0.835±0.006 34.86 (Phillis et al., 1996) 
SD  145-155 g Microwave irradiation 
HPLC 
[µmol/g wwt] 
 
Cortex 2.92±0.045 0.78±0.017 0.14±0.009 0.86±0.004 38.4 (Phillis et al., 1995) 
Wistar  140-160 g Whole animal freezing 
HPLC 
[nmol/mg protein] 
 
Striatum 23.6±2.2 3.1±0.4 3.4±0.4 0.83±0.08 30.1 (Milusheva et al., 1996)* 
SD  140-170 g Microwave irradiation 
HPLC 
[nmol/mg protein] 
 
Whole brain 28.8±2.4 13.5±0.5 2.2±0.3 0.80±0.1 44.5 (Delaney and Geiger, 1996)* 
Wistar  220-270 g In situ freezing 
HPLC/fluorimetric 
[µmol/g wwt] 
 
forebrain 2.79±0.07 0.29±0.02 0.024±0.003 0.945±0.003 31.04 (Onodera et al., 1986) 
Wistar  240-320 g In situ freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
 
Cortex 3.01±0.09 0.36±0.03 0.026±0.010 0.94±0.006 33.96 (Yoshida et al., 1982) 
Wistar  270-330 g In situ freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
 
Hippocampus 2.67±0.07 0.31±0.01 0.06±0.01 0.93±0.01 30.4 (Folbergrova et al., 1997) 
Wistar  290-400 g In situ freezing 
HPLC[µmol/g wwt] 
Cortex 2.83±0.07 0.158±0.008 0.008±0.002 0.971±0.002 29.96 (Chapman et al., 1981) 
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species Age/weight Detection Brain region ATP ADP AMP EC 
TAN 
[nmol/mg 
protein] 
(estimated) 
Reference 
rats  Reeze-blowing 
technique  
Spectrophotometrically 
[nmol/g wwt] 
 
Whole brain 2.75±0.10 0.377±0.022 0.038±0.007 0.934±0.003 31.65 (Winn et al., 1979) 
rats 275-425 g In situ freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
 
Whole brain 3.06±0.07 0.27±0.007 0.03±0.001 0.951±0.001 33.6 (Ljunggren et al., 1974) 
Wistar 250-300 g In situ freezing 
Enzymatic 
[nmol/mg dwt] 
 
Cortex 
 
Hippocampus 
 
Brain stem 
 
14.4±2.0 
 
15.5±2.1 
 
10.9±2.1 
   nd (Xu et al., 2006) 
Wistar  300 g Urethane/ 
Microwave irradiation 
Fluorimetric/enzymatic 
[nmol/mg protein] 
Cerebral cortex 
 
Superioror colliculus 
 
Hippocampus 
 
Cerebellum 
 
23.7±1.0 
 
20.9±0.8 
 
26.5±1.0 
 
26.1±0.6 
   nd (Kobayashi et al., 1998) 
SD  304-403 g In situ freezing 
HPLC 
[µmol/g wwt] 
 
Cortex 2.47 0.4 0.06 0.91 29.3 (Verhaegen et al., 1995) 
Wistar  300-365 g In situ freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
Cortex 
 
Hippocampus 
 
Cerebellum 
 
2.8±0.05 
 
2.93±0.02 
 
2.61±0.03 
0.3±0.006 
 
0.3±0.018 
 
0.24±0.01 
0.043±0.002 
 
0.044±0.006 
 
0.039±0.002 
0.938±0.002 
 
0.941±0.002 
 
0.945±0.002 
31.43 
 
32.74 
 
28.89 
(Folbergrova et al., 1981) 
SD  330-450 g In situ freezing 
HPLC 
[µmol/g dwt] 
 
Cortex 11.4±0.6 1.4±0.1 0.18±0.03 0.94±0.01  (Marklund et al., 2006) 
Chapter 12 
 
 
221 
 
 
 
Table 12.1: Reported in vivo adenine nucleotide concentrations in rat brain. wwt wet weight ; dwt dry weight; EC energy charge 
(ATP+0.5xADP/TAN); SD Sprague Dawley; All total adenine nucleotide values (TAN = [ATP] + [ADP] + [AMP]) are expressed as 
nmol/mg protein on a wwt/protein ratio of 1:10 obtained from our own data and published reports (Whittingham and Lipton, 1981) and a 
wwt/dwt ratio of 1:5  (Xu et al., 2006). All rats older than p7 were male; all animals were under anesthesia, apart from references signed 
with an asterix (*). Data is presented in ascending age of the animals. 
 
 
 
 
species Age/weight Detection Brain region ATP ADP AMP EC 
TAN 
[nmol/mg 
protein] 
(estimated) 
Reference 
Han:Wist  
 
1 year In situ freezing 
Fluorimetric/enzymatic 
[µmol/g wwt] 
 
Cortex 2.68±0.15 0.27±0.03  0.937±0.009 nd h and Hoyer, 1991) 
Wistar 1 year  
(490 g) 
In situ freezing 
HPLC 
[µmol/g wwt] 
Cortex 
 
Hippocampus 
2.74±0.11 
 
2.49±0.22 
0.40±0.02 
 
0.44±0.03 
 
  nd 
 
nd 
(Hoyer and Lannert, 2008) 
Wistar 15-20 weeks Microwave irradiation/ 
HPLC 
[nmol/mg protein] 
Cortex 
 
Hypothalamus 
 
Hippocampus 
 
Striatum 
 
Cerebellum 
27.4±3.3 
 
22.3±5.1 
 
28.1±1.8 
 
30.1±3.2 
 
24.7±3.0 
8.6±1.0 
 
5.8±0.9 
 
9.0±1.8 
 
9.4±0.8 
 
6.0±0.9 
2.5±0.6 
 
3.2±0.5 
 
3.2±1.4 
 
2.8±1.0 
 
1.6±0.3 
 38.5 
 
31.3 
 
40.3 
 
42.3 
 
32.3 
(Yamada et al., 1988) 
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Table 12.2: Reported adenine nucleotide concentrations in rat brain slices. EC energy charge; TAN total adenine nucleotides [nmol/mg 
protein]; all animals were male. 
 
species Age/weight Preparation Detection Brain region 
Incubation 
conditions 
ATP ADP AMP TAN EC Reference 
Wistar  140-160 g Dopamine 
incubation 
Freezing  
HPLC 
[nmol/mg protein] 
 
Striatum 
400 µm (tissue 
chopper) 
90 min 11.82±1.48 4.82±2.24 2.72±1.37 19.36±4.15 0.73±0.04 (Milusheva et al., 
1996) 
SD  180-240 g nd Freezing 
HPLC 
[nmol/mg protein] 
 
Hippocampus,  
400 µm (tissue 
chopper) 
interface 8.3 1.1 0.2  0.9 (Fredholm et al., 
1984) 
SD 250 – 300 g Anesthesia/ ice 
cold aCSF 
Kynurenic 
ascorbic acid 
Freezing  
Bioluminescence 
[nmol/mg protein] 
Hippocampus, 300  
µm (Vibratome)  
Interface? 13.3±1.1     (Galeffi et al., 
2000) 
Holtzman  110-130 
days 
3°C 
aCSF 
Freezing 
Enzymatic/fluorimetric 
[nmol/mg protein] 
 
Hippocampus 
~500 µm (free 
hand) 
37°C, 60 min  
submerged 
13.4±0.4   19.0±0.6 0.85±0.01 (Kass and Lipton, 
1982) 
Wistar 350-450 g Anesthesia 
aCSF 
Freezing  
Enzymatic/fluorimetric 
[nmol/mg protein] 
 
Hippocampus  
400 µm (tissue 
chopper) 
36.5°C, 60 
min/ 5h 
submerged 
12.78±1.03 3.38±0.22 0.95±0.18 17.10±1.18 0.84±0.012 (Whittingham et 
al., 1989) 
Fisher 2-3 month Anesthesia 
 
Freezing 
HPLC 
[nmol/mg protein] 
Hippocampus 
400 µm (tissue 
slicer) 
aCSF+amino 
acids 
submerged 
31°C  
9.4±0.5 
 
34°C  
13.4±1.4 
 
37°C  
10.1±0.8 
 
    (Paschen and 
Djuricic, 1995) 
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13.1 Stability of total adenine nucleotides over a 9 h 
incubation period 
 
In order to establish the metabolic integrity of brain slices over a prolonged 
incubation period I measured the total adenine nucleotide (TAN) levels of brain 
slices incubated in standard aCSF (green dots), 10 mM Sucrose (black dots, osmotic 
control), 10 mM Glucose (blue dots) as well as 10 mM Ribose (red dots) after 3 h (N 
= 4 - 14), 5 h (N = 3 - 7) and after 9 h (N = 2) incubation at 34°C (Figure 13.1 A). 
There was a ~ 20 % drop in the TAN levels after 9 h and a rise in IMP levels (Figure 
13.1 B) in all slices. Interestingly Ribose-treated slices always had higher IMP 
levels, potentially due to increased purine salvage or de novo synthesis. Due to the 
drop of TAN levels after 9 h incubation I tried to keep the experimental window at ≤ 
8 h since the metabolic integrity of hippocampal brain slices has been shown to be 
stable over that incubation period (Whittingham et al., 1984b). 
 
Figure 13.1: Stability of A the total adenine nucleotide (TAN) pool and B IMP 
levels, over a prolonged incubation period in brain slices incubated in standard 
aCSF (green dots), 10 mM Sucrose (black dots, osmotic control), 10 mM Glucose 
(blue dots) as well as 10 mM Ribose (red dots). There was a 20 % reduction of the 
TAN pool after a 9 h incubation period (N = 2). IMP levels increased over that 
incubation time and interestingly IMP levels in Ribose treated slices were 
consistenly elevated, suggesting increased purine salvage or purine de novo 
synthesis.  
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13.2 Time course of Xanthine Oxidase inhibition by 
Allopurinol 
 
Adenosine biosensors contain all of the enzymes, including xanthine oxidase, 
required to convert adenosine to hydrogen peroxide, which oxidises on a polarised 
platinum wire and produces a current proportional to the adenosine concentration. 
The xanthine oxidase inhibitor allopurinol is converted to the active inhibitor 
oxypurinol by xanthine oxidase itself, thereby producing hydrogen peroxide. 
Therefore adenosine biosensors were used to determine the effectiveness of 
allopurinol to inhibit the adenosine signal, by incubating them with allopurinol for 
up to 3 h and measuring the response to adenosine applied in the continuous 
presence of allopurinol (Figure 13.2 A).  
These experiments were performed by Holly Baum, a project student under my 
supervision. The initial response to 10 µM adenosine was similar to the response to 
10 µM allopurinol (Figure 13.2 B). The initial response to adenosine was depressed 
by 32 % after 10 min incubation with allopurinol (N = 3), by 61 % after 1 h 
incubation (N = 3) and by 78 % after 2 h incubation (N = 3). After 3 hours 
incubation with allopurinol, the response to 10 µM adenosine was nearly abolished 
(96% depression of the original signal, N = 2, Figure 13.2 C). This suggests that 
allopurinol is effectively inhibiting xanthine oxidase and that a 3 hr incubation 
period is needed for a nearly complete inhibition. 
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Figure 13.2: Allopurinol inhibits the adenosine signal on adenosine biosensors: A 
Representative adenosine sensor trace showing the time-dependent inhibition by 
allopurinol on the adenosine response. Sensors were exposed to 10 µM adenosine 
alone and after 10 min, 1 h or 2 h incubation (see red horizontal lines) with 10 µM 
allopurinol (as indicated by the grey line). B The maximum initial current detected 
in response to stimulation with 10 µM adenosine or 10 µM allopurinol was the 
same. C The percentage depression of the adenosine signal detected in the 
continuous presence of allopurinol was calculated relative to that with adenosine 
alone for each experiment. All values are presented as mean ± S.E.M. 
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13.3 Effect of high Ribose and Glucose on adenine 
nucleotide levels 
 
To study the effect of Glucose and Ribose (Rib) on pre- and post-ischemic TAN 
levels, slices were incubated with 10 mM sucrose (osmotic control), Rib, or an 
additional 10 mM glucose (total glucose concentration in the aCSF was 20 mM) for 
3 h, before being exposed to oxygen/glucose deprivation (OGD). Thereafter slices 
were transferred back to sucrose-, Rib- or glucose-supplemented aCSF for various 
reperfusion times (Figure 13.3). Although there were no significant differences 
between slices incubated with the different sugars, the TAN and ATP levels in 
glucose- and especially Rib-treated slices were consistently higher after OGD than 
TAN levels in sucrose-treated slices (Figure 13.3 A and D). The reason for the better 
recovery in glucose-treated slices might lie in the fact that there was still some 
glucose surrounding the tissue during OGD, which might explain the higher energy 
charge (EC) in glucose-treated slices during 5 min OGD (EC = 0.73 ± 0.02 
compared to 0.55 ± 0.07 in ribose and 0.53 ± 0.06 in sucrose treated slices, data not 
shown). However, the beneficial effect of Rib on TAN levels after the ischemic 
insult might be due to enhanced purine salvage during OGD, as seen in the 
significantly higher IMP levels (Figure 13.3 C), the product of the hypoxanthine 
guanine phosphoribosyltransferase (HGPRT) catalysed reaction (hypoxanthine + 
PRPP → IMP). Furthermore AMP levels were not significantly elevate in Rib-
treated slices (Figure 13.3 B) compared to glucose- and sucrose-treated slices, 
further suggesting that the increased IMP levels are unlikely to be derived from 
increased degradation of AMP.  
However upon 10 min OGD and reperfusion there was no complete recovery of pre-
ischemic TAN and ATP levels in either condition. In fact the TAN levels decreased 
further upon 6 h reperfusion, which might be due to a complete disturbance of the 
energy metabolism. However, in control slices incubated for 9 h (time control, see 
Figure 13.1 A) I also observed a reduction of the TAN pool by 20 %, suggesting a 
slow degradation of the tissue during the incubation period. 
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Figure 13.3: Effect of sucrose, D-ribose and glucose on pre- and post-ischemic A 
ATP, B AMP, C IMP and D total adenine nucleotide (TAN) levels. Slices were 
incubated for 3 h with 10 mM sucrose, ribose or glucose before they were washed in 
aCSF (to remove residual glucose), exposed to oxygen/glucose deprivation (OGD) 
and transferred back into sucrose, glucose or ribose supplemented aCSF for various 
reperfusion (rep) time points. All values are expressed as mean ± S.E.M; N = 3 - 6; 
(*) p < 0.05, one way ANOVA with Bonferroni’s multiple comparison test.  
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13.4 Effect of 8-CPT on the recovery of synaptic 
transmission in Rib/Ade treated slices after OGD 
 
In order to test whether the incomplete recovery of synaptic transmission after OGD 
in Rib/Ade treated slices was due to increased levels of extracellular adenosine I 
applied 1 µM 8-CPT to the slices after 1 h reperfusion (Figure 13.4). The fEPSP 
traces increased by 250 % in one experiment and by 28 % in the two other 
experiments, suggesting that the extracellular adenosine levels were close to the pre-
ischemic adenosine levels in control slices (21 % increase in control slices, Chapter 
6). 
 
Figure 13.4: Effect of the A1 receptor antagonist 8-CPT (1 µM) on the recovery of 
synaptic transmission after 1 h reperfusion in Rib/Ade treated slices (N = 3). The 
fEPSP traces increased by 250 % in one experiment and by 28 % in the two other 
experiments, showing that the extracellular adenosine levels were close to the pre-
ischemic adenosine levels in control slices (21 % increase). 
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13.5 Effect of 5 mM Creatine on the decline and recovery 
of synaptic transmission during OGD 
 
In order to test whether higher creatine concentrations resulted in further delayed 
decline of synaptic transmission during OGD or improved recovery after OGD, I 
treated 2 slices with 5 mM creatine and compared the results to the ones observed for 
1 mM creatine (Figure 13.5). The decline in synaptic transmission was similar 
between the two (Figure 13.5 A), and anoxic depolarisation occurred after 12 and 
14.5 min in the two slices, which is slightly longer than the mean time to AD in 1 
mM creatine treated slices (13.5 ± 0.9 min, see Chapter 7). The recovery of synaptic 
transmission seemed to be slightly delayed in 5 mM Creatine treated slices (Figure 
13.5 B).  
 
 
Figure 13.5: Effect of 5 mM creatine on decline and recovery of synaptic 
transmission. 2 slices were treated with 5 mM creatine for ≥ 3 h and exposed to 
OGD until anoxic depolarisation (AD) occurred and perfused again with 5 mM 
creatine. A There was no difference in the decline of synaptic transmission between 
5 and 1 mM creatine treated slices. The increase in fEPSPs during OGD marks the 
epileptiform activity, after which the AD occurred. The dashed grey line refers to the 
duration of OGD, which was 12 and 14.5 min in the two slices treated with 5 mM 
creatine (time until AD). B The recovery of synaptic transmission in 5 mM creatine 
seemed to be slightly delayed compared to 1 mM creatine. 
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13.6 Addition of Rib/Ade and creatine after the ischemic 
insult 
 
In additional sets of experiments, I tested the effect of Rib/Ade or creatine on the 
recovery of synaptic transmission if added after the ischemic insult (OGD till AD) 
during a 150 min reperfusion period. However as seen in Figure 13.6, the results 
were very variable and have to be repeated. I did not observe a clear effect of either 
of the treatments, although a trend towards improved synaptic transmission could be 
seen in creatine treated slices, which is potentially linked to its radical scavenging 
properties (Lawler et al., 2002; Sestili et al., 2006). 
 
Figure 13.6:  Effect of Rib/Ade or creatine application on the recovery of synaptic 
transmission if added after the ischemic insult. Slices were exposed to OGD until 
the AD occurred and perfused with sucrose (osmotic control, 1 mM, N = 2), Rib/Ade 
(1 mM/ 50 µM, N = 3) or creatine (1 mM, N = 4). A fEPSP traces and B scatter plot 
showing the amount of recovery after 150 min reperfusion for all experiments.  
 
 
 
 
 
Chapter 13 
 
 
232 
 
13.7 Manipulations of intracellular tissue ATP levels affect 
the adenosine release during OGD 
 
Figure 13.7 shows the full time course of adenosine release and fEPSP decline and 
recovery upon exposure to 5 min OGD in control slices and slices pre-treated with 
Rib/Ade, creatine or Rib/Ade + creatine. Rib/Ade treatment results in significantly 
higher adenosine release, but does not affect the pattern of release whereas creatine, 
which significantly reduces adenosine release also changes the pattern of release. 
Likewise Rib/Ade + creatine pre-treatment reduces the adenosine release, suggesting 
that despite the increased ATP levels the buffer capacity of phosphocreatine is still 
sufficient to delay the degradation of ATP.  
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Figure 13.7: Modulation of intracellular adenine nucleotides influences adenosine 
release during OGD: A mean traces for adenosine sensor recordings and B fEPSPs 
of control slices (black trace, N = 4), slices pre-treated with Rib/Ade (1 mM/ 50 µM, 
N = 4), Creatine (red trace,1 mM, N = 3) or Rib/Ade + Creatine (N = 3) and 
exposed to 5 min oxygen/glucose deprivation (OGD) and subsequent 30 min 
reperfusion.  
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13.8  Subsequent ischemic periods 
 
In order to test whether Rib/Ade could be used to replenish the reduced adenosine 
release upon subsequent ischemic periods, I tried to establish a protocol that would 
allow for a reduced recovery after the first ischemic insult and a faster recovery after 
the second as shown before (Pearson et al., 2001). However, 5 min was too short 
since all slices nearly completely recovered. 6.25 min, as suggested before, resulted 
in variable responses, as shown in Figure 13.8. Some slices recovered completely 
and underwent anoxic depolarisation during the second ischemic period (see red 
trace) and some slices recovered completely after both ischemic insults (see black 
trace). If the AD occurred during the first ischemic period (after about 7 min) there 
was a complete loss of synaptic transmission during the second ischemic period. 
Therefore, I did not pursue these experiments.  
 
 
Figure 13.8: Effect of three subsequent ischemic periods on the recovery of 
synaptic transmission. Slices were exposed to 6.25 min OGD, allowed to recover for 
45 min and exposed to 6.25 min OGD, allowed to recover for 60 min and exposed to 
6.25 min OGD again. Sometimes the anoxic depolarisation occurred during the 
second ischemic period (see red trace) resulting in an incomplete recovery of 
synaptic transmission. If AD did not occur there was a complete recovery of synaptic 
transmission as seen in the black trace.  
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Intracellular ATP Influences Synaptic Plasticity in Area CA1
of Rat Hippocampus via Metabolism to Adenosine and
Activity-Dependent Activation of Adenosine A1 Receptors
Stephanie zur Nedden,1 Simon Hawley,2Naomi Pentland,2,3D. Grahame Hardie,2 Alexander S. Doney,4
and Bruno G. Frenguelli1,3
1School of Life Sciences, University of Warwick, Coventry, CV4 7AL, United Kingdom, 2Division of Molecular Physiology, College of Life Sciences,
University of Dundee, Dundee, DD1 5EH, United Kingdom, and Departments of 3Pharmacology and Neuroscience and 4Medicine and Therapeutics,
University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, United Kingdom
The extent to which brain slices reflect the energetic status of the in vivo brain has been a subject of debate. We addressed this issue to
investigate the recovery of energetic parameters and adenine nucleotides in rat hippocampal slices and the influence this has on synaptic
transmissionandplasticity.Weshowthat, althoughadeninenucleotide levels recover appreciablywithin10minof incubation, it takes3h
for a full recovery of the energy charge (to0.93) and that incubation of brain slices at 34°C results in a significantly higher ATP/AMP
ratio and a threefold lower activity of AMP-activated protein kinase compared with slices incubated at room temperature. Supplemen-
tation of artificial CSF with D-ribose and adenine (Rib/Ade) increased the total adenine nucleotide pool of brain slices, which, when
corrected for the influence of the dead cut edges, closely approached in vivo values. Rib/Ade did not affect basal synaptic transmission or
paired-pulse facilitation but did inhibit long-term potentiation (LTP) induced by tetanic or weak theta-burst stimulation. This decrease
in LTPwas reversed by strong theta-burst stimulation or antagonizing the inhibitory adenosine A1 receptor suggesting that the elevated
tissue ATP levels had resulted in greater activity-dependent adenosine release during LTP induction. This was confirmed by direct
measurement of adenosine release with adenosine biosensors. These observations provide new insight into the recovery of adenine
nucleotides after slice preparation, the sources of loss of such compounds in brain slices, the means by which to restore them, and the
functional consequences of doing so.
Introduction
The use of brain slices has revolutionized the study of the
mammalian CNS, and they have now become a standard prep-
aration in many laboratories and in many areas of neurosci-
ence. Hippocampal brain slices are particularly widely used
for studies into the fundamental properties of synaptic trans-
mission and plasticity.
However, it is an unavoidable fact that their preparation is
associated with ischemia (decapitation) and tissue trauma (dis-
section/slice cutting), whichwill affectmetabolic status and result
in departure from the in vivo state. Indeed, a substantially com-
promised energetic state of brain slices at the time of cutting has
been demonstrated (Fredholm et al., 1984; Whittingham et al.,
1984b), with high energy phosphate levels (ATP, phosphocre-
atine) in brain slices being asmuch as 50% lower than their in situ
values (Thomas, 1957; Whittingham et al., 1984a; Schurr and
Rigor, 1989). Accordingly, basal conditions in hippocampal slices
have been described as reflecting a post-ischemic recovery state
(Hossmann, 2008).However, as described as far back as the 1950s
(McIlwain et al., 1951; McIlwain, 1952), brain slices do show
remarkable metabolic recovery after preparation, and it is now
common practice to allow a period of incubation (usually 1 h)
before they are used for experiments.
Given the widespread use and importance of brain slices to
neuroscience, the aims of our study were threefold: first, to assess
the metabolic status of brain slices by studying the temperature-
dependent recovery and stability of adenine nucleotide levels and
energetic parameters, including the activity of AMP-activated
protein kinase (AMPK), an enzyme involved in regulation of
cellular energy homeostasis and exquisitely sensitive to the cellu-
lar ATP/AMP ratio; second, to investigate the potential causes for
the reduced ATP content of brain slices compared with reported
in vivo values and to evaluate whether the lower ATP levels are
attributable to a lack of adenine nucleotide precursors by incu-
bating slices with the free purine base adenine and the sugar
precursor of adenylates, D-ribose; finally, to test whether elevated
slice ATP levels change the electrophysiological properties of the
tissue, such as the probability of transmitter release or the induc-
tion and expression of long-term potentiation (LTP).
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Our findings provide new insights into the energetic status of
brain slices: they show that the loss of ATP precursors is respon-
sible for the decreased ATP content of brain slices and that, by
supplementing the artificial CSF (aCSF) with adenine and
D-ribose, the recovery of tissue ATP levels can be improved.
However, this has measurable consequences in terms of greater
activity-dependent release of extracellular adenosine and, via ac-
tivation of adenosine A1 receptors (A1Rs), the raising of the
threshold for the induction of long-term potentiation.
Materials andMethods
Preparation of brain slices.Male Sprague Dawley rats (17–27 d old) were
killed by cervical dislocation in accordance with Schedule 1 of the United
Kingdom Government Animals (Scientific Procedures) Act 1986 and
with local ethical review procedures. Sagittal brain slices (400m thick),
composed of hippocampus and overlying neocortex, were prepared un-
der standardized conditions in ice-cold aCSF containing 10 mM Mg2-
using a Microm HM 650 V microtome as described previously (Dale et
al., 2000; Frenguelli et al., 2007). Slices were either analyzed immediately
during cutting for their purine nucleotide content or transferred to the
recording chamber or an incubation chamber (50–100 ml) (Edwards et
al., 1989) and submerged in continuously circulating, oxygenated stan-
dard aCSF at room temperature (22 0.5°C) or 34 1°C. The compo-
sition of the standard aCSF solution included the following (in mM): 124
NaCl, 3 KCl, 2 CaCl2, 26 NaHCO3, 1.25 NaH2PO4, 10 D-glucose, and 1
MgSO4, pH 7.4 (with 95% O2/5% CO2).
In a separate set of experiments, nucleotide concentrations of (1) the
intact hippocampus and cortex and (2) slices of varying thickness were
analyzed. For this purpose, one hemisphere was used to dissect and sep-
arate hippocampus and cortex, and the other hemisphere was used to cut
slices of varying thickness (200–3600 m). Because with the microtome
used no slices1500m could be cut automatically, 3600mhad to be
measured with a guide. For these experiments, all nucleotide extractions
were performed immediately after preparation (zur Nedden et al., 2009).
Nucleotide extraction. To determine the total adenine nucleotide
(TAN) content of 400 m brain slices, two slices for each time point
[from time of cutting (time 0) to 5 h after cutting at 10 min, 30 min, 1 h,
2 h, 3 h, and 5 h] were transferred into ice cold aCSF to stop enzymatic
activities. To minimize transfer of aCSF into the reaction mixture, slices
were removed with a small spatula into a 1.5 ml microcentrifuge tube
containing 1 ml of 5% perchloric acid (PCA). Nucleotide extraction was
performed as described in detail previously (zur Nedden et al., 2009).
Extracts were neutralized by a threefold organic extraction with 1 ml of
tri-n-octylamine dissolved in 1,1,2-trichlorotrifluoroethane (1:1; v/v).
The protein pellet was resuspended in 1 ml of 0.5 M NaOH, and the
protein concentration was determined by Bradford assay, with bovine
serum albumin (BSA) as standard.
For analysis of the TAN content of whole hippocampus and neocortex
and 1200, 1500, and 3600 m slices, the tissue was first homogenized in
500 l of 5% PCA. The amount of this suspension containing 20 mg wet
weight (equivalent to four 200 m, two 400 m, or one 800 m slice) of
the tissue was mixed with 5% PCA to a final volume of 1 ml and neutral-
ized as described above.
We have shown previously that snap freezing in liquid N2 and freeze
thawing of brain tissue results in a degradation of adenine nucleotides
and an underestimation of the energy charge (zur Nedden et al., 2009).
For this reason, nucleotides were only extracted from fresh brain tissue
and were analyzed on the same day.
Protein extraction. For each time point, two to three brain slices were
placed in ice-cold aCSF to stop enzymatic activities. Slices were homog-
enized in 100 l of protein lysis buffer with a Kontes pellet pestle motor
(Sigma-Aldrich). The suspensionwas centrifuged (30min, 4°C, 16,060
g), and the supernatant was stored at80°C for kinase assays andWest-
ern blot analysis. The composition of the protein lysis buffer was as
follows: 50mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 1mM EDTA, 1%Triton
X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM so-
dium pyrophosphate, 270 mM sucrose, 0.1% -mercaptoethanol, 0.02%
sodium azide, and 1 protease inhibitor tablet for 16.6 ml of lysis buffer.
HPLC. For analysis of purine nucleotides and nucleosides, an ion pair
reversed-phase HPLCmethod with tetrabutylammonium hydrogen sul-
fate (TBAHS)was used, as described previously (zurNedden et al., 2009).
Analytical separation was performed on a Supelcosil LC-18-T reversed-
phase column (150  4.6 mm; inner diameter, 3 m), with a gradient
profile from 100% buffer A (65 mM potassium phosphate, pH 6.0, 4 mM
TBAHS) to 100% buffer B (65 mM potassium phosphate, pH 6.0, 25%
methanol) in 13 min. Peak identities were confirmed by comparison of
the retention times of sample peaks with peaks of standard compounds,
spiking the samples with individual standards and by comparison of the
UV spectra with standard compounds. Concentrations were calculated
by comparing the peak area of sample peaks with calibration curves for
peak areas of each standard compound. All concentrations are expressed
as nanomoles per milligram of protein.
Kinase assays. AMPK from extracts was immunoprecipitated with a
mixture of 1 and 2 antibodies, and AMPK activity in the immunopre-
cipitates was determined using the AMARA peptide assay as described
previously (Hardie et al., 2000; Gadalla et al., 2004).
Western blot analysis. The detection of dual-labeled Western blots by
infrared imaging was performed as described previously (Hawley et al.,
2003), except that, in the present study, the phosphorylation state of the
native full-length protein was determined.
Electrophysiological recordings. Except for one series of experiments,
slices (comprising hippocampus and overlying neocortex) were incu-
bated for 3–8 h in standard aCSF or for 2 h in aCSF supplemented with 1
mM ribose/50 M adenine (Rib/Ade) and 1–6 h in standard aCSF before
being transferred to a recording chamber and fully submerged in aCSF at
33.4 0.2°C and a flow rate of 6–7 ml/min. In the other series of exper-
iments, slices were immediately transferred to the recording chamber
during slice cutting to monitor the recovery of synaptic transmission in
control and Rib/Ade-containing aCSF. A twisted bipolar Teflon-coated
tungsten wire was placed to stimulate the Schaffer collateral/commis-
sural pathway every 15 s, and field EPSP (fEPSPs) were recorded from
stratum radiatum in area CA1 of the hippocampus with a glass micro-
electrode filledwith aCSF (1M). The stimulus intensity was adjusted to
50–60% of that required to evoke a population spike. LTP was induced
with tetanic stimulation (one train of 100 stimuli at 100 Hz) or with
theta-burst (TBS) stimulation (0.5, 1, 2, or 3 10 trains of four stimuli at
100 Hz repeated at 200 ms intervals).
Adenosine biosensors. Adenosine and null microelectrode biosensors
(50 m diameter and 500 m length) were purchased from Sarissa Bio-
medical Ltd. and were used tomeasure the real-time release of adenosine
during LTP induction. The use of the sensors in hippocampal slices has
been described previously (Frenguelli et al., 2003, 2007). The adenosine
sensor relies on an enzyme cascade immobilized within a matrix on the
surface of a platinum/iridium electrode tometabolize adenosine, thereby
liberating H2O2, which is oxidized on the platinum/iridium electrode.
This gives rise to an oxidation current proportional to the concentration
of adenosine. The null sensor lacks enzymes and is used to establish the
presence of any electroactive interferents. Both sensorswere inserted into
the stratum radiatum of the CA1 region of hippocampal slices between
recording and stimulating electrodes. After insertion, slices were allowed
to recover for 30–45 min before electrical stimulation for the recording
of fEPSPs was started. After a stable fEPSP baseline of 15–20 min was
collected, adenosine release was evoked with three TBS given 10 s apart.
fEPSPs, adenosine and null sensor traces were recorded simultaneously.
Thirty minutes after LTP induction, sensors were either taken out of the
tissue or drugs were applied for 15–30 min before TBS was repeated.
After each experiment, sensors were calibrated with 10 M adenosine in
the recording chamber. Because no nonspecific electroactive release
could be detected on the null sensor, adenosine release was calculated
without subtraction of the null trace, and the values are given as M to
reflect that the adenosine sensor measures adenosine and its metabolites
(Frenguelli et al., 2007). To integrate the area under the curve of adeno-
sine sensor traces, the baseline had to be set to 0, which was achieved by
subtracting from the sensor trace a linear regression based on 5 min of
baseline.
Statistical analysis. All values are expressed as mean  SEM. For the
electrophysiological and adenosine sensor measurements, n values refer
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to the number of slices per experimental condition, which for most cases
is also equal to the number of animals used. Slices were used in duplicate
for nucleotide extraction and in triplicate for protein extraction. In these
cases, n values represent the number of animals used. For statistical anal-
ysis of more than two groups, one-way ANOVA with Bonferroni’s mul-
tiple comparison test was applied, whereas for comparisons between two
independent groups, unpaired t tests were used. For comparison of the
adenosine release before and after application of different drugs, a paired
t test was applied. Calculations were performed with Prism 4; p values
0.05 were considered as statistically significant.
Chemicals. All HPLC standards, 1,1,2-trichloro-1,1,2-trifluoroethane
(HPLC grade), EGTA, EDTA, sodium fluoride, sodium orthovanadate,
sodium pyrophosphate, sodium azide, BSA, TBAHS, D-ribose, adenine,
8-cyclopentyltheophylline (8-CPT), nitrobenzylthioinosine (NBTI), di-
pyridamole (DIPY), N 6-cyclopentyladenosine (N 6-CPA), sodium poly-
oxotungstate (POM-1), and the Bradford reagent were obtained from
Sigma-Aldrich. Protease inhibitor cocktail tablets and ATP were from
Roche. HPLC-grade methanol, perchloric acid, orthophosphoric acid,
tri-n-octylamine, Triton X-100, Tris base, and all salts used in the aCSF
were obtained from Thermo Fisher Scientific. Protein G Sepharose was
from GE Healthcare. Pyridoxalphosphate-6-azophenyl-2,4-disulfonic
acid (PPADS) and forskolin were purchased from Ascent. Sheep anti-
bodies against the 1 and 2 subunits of AMPK were described previ-
ously (Woods et al., 1996), and the antibody against the phosphorylated
Thr-172 was from Cell Signaling Technologies.
Results
Metabolic recovery after slice cutting
Recovery of adenine nucleotides
To study the recovery of adenine nucleotides after slice prepara-
tion,HPLC analysis of slice extracts was performed on fresh slices
immediately after cutting and after various incubation time
points in aCSF (10 min to 5 h) at room temperature (22°C) and
34°C (Fig. 1A).
Immediately after cutting, ATP, ADP, and AMP were present
in nearly equal amounts (6.0  0.3, 4.0  0.4, and 5.2  0.8
nmol/mg protein, respectively; n	 7) (Fig. 1B–D) (supplemen-
tal Table 1, available at www.jneurosci.org as supplemental ma-
terial). ATP levels significantly increased after only 10 min
incubation (10.7 1.0 and 11.0 0.9 nmol/mg protein at 22°C
and 34°C, respectively; n	 7; p 0.001, one-way ANOVA) with
a concomitant decrease of ADP (1.9 0.3 and 1.5 0.1 nmol/mg
protein at 22°C and 34°C, respectively; n	 7; p 0.001, one-way
ANOVA) and AMP (1.1 0.3 and 0.5 0.1 nmol/mg protein at
22°C and 34°C respectively; n	 7; p 0.001, one-way ANOVA)
levels. ATP degradation metabolites (IMP, adenosine, inosine,
hypoxanthine, and xanthine) were all elevated at the time of cut-
ting and together accounted for 
5 nmol/mg protein (supple-
mental Table 2, available at www.jneurosci.org as supplemental
material). The levels of these metabolites declined after slice cut-
ting and stabilized after 10–60 min of incubation.
After the initial recovery, ATP, ADP, and AMP levels did not
significantly change during the incubation time points tested (up
to 5 h incubation), and there were no significant differences be-
tween adenine nucleotides of slices kept at 22°C and 34°C (Fig.
1B–D). As a consequence of these complementary changes in
individual nucleotides, the total adenine nucleotide pool (TAN	
[ATP] [ADP] [AMP]) (Fig. 1E) did not significantly change
when slices were transferred from the ice-cold cutting solution
(15.2 1.1 nmol/mg protein; n	 7) into aCSF at 22°C (13.7
1.4 nmol/mg protein; n	 7) or 34°C (13.0 1.1 nmol/mg pro-
tein; n 	 7), suggesting that most of the accumulated AMP is
rephosphorylated to ATP rather than dephosphorylated to aden-
osine (via cytosolic 5-nucleotidase, EC 3.1.3.5.) or deaminated
to IMP (via AMP deaminase, EC 3.5.4.6.). The TAN pool re-
mained stable over an incubation period of 5 h. Average TAN
concentrations from all time points tested (10 min to 5 h) were
14.1 0.3 nmol/mg protein in slices at 22°C and 15.4 0.9 in
slices at 34°C, with ATP accounting for 
85 and 89%,
respectively.
Recovery of energetic parameters and AMPK activity
Two widely used measures of cellular energetic state are the ade-
nylate energy charge, EC	 ([ATP] 0.5 [ADP])/[TAN] (Atkin-
son, 1968), which has amaximum value of 1 when all the adenine
nucleotides are in the form of ATP and the ATP/AMP ratio.
Because of the nearly equal amounts of ATP, ADP, and AMP
at the time of cutting, the EC was very low (0.54  0.03; n 	 7)
(Fig. 2A) (supplemental Table 3, available at www.jneurosci.org
as supplemental material) but recovered significantly after only
10 min incubation at 22°C (0.86  0.019; n 	 7; p  0.001,
one-way ANOVA) and 34°C (0.90  0.007; n 	 7; p  0.001,
one-way ANOVA). After 3 h the EC stabilized at 0.93 0.003 for
slices kept at 22°C and at 0.95 0.002 for slices kept at 34°C, and,
as for adenine nucleotides, there were no significant differences
between slices at 22°C and 34°C.
The ATP/AMP ratio significantly recovered from time of cut-
ting (1.4 0.4; n	 7) (Fig. 2B) (supplemental Table 3, available
atwww.jneurosci.org as supplementalmaterial) after only 10min
in slices at 34°C (22.9 2.7; n	 7; p 0.001, one-way ANOVA),
whereas it took 
30 min to recover in slices incubated at 22°C
(20.1 1.8; n	 6; p 0.001, one-way ANOVA). Similar to the
EC, the ATP/AMP ratio stabilized after 3 h but with considerable
differences between slices incubated at 22°C and at 34°C. At 22°C,
the ATP/AMP ratio ranged between 35.2 and 38.0, whereas at
34°C, the ATP/AMP ratio was much higher between 63.5 and
64.2. The differences in the ATP/AMP ratio values between the
two incubation temperatures became statistically significant after
30 min (n 	 6–8; p  0.01, one-way ANOVA) and remained
statistically significant for the rest of the incubation period (n	
5–8; p 0.001, one-way ANOVA).
The cellular ATP/AMP ratio is monitored by AMPK (EC
2.7.11.31), a key sensor and regulator of cellular energy metabo-
lism (Hardie and Hawley, 2001; Hardie, 2007). AMPK is acti-
vated by phosphorylation of Thr172 by the upstream kinases
LKB1 (Hawley et al., 2003) and calcium/calmodulin-dependent
protein kinase kinase  (Hawley et al., 2005; Woods et al., 2005).
In addition, an increase in cellular AMP provides both allosteric
activation of the enzyme and protection of Thr172 from dephos-
phorylation, whereas both of these effects are antagonized by
high intracellular ATP levels (Hardie et al., 2006; Sanders et al.,
2007). Therefore, we investigated whether the lower ATP/AMP
ratio in slices at 22°C was reflected by a higher AMPK activity.
AMPK activity (Fig. 2C) decreased from 0.066 0.003 U/mg
protein at time of cutting to 0.04 0.001 U/mg protein after 30
min at 22°C (1.6-fold decrease; n 	 3; p  0.001, one-way
ANOVA), by which time at 34°C AMPK activity had fallen 3.4-
fold (n	 2). After 3 h, AMPKwas three timesmore active in slices
at 22°C (0.03 0.003 U/mg protein; n	 3) than in slices at 34°C
(0.01  0.001 U/mg protein; n 	 3; p  0.001, one-way
ANOVA).Western blots (Fig. 2D) showed that the ratio of phos-
pho-AMPK/total AMPK decreased from 2.8 at time of cutting to
1.9 in slices at 22°C and to 1.1 in slices at 34°C after 3 h incubation
(n 	 2) (supplemental Fig. 1, available at www.jneurosci.org as
supplemental material). Likewise, the phospho/total ratio of a
substrate, acetyl-CoA carboxylase (ACC), decreased from 1.6 at
time of cutting to 1.0 in slices at 22°C and to 0.5 in slices at 34°C
after 3 h incubation (Fig. 2D) (supplemental Fig. 1, available at
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www.jneurosci.org as supplemental ma-
terial). These observations suggest that,
despite similarities between TAN pools
and EC values between slices incubated
at room temperature and more physio-
logical temperatures, the ATP/AMP ratio
can influence the activity of key intracel-
lular enzymes with potentially impor-
tant consequences for neuronal and
glial properties.
Basis of reduced TAN concentration
in slices
EC values of brain slices reported here
(Fig. 2A) (supplemental Table 3, available
at www.jneurosci.org as supplemental
material) are comparable with those re-
ported in vivo (supplemental references,
available at www.jneurosci.org as supple-
mentalmaterial).However, absolute TAN
levels here (Fig. 1E) (supplemental Table
1, available at www.jneurosci.org as sup-
plemental material) and in the in vitro
literature (supplemental references, avail-
able at www.jneurosci.org as supplemen-
tal material) are 
40–60% lower than
published in vivo values for rat brain,
which are typically
33.6 4.7 nmol/mg
protein (arithmetic mean  SD of all in
vivo published data in supplemental refer-
ences, available at www.jneurosci.org as
supplemental material) (Fig. 3A). In our
study, the loss of adenine nucleotides oc-
curred either before or during slice prep-
aration, because TAN levels were already

55% (
18.4 nmol/mg protein) lower at
the time of cutting than published in vivo
studies. We investigated several possible
explanations for this observation.
The ischemic period leads to loss of
diffusible ATP degradation products
The sum of ATP degradation metabo-
lites (adenosine, inosine, hypoxanthine,
xanthine, and IMP) at time of cutting
was approximately 
5 nmol/mg protein
(supplemental Table 2, available at www.
jneurosci.org as supplementalmaterial). Al-
though, like ADP and AMP levels, these
metabolites declined during the first 10–30
min of incubation, there was no corre-
sponding rise in the TAN pool. Thus, they
are likely to be lost from the tissue and
thereby contribute to the reduced adenine
nucleotide content of brain slices.
The tissue suffers from physical damage causing additional loss of
adenine nucleotides
To establish whether the dissection of tissue associated with slic-
ing caused additional loss of adenine nucleotides, we determined
the TAN content immediately after decapitation/dissection in
entire hippocampus and cortex (because slices in this study were
composed of hippocampus and overlaying neocortex). The TAN
content of intact hippocampal and cortical tissue was higher than
that in combined hippocampal/neocortical slices at 23.0  2.1
and 28.9  2.9 nmol/mg protein, respectively (Fig. 3A) (n 	 5;
p  0.05 between hippocampal and cortical tissue, unpaired t
test). The value for cortex is close to that reported in vivo (33.6
4.7 nmol/mg protein) (Fig. 3A), but TAN levels in the hippocam-
pus are lower than those reported in vivo. This suggests that the
ischemic period during decapitation results in a loss of adenine
nucleotides, especially in hippocampal tissue (
10 nmol/mg
protein, 
29%), which additionally requires more physical and
Figure 1. Rapid recovery of adenine nucleotides after slice preparation. A, Representative HPLC traces obtained from brain
slices after slice cutting and various incubation times in aCSF at room temperature (22°C; left traces) and 34°C (right traces). Note
the consistently higher AMP levels in slices incubated at 22°C. Numbers on traces refer to the following compounds: 1, adenosine;
2, GDP; 3, GTP/UTP. Arrowheads indicate, from left to right, AMP, ADP, andATP;mAU,milli absorbance units.B–E, Recovery of ATP
(B), ADP (C), AMP (D), and total adeninenucleotides (TAN	 [ATP][ADP][AMP]) (E) from timeof cutting (white squares, time
0) and various incubation times (0.1–5 h) in aCSF at 22°C (white triangles) or 34°C (black circles). Values are presented asmean
SEM; n	 5–8. ###p 0.001 for slices at 22°C and 34°C compared with time of cutting, one-way ANOVA with Bonferroni’s
multiple comparison test. When no error bars can be seen, they are smaller than the symbol.
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potentially traumatic dissection for removal. In contrast, neocor-
tex may undergo more rapid cooling when the brain is dropped
into ice-cold aCSF, which may better preserve adenine
nucleotides.
Figure 2. Differential influence of temperature on the recovery of energetic parameters and
AMPKactivity after slice cutting. Recovery of the tissue energy charge [(ATP 0.5 ADP)/TAN] is
not influenced by temperature (A), whereas the ATP/AMP ratio is significantly higher at ele-
vated temperature (n	 5–8) (B). C, Accordingly, AMPK activity in brain slices, asmeasured by
pseudo-substrate phosphorylation, is lower at higher incubation temperature, reflecting the
higher ATP/AMP ratio (n	 3 except for 0.5 h, 34°C, n	 2). White squares, Slices at time of
cutting (time 0); white triangles, slices incubated in aCSF at room temperature (22°C); black
circles, slices incubated in aCSF at 34°C. D, Confirmation of increased AMPK activity through
Western blot analysis of increased phosphorylation of AMPK (p-AMPK) and a downstream
target, ACC (p-ACC). Also shownare total AMPKandACC at different durations and temperature
of incubation in two separate sets of slices. All values are presented as mean SEM. ###p
0.001 for slices at 22°C and 34°C compared with time of cutting; **p 0.01, ***p 0.001
compared between slices at 22°C and 34°C, one-way ANOVA with Bonferroni’s multiple com-
parison test. When no error bars can be seen, they are smaller than the symbol.
Figure 3. Tissue thickness and handling influences calculation of adenine nucleotide con-
tent of brain tissue. A, TAN content of whole hippocampus (n	 5) and cortex (n	 5) imme-
diately after dissection and hippocampal (n	 3) and neocortical slices (n	 3) immediately
after cutting. Note that whole tissue TAN levels are lower than reported in vivo values (dotted
black line represents thearithmeticmeanSDas shownby thegrayarea for all reportedvalues
from supplemental references, available atwww.jneurosci.org as supplementalmaterial), pos-
sibly reflecting increased handling/trauma, with only whole cortex approaching in vivo values.
B, TAN levels of neocortical/hippocampal slices of varying thickness (200, 400, 800, 1200, 1500,
and 3600m) immediately after cutting. All values in A and B are presented as mean SEM;
n	 3–8. C, Theoretical curves (Y	 1 , where 	 d/l; dotted lines) to estimate the
relative contribution of dead cut edges (d) to the total tissue thickness of slices (l, ranging from
100 to 2000m in 20m steps), assuming a total thickness for the two dead cut edges of 40
m (light gray dotted line, 20mon each side of the slice), 70m (black dotted line, 35m
on each side of the slice), or 100m(dark gray dotted line, 50mon each side of the slice). By
normalizing the TAN levels obtained from slices at different thicknesses from B to the TAN
values obtained for 3600 m slices (plotted as black dots), we found that these normalized
values fit the curve for a total dead cut edge layer of 70m (black dotted line). D, Theoretical
curve for the ratio of the thickness of cut dead edges (d; 70 m) to the tissue thickness (l;
ranging from 100 to 3600m in 20m steps), showing that, with increasing slice thickness,
the relative contributionof the thickness of the cut edgesdecreases, approachinga valueof 0.99
(black circles).
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The difference in TAN levels between cortex and hippocam-
pus can also be seen in slices (Fig. 3A). Hippocampal slices had
significantly lower TAN levels than cortical slices (16.4 1.1 and
20.7  0.7 nmol/mg protein, respectively; n 	 3; p  0.05, un-
paired t test). These values were
28% lower than the respective
whole tissue values reported above and 
38% (cortex) to 50%
(hippocampus) lower than reported in vivo values (Fig. 3A).
The dead layer on slice surfaces distorts adenine nucleotide
measurements
Empirical observations. To test whether the protein content of
dead slice edges (typically 35–50 m) (Feig and Lipton, 1990;
Siklo´s et al., 1997; Frenguelli et al., 2003) results in an underesti-
mate of ATP in the viable core of the slice, we prepared neocor-
tical/hippocampal slices of different thickness, thereby changing
the ratio of dead to viable tissue. Because therewere no significant
changes in the TAN levels between slice cutting and 5 h incuba-
tion (Fig. 1E) (supplemental Table 1, available at www.jneurosci.
org as supplemental material) and to bypass the problem of a
possible emerging nutrient-deprived core in very thick slices, the
analysis was performed immediately after cutting.
The TAN content of slices, relative to the amount of protein,
increased 
26% with increasing thickness from 15.2  1.7
nmol/mg protein in a 200 m slice to 20.6 1.0 nmol/mg pro-
tein in a 1200 m slice (Fig. 3B) (n	 5–8; p 0.05, unpaired t
test). There was no additional increase in the TAN levels in 1500
m slices (20.3 2.3 nmol/mg protein; n	 4), and we obtained
a value of 21.1 2.6 nmol/mg protein for 3600mslices (n	 3).
Theoretical predictions. To better understand the dependence
of TAN content on slice thickness, we made the assumption that
the TAN is proportional to the volume of the tissue (l3) as defined
by a unit of length l. If in a slice there is a layer of dead tissue of
thickness d devoid of adenine nucleotides at either face of the
slice, then the volume of tissue contributing to the TAN is l2(l
d).We further assumed that d is constant and does not depend on
slice thickness and expressed d as a proportion of l (d	 l). The
volume of tissue contributing to the TAN is thus l3(1 ). If we
consider a unit of volume (i.e., l	 1), then a plot of 1 against
the normalized TAN for different slice thicknesses, assuming
constant d, should fit our observed data and provide a theoretical
estimate of the dead layer of tissue at either face of the slice. In
Figure 3C, we have plotted theoretical curves for the relative con-
tribution of a dead tissue layer (d) of 20 m (40 m in total), 35
m (70 m in total), and 50 m (100 m in total) on both slice
edges to the total tissue thickness (l, from100 to 2000mslices in
20msteps). By normalizing themeasured TANvalues in Figure
3B to the TAN value obtained for 3600 m slices (21.1 nmol/mg
protein) and plotting it on the same graph, we observed a very
good fit of our measured values to the theoretical curve obtained
for an estimated total dead cut edge layers of 70m, or 35m for
each edge (Fig. 3C,D, black dotted lines).We previously reported
a value of 35 m as an estimate of the dead slice layer based on
histological assessment of 400 m slices (Frenguelli et al., 2003),
revealing a remarkable degree of consistency between our exper-
imental observation and our theoretical model.
With this curve (ranging from100 to 3600min 20msteps)
(Fig. 3D), an asymptotic value is approached at a tissue thickness
of 3600 m (1 	 0.980), suggesting that the dead cut edges
account for only 2% of the whole tissue thickness. Therefore,
assuming a maximal TAN value of 21.1 nmol/mg protein (3600
m slices) in slices, we might underestimate the TAN content of
the viable core tissue in a 400 m slice (17.1  1.5 nmol/mg
protein) by
4nmol/mgprotein,
19%.Nonetheless, when cor-
rected for this amount, slice TAN levels in 400 m neocortical/
hippocampal slices remain 
37% (
12.5 nmol/mg protein)
lower than reported in vivo values (33.6 4.7 nmol/mg protein
as shown by the gray area for the mean SD in Fig. 3B). Hence,
this difference is likely attributable to the loss of adenine nucleo-
tides and precursors during the ischemia and physical trauma
associated with slice preparation.
Supplementation of aCSF with adenine nucleotide precursors
improves cellular ATP levels
In vivo cerebral TAN or ATP levels recover after brief periods of
ischemia (1–5 min) to pre-ischemic values after 60–90 min rep-
erfusion (Ljunggren et al., 1974; Kobayashi et al., 1977; Nowak et
al., 1985). However, there was no significant increase in TAN
levels in slices over a 5 h incubation period (Fig. 1E). This might
be attributable to a lack of purine precursor metabolites in the
aCSF, which might otherwise be used to restore tissue ATP levels
via purine salvage or de novo synthesis.
Because two key components of the purine salvage pathway,
which is believed to predominate in brain (Gerlach et al., 1971;
Mascia et al., 2000; Barsotti and Ipata, 2002), are adenine and
D-ribose (Fig. 4A), we tested these compounds in brain slices.
Incubating slices in 50 M Ade and 1 mM Rib resulted in tissue
levels of Ade reaching a maximum after 1 h incubation (0.92 
0.07 nmol/mg protein), with no additional increase after 3 h
(0.95  0.04 nmol/mg protein; n 	 3–5) (data not shown). In-
terestingly, the uptake of Ade was facilitated by 1mMRib (0.56
0.09 nmol/mg protein after 3 h incubation in 50 M Ade alone
comparedwith 0.95 0.04 nmol/mg protein after 3 h incubation
in 1 mM Rib/50 M Ade; p  0.05, one-way ANOVA), with no
additional increase observed with higher Rib concentrations
(0.83  0.06 nmol/mg protein after 3 h incubation with 10 mM
Rib/50 M Ade, n	 3) (data not shown).
To test whether Ade and Rib could be used by the purine
salvage pathway to restore adenine nucleotide levels in brain
slices, we incubated freshly cut slices in aCSF supplemented with
1 mM Rib and 50 M Ade (Fig. 4). The TAN content in slices
incubatedwith Rib/Ade increased to 25.8 0.7 nmol/mg protein
after 3 h incubation (compared with 19.1 1.2 nmol/mg protein
in slices incubated in standard aCSF; n	 3–5; p 0.01, one-way
ANOVA) (Fig. 4B), with ATP accounting for
92%. When cor-
rected for the influence of the protein content of the dead slice
edges (
4 nmol/mg protein) (Fig. 4B), these values (
30
nmol/mg protein) are close to the values reported for in vivo
tissue (33.6  4.7 nmol/mg) (Fig. 4B). The elevation of tissue
TAN and ATP levels by Rib/Ade did not significantly impact on
the EC, which stabilized at 0.96 0.001, and the ATP/AMP ratio,
which reached an asymptotic value after 3 h at 141.7  17.5
compared with 94.9 23.5 for slices incubated in standard aCSF
(n	 3–5; p 0.05, one-way ANOVA) (Fig. 4C).
Lower Rib concentrations (500 M) were not as effective in
increasing TAN levels and higher Rib concentrations (2.5–10
mM) did not further increase the TAN content of slices (data not
shown). Furthermore, Ade (50 M) on its own, as well as higher
Rib concentrations (2.5 or 10 mM) on its own did not signifi-
cantly increase the TAN content in slices (supplemental Table 4,
available at www.jneurosci.org as supplemental material). This
suggests that bothmetabolites are needed for effective conversion
to adenine nucleotides during a 3 h incubation period.
To establish whether these elevated levels of TAN and ATP
persisted when Rib/Ade was removed, we incubated slices in
standard aCSF for 2 h after 3 h in Rib/Ade. During this time,
tissue adenine content decreased back to baseline (0.1  0.05
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nmol/mg protein; n	 3) (data not shown). However, the higher
TAN levels weremaintained evenwhenRib andAdewerewashed
out of the slices (Fig. 4B) (supplemental Table 4, available at
www.jneurosci.org as supplemental material) (24.9  0.4
nmol/mg protein; n	 3; p 0.01 compared with standard slices,
one-way ANOVA), as were the energy charge and ATP/AMP
ratio (Fig. 4C).
These data suggest that the full recovery of slice ATP levels is
limited by the lack of ATP precursors in the aCSF. In addition,
these data also indicate that providing ATP precursors in the
form of Rib/Ade allows the viable core of brain slices to restore
ATP levels to values close to those reported in vivo.
Electrophysiological properties of slices incubated in Rib/Ade
To establish whether the higher ATP and TAN levels in slices
incubated in Rib/Ade would alter the electrophysiological prop-
erties of brain slices, we performed extracellular recordings from
the CA1 region of hippocampal slices. Input–output curves,
paired-pulse facilitation, and LTP were compared between slices
incubated for 3–8 h in standard aCSF and slices incubated for 2 h
in 1 mM Rib and 50 M Ade then for 1–6 h in standard aCSF to
wash these agents out of the tissue. A 2 h incubation period in
Rib/Ade was chosen, because slice TAN levels reached an asymp-
totic value at that time (25.4  2.3 nmol/mg protein), with no
additional increase after 3 h (25.8  0.6 nmol/mg protein; n 	
3–5) (data not shown).
Basal synaptic transmission is normal in Rib/Ade-treated slices
The recovery of synaptic transmission after slice cutting was not
different between standard and Rib/Ade-treated slices (supple-
mental Fig. 2, available at www.jneurosci.org as supplemental
material). Furthermore, in a separate series of slices, there was no
significant difference in input–output curves (Fig. 5A; n 	 15–
16) and paired-pulse ratios (Fig. 5B; n	 18–22) between the two
set of slices ( p  0.05, one-way ANOVA). Likewise, 50 M Ade
on its own (Fig. 5C; n	 4) or in combinationwith 1mMRib (Fig.
5D; n 	 6) did not change paired-pulse ratios when acutely ap-
plied to slices. This suggests that, under conditions of low-
frequency stimulation of afferent fibers, the enhanced tissue ATP
levels inRib/Ade-treated slices is not being released to formaden-
osine in the extracellular space, whichwould, via inhibitory A1Rs,
inhibit glutamate release and raise the paired-pulse facilitation
ratio. These negative results suggest that the activation A1Rs and
basal handling of adenosine is normal between standard and Rib/
Ade-treated slices. To test this directly, we applied the selective
A1R agonist N
6-CPA (10 nM) (Gadalla et al., 2004) or the aden-
osine uptake inhibitors NBTI (5 M)/DIPY (10 M) (Frenguelli
et al., 2007; Etherington et al., 2009) to both sets of slices (Fig.
5E,F). The concentrations chosen were submaximal for com-
plete depression of the fEPSP to avoid a “floor effect” obscuring
potential differences between the two sets of slices. Furthermore,
we have shownpreviously thatNBTI/DIPY causes a depression of
the fEPSP that can be reversed with A1R antagonists (Pearson et
al., 2001) and have demonstrated the increase in extracellular
adenosine directly with adenosine biosensors (Frenguelli et al.,
2007; Etherington et al., 2009).
The rate and extent of fEPSP depression after a 15 min appli-
cation of N6-CPA was the same in control (50.0 1.6%; n	 5)
and Rib/Ade-treated (50.4  1.6%; n 	 5; p  0.05, unpaired t
test) slices (Fig. 5E). Likewise, the application NBTI/DIPY for 40
min resulted in the same rate and amount of depression in both
sets of slices (40  5.9% for standard slices; 43  3.3% for Rib/
Ade treated slices; n 	 4; p  0.05, unpaired t test) (Fig. 5F).
These data suggest that Rib/Ade pretreatment does not influence
the sensitivity of the A1R to agonists, nor is the activity of equili-
brative adenosine transporters affected.
Furthermore, the fact that acute application of Ade did not
change paired-pulse ratios (Fig. 5C,D), shows that the recently
described Gi-protein-coupled adenine receptor (Bender et al.,
2002; von Ku¨gelgen et al., 2008), if present in the hippocampus,
Figure 4. A, Degradation of ATP and pathway for Ade and Rib utilization: 1, adenylate
kinase; 2, ATPases; 3, ATP synthase; 4, 5nucleotidase; 5, adenosine deaminase; 6, purine nu-
cleoside phosphorylase; 7, xanthine oxidase; 8, ribokinase; 9, phosphoribosylpyrophosphate
synthetase; 10, adenylosuccinate synthetase; 11, adenylosuccinate lyase. APRT, Adenine phos-
phoribosyltransferase; HGPRT, hypoxanthine phosphoribosyltransferase. Solid lines indicate
direct routes, and dashed lines indicate indirect routes. The reactions of the purine salvage
pathway are catalyzed by HGPRT and APRT. B, Improved recovery of TAN (left y-axis) and ATP
(right y-axis) levels in slices after 3 h incubation in standard aCSF (, black bars) or aCSF
supplemented with 1 mM D-ribose/50M adenine (, gray bars). Under these conditions and
with the correction for dead tissue on the edge of slices (
4 nmol/mg protein), slice TAN levels
(*, dashed gray bar) are close to those reported in vivo (dotted black line represents the
arithmetic mean SD as shown by the gray area for all reported values from supplemental
references, available at www.jneurosci.org as supplemental material). Elevated TAN levels are
maintained when ribose/adenine are washed out (w) of the tissue (hatched gray bars) by
transferring the slices to standard aCSF for 2 h.C, Energy charge (left y-axis) andATP/AMP levels
(right y-axis) are not significantly different in slices after 3 h incubation in standard aCSF (,
black bars), in aCSF supplemented with 1 mM D-ribose/50M adenine (, gray bars) or after
washout (w) of ribose/adenine (hatched gray bars) by transferring the slices to standard aCSF
for 2 h. All values are presented as mean SEM; n	 3–5. **p 0.01 compared with slices
incubated in standard aCSF, one-wayANOVAwithBonferroni’smultiple comparison test.When
no error bars can be seen, they are smaller than the symbol.
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does not have any presynaptic effects on
neurotransmitter release. However, to
further exclude the possibility of differ-
ences in cAMP formation between Rib/
Ade-treated slices and slices incubated in
standard aCSF, we applied 50 M forsko-
lin to both sets of slices and compared the
increase in fEPSP slopes (Fig. 5G,H ).
There was no significant difference in
forskolin-induced potentiation between
Rib/Ade-treated slices and slices incu-
bated in standard aCSF (Fig. 5G) (147.4
9.8% in standard slices and 159.1 12.9%
in Rib/Ade-treated slices; n 	 3–4; p 
0.05 compared with baseline before appli-
cation of forskolin, p 0.05 between stan-
dard slices and Rib/Ade-treated slices at
20min after application of forskolin, one-
way ANOVA). Paired-pulse facilitation
(50 ms interpulse interval) was similarly
affected by forskolin in standard slices and
Rib/Ade-treated slices (Fig. 5H) (n 	
3–4; p 0.05 between standard slices and
Rib/Ade-treated slices, unpaired t test).
This suggests that adenylyl cyclase activa-
tion and cAMP production is not im-
paired in Rib/Ade-treated slices.
Long-term potentiation is impaired in
Rib/Ade-treated slices
Slices incubated in standard aCSF showed
robust LTP 55–60 min after tetanic stim-
ulation (one train of 100 shocks at 100Hz;
135 5.8% of baseline; n	 9; p 0.001
compared with 5 min baseline before te-
tanic stimulation, one-wayANOVA) (Fig.
6A). However, LTP in slices incubated for
2 h in 1 mM Rib and 50 M Ade decayed
back to baseline 60 min after tetanic stim-
ulation (108  4.9% of baseline; n 	 11;
p 0.05 compared with 5 min baseline be-
fore tetanic stimulation, one-way ANOVA)
and was significantly lower in amplitude
thanLTP in control slices incubated in stan-
dard aCSF ( p  0.001 from 55 to 60 min
after LTP induction, one-way ANOVA).
Stable recordings could be achieved in Rib/
Ade-treated slices over the same timeperiod
(94  6.6% of baseline at 75 min; n 	 3)
(data not shown), which argues against
baseline drift as being the cause for the ob-
served decay in LTP. In contrast, acute
application of Ade or Rib alone, or in
combination, did not impair tetanus-
induced LTP (133  5% of baseline for
standard slices, 13113%after acute appli-
cation of 50 M Ade, 140 9% after acute
applicationof1mMRib, and1318%after
acute application of 1mMRib/50MAde at
60min after LTP induction; n	 4–5) (data
not shown), implying a requirement for up-
take and intracellular conversion to adenine
nucleotides.
Figure 5. Basal synaptic transmission, adenosine A1 receptor activation, and adenosine uptake are not different between slices incu-
bated instandardaCSFandslices treated for2h in1mMRiband50MAde. Input–outputcurves (n	15–16) (A)andpaired-pulse ratios
(n	 18–22) (B) for slices incubated in standard aCSF (black circles) and slices treated for 2 h with Rib/Ade-supplemented aCSF (gray
circles). Insets are representative fEPSPs from10–300A (A) and at 50ms interpulse interval (B) for controls andRib/Ade-treated slices.
C,D,Paired-pulseratios forslices incubated instandardaCSFbefore(blackcircles)andafteracuteapplicationof50MAde(C,whitecircles,
n	4)or50MAdeand1mMRib(D,whitecircles,n	6). InsetsarerepresentativefEPSPsat50msinterpulseintervalbefore(blacktraces)
and after application of Ade or Rib/Ade (dotted gray traces). There was no difference in the rate or magnitude of fEPSP depression in
responsetotheselectiveA1RagonistN
6-CPA(10nM;n	5)(E)orthecombinationoftheadenosineuptakeinhibitorsNBTI(5M)/DIPY(10
M;n	4) instandardslicesorRib/Ade-treatedslices (F ).G, Forskolin-inducedpotentiation instandardslices (blackcircles)andRib/Ade-
treated slices (gray circles). Forskolin at 50 M was applied to slices for 20 min and no differences were observed in the amount of
potentiation (147.4 9.8% in standard slices and 159.1 12.9% in Rib/Ade treated slices; n	 3–4) or the decrease in paired-pulse
facilitation (n	 3–4) (H ). Recordingswere performed at 33.4 0.2°C at a flow rate of 7–8ml/min after a3 h recovery period from
slice cutting. All values are presented asmean SEM. No significant differences observed between standard and Rib/Ade-treated slices
withunpaired t testsorone-wayANOVAwithBonferroni’smultiple comparisontest.Whennoerrorbars canbeseen, theyaresmaller than
the symbol.
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A potential reason for the impaired LTP stabilization in Rib/
Ade-treated slices might be that, because of the higher TAN pool,
enhanced synaptic activity during tetanic stimulation causes the
activity-dependent release of ATP and/or its metabolite adeno-
sine. To test this, we incubated slices in the ATP P2 receptor
antagonist PPADS (10 M) and A1R antagonist 8-CPT (1 M)
before the induction of LTP. Preincubation with PPADS did not
prevent the decay of LTP in Rib/Ade-treated slices (108 15%of
baseline 60 min after LTP induction; n	
4) (data not shown). These observations
suggest that, if ATP is being released dur-
ing tetanic stimulation, it is not directly
responsible via P2 receptors for the im-
pairment of LTP.
To test for a role for adenosine A1 re-
ceptors, we applied 8-CPT (1M), a selec-
tive A1R antagonist, to slices that had
either been pretreated with Rib/Ade or in-
cubated in standard aCSF. Ten minutes
after acute application of 8-CPT, fEPSPs
had increased to 121.4 0.7% in standard
slices (n 	 6) (data not shown) and to
124.1  0.5% in Rib/Ade-treated slices
(n	 8) (data not shown) and was associ-
atedwith a similar decrease in PPF in both
(data not shown). Both these changes in
synaptic transmission are indicative of
the removal of a basal adenosine A1R-
dependent inhibitory tone. The fact that
the changes were similar between the two
conditions argues against the possibility
of an increased basal adenosine tone in
Rib/Ade-treated slices. This is consistent
with the following observations: (1) simi-
lar tissue adenosine levels in both sets
of slices after a 3 h incubation (standard
slices, 0.05 0.004 nmol/mg protein, n	
3; Rib/Ade-treated slices, 0.04  0.002;
n	 3; p 0.05, unpaired t test) (data not
shown), (2) normal basal transmission
and paired-pulse facilitation in Rib/Ade-
treated slices (Fig. 5A–D), (3) identical
effects of A1R activation and uptake inhi-
bition (Fig. 5E,F), and (4) equal effects of
forskolin (Fig. 5G,H).
Having established that the basal han-
dling and effects of adenosinewere similar
in control and Rib/Ade-treated slices, we
next examined the effect of the A1R antag-
onist on tetanus-induced LTP with or
without previous treatmentwith Rib/Ade.
LTP was induced when a stable fEPSP
baseline of 15 min was collected,
30–40
min after application of 8-CPT. Both sets
of slices showed robust LTP in the pres-
ence of 8-CPT 55–60 min after tetanic
stimulation (Fig. 6B) (143  6.0% in
standard slices and 154  6.7% in Rib/
Ade-treated slices; n 	 5–6; p  0.001
compared with 5 min baseline before te-
tanic stimulation, p 0.05 between stan-
dard slices and Rib/Ade-treated slices
55–60 min after tetanic stimulation, one-
way ANOVA). This suggests that the activity-dependent release
of adenosine contributes to the impairment of LTP induction in
Rib/Ade-treated slices.
We hypothesized that this deficit in LTP induction repre-
sented a raising of the threshold for LTP by the activity-
dependent accumulation of extracellular adenosine and
activation of inhibitory A1Rs. This hypothesis predicted that
stronger activation of postsynaptic neurons should overcome
Figure 6. LTP induction with tetanic stimulation is impaired in slices treated for 2 h in 1 mM Rib and 50 M Ade in an
A1R-dependent manner. A, LTP after tetanic stimulation (1 100 stimuli at 100 Hz) in slices incubated for 2 h in Rib/Ade-
supplemented aCSF (gray circles; n 	 11) and slices incubated in standard aCSF (black circles; n 	 9). B, LTP after tetanic
stimulation and in the presence of 8-CPT in slices incubated for 2 h in Rib/Ade-supplemented aCSF (gray circles; n	 6) and slices
incubated in standard aCSF (black circles;n	 5). C,D, LTP is not different in slices incubated for 2 h in Rib/Ade-supplemented aCSF
(gray circles) and standard aCSF (black circles)when either two (C; 5min apart; 80 pulses; n	 6–7) or one (D; 40 pulses; n	 6 for
both) TBS are delivered (TBS: 10 trains of 4 pulses at 100 Hz, 200 ms interval). E, In contrast, a briefer TBS (5 trains, 20 pulses)
resulted in significant LTP in standard slices 55–60 min after TBS (black circles; n	 3 from 2 animals) but not Rib/Ade-treated
slices (gray circles;n	4 from3animals).F, Plot of pulse number versusmagnitudeof LTP55–60min (20, 40, 80pulses) or 30min
(120 pulses) after induction in standard and Rib/Ade-treated slices. Note that, throughout the pulse number range, Rib/Ade-
treated slices give rise to lower LTP, which falls below significant LTP induction threshold at 20 pulses. Data for 120 pulses from
Figure 7 with 120 pulses delivered via 3 40 pulse theta trains at 10 s intervals with LTP measured after 30 min. All insets are
representative of fEPSPs before (solid lines) and 60 min after the induction of LTP (dashed lines). Recordings were performed at
33.40.2°Cat a flow rateof 7–8ml/minafter a3h recoveryperiod fromslice cutting.All values arepresentedasmeanSEM.
zur Nedden et al. •Metabolic Regulation of Synaptic Plasticity J. Neurosci., April 20, 2011 • 31(16):6221–6234 • 6229
this threshold. Accordingly, we used a TBS LTP induction proto-
col (Larson et al., 1986), which is known to deliver sustained
glutamatergic excitation while causing fatigue of GABA-
mediated inhibition and hence greater activation of NMDA re-
ceptors (Chen et al., 2010).
Control and Rib/Ade-treated slices were stimulated with two
TBS at 5min intervals (2 10 trains of four pulses at 100Hzwith
200ms intervals, i.e., 80 pulses in total). This protocol resulted in
robust LTP in both standard and Rib/Ade-treated slices 55–60
min after TBS (Fig. 6C) (150.2  7.6% in standard slices and
140.0  7.1% in Rib/Ade-treated slices; n 	 6–7; p  0.001
compared with 5 min baseline before TBS, p  0.05 between
standard slices and Rib/Ade-treated slices at 55–60 min after
TBS, one-way ANOVA). One TBS (40 pulses) resulted in smaller
LTP 55–60 min after TBS and showed little difference between
standard and Rib/Ade-treated slices (Fig. 6D) (137.7  9.5% in
standard slices and 126.2 5.0% inRib/Ade-treated slices; n	 6;
p  0.01 for standard slices and p  0.05 for Rib/Ade-treated
slices compared with 5 min baseline before TBS, p  0.05 be-
tween standard slices and Rib/Ade-treated slices at 55–60 min
after TBS, one-way ANOVA).
To confirm that TBS resulted in greater depolarization com-
pared with tetanic stimulation, we measured the area associated
with each pulse induced by tetanic stimulation (100 pulses) and
TBS (40 pulses) in a manner similar to that described recently
(Chen et al., 2010). A comparison of the normalized cumulative
area evoked by each pulse in a tetanus and TBS (supplemental
Fig. 3A, available at www.jneurosci.org as supplementalmaterial)
revealed a dramatic difference between the two: in a tetanus,most
of the depolarization had occurred within the first 20 pulses,
whereas during TBS, the depolarization increased almost linearly
during the 40 pulse train.
Furthermore, during a tetanus, there was evidence of an influ-
ence of Rib/Ade in causing fatigue of transmission during the
later stages of the train (20 pulses) (supplemental Fig. 3A, avail-
able at www.jneurosci.org as supplemental material). This was
prevented in slices treated with 8-CPT (supplemental Fig. 3B,
available at www.jneurosci.org as supplemental material) and is
consistent with a gradual synaptic accumulation of adenosine.
Indeed, the apparent enhancement in 8-CPT/Rib/Ade-treated
slicesmay reflect an action of adenosine on facilitatory adenosine
A2 (Kessey and Mogul, 1998; Fujii et al., 1999; Almeida et al.,
2003) or A3 (Costenla et al., 2001) receptors. In contrast, this
Rib/Ade-induced fatigue was hardly present during one TBS
(supplemental Fig. 3A, available at www.jneurosci.org as supple-
mental material), two TBS given 5 min apart (supplemental Fig.
3C, available at www.jneurosci.org as supplemental material), or
three TBS given 10 s apart (supplemental Fig. 3D,E, available at
www.jneurosci.org as supplemental material), suggesting rapid
clearance of adenosine in the 200 ms between each 4  100 Hz
stimuli.
An examination of the cumulative depolarization evoked
by tetanic stimulation (supplemental Fig. 3A, available at www.
jneurosci.org as supplemental material) predicted that 
20
pulses was the threshold for Rib/Ade to inhibit the induction of
TBS LTP: this was the point at which cumulative tetanic depolar-
izations diverged when Rib/Ade was present and also equivalent
to the number of TBS pulses required to evoke the maximal te-
tanic depolarization in Rib/Ade. Accordingly, delivery of 20 TBS
pulses (5 4 pulses at 100 Hz, 200 ms apart) resulted in signifi-
cant LTP in standard slices but not in Rib/Ade-treated slices
55–60min after TBS (Fig. 6E) (131.6 2% in standard slices and
117.8  6.6% in Rib/Ade-treated slices; n 	 3–4; p  0.01 for
standard slices and p 0.05 for Rib/Ade-treated slices compared
with 5 min baseline before TBS, one-way ANOVA). A compari-
son of the magnitude of LTP versus the number of TBS pulses
(Fig. 6F) reveals a consistent inhibitory influence of Rib/Ade
treatment on the magnitude of LTP.
These data point to the release of either ATP or adenosine
during electrical stimulation, which, via adenosine A1Rs, inhibits
the induction of LTP in response to tetanic stimulation in Rib/
Ade-treated slices. Importantly, this impairment can be over-
come by additional stimulation, suggesting that the elevated
levels of tissue ATP translate into raising the threshold for LTP
induction.
Real-timemeasurement of adenosine release during
LTP induction
To further test whether the higher TAN levels in Rib/Ade-treated
slices resulted in a greater accumulation of adenosine during pe-
riods of electrical stimulation of afferent fibers, we used adeno-
sine biosensors (Frenguelli et al., 2003) to measure the real-time
release of adenosine during TBS and LTP induction. The sensors
(adenosine and null sensors) were placed in stratum radiatum of
the CA1 region of hippocampal slices between the recording and
stimulating electrodes.
We could not detect anymeasurable release of adenosine dur-
ing tetanic stimulation (100Hz, 1 s) or consistently with one TBS
(data not shown), presumably because the released adenosine is
below the limit of detection for adenosine biosensors (50 nM) or
because the released adenosine remained close to the site of re-
lease and was not available for detection by the sensor. For this
reason, we used a more intense protocol that would be more
likely to result in greater adenosine release and sufficient spillover
of adenosine to be detected by the sensors. Accordingly, with a
multiple TBS protocol (10 trains of four pulses at 100 Hz, 200ms
apart, repeated three times at 10 s intervals) (Fig. 7A), we were
able to detect a rise in extracellular adenosine in slices incubated
in standard aCSF and slices treated with Rib/Ade (Fig. 7B).
Rib/Ade-treated slices released significantly more adenosine
during TBS as measured by integrating the area under the aden-
osine signal at the start of TBS to 5min after stimulation (Fig. 7B)
(0.64  0.1 M*min in slices incubated in standard aCSF and
1.98  0.1 M*min in Rib/Ade-treated slices; n 	 3; p  0.01,
unpaired t test). Despite this greater release of adenosine, we
could not observe any differences in LTP (Fig. 7A) between the
two sets of slices as measured at 30 min after TBS. This is likely
attributable to the fact that the strong stimulation protocol (Fig.
6C,D) overcame the inhibitory effects of A1R.
These results suggest that higher intracellular TAN or ATP
levels result in increased activity-dependent adenosine release
during periods of strong electrical stimulation, which can mod-
ulate the induction threshold for LTP.
Mechanism of activity-dependent adenosine release
To establish whether the released adenosine arose from direct
release of adenosine or from extracellular degradation of ATP, we
used adenosine uptake inhibitors (NBTI/DIPY) and POM-1, a
noncompetitive inhibitor of ectonucleotidases (Mu¨ller et al.,
2006; Wall et al., 2008). To assess the effect of these drugs on
adenosine release, TBS-induced adenosine release was evoked
twice (45–60 min apart): the first TBS was in control aCSF (in
either standard slices or Rib/Ade-treated slices), and the second
was in the presence of NBTI (5 M)/DIPY (10 M) or POM-1
(100 M), which were applied 30 min after the initial TBS. Re-
peating TBS twice within 45–60 min did not affect adenosine
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release (supplemental Fig. 4A, available at www.jneurosci.org as
supplemental material). If adenosine was released directly, we
would expect the transport inhibitors to reduce TBS-induced
adenosine accumulation as they represent amajor efflux pathway
for adenosine into the extracellular space (Baldwin et al., 2004). If
extracellular adenosine arose from the metabolism of ATP,
POM-1 should reduce TBS-induced adenosine release.
The effectiveness of POM-1 to inhibit ATP breakdown in hip-
pocampal brain sliceswas assessed by inserting adenosine biosen-
sors into slices and measuring adenosine production after
exogenous ATP application in the presence and absence of
POM-1 (Wall et al., 2008). POM-1 caused a time-dependent in-
hibition of ATP breakdown: in the absence of POM-1, 50 M
ATP yielded 3.5  0.2 M adenosine. After application of
POM-1 for 5 min, ATP breakdown was inhibited by 30  3%
(2.5 0.1 M; n	 3; p 0.05 compared with initial response,
one-way ANOVA), whereas after 15min, themetabolism of ATP
was inhibited by 42 2% (2 0.2M;n	 3; p 0.05 compared
with initial response, one-way ANOVA) (supplemental Fig.
4B,C, available at www.jneurosci.org as supplemental material).
We therefore decided to wait 15 min after POM-1 application to
study the effect of POM-1 on TBS-induced adenosine release.
In the presence of POM-1, TBS-induced adenosine release
was variable but showed no evidence of inhibition of adenosine
release. In fact, the reverse was observed: POM-1 seemed to in-
crease TBS-induced adenosine release in both standard and Rib/
Ade slices (supplemental Fig. 4A, available at www.jneurosci.org
as supplemental material). This could represent an off-target ef-
fect, as we have suggested exist in the use of POM-1 (Wall et al.,
2008), or could reflect a previously described ATP-mediated fa-
cilitation of adenosine release via the activation of ATP P2 recep-
tors (Almeida et al., 2003). To address this, we incubated Rib/
Ade-treated slices with the P2 antagonist PPADS (10 M) for 10
min before TBS. PPADS had no significant effect on adenosine
release in Rib/Ade-treated slices (2.0  0.41 M*min for Rib/
Ade-treated slices; n	 10; and 2.0 0.61M*min for Rib/Ade-
treated slices in the presence of PPADS; n	 3; p 0.05, unpaired
t test,) and indeed did not affect the increased TBS-induced aden-
osine release in the presence of POM-1 (2.8 0.45 M*min for
Rib/Ade-treated slices after POM-1 application; n 	 4; and 2.3
and 3.3M*min in two Rib/Ade-treated slices in the presence of
POM-1 and PPADS) (supplemental Fig. 4A, available at www.
jneurosci.org as supplemental material). These negative results
with the ectonucleotidase inhibitor POM-1 argue against an
appreciable release of ATP and extracellular conversion to
adenosine.
In contrast, application of NBTI/DIPY for 30 min resulted in
a 50% reduction in TBS-induced adenosine release in both sets of
slices (supplemental Fig. 4A, available at www.jneurosci.org as
supplemental material) (50.3  17.0% for control slices, n 	 4,
p 	 0.06; 49.2  11.0% for Rib/Ade-treated slices, n 	 3, p 	
0.04, paired t test), suggesting a role of equilibrative adenosine
transporters in the release of adenosine in response to high-
frequency stimulation of afferent fibers.
Discussion
Despite the importance and widespread use of brain slices as
models of themammalianCNS, criticisms remain regarding their
metabolic integrity. Our aimwas to address this issue to study (1)
the energetic recovery of brain slices, (2) the reasons for reduced
levels of ATP, (3) the possibility of improving cellular ATP, and
(4) the functional consequences of raising tissue ATP levels.
Energetic recovery after slice preparation
In accordance with previous findings (Fredholm et al., 1984;
Whittingham et al., 1984a,b), our results show that adenine nu-
cleotide levels in brain slices recover quickly and remain stable for
at least 5 h, independently of the incubation temperature. Like-
wise, the EC andATP/AMP ratio show a rapid recovery after slice
preparation, but it takes 3 h until they stabilize, well beyond the
time conventionally allowed for slices to recover. Provided with
an adequate supply of nutrients, it is likely that both interface and
submerged slices will recover similarly in terms of adenine nucle-
otides and energetic parameters. Indeed, TAN and adenosine
levels for interface hippocampal slices (
10.5 nmol/mg protein
and 40 pmol/mg protein, respectively) (Fredholm et al., 1984) are
not different from our results (
9.8 nmol/mg protein and 50
pmol/mg protein, respectively).
However, it is worth noting that other metabolites, such as
cGMP and cAMP, lactate, or phosphocreatine, also require 1–3 h
to achieve a steady state (Whittingham et al., 1984b). Likewise,
the phosphorylation status of proteins involved in synaptic plas-
ticity, such as GluA1, ERK2, and MEK1/2, changes during the
first 3 h of incubation (Ho et al., 2004), whereas a recovery period
of 4 h has been suggested for achieving stable long-term record-
ings of LTP in brain slices (Sajikumar and Frey, 2004; Sajikumar
et al., 2005; Redondo et al., 2010).
Figure 7. Real-timemeasurement of adenosine release during LTP induction reveals signif-
icantly higher adenosine release in slices treated for 2 h in 1 mM Rib and 50M Ade. A, fEPSP
slopes after LTP inductionwith TBS (10 trains of 4pulses, at 100Hz200msapart, applied3 times
with 10 s intervals) are not different in slices incubated for 2 h in Rib/Ade-supplemented aCSF
(gray circles; n	 4) and slices incubated in standard aCSF (black dots; n	 5). B, fEPSP slopes
and adenosine sensor traces from1minbefore and5min after TBS, as shownby thegray dotted
lines in A. Adenosine sensor traces show pooled traces of all experiments for standard slices
(white line with black area for mean SEM, respectively; n	 3) and Rib/Ade-treated slices
(black line with gray area for mean SEM, respectively; n	 3). Adenosine sensors placed
between the recording and stimulating electrodes show significantly higher adenosine release
in Rib/Ade-treated slices during LTP induction. All values are presented as mean SEM.
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Temperature dependence of the ATP/AMP ratio and
AMPK activity
Our results indicate that slices maintained at 34°C have a signif-
icantly higher ATP/AMP ratio comparedwith slices at room tem-
perature. This is likely attributable to the activity of adenylate
kinase (EC 2.7.4.3; 2 ADP7 ATP  AMP), which is greater at
temperatures above 32°C (Sheng et al., 1999; Lu and Wang,
2008). Accordingly, slices incubated at 22°C had a lower ATP/
AMP ratio and showed a threefold higher AMPK activity than
slices maintained at 34°C. This translated into increased phos-
phorylation of a downstream target, ACC, and suggests that other
downstream targets are likely to be similarly affected.
Of the known AMPK targets relevant to synaptic physiology,
AMPK phosphorylates GABAB receptors (Hardie and Frenguelli,
2007; Kuramoto et al., 2007) and calcium-activated potassium
channels (Wyatt et al., 2007). Furthermore, a proteomic screen
revealed 12 brain-specific downstream targets of AMPK, includ-
ing synapsin I and PACSIN1, further suggesting a role for AMPK
in regulating synaptic activity (Tuerk et al., 2007). Indeed, en-
hancing AMPK activity inhibits long-lasting LTP (Potter et al.,
2010). Hence, incubating slices at elevated temperatures will
more closely replicate metabolism in vivo with respect to the
activity of enzymes and properties of synaptic transmission.
Basis of reduced tissue ATP content in brain slices
As seen in this andmany other reports (McIlwain, 1952; Thomas,
1957; Kass and Lipton, 1982; Fredholm et al., 1984;Whittingham
et al., 1989; Paschen and Djuricic, 1995; Milusheva et al., 1996),
brain slices have
40–60% lower ATP and TAN levels than the
in vivo brain (Supplemental References). Our results suggest that
this is attributable to the loss of adenine nucleotides and/or their
metabolites, especially in hippocampal tissue, during slice prep-
aration. However, incubation of slices in Rib/Ade-supplemented
aCSF allowed the tissue to appreciably increase TAN levels.When
corrected for the influence of the dead slice edges, whichwe could
model accurately andwhich agreedwith histological estimates we
made previously (Frenguelli et al., 2003), TAN levels were within
the range reported in vivo. This suggests that the recovery of ATP
levels in brain slices is limited by the lack of precursors in the
aCSF and does not necessarily reflect an intrinsic metabolic
handicap.
Implications of improving the tissue ATP content in
brain slices
Although Rib/Ade restored tissue nucleotide levels close to those
observed in vivo, this did not have a bearing on basal synaptic
transmission, paired-pulse facilitation, or the tonic handling and
effects of extracellular adenosine. Instead, Rib/Ade inhibited LTP
after tetanic stimulation andweakTBS. That the application of an
A1R antagonist reversed the fatigue of the fEPSP during the teta-
nus and prevented the decline of tetanus-induced LTP in Rib/
Ade-treated slices suggests that the higher TAN levels resulted in
greater activity-dependent adenosine release, thereby preventing
the stable expression of LTP. This suggests that endogenous
adenosine exerts an inhibitory influence on LTP induction (de
Mendonc¸a and Ribeiro, 1994; Forghani and Krnjevic´, 1995; Fujii
et al., 2000; Rex et al., 2005), especially when used with weak
stimulation protocols (Arai and Lynch, 1992; de Mendonc¸a
and Ribeiro, 2000). Interestingly, the threshold for adenosine-
dependent regulation of TBS, based on the facilitatory actions of
an A1R antagonist, was 20 pulses (Arai and Lynch, 1992; deMen-
donc¸a and Ribeiro, 2000), consistent with our predictions based
on tetanic and TBS cumulative depolarizations and experiments
with Rib/Ade-treated slices. These observations and our own re-
sults point toward an adenosine A1R-dependent regulation of
LTP, which is influenced by the levels of intracellular adenine
nucleotides.
However, our analysis of the TBS stimulus trains revealed no
A1R-dependent fatigue of the fEPSP. Thismay reflect the fact that
the 200 ms burst spacing may allow time for the removal of ex-
tracellular adenosine between stimulus trains through metabo-
lism, reuptake, or diffusion. Thus, to the two known actions of
TBS that make it an effective and naturalistic stimulus for LTP
induction, maximizing both postsynaptic depolarization and
GABAergic fatigue, we may now potentially add a third: mini-
mizing the intraburst synaptic accumulation of extracellular
adenosine.
Using adenosine biosensors, wewere able to detect in real time
the release of adenosine during TBS. Rib/Ade-treated slices re-
leased significantlymore adenosine, consistent with the availabil-
ity of a greater precursor pool of ATP. To establish whether ATP
or adenosine was released in response to high-frequency stimu-
lation, we used the noncompetitive ectonucleotidase inhibitor
POM-1 (Mu¨ller et al., 2006; Wall et al., 2008) and the equilibra-
tive nucleoside transporter (ENT) inhibitors DIPY/NBTI (Fren-
guelli et al., 2007; Etherington et al., 2009). POM-1 failed to
reduce, and indeed facilitated, TBS-induced adenosine release.
This is unlikely to be attributable to ATP P2 receptor-mediated
facilitation of adenosine release reported by others (Almeida et
al., 2003) because the facilitation was not affected by the P2 an-
tagonist PPADS. Instead, this facilitation may involve nonspe-
cific actions of POM-1 (Wall et al., 2008) or could potentially
involve ATP heteroexchange with adenosine (Sperla´gh et al.,
2003), which is insensitive to P2 receptor antagonists but sensitive
to ENT inhibition. Accordingly, DIPY/NBTI caused a 50% re-
duction in TBS-induced adenosine release, which is consistent
with the direct release of adenosine during high-frequency stim-
ulation (Wall and Dale, 2008; Klyuch et al., 2011).
In a wider context, the reduced tissue ATP levels observed
after cerebral ischemia in vivo may, via reduced extracellular
adenosine and reduced activation of the anticonvulsant A1R
(Boison and Stewart, 2009; Dale and Frenguelli, 2009), contrib-
ute to the development of post-ischemic epilepsy (Camilo and
Goldstein, 2004; Kadam et al., 2010). Indeed, the influence of
intracellular ATP on extracellular adenosine and neuronal excit-
ability has been described recently (Kawamura et al., 2010) and
may be the basis for the reduced incidence of seizures during a
ketogenic diet (Masino andGeiger, 2008). Accordingly, elevation
of tissue ATP levels with Rib/Ade may be of value in the post-
ischemic brain. In fact, Rib has been used to improve post-
ischemic cardiac function in vitro, in vivo, and in humans
(Zimmer, 1998; Omran et al., 2003; Shecterle et al., 2010). Al-
though Ade has to be administered with a xanthine oxidase in-
hibitor (Watts et al., 1974; Simmonds, 1986) to prevent its
conversion to an insoluble metabolite, this may be beneficial
(Phillis et al., 1995) because it would prevent the formation of
nonsalvageable xanthine, thereby providing greater substrates for
the purine salvage pathway in the post-ischemic brain. Thus,
Rib/Ade may be of value in restoring ATP levels and adenosine
release after brain injury.
In summary, the data presented address long-standing issues
in the use of brain slices as in vitro models for the mammalian
CNS. We confirm the long-held view that tissue adenine nucleo-
tides are 
50% of the values reported in vivo but demonstrate
that this is an underestimate (by
20%) because of the contribu-
tion of damaged slice edges. Moreover, we show that slices have
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an appreciable capacity, through the purine salvage pathway, to
restore andmaintain tissue ATP levels close to in vivo levels when
presented with the ATP precursors Ade and Rib. The physiolog-
ical consequences of elevated tissue ATP levels are in the greater
activity-dependent release of adenosine and the raising of the
threshold for the induction of LTP.
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Knowledge of the energetic state of tissue is required in a wide range of experimental studies, particularly
those investigating the decline and recovery of cellular metabolism after metabolic stress. Such informa-
tion can be obtained from high-performance liquid chromatography (HPLC) determination of tissue lev-
els of adenine nucleotides (ATP, ADP, and AMP) and their interrelationship in the tissue energy charge
(EC). Accordingly, a large range of techniques with which to measure these molecules and their down-
stream metabolites have been reported. However, the accurate determination of the tissue EC also
depends on the nucleotide extraction procedure given that changes in adenine nucleotide levels take
place very quickly when ATPases are not inactivated immediately. In this article, we describe an ion-pair
reversed-phase HPLC method by which separation of adenine nucleotides can be performed rapidly,
allowing multiple analyses in 1 day, with both high sensitivity and extraction efﬁciency and using fresh
samples, thereby avoiding freeze–thaw degradation of nucleotides. We applied this method to hippocam-
pal brain slice extracts and show that same-day extraction and analysis results in a more accurate deter-
mination of the in situ energetic state than does the commonly used snap-freezing in liquid nitrogen.
 2009 Elsevier Inc. All rights reserved.The quantiﬁcation of adenine nucleotides is frequently used for
the assessment of the energetic state of tissues or cells because the
relationship between the individual nucleotides in the total ade-
nine nucleotide pool {[TAN] =
P
([ATP] + [ADP] + [AMP])}1 reﬂects
the energy supply-to-demand relationship [1]. Equations such as
the adenylate energy charge {EC = ([ATP] + 0.5[ADP]/[TAN])} [2],
which describes the ratio of charged adenylates (in terms of phosp-
hoanhydride bonds) to the TAN pool, are commonly used to indicate
the energy status of tissues. As such, accurate determinations of ade-
nine nucleotide concentrations are required for many investigations
into the energetic state of tissue.
There are several possible ways of measuring tissue adenylate
levels, with bioluminescence assays and high-performance liquid
chromatography (HPLC) methods being most commonly used [3].
Ultraviolet (UV)-based HPLC has the advantage of high sensitivity
and allows the separation and quantiﬁcation of a wide range of
nucleotides/nucleosides and free bases in one run.ll rights reserved.
ur Nedden).
EC, energy charge; HPLC, high-
BSA, bovine serum albumin;
erchloric acid; aCSF, artiﬁcial
limit of quantiﬁcation; SEM,Because metabolic stress, such as ischemia, leads to further deg-
radation of adenine nucleotides, resulting in formation of purine
nucleosides (adenosine and inosine) as well as free purine bases
(adenine, hypoxanthine, and xanthine), HPLC analysis can indicate
a broad spectrum of metabolic changes. For the simultaneous mea-
surement of purine nucleotides, nucleosides, and bases, ion-pair
reversed-phase HPLC is most commonly used [4,5] because the
separation of purine nucleotides is difﬁcult with reverse-phase col-
umns and purine nucleosides are only poorly retained in anion ex-
change HPLC [6].
We have developed a fast and sensitive ion-pair reversed-phase
UV-based HPLC method that allows the analysis of at least 11 pur-
ine metabolites, including adenine nucleotides and their most
important degradation metabolites (adenosine, inosine, hypoxan-
thine, xanthine, and IMP). This method is suitable for low-analyte
concentrations, and its rapidity (13 min runtime) means that many
fresh samples can be run in 1 day, avoiding degradation of adenine
nucleotides in frozen tissue or on thawing [7]. Furthermore, keep-
ing the separation runtime short also helps to reduce the cost of
each analysis given that ion-pairing agents are expensive.
We describe how the analytical separation is obtained using a
3 lm Supelcosil LC-18-T column with a gradient elution at room
temperature. We have used this method to determine the ener-
getic state of hippocampal brain slices and, furthermore, to evalu-
ate changes in adenine nucleotide levels caused by snap-freezing
in liquid nitrogen.
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Materials
HPLC standards, 1,1,2-trichloro-1,2,2-triﬂuoroethane, CHRO-
MASOLV, bovine serum albumin (BSA), tetrahydrofuran, tetrabu-
tylammonium hydrogen sulfate (TBAHS), and the Bradford
reagent, used for protein determination, were obtained from Sig-
ma–Aldrich (Poole, UK). ATP was obtained from Roche (Mannheim,
Germany). Perchloric acid (PCA), orthophosphoric acid, tri-n-octyl-
amine, HPLC-grade methanol, HPLC-grade acetonitrile, dipotas-
sium hydrogen phosphate, potassium dihydrogen phosphate, and
all salts used in the artiﬁcial cerebrospinal ﬂuid (aCSF) were ob-
tained from Fisher Scientiﬁc (Loughborough, UK).
HPLC apparatus
TheHPLCsystem(ThermoScientiﬁc,HemelHempstead,UK) con-
sisted of a vacuumdegasser (SCM1000), Spectra System binary gra-
dient pumps (P2000), an injector with a 20 ll injection valve, and a
Spectra System photodiode array UV detector (UV 6000) equipped
with a 10-ll ﬂow cell. A Supelcosil LC-18-T reverse-phase column
(150  4.6 mm i.d., 3 lm) protected with an HPLC Security Guard
Cartridge (C8, 4  3.0 mm, Phenomenex,Macclesﬁeld, UK)was used
throughout the entire study. For peak analysis and quantiﬁcation,
ChromQuest software (version 4.2.34) was used. HPLC chromato-
grams were obtained at a wavelength of 254 nm. However, the UV
spectrum from220 to 360 nmwas scanned for all runs andwas used
for spectral and purity analysis of sample and standard peaks.
HPLC method
The mobile phase consisted of buffer A (65 mM potassium
phosphate buffer composed of 39 mM dipotassium hydrogen phos-
phate and 26 mM potassium dihydrogen phosphate, adjusted to
pH 6 with orthophosphoric acid and 4 mM TBAHS) and buffer B
(65 mM potassium phosphate buffer composed of 39 mM dipotas-
sium hydrogen phosphate and 26 mM potassium dihydrogen
phosphate, adjusted to pH 6 with orthophosphoric acid and 25%
methanol). Both buffers were prepared in deionized water and ﬁl-
tered through a 0.4 lm ﬁlter before use. For each day of analysis,
the column was equilibrated with 10 column volumes of buffer B
and 30 column volumes of buffer A (ﬂow rate of 1 ml/min). The
retention times of standard compounds stabilized after two blank
injections (gradient proﬁle described below), and analytical sepa-
ration could then be performed. The ﬂow rate was 1 ml/min, and
the gradient proﬁle used was as follows: 1 min 100% buffer A,
3 min to 30% buffer B, 7.5 min to 80% buffer B, and 10 min to
100% buffer B. The run was kept at 100% buffer B for an additional
3 min before it was completed and the gradient was returned to
100% buffer A. The runtime for the elution of relevant compounds
was 13 min. A 10-min reequilibration between runs was sufﬁcient
to restore initial conditions. Concentrations were calculated by
comparing the peak area of sample peaks with calibration curves
for peak areas of each standard compound. All concentrations are
expressed as nanomoles per milligram (nmol/mg) protein. Stan-
dard solutions were prepared in deionized water as stock solutions
at 1 and 10 mM concentrations and were stored at 20 C.
Column protection
To keep the column performance at its best, special care was ta-
ken in column protection. The column was washed after each day
with 25 column volumes of 25% methanol to remove any residual
phosphate buffer. The guard cartridge was changed after 200 to
300 injections. When the peak shapes started to show broadeningand the backpressure increased (250–350 injections), the column
was regenerated by ﬂushing it with 30 column volumes of water
(40 C), 100% methanol, 100% acetonitrile, 20 column volumes of
100% tetrahydrofuran, and 100% methanol in reverse-ﬂow direc-
tion at a ﬂow rate of 0.4 ml/min, as per the manufacturer’s
instructions.
Method validation
The lower limit of detection (LOD, signal-to-noise ratio > 3) and
limit of quantiﬁcation (LOQ, signal-to-noise ratio > 10) were mea-
sured for standard compounds dissolved in deionized water and
standard compounds added to sample extracts at low concentra-
tions. For the recovery of standard compounds after PCA extrac-
tion, two brain slices were homogenized in 1 ml of PCA. Half of
the sample was spiked with various concentrations of a standard
mixture (5–30 lM), and a similar amount of deionized water was
added to the other half. Neutralization was performed as described
below except that 500 ll (instead of 1 ml) of tri-n-octylamine in
1,1,2-trichlorotriﬂuoroethane (1:1, v/v) was used. The percentage
recovery of standard compounds was calculated: (spiked sample
peak area  100)/(standard peak area + unspiked sample peak
area). To estimate the intrasample variability in the peak area of
individual sample peaks in both aliquots of the same brain slice ex-
tract, we prepared PCA homogenates of two brain slices, divided
and neutralized them as described above, but analyzed both halves
without adding additional standard compounds. The percentage
difference of the peak area for individual compounds was calcu-
lated: (difference between two peak areas  100)/average peak
area for two peaks.
Preparation of brain slices
Hippocampal/neocortical brain slices (400 lm thick) were pre-
pared from 19- to 24-day-old male Sprague–Dawley rats as de-
scribed previously [8,9]. After slice cutting, slices were
transferred to an incubation chamber and submerged within a bea-
ker of continuously circulating, oxygenated standard aCSF [10] at
34 ± 0.5 C for 3 h. The composition of the standard aCSF solution
was as follows: 124 mM NaCl, 3 mM KCl, 2 mM CaCl2, 26 mM NaH-
CO3, 1.25 mM NaH2PO4, 10 mM D-glucose, and 1 mM MgCl2 at pH
7.4 with 95% O2/5% CO2.
Nucleotide extraction
Two brain slices were placed in ice-cold standard aCSF to stop
any enzymatic degradation. Slices were transferred into 1 ml of
ice-cold 5% PCA with a small spatula to minimize ﬂuid transfer
and were immediately homogenized with a Kontes pellet pestle
motor (Sigma–Aldrich). After centrifugation (2 min, 4 C,
16,060g), the PCA was precipitated with 1 ml of tri-n-octylamine
in 1,1,2-trichlorotriﬂuoroethane (1:1, v/v) [11]. The suspension
was vortexed for 20 s and kept on ice for 10 min. After centrifuga-
tion (2 min, 12,100g), the organic extraction was repeated twice
with the upper aqueous phase. Thereafter, the aqueous phase
had a pH of 6 and contained water-soluble cell components such
as purine nucleotides/nucleosides and bases. HPLC analysis of ex-
tracts was performed on the same day. The protein pellet was
resuspended in 1 ml of 0.5 M NaOH, and protein concentration
was determined by Bradford assay with BSA as standard. For deter-
mination of the effect of liquid nitrogen freezing, slices were trans-
ferred into ice-cold aCSF and dropped into liquid nitrogen with a
small spatula. After 30 to 60 min in liquid nitrogen, slices were
powdered under liquid nitrogen and homogenized in PCA. Extrac-
tion was performed as described above, and extracts were ana-
lyzed on the same day.
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All values are expressed as means ± standard errors of the mean
(SEM), and n values represent means of duplicate slices from n
number of rats. For statistical analysis, an unpaired Student’s t test
was used. Calculations were carried out with Prism 4 software, and
P values < 0.05 were considered as statistically signiﬁcant.
Results
Chromatographic separation
Using the chromatographic procedure developed in this study, at
least 12 different purine metabolite standards could be separatedFig. 1. HPLC chromatograms of purine standards. (A) A 100-lM standard mixture of
12 compounds. (B) A500nMmixture of CTP,GTP, ADP, andATP injected after 5 minof
reequilibration time. Numbers on traces refer to the following compounds: 1,
hypoxanthine; 2, xanthine; 3,GMP;4, IMP;5, inosine; 6, adenosine; 7, AMP;8,GDP; 9,
CTP; 10, GTP; 11, ADP; 12, ATP. d, baseline peak. mAU, milli-absorbance units.
Table 1
HPLC method validation.
Compound LOD LOQ Retent
time (
ATP 500 nM (10 pmol) 500 nM (10 pmol) 11.99
ADP 500 nM (10 pmol) 500 nM (10 pmol) 10.60
GTP 500 nM (10 pmol) 500 nM (10 pmol) 10.47
CTP 100 nM (2 pmol) 500 nM (10 pmol) 9.68
GDP 50 nM (1 pmol) 100 nM (2 pmol) 8.65
AMP 50 nM (1 pmol) 100 nM (2 pmol) 8.30
Adenosine 5 nM (0.1 pmol) 25 nM (0.5 pmol) 7.76
Inosine 5 nM (0.1 pmol) 25 nM (0.5 pmol) 6.32
IMP 10 nM (0.2 pmol) 100 nM (2 pmol) 5.47
GMP 10 nM (0.2 pmol) 50 nM (1 pmol) 5.35
Xanthine 10 nM (0.2 pmol) 50 nM (1 pmol) 4.48
Hypoxanthine 10 nM (0.2 pmol) 50 nM (1 pmol) 3.90
Note. The LOD of standard compounds dissolved in deionized water was classiﬁed as the
analyte concentration 10 times the noise level. At 10 min of reequilibration between runs
of 2000 pmol), measured at 254 nm, is also indicated. Recovery of standard compounds
concentrations of standard compounds. All values are presented as means from three towithin 13 min, as shown in Fig. 1A (100 lM standard mixture,
2000 pmol). To keep the relative standard deviation of the retention
times for each compound (Table 1) below ±2.5%, the reequilibration
timeafter each runwaskept at 10 min. Shorter reequilibration times
(5 min) led to unstable retention times of hypoxanthine and xan-
thine, whereas longer reequilibration times (15 min) resulted in
coelution of GMP and IMP at 5.5 min (data not shown). Although
the retention times of CTP, GTP, ADP, and ATPwere very stable even
after a 5-min reequilibration time (Fig. 1B, 500 nM, 10 pmol), we
chose toadopta constant reequilibration timeof10 minbecause this
allowed optimal and consistent separation of all compounds of
interest. Furthermore, the retention times of all standard com-
pounds did not change when the ﬂow direction of the column was
reversed, allowing us to use the column for a longer time.
At high gain, the baseline showed several small peaks eluting after
10 min and a larger ghost peak eluting after ATP (black dots in Fig. 1A
andB)whose size increasedandwhose retention timedecreasedwith
the column life time. The nature of these peaks could not be clearly
determined. They were not due to an impurity in any of the buffer
components, to contamination of the injection valve, to the reequili-
bration time, or to the fact that the ion-pairing agent was used only
in buffer A. A possible reason could be a precipitationof TBAHSduring
the gradient elution that can occur when using potassium phosphate
buffers. However, because the ghost peak could be clearly distin-
guished from the ATP peak even at low concentrations of ATP, and
tokeepthe runtime toa reasonable length,neither thegradientproﬁle
nor the buffer composition was changed.
UV absorbance spectra
The UV absorbance spectra (220–360 nm) for all standard and
sample compounds were measured for all runs. Fig. 2A shows a con-
tour graph andFig. 2B shows the respective three-dimensional graphs
of all standard compounds (100 lM, 2000 pmol). The two-dimen-
sional UV absorbance spectra for trinucleotides, nucleosides, and free
purine bases are shown in Fig. 2C and D, and the respective UV absor-
bancemaximaaresummarized inTable1.Hypoxanthine, inosine, and
IMPhad the lowestUVabsorbancemaximum(247 nm),whereasxan-
thine (267 nm) and CTP (270 nm) had the highest absorbance max-
ima. The quantitative analysis was performed at a wavelength of
254 nm (black line in Fig. 2A). This was chosen to encompass the
absorbance spectra of all separated compounds.
Limits of detection and quantiﬁcation
The LOD (evaluated with a signal-to-noise ratio > 3) and LOQ
(evaluated with a signal-to-noise ratio > 10) are summarized in Ta-ion
min)
UV absorbance
maximum (nm)
Correlation
coefﬁcient (R2)
% Recovery after
PCA extraction
258 0.996 102.8 ± 4.0
259 0.996 109.3 ± 7.4
252 0.999 95.3 ± 5.7
270 0.999 90.9 ± 4.9
252 0.998 100.5 ± 2.4
259 0.997 99.4 ± 2.5
259 0.999 103.8 ± 2.5
247 0.991 95.8 ± 2.6
247 0.999 98.1 ± 2.3
252 0.999 99.4 ± 1.7
267 0.994 103.7 ± 10.1
250 0.999 102.2 ± 5.5
concentration of the analyte 3 times the noise level. The LOQ was classiﬁed as the
, the retention times varied by 6± 2.5%. The R2 value for each calibration curve (LOQ
after PCA extraction was determined by spiking sample homogenates with various
nine determinations.
Fig. 2. Spectral view of HPLC chromatograms obtained from a 100-lM standard mixture. (A and B) Contour graph (A) and three-dimensional graph of all separated standard
compounds. The y axis indicates the wavelength (220–360 nm). The x axis shows the retention time. The z axis shows the absorbance intensity in milli-absorbance units
(mAU). The black dotted line in panel A indicates 254 nm, the wavelength that was used for quantitative analysis of standard and sample compounds. Compounds are
numbered as in Fig. 1. (C and D) UV absorbance spectra (220–360 nm) for purine nucleotides (C) and purine nucleosides and free bases (D). UV absorbance maxima are
summarized in Table 1.
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pounds dissolved in deionized water ranged between 0.1 and
10 pmol, whereas the LOQ ranged between 0.5 and 10 pmol at
254 nm. The higher LOD and LOQ for GTP, ADP, and ATP were
due to the baseline peaks shown in Fig. 1B, which merged with
the standard peaks at concentrations below 500 nM (10 pmol),
thereby making an accurate determination of the analyte peaks
unreliable.
The LOQ estimated for sample peaks was among 1 pmol (hypo-
xanthine, xanthine, IMP, GMP, and inosine), 2 pmol (adenosine,Fig. 3. Calibration curves for adenine nucleotides. (A) LOD (signal-to-noise
ratio > 3) and LOQ (signal-to-noise ratio > 10) for AMP. (B) Calibration curves for
ATP, ADP, and AMP (LOQ of 2000 pmol).AMP, and GDP), and 10 pmol (CTP, GTP, ADP, and ATP). The small-
est amount of standards added to samples, which could be reliably
detected by an increase in peak height, ranged between 1 and
2 pmol for hypoxanthine, xanthine, IMP, GMP, inosine, adenosine,
AMP, and GDP. Due to the baseline peaks eluting after 10 min
(see Fig. 1B), and due to the larger size of GTP and ATP peaks in
samples (see Fig. 4A), the smallest amount of reliably detectable
standards, determined by an increase in the peak area for CTP,
GTP, ADP, and ATP, was 10 pmol.
Linearity
A linear response, as indicated by correlation coefﬁcients (R2) in
excess of 0.99, was observed for each compound ranging from the
LOQ for standard compounds in water to at least 2000 pmol
(100 lM). The calibration curves for ATP, ADP, and AMP are shown
in Fig. 3B, and the respective R2 values for all resolvable standard
metabolites are summarized in Table 1. This linear range encapsu-
lates the values observed for these compounds in brain tissue (see
below).
Recovery of standard compounds after PCA extraction
PCA is commonly used to precipitate proteins of tissue samples
and thereby to extract acid-soluble cell compounds, such as nucle-
otides, for subsequent analysis. However, during the neutralization
process of PCA extracts, ATP can be adsorbed to the perchlorate
precipitate [12,13]. To evaluate the extent to which PCA extraction
inﬂuenced the yield of nucleotides and metabolites, standard com-
pounds were added to half of a brain slice sample, whereas the
other half had an equivalent volume of distilled water added. Both
samples were subjected to PCA extraction and were subsequently
neutralized to pH 6 by a threefold organic extraction with tri-n-
octylamine/trichlorotriﬂuoroethane.
Because this protocol required the injection of two aliquots
from the same brain sample (spiked and unspiked), we ﬁrst needed
to determine the intrasample variability of these two injections.
For two unspiked aliquots of the same brain sample, as treated
above, the differences between the two peak areas, expressed as
percentages of the mean peak area, were 2.1 ± 0.9% (ATP),
6.8 ± 1.6% (ADP), and 14.4 ± 8.2% (AMP) (n = 4). These values likely
overestimate any variability because the percentages do not take
Fig. 4. Representative HPLC chromatogram from neutralized hippocampal brain slice extracts. Brain slices were incubated for 3 h in aCSF at 34 C, and nucleotide extraction
was performed on fresh tissue without prior freezing in liquid nitrogen. (A) Representative HPLC chromatogram obtained at 254 nm. (B and C) Contour graph (B) and three-
dimensional graph (C) for separated compounds. Numbers on traces refer to the following compounds: 8, GDP; 9, CTP; 10, GTP/UTP. d, ghost peak. mAU, milli-absorbance
units. (D) Sample ATP peak veriﬁcation by peak purity analysis (a) and spectral library search (b). Sim. Index, similarity index = 0.99. Sample ATP UV absorbance spectrumwas
100% similar to standard ATP absorbance spectrum.
112 Determination of fresh tissue adenine nucleotides / S. zur Nedden et al. / Anal. Biochem. 388 (2009) 108–114into account the size of the peak areas. Thus, for smaller peaks (e.g.,
AMP), subtle differences between aliquots would have a propor-
tionately larger effect. This may also explain the reduction in
apparent variability as the peaks become larger from ADP to ATP.
Nonetheless, to test whether these values reﬂected variability in
the detection system, we injected sequential aliquots from solu-
tions of standard compounds. This yielded much lower variability;
the differences of the peak areas of subsequent injections of 20 lM
(400 pmol) ATP, ADP, and AMP standards from the mean peak area
were 1.3 ± 0.5%, 1.1 ± 0.4%, and 0.2 ± 0.1%, respectively (n = 7).
Hence, the variability between the peak areas of two aliquots from
the same brain slice is not due to poor precision of the system and
more likely reﬂects subtle differences between the initial aliquots,
which involved separating the homogenized tissue in two, a possi-
ble source of intrasample variability. This was performed only dur-
ing these spiked sample experiments.
We observed that the recovery of all standard compounds in
spiked brain samples was between 90% and 109% of the standard
when dissolved in water (Table 1). Given the intrasample variabil-
ity described above, we assumed a 100% recovery for all standard
metabolites.
Analysis of brain slice extracts
To evaluate whether this HPLC method is suitable for studying
the adenine nucleotide levels of biological tissue, we applied it to
neutralized PCA extracts of hippocampal brain slices. A representa-
tive HPLC chromatogram is shown in Fig. 4A, and the contour and
three-dimensional graphs of the absorbance spectra are shown in
Fig. 4B and C. The identity of each sample peak was determined
by comparison of the retention time with the respective standard
compound, by spiking samples with standards, by comparison ofthe UV spectra with the particular standard compound, and by
peak purity analysis, as shown for ATP in Fig. 4D. Peak purity anal-
ysis showed that sample adenine nucleotides were as pure as stan-
dard adenine nucleotides. However, the GTP peak was
contaminated due to coelution with UTP. It is possible that these
compounds could be resolved individually by appropriate changes
to the buffer gradient proﬁle, but because all adenine nucleotides
were clearly separated, this was not pursued.
Effect of liquid nitrogen freezing on tissue adenylate levels
It is often convenient to snap-freeze tissue after the experiment
for analysis at a later date. This may be the case when the analysis
procedure or HPLC runtime is lengthy, thereby obviating the possi-
bility of running several fresh samples on the day of the experi-
ment. Given the known labile nature of adenine nucleotides, we
sought to determine whether snap-freezing in liquid nitrogen
and/or subsequent extraction results in a change of adenine nucle-
otide levels. For this purpose, brain slices were transferred into ice-
cold aCSF. One set of slices was immediately homogenized in PCA,
and another set of slices was frozen in liquid nitrogen for 30 to
60 min. Frozen slices were powdered under liquid nitrogen and
subsequently homogenized in PCA. All neutralized extracts were
analyzed on the same day of slice preparation.
Representative HPLC chromatograms, with adenine nucleotide
and EC levels of fresh and liquid nitrogen frozen brain slices, are
shown in Fig. 5. EC values from fresh tissue slices are very high
(0.95 ± 0.003, n = 4), indicating that the slices are in good metabolic
condition.
In contrast, snap-freezing in liquid nitrogen led to signiﬁcantly
higher ADP levels (1.1 ± 0.2 nmol/mg protein for fresh slices and
2.5 ± 0.3 nmol/mg protein for snap-frozen slices, n = 4, P < 0.01, un-
Fig. 5. Effect of liquid nitrogen freezing on adenine nucleotide levels. (A and B) HPLC chromatograms from unfrozen brain slices (A) and frozen brain slices (B). Numbers on
traces refer to the following compounds: 8, GDP; 9, CTP; 10, GTP/UTP. d, ghost peak. The rising baseline in panel B is due to a short reequilibration time between runs. (C and
D) ATP and TAN levels (C) and ADP, AMP, and EC values (D) of fresh and liquid nitrogen frozen slices. Values are expressed as means ± SEM (n = 4). **P < 0.01, ***P < 0.001 for
AMP and EC (unpaired t test).
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slices and 0.5 ± 0.04 nmol/mg protein for snap-frozen slices, n = 4,
P < 0.001, unpaired t test), indicating degradation of ATP during
the freezing/extraction process. This results in signiﬁcantly lower
EC values (0.95 ± 0.003 for fresh slices and 0.88 ± 0.009 for snap-
frozen slices, n = 4, P < 0.001, unpaired t test). However, there
was no further degradation of adenine nucleotides in snap-frozen
slices because the TAN pool was not signiﬁcantly different between
both groups (15.9 ± 1.4 nmol/mg protein for fresh slices and
14.2 ± 1.4 nmol/mg protein for snap-frozen slices, n = 4, P > 0.05,
unpaired t test). This degradation of ATP is dependent on the pres-
ence of tissue given that freezing of standard ATP in liquid nitrogen
did not lead to ATP breakdown (data not shown).
Discussion
The accurate determination of adenine nucleotides is critical in
the study of energy metabolism. We therefore aimed to develop a
fast, high-resolution, ion-pair reversed-phase HPLCmethod that al-
lows the analysis of multiple fresh samples in 1 day, thereby avoid-
ing freeze–thaw degradation of nucleotides. With the method
described here, at least 11 different purine compounds can be sep-
arated within 13 min with a subsequent 10-min reequilibration
time. This method is particularly useful for studying changes in
the adenine nucleotide levels associated with experimental manip-
ulations, extraction efﬁciency, or tissue storage. The short time of
analysis and the accurate evaluation of the compounds make this
method useful for routine and relatively high-throughput use.
The sensitivity, as determined by the LOQ, lies in the range of
previously published UV-based HPLC methods [5,14], and calibra-
tion curves for standard compounds showed that they were linear
over a wide concentration range (LOQ to 2000 pmol). As the signalof each standard compound increases linearly with increasing
injection volume [5], injecting more than 20 ll on the column
may result in even lower LOD and LOQ. Nonetheless, the absolute
sensitivity is still lower than ﬂuorescence-based HPLC analysis of
adenine nucleotides [15]. However, for this method, purine com-
pounds of sample extracts need to be etheno-derivatized with
chloroacetaldehyde, a process that requires incubation at high
temperatures (most commonly 80 C) and limits the analysis to
compounds containing an amino group in the purine or pyrimidine
ring (e.g., adenine, cytosine). Furthermore, the derivatization efﬁ-
ciency of standard ATP is variable and never reaches 100% (see
Supplemental Fig. 1A in the supplementary material). This pre-
cludes an accurate determination of the energetic state due to deg-
radation of ATP during this process and thereby underestimates
key parameters such as the energy charge. Therefore, UV-based
HPLC analysis of adenine nucleotides (see Supplemental Fig. 1B),
although less sensitive, results in a more reliable detection of the
in situ energetic state.
To evaluate whether our method is suitable for the analysis of
tissue samples, we analyzed hippocampal brain slices. Tissue
nucleotides were extracted with PCA, and for neutralization a
threefold organic extraction with tri-n-octylamine/trichlorotriﬂuo-
roethane was used. It is known that acid extraction and subsequent
neutralization can lead to adsorption of ATP to the acid–salt pre-
cipitate [12,13], and the recovery of ATP has been reported to be
between 45% and 96% [5,16–18], depending on the type of extrac-
tion and neutralization. In our hands, there was a complete recov-
ery of standard compounds added to sample extracts. This may be
due to our use of tri-n-octylamine/trichlorotriﬂuoroethane given
that it has been reported that the removal of PCA with tri-n-octyl-
amine/trichlorotriﬂuoroethane can result in a better recovery of
nucleotides than, for example, precipitation as KClO4 [19]. The
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roethane for neutralization of acid extracts have been pointed
out previously [20]. Most importantly this method does not
introduce into the extracts additional salts that could interfere
with HPLC separations. Furthermore, there is no possibility of
making the solution too alkaline. In fact, the threefold organic
extraction used in this study always resulted in a pH of 6, which
allowed the best separation of all sample/standard compounds in
the method described here given that the buffers used had the
same pH.
HPLC chromatograms obtained from hippocampal brain slice
extracts showed that all purine nucleotide compounds were clearly
separated. Peak purity analysis and UV absorbance spectra com-
parisons further established the nature of the speciﬁc sample com-
pounds. Including the time for slice preparation (30 min), slice
incubation (3 h), extraction for tissue nucleotides (30 min), and
washing of the column after use (50 min), at least 10 sample ex-
tracts could be analyzed in 1 day.
An interesting observation of this study is that freezing the
brain tissue in liquid nitrogen and/or subsequent extraction can re-
sult in a signiﬁcant change of adenine nucleotide levels. This has
implications for the storage of tissue, especially if it is to be used
for metabolic studies.
Due to the high activities of ATPases in fresh samples, changes
in the adenine nucleotide levels take place very quickly when ATP-
ase enzymes are not inactivated immediately. Snap-freezing of tis-
sues in liquid nitrogen is a simple and widely used way to instantly
stop any enzymatic activities and to store the sample for subse-
quent extraction. However, the maintenance of freezing conditions
during the nucleotide extraction procedure is critical because
thawing of the tissue will result in a recovery of enzymatic activi-
ties and potential degradation of ATP. Although samples in this
study were kept and powdered in liquid nitrogen, there was a sig-
niﬁcant change in adenine nucleotide levels. This resulted in signif-
icantly lower EC values compared with fresh sample extracts.
Freezing of standard ATP in liquid nitrogen did not lead to a degra-
dation of ATP. Furthermore, it is unlikely that snap-freezing is not
quick enough to stop enzymatic degradation of ATP or that enzy-
matic activities recover at such low temperatures. Because brain
slices were powdered under liquid nitrogen, the degradation of
ATP most likely occurs during the homogenization procedure.
The tissue powder might thaw and, therefore, ATPase activities
might recover before proteins are effectively precipitated with
PCA.
Because tissue is frequently frozen in liquid nitrogen and stored
at 80 to 20 C for subsequent extraction and HPLC analysis,
assumptions about the EC need to be made very carefully given
that they might not reﬂect the in situ values. Hence, transferring
tissue slices into ice-cold aCSF and performing the PCA extraction
immediately lead to a more reliable evaluation of adenine nucleo-
tide levels.
In summary, we have reported a method that is suitable for the
detailed analysis of tissue adenine nucleotide levels and, due to its
rapidity, allows within-day sample analysis. This helps to bypass
the problem of freeze–thaw degradation of adenine nucleotides
and results in an accurate determination of the tissue energy
charge.Acknowledgments
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